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Zusammenfassung 
Formale Totalsynthese von Kendomycin mittels Alkinmetathese/Goldkatalyse  
Kendomycin 1 [(–)-TAN 2162] tritt als natürliches Stoffwechselprodukt von Streptomyces 
violaceoruber auf. Das vielfältige biologische Profil umfasst Aktivität als Endetholinrezeptor-
Agonist, Antiosteoporotikum und eine bemerkenswerte antibakterielle und zytotoxische 
Wirkung. Der polyketidische 18-gliedrige Carbozyklus besteht aus einem para-Chinonmethid-
Grundgerüst und einem hochsubstituierten Tetrahydropyranring. Die vielseitigen 
pharmakologischen Eigenschaften und die faszinierende Struktur des Kendomycins 
veranlassten bereits zahlreiche andere Forschungsgruppen, Bemühungen hinsichtlich einer 
Totalsynthese zu unternehmen. 
 
Abbildung 1: Retrosynthetische Analyse des Polyketids Kendomycin 1.  
Eine Ringschluss-Alkinmetathese (RCAM) und die direkte postmetathetische Umsetzung des 
Alkinmakrozyklus zum Benzofuran mittels -Säureaktivierung sollten die Schlüsselschritte der 
hier vorgestellten Totalsynthese darstellen.  
Das benötigte polyketidische Fragment 4 (12 Stufen) konnte mittels einer Alkyl-Suzuki-
Kupplung zwischen einem Alkenyliodid und einem Alkyliodid aufgebaut und anschließend mit 
Phenol 5 (3 Stufen) verestert werden. Unter Verwendung einer weiteren Variante der Suzuki-
Miyaura Kupplung wurde das zweite Alkin eingeführt und der Alkinmetathese-Vorläufer 
erhalten. Der Ringschluss des erhaltenen Dialkins erfolgte unter milden Bedingungen in 
Anwesenheit eines Molybdän-Alkylidinkatalysators. Nach Abspaltung der Acetatschutzgruppe 
wurde der Heterozyklus in Anwesenheit eines elektrophilen Goldkomplexes gebildet, während 
z.B. einfache Platin(II)- oder Gold(I/III)chloride keinen Erfolg brachten. Weiterhin konnte durch 
Foto-Fries Umlagerung eine Ringkontraktion herbeigeführt werden, durch die das gewünschte 
hexasubstituierte Cyclophan erhalten wurde. Die anschließenden Redoxschritte und 
 
 
Schutzgruppenmanipulationen führten in Analogie zur Literatur zum angestrebten Naturstoff 
1.  
Totalsynthese eines halogenierten marinen 4-Pyron-Derivats  
Im weiteren Verlauf der Doktorarbeit sollte ein aus roten Algen der Spezies Phacelocarpus 
labillardieri isolierter -Pyron-haltiger makrozyklischer Naturstoff synthetisiert werden. Erste 
biologische Tests zeigten eine Inhibition der Phospholipase A2 bei mikromolarer 
Konzentration (IC50 < 4,4 M).  
 
Abbildung 2: Retrosynthetische Strategie für den marinen Naturstoffs 6.  
Der polyungesättigte Metabolit 6 gehört einer interessanten und seltenen 
Verbindungsklasse an, die sich durch ein dibromiertes Molekülskelett mit einem Ketenacetal 
als einzigartiges Strukturmotiv auszeichnet. Zur Aufklärung der bis dahin unbekannten 
relativen Stereochemie sollten zwei mögliche Diastereomere syn-6 und anti-6 synthetisiert 
werden.  
Der Schlüsselschritt der Synthese sollte eine -Säure-katalysierte Cycloisomerisierung des 
entsprechenden -Ketoesters zum -Pyron sein, gefolgt von einer RCAM zum Aufbau des 
Cycloalkins. Dazu wurde zunächst das entsprechende Alkoholfragment (8 Stufen) unter 
Inversion an C19 bromiert und nach Entschützung mit einer -Ketosäure (6 Stufen) verestert. 
Die Pyronsynthese sowie die darauffolgende Makrozyklisierung mittels Alkinmetathese 
verliefen problemlos. Die finale Bromierung am -Pyron konnte erfolgreich unter 
elektrophilen Bromierungsbedingungen durchgeführt werden. Jedoch konkurrierte diese in 
deutlichem Maße mit einer cis/trans-Isomerisierung der (Z)-Olefine. Ausgehend von einem 
späten Intermediat konnte durch doppelte Inversion die diastereomere Verbindung anti-6 
hergestellt werden. Ein Vergleich der NMR-spektroskopischen Daten von syn-6 und anti-6 
ergab, dass die Substituenten an C19 – C20 im Naturstoff syn zueinander stehen. Somit 
konnte die relative Stereochemie des Naturstoffs ermittelt werden.   
Summary 
Formal Total Synthesis of Kendomyicn via Ring-Closing Alkyne Metathesis 
Kendomycin 1 [(–)-TAN 2162] occurs as a metabolite of the species Streptomyces 
violaceoruber. The multifarious biological profile of this compound comprises activity as 
endetholin receptor agonist, exeptional antiosteoporotic and antibiotic properties and a 
remarkable cytotoxicity. The polyketidic 18-membered macrocycle exhibits a para-quinone 
methide core and a highly substituted tetrahydropyran. The versatile pharmacological 
activity and the unique structural features have prompted several research groups to pursue 
a synthesis of kendomycin 1. 
 
Scheme 1: Retrosynthetic analysis of kendomycin 1.  
A ring-closing alkyne metathesis (RCAM) and a subsequent postmetathetic transformation of 
the cycloalkyne to the benzofuran by -acid catalyzed hydroalkoxylation were designed to 
be the key steps of our total synthesis.  
The required polyketide fragment 4 (12 steps) was constructed by an alkyl-Suzuki cross-
coupling of a vinyl iodide and an alkyl iodide. The resulting fragment was esterified with 
phenol 5 (3 steps) before the second alkyne was introduced by another variant of the Suzuki-
Miyaura coupling to yield the RCAM precursor. Ring-closure of the obtained diyne was 
achieved under mild conditions using a molybdenum alkylidyne catalyst. After deprotection 
of the phenol group, the heterocycle was quickly formed in the presence of catalytic 
amounts of an electrophilic gold-catalyst, whereas it could not be assembled by simple 
platinum(II)- oder gold(I/III) chlorides. Furthermore, a ring-contraction by photo-Fries 
rearrangement gave the desired hexasubstituted cyclophane. Finally, the natural product 
was obtained after the remaining redox and protecting group manipulations had been 
carried out according to a literature precedent.  
  
 
 
Total Synthesis of a Polyunsaturated, Marine 4-Pyrone Derivative 
In the further course of this PhD thesis, the marine 4-pyrone derivative 6 from the red alga 
of the species Phacelocarpus labillardieri was selected for a total synthesis. This compound 
displayed an impressive inhibitory activity of the phospholipase A2 in preliminary biological 
tests (IC50 < 4,4 M).  
 
Scheme 2: Retrosynthetic strategy for the marine natural product 6.  
The polyunsaturated metabolite 6 is a representative of a family of compounds that exhibit a 
dibrominated, keteneacetal-comprising macrocycle as an extraordinary structural feature. 
The unknown relative configuration of 6 was to be elucidated by the total syntheses and 
comparison of the two possible diastereomers syn-6 and anti-6.  
The key transformation of the synthesis was a -acid catalyzed cycloisomerization of a 
corresponding -ketoester to the 4-pyrone and a RCAM to construct the cycloalkyne. At first, 
the required alcohol fragment (8 steps) was brominated at C19 with inversion of 
configuration, deprotected and esterified with the corresponding -ketoacid (6 steps). The 
formation of the 4-pyrone and the subsequent macrocyclization by RCAM proceeded very 
efficiently. At last, the second bromine atom on the 4-pyrone was installed under 
electrophilic bromination conditions. However, the desired bromination competed 
significantly with the cis/trans isomerization of the (Z)-olefins. Starting from a late-stage 
intermediate of the alcohol fragment, the diastereomeric compound anti-6 was prepared by 
twofold inversion of the stereogenic center at C19. By comparison of the NMR data of syn- 
and anti-6 to the data of the natural product, the relative configuration of the substituents 
at C19 and C20 was determined to be syn. Thus, the relative stereochemistry of the natural 
product 6 was elucidated.   
  
 
 
 
  
 
 
Formal Total Synthesis of Kendomycin  
& 
Total Synthesis of a Marine 4-Pyrone 
 
  
 
 
  
Content 
1. Introduction ............................................................................................................... 1 
1.1. Natural Product Synthesis ..................................................................................................... 1 
1.2. Ring-Closing Alkyne Metathesis (RCAM) ............................................................................... 2 
1.3. Acid Catalysis with Gold .................................................................................................... 6 
2. Aims and Scope .......................................................................................................... 9 
3. Formal Total Synthesis of (−)-Kendomycin .............................................................. 10 
3.1. Introduction ......................................................................................................................... 10 
3.1.1. Structure .............................................................................................................................. 10 
3.1.2. Isolation & Structure Validation .......................................................................................... 10 
3.1.3. Elucidation of the Biosynthetic Pathway............................................................................. 11 
3.1.4. Biological Activity ................................................................................................................ 13 
3.2. Preceding Synthetic Studies ................................................................................................ 15 
3.2.1. Early Studies and Total Syntheses by Mulzer and Coworkers ............................................. 17 
3.2.2. Mulzer´s Total Syntheses of (−)-Kendoymcin by RCM and Photo-Fries Reaction ............... 18 
3.2.3. Lee´s Total Synthesis of (−)-Kendomycin by Glycosidation ................................................. 22 
3.2.4. Contributions by the Arimoto Group .................................................................................. 24 
3.2.5. Smith´s Total Synthesis of (−)-Kendomycin by RCM ........................................................... 25 
3.2.6. Contributions by the White Group ...................................................................................... 28 
3.2.7. Contributions to the Synthesis of the ansa-Chain by Williams and Coworkers .................. 29 
3.2.8. Panek´s Total Synthesis of (−)-Kendomycin by an Intramolecular Barbier Reaction .......... 31 
3.2.9. Two Formal Total Syntheses of (−)-Kendomycin by Rychnovsky and Coworkers ............... 32 
3.2.10. Saikawa´s and Nakata´s Total Synthesis of (−)-Kendomycin by Dötz Benzannulation ........ 34 
3.2.11. Conclusion ........................................................................................................................... 37 
3.3. Retrosynthetic Analysis of Kendomycin: The Key Steps ..................................................... 37 
3.4. Model Studies for the RCAM ............................................................................................... 38 
3.5. Retrosynthetic Analysis of (−)-Kendomycin: Fragment Assembly & Synthesis of a RCAM 
Precursor ............................................................................................................................. 41 
3.6. Forward Synthesis: The Lithiation/Addition Approach ....................................................... 42 
3.6.1. Synthesis of the Northwestern Polyketide Fragment ......................................................... 42 
 
 
3.6.2. Synthesis of the Eastern Fragment (C15-C19) ..................................................................... 48 
3.6.3. Synthesis of the Aromatic Core ........................................................................................... 49 
3.6.4. Further Model Studies Towards the Total Synthesis of Kendomycin ................................. 57 
3.6.5. Fragment Assembly via Lithiation/Addition & RCAM Studies ............................................. 59 
3.6.6.  Revision of the Aromatic Fragment: The Photo-Fries Approach ........................................ 61 
3.6.7. RCAM, Gold-Catalyzed Hydroalkoxylation & Endgame ...................................................... 63 
4. Total Synthesis of a 4-Pyrone Marine Natural Product ........................................... 69 
4.1. Isolation & Structure ........................................................................................................... 69 
4.2. Biological Activity ................................................................................................................ 70 
4.3. Biosynthetic Hypothesis ...................................................................................................... 72 
4.4. An Overview of Methods for the Synthesis of 2- and 4-Pyrones ........................................ 73 
4.4.1. Traditional Protocols ........................................................................................................... 73 
4.4.2. Transition Metal Catalysis-Based Methods ......................................................................... 75 
4.5. Preceding Studies of the Fürstner Group on Macrocyclic Pyrone Derivatives ................... 77 
4.6. Total Synthesis of a 4-Pyrone Natural Product ................................................................... 80 
4.6.1. Preliminary Considerations ................................................................................................. 80 
4.6.2. Model Studies for the Electrophilic Bromination of the 4-Pyrone ...................................... 81 
4.6.3. Total Synthesis of a 4-Pyrone Natural Product: Retrosynthetic Analysis............................ 85 
4.6.4. Synthesis of the Eastern -Ketoacid Fragment ................................................................... 86 
4.6.5. Synthesis of the Western 1,2-Diol Fragment (Route A) ...................................................... 87 
4.6.6. Assembly of the Fragments and Formation of the Macrocycle (Route A) .......................... 89 
4.6.7. Revised Strategy for the Western Alcohol Fragment (Route B) .......................................... 90 
4.6.8. Completion of the Total Synthesis of syn-11 (Route B) ...................................................... 93 
4.7. Total Synthesis of anti-11 .................................................................................................... 95 
4.8. Structure Elucidation and Conclusion ................................................................................. 96 
5. Summary & Conclusions .......................................................................................... 98 
6. Experimental Procedures ...................................................................................... 106 
6.1. General Experimental Details ............................................................................................ 106 
6.2. Formal Total Synthesis of Kendomycin ............................................................................. 107 
6.2.1. Synthesis of a Model for the Ring-Closing Alkyne Metathesis .......................................... 107 
6.2.2. Early Approaches to the C9−C14-Fragment ...................................................................... 113 
6.2.3. Synthesis of the Northwestern Fragment ......................................................................... 118 
6.2.4. Strategies Towards the Aromatic Core ............................................................................. 123 
6.2.5. Synthesis of the Aromatic Core – Final Route ................................................................... 132 
6.2.6. Assembly of the Fragements ............................................................................................. 137 
6.3. Synthesis of a 4-Pyrone Natural Product .......................................................................... 145 
6.3.1.  Preparation of Model Compounds .................................................................................... 145 
6.3.2. Synthesis of the -Ketoester Fragment ............................................................................. 148 
6.3.3. Synthesis of the Epoxide ................................................................................................... 151 
6.3.4. Synthesis of the Skipped Diene/Yne Fragment ................................................................. 152 
6.3.5. Revised Synthesis of the Skipped Diene/Yne Fragment .................................................... 158 
7. Bibliography ........................................................................................................... 178 
8. Appendix ................................................................................................................ 189 
8.1. List of Abbreviations .......................................................................................................... 189 
8.2. Crystallographic Data of 4-Pyrone syn-11 ......................................................................... 193 
8.3. Comparison of NMR Data of the Natural 4-Pyrone and Synthetic syn- and anti-11 ........ 195 
8.4. NMR Spectra of 267, 61, 62, 63, syn-11 and anti-11 ........................................................ 197 
 
 
 
 
  
 
 
  
Introduction 1 
 
1. Introduction 
1.1. Natural Product Synthesis 
“There is excitement, adventure, and challenge, and there can be great art in organic 
synthesis.”[1] 
With these words Robert B. Woodward describes to the point what has driven generations 
of synthetic organic chemists to pursue the synthesis of more or less complex organic 
molecules. Of course, the reasons and motivations behind each and every synthetic 
endeavor are manifold. The most important drivers will be elucidated in the following.  
Natural products from bacteria, fungi and plants fulfil different tasks in their natural 
surroundings, for example as repellents in defense mechanisms. Frequently, a strong 
biological activity is observed even towards completely unrelated targets. A few natural 
products have found direct application as drugs but, in fact, a great number of compounds 
has served as chemical leads for pharmaceutical and agrochemical agents.  
 
Scheme 1: Highly cytotoxic marine natural products prepared by total synthesis: bryostatin 1 (1),  
(+)-spongistatin 1 (2) and halochondrin B (3).
[2]   
In many cases however, a new compound is isolated in low yield from its natural source and 
often the natural supply of the producing organisms is limited. This is how organic synthesis 
comes into play as a powerful and versatile tool to provide a reliable amount of material that 
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is sufficient for a complete analysis of the biological properties and even for the application 
as a drug. For example, the highly cytotoxic marine natural products 1−3 (scheme 1), which 
serve as chemical leads, can only be provided by total synthesis in the large amounts of 
material that are necessary to study their structure-activity relationship.[2]  
Furthermore, natural product synthesis has also become a driver for the development of 
new methods. As synthetic organic chemists have taken the challenge to make bigger and 
more complex molecules in the course of time, they have perpetually revealed new 
synthetic questions and, in the search for answers, novel strategies and transformations 
were established. In this way, organic synthesis and methodology development make a 
synergy that propels chemical research.  
1.2. Ring-Closing Alkyne Metathesis (RCAM) 
Ring-closing alkyne metathesis (RCAM) is one of the key technologies that were applied in 
the course of this PhD thesis. Therefore, a short summary containing the underlying 
principles of this method will be described in the following.  
Alkyne metathesis has its origin in the intermolecular alkyne homo- or cross metathesis 
variants (ACM). In 1974, Mortreux and Blanchard observed that a  mixture of [Mo(CO6)] and 
resorcinol was catalytically active in scrambling the substituents of acetylene derivatives.[3]  
 
Scheme 2: Alkyne metathesis with a [Mo(CO)6]-resorcinol catalyst.
[3]
  
Even though the experimental procedure was simple and practical, the applicability of the 
reaction suffered from the forcing conditions prohibiting functional group tolerance. At the 
required reaction temperature of 160 °C the phenolic groups of the ligand are non-innocent 
bystanders. Shortly after the initial discovery, the mechanism of alkyne metathesis was 
proposed by Katz and McGinnis.[4] The reaction follows the basic logic of the Chauvin cycle 
that is commonly accepted for olefin metathesis (scheme 3).[5] Below, the mechanism will be 
illustrated by an example with two methyl-capped alkyne derivatives as substrates.  
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Scheme 3: Mechanism of alkyne metathesis as proposed by Katz and McGinnis.
[4]
 For clarity, the ancillary 
ligands were removed from the metal center.  
The principle of microscopic reversibility is underlying the course of the process. A metal 
alkylidyne species A undergoes a formal [2+2]-cycloaddition to form a metallacyclobutadiene 
that can be described by two resonance structures B and B´. By cycloreversion the new 
acetylene species is released and a metal alkylidyne C is formed that repeats the same steps 
to complete the catalytic cycle. Butyne is released as a byproduct in this reaction.  
This mechanistic proposal was validated early on by different observations made by Schrock 
and coworkers.[6] Apart from the high-valent complexes of molybdenum, the rhenium and 
tungsten alkylidynes were found to be catalytically active. However, broad applications were 
missing for several decades.[7] It was only in 1998 that research around this methodology 
was accelerated as the intramolecular version - the ring-closing alkyne metathesis - was 
identified as a method for the construction of macrocyclic frameworks.[7-8]  
 
Scheme 4: Overview of different types of alkyne metathesis catalysts.  
As Fischer carbyne complexes were found to be generally inactive in alkyne metathesis, the 
development and improvement of the catalysts focused on Schrock alkylidynes. In these 
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complexes, the metal is usually in its highest oxidation state and the alkylidyne is considered 
a trianionic ligand. The metal-carbon triple bond is not strongly polarized; however, a 
distinct nucleophilicity of the -carbon is observed.  
The first well-defined alkyne metathesis catalyst was the tris(tert-butoxy) tungsten 
neopentylidyne C1 which was reported by Schrock et al.[9] The complex is reasonably stable 
as the bulky tert-butoxy groups prevent dimerization and decomposition. The highly Lewis 
acidic property of the tungsten center somewhat limits the scope, as amines, thioesters or 
acid labile functional groups are not tolerated.  
Another benchmark catalyst was developed by Cummins and coworkers. The tris(amido) 
molybdenum complex C2 was originally established for the cleavage of nitrogen.[10] Yet, it 
was discovered that it reacts with dichloromethane to give a catalytically active species.[11] 
This precatalyst system was frequently applied because it displays good functional group 
tolerance towards polar substituents such as basic amines. A drawback of this catalyst is its 
exceptional lability towards oxidation and hydrolysis.  
Furthermore, some nitride complexes should be mentioned.[12] An effective representative 
of the class is C3 which is depicted as the stabilized pyridine adduct (scheme 4). This kind of 
molybdenum nitride species also serves as precatalyst for alkyne metathesis and attracted 
some attention for its considerable functional group tolerance.[13]  
More recently, the Fürstner group[13b, 13c] developed a new catalyst system C4 (scheme 4) 
based on triphenylsilanolate ligands which seemed to be an excellent match for the 
molybdenum core. Furthermore, the Lewis acidity of the metal center is adjusted such that 
the species remains highly reactive, yet is even more functional group tolerant.  
A scalable, safe and reliable procedure was described for the preparation of C4.[13c] An 
interesting feature of the molybdenum alkylidyne C4 is that it can be rendered air-stable by 
complexation with 1,10-phenanthroline. The re-activation of the catalyst by removal of the 
extra ligand can be achieved by treatment with metal salts such as MnCl2 or ZnCl2. Overall, 
this system is user-friendly and applicable to many functionalized substrates.  
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Scheme 5: Tris(triphenylsilanolate) molybdenum alkylidyne catalyst developed by Fürstner et al.
[13b, 13c]
 
A priori, all steps of an alkyne metathesis reaction are reversible. In order to support product 
formation, the butyne needs to be removed from the equilibrium. Formerly, this was 
achieved by either heating of the reaction solution or application of low-pressure. A seminal 
discovery by the Fürstner group was the use of 5 Å molecular sieves for trapping the butyne, 
thus making the last step of the catalytic cycle irreversible.  
 
Scheme 6: RCAM as an entry to structurally diversity.  
As discussed before, the alkyne metathesis has gained importance especially in the 
intramolecular version. Today, ring-closing alkyne metathesis (RCAM) is on the rise[7] as a 
powerful tool in organic synthesis. The resulting cycloalkynes are predestined for further 
postmetathetic transformations because triple bonds are versatile precursors and therefore 
valuable species. Initially, the newly formed triple bond was subjected to hydrogenation to 
access cis-olefins selectively. Alkynes also offer a handle for hydrometalation or 
carbometalation, and intramolecular reactions such as hydroalkoxylations, enyne reactions 
and cycloadditions are further possible options.  
Meanwhile, a range of natural products has been successfully prepared by RCAM in 
combination with adequate postmetathetic modifications. Thus, RCAM has become a C-C 
bond-forming tool that has enabled new disconnections for the formation of structurally 
diverse motifs. 
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1.3. Acid Catalysis with Gold 
The second key technology that is at the focal point of this work is -acid-catalysis with gold. 
As gold basically does not play a role in classic redox-catalysis, this metal did not attract 
much attention of organic chemists until -acid catalysis was gaining importance at the 
beginning of this century. Thus, gold-catalysis is still an adolescent field.[14]  
Due to the strong relativistic effect, late transition metals such as gold and platinum exhibit 
special properties. These late elements of the sixth period display a significant contraction of 
the s-orbitals because of the increased positive charge at the atom nucleus. This leads to an 
expansion of the d- and f-orbitals which are consequentially diffuse and polarizable. This fact 
is reflected by the soft character of these metals, e.g. gold (I). In accordance with the HSAB 
concept,[15] the soft gold cation shows a strong preference to interact with soft -systems 
such as triple bonds. They can be activated selectively by a gold (I) complex for attack by a 
nucleophile (intermediate I, scheme 9). This mode of action results in a formal trans-addition 
as first described for Pt (II).[16] However, investigations using Au (I) followed quickly and 
gained particular popularity.[14a, 17]  
 
Scheme 8: Polarization of a triple bond by an electrophilic gold (I) species.
[18]
  
The neutral gold complex (LAuCl) bearing for example a phosphine or an N-heterocyclic 
carbene as ligand L can be activated with silver salts (e.g. AgBF4, AgNTf2) to form a cationic 
species that can coordinate to -systems. A computer-based analysis indicated a 
predominant contribution of a -binding interaction by the donation of electron density of 
the -bond of the acetylene into the empty dz2-orbital of the metal center. A weaker but still 
significant backdonation is made by an occupied d-orbital of the gold atom into the *-
orbital of the alkyne. Certainly, electrostatic interactions also play an important role in these 
binding interactions.[19] The effect of a simple AuCl-complex on an acetylene group is 
evidenced by the increased bond length and the contorted bond angle that correspond to 
the reduced triple bond character (scheme 8).  
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Scheme 9: Gold (I) can activate triple bonds for nucleophilic attack.  
Computational studies suggest that a “slippage” of the metal complex along the -system 
contributes to the activation.[20] After attack of the nucleophile a proton is usually 
transferred and finally the product V is released by proto-deauration (scheme 9). There are 
two things to note about this mechanism: First of all, the intermediate gold species are 
drawn as only one resonance extreme. It was also shown that in some cases the binding 
mode can be more accurately described by a carbenoid species.[14b, 17a, 17d, 21] Secondly, an 
important observation was the positive influence of protic solvents[22] which are assumed to 
promote the proto-deauration of intermediate IV which is also prone to undergo diauration 
– a pathway that infringes on the catalytic cycle.  
To underline the increasing number of applications of -acid catalysis, the following three 
examples were chosen (scheme 10): The first example is an excerpt from the formal total 
synthesis of polycarvenoside A.[23] One of the key transformation is a transannular 
hydroalkoxylation which is based on an electrophilic gold-catalyst.  
The second example depicts a sequence from the synthesis of the antidepressant candidate 
GSK 13600707.[24] A gold-(I)-complex bearing a chiral phosphoramidite ligand is used to 
induce an asymmetric enyne cylcoisomerization that forms a cyclopropane ring with 
excellent enantioselectivity.  
The third precedent showcases the key step of the total synthesis of amphidinolide F.[25] A 
platinum-(II)-catalyzed 5-endo-dig cyclization furnished a dihydrofuran, which was the 
gateway for the preparation of a 1,4-diketone moiety present in this target (scheme 10).  
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Scheme 10: Three examples for recent applications of -acid catalysis.
[23-25]
  
In conclusion, -acid catalysis can be used to generate great structural complexity starting 
from alkynes. Furthermore, as can be seen in scheme 10, the inherent soft character of the 
Lewis acidic catalysts ensures compatibility with many functional groups. The highly 
sophisticated exercises by numerous research groups[14, 17, 21] highlight the broad spectrum 
of mechanistically different transformations that are enabled by -acid catalysts, in some 
cases even with excellent asymmetric induction.[24, 26]  
The gold-catalyzed preparation of pyrone-derivatives is another exciting application. 
However as this topic specifically coheres with the second project of this PhD thesis, a 
detailed discussion will be given in chapter 4.  
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2. Aims and Scope 
The work presented in this PhD thesis can be seen against the backdrop of the growing 
confidence in RCAM as a key operation in natural product synthesis and the application of 
this methodology in concert with a postmetathetic modification based on gold-catalysis. Two 
target structures were chosen that we considered suitable for the application of these 
methods.  
 
Scheme 11: Natural products that were to be synthesized via RCAM and -acid catalysis with gold (I).   
A common goal of both synthetic endeavors was to find highly convergent and efficient 
routes for the preparation of the natural compounds. First of all, the macrocyclic polyketide 
(−)-kendomycin (10) was identified as a prime target to employ our recently developed 
RCAM catalyst for the ring-closure. The highly functionalized and sterically congested 
compound should challenge the molybdenum alkylidyne complex in terms of functional 
group tolerance and steric bulk. The formed cycloalkyne should offer a handle for the 
envisioned gold-catalyzed construction of the benzofuran unit.  
Secondly, a dibrominated marine natural product 11 was selected. This macrocyclic molecule 
contains an immanent acetylene group that we identified as a predestined site of 
disconnection by RCAM. In the context of a highly sensitive skipped diene/yne moiety, the 
compatibility of C4 would be put to test. Furthermore, this highly functionalized 2-alkoxy-3-
bromo-4-pyrone was an unprecedented motif that could be constructed from an acetylenic 
precursor using a -acid catalyst.  
These two synthesis projects were therefore chosen to challenge the scope of ring-closing 
alkyne metathesis and validate the performance of our state-of-the-art catalyst. Moreover, 
the scope of -acidic gold-catalysts should be extended by elaborating internal alkynes into 
complex heterocyclic structures. 
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3. Formal Total Synthesis of (−)-Kendomycin 
3.1. Introduction 
3.1.1. Structure 
Kendomycin [(−)-TAN 2162] (10) has been a highly pursued target molecule of synthetic 
organic and medicinal chemists.[27] This interest can most likely be explained by the 
impressive biological profile as well as the highly intriguing structural motifs. Kendomycin is 
a densely functionalized 18-membered oxa-bridged macrocylic polyketide that features a 
unique quinone methide chromophore with a C-glycosidic linkage to a highly substituted 
tetrahydropyran. The pentasubstituted quinoid is embedded in an ansa-backbone that is 
decorated with nine stereogenic centers, one of them being a lactol, and a trisubstituted (E)-
double bond.  
3.1.2. Isolation & Structure Validation 
 
Scheme 12: (−)-Kendomycin (10); derivatization to Mosher esters (13a and 13b): a) FeCl3, acetone, rt, 26%; b) 
(R)-MTPA for 13a or (S)-MTPA for 13b, DMAP, CH2Cl2, pyridine.
[28]
  
(−)-Kendomycin (10) was first isolated in 1996 from two different Streptomyces species by 
scientists at Takeda Chemical Industries Ltd.[29] and was re-isolated in 2000 from 
Streptomyces violaceoruber (strain 3844-33C) by Zeeck and coworkers.[28] The strain used to 
produce kendomycin was grown in a medium of soybean (2%), mannitol (2%), agar (1.5%) 
and deionized water. The seed culture was fermented and the fermentation broth was 
extracted, concentrated and filtered. After evaporation of the solvent, the crude product 
was recrystallized from CH2Cl2 and was subsequently chromatographed. This process has so 
far produced multi-gram quantities of the intensely yellow natural product.[30] The previously 
reported structure and relative configuration[29a, 29b] were confirmed by 2D-NMR 
experiments and single crystal X-ray diffraction. At the same time, the previously reported 
13C NMR assignments were corrected. For clarification of the absolute configuration of the 
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ansa-chain, kendomycin was derivatized by introduction of an acetal at C19/C20 to give 
kendomycin acetonide 12. The single remaining unprotected hydroxyl function at C7 was 
then used for Mosher´s ester analysis.[31] The C7-center was identified to be S-configured 
thus defining the absolute stereochemistry of 10.[28]  
3.1.3. Elucidation of the Biosynthetic Pathway 
Polyketides usually originate from decarboxylative condensation reactions of malonyl-CoA 
14. Bode and Zeeck (scheme 13)[28] proposed a bacterial type I polyketide pathway for the 
formation of the aliphatic chain of kendomycin (10). The ancestry of the quinone methide 
core, however, presented a fascinating biosynthetic question. Müller and coworkers clarified 
the isssue later using gene expression experiments.[32] In fact, the origin of every oxygen 
atom was ascertained by extensive isotope labeling experiments (13C, 18O). Feeding studies 
revealed that most oxygen atoms are introduced via acetate (C1), malonate (C3) or 
methylmalonate units (C7, C9, C19). Only the oxygen atom at C4 derives from molecular 
oxygen. The C2-methyl group on the chromophore did not exhibit a label in any of the 
conducted studies, pointing to the involvement of a one-carbon donor (e.g. SAM = S-
adenosyl methionine) in the course of forming this methyl substituent.  
 
Scheme 13: Zeeck´s hypothesis regarding the biogenetic origin of (−)-kendomycin´s chromophore.
[30]
  
13C-labeling experiments indicated that the biosynthesis of the ansa chain proceeds from C5 
to C20. Hydroquinone 18 or quinone 19 were identified as starter units. These are 
constructed from acetate and malonate building blocks and loaded onto polyketide 
synthases (PKS). The -keto thioester intermediates undergo oxidation/reduction sequences 
to form the acyclic precursor 16, which cyclizes under release of CO2. Reaction with 
additional oxidases and a methyl transferase completes the substitution pattern of the 
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chromophore. Chain elongation is assumed to proceed via typical malonic/methylmalonic 
acid thioesters and the derived -keto thioesters. 
 
Scheme 14: Top: two possible biosynthetic pathways for tetrahydropyrane formation; bottom: putative aldol-
type macrocyclization.  
It remains unclear whether the tetrahydropyranyl ring is closed before or after the 
macrocyclization and two different pathways for the reductive cyclization have been 
discussed. Path A is based on a dehydration mechanism forming a double bond at C5-C6. In 
path B the phenolic hydroxy group participates by forming an ortho-quinone methide with a 
double bond at C4a-C5 as dehydration takes place. Both routes have a subsequent reduction 
step in common. The macrocyclization at C20-C20a is proposed to resemble an aldol-type 
condensation. Following cleavage of the enzyme-polyketide complex, decarboxylation 
generates a nucleophilic site that attacks the quinone. Dehydration gives the aldol 
condensation product and hemiacetal formation establishes kendomycin (10). This proposed 
pathway is supported by the biosynthetic data of related polyketide macrolides.[33]  
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3.1.4. Biological Activity 
 
Scheme 15: Hydrolysis product of kendomycin (29) and piperidone ketal derivative 30.  
Kendomycin was initially reported as a potent endothelin receptor agonist and displays 
antiosteoporotic properties. Upon its reisolation by Zeeck and coworkers, diverse antibiotic 
activity against Gram-positive and Gram-negative bacteria (e.g. multiresistant 
Staphylococcus aureus strains) and a strong cytotoxicity against human stomach 
adenocarcinoma (HMO2), hepatocellular carcinoma (HEP G2) and breast adeno-carcinoma 
(MCF7) cell lines were observed. In part, an increased growth inhibition (GI50 <0.1 M) 
similar to state-of-the-art drugs such as doxorubicin and cisplatin was found.[30] Remarkably, 
the acetonide derivative 12 exhibited similar cytotoxic properties in in vitro cell assays with 
three human tumor cell lines (HMO2, HEP G2, MCF7, GI50 < 1 M).
[28] The potent cytotoxic 
effects were initially attributed to an impairment of the ubiquitin proteasome system, but 
the exact mode of action remained unclear. In later studies, Janssen et al.[34] reported that 
kendomycin (10) disrupts the protein-protein interaction of the anti-apoptotic enzymes B-
cell lymphoma-extra large (Bcl-xl) and Bak peptides.[35]  
Table 1: Selected biological data of kendomycin (10) and some active derivatives 12, 29-30.
[34]
  
Bcl xL-inhibition cytotoxicity 
IC50 (M) Emax (%)
a) IC50 (M) 
10  12.3 70 16 
12  9.5 22 14 
29  230 35 25 
30 5.0 66 14 
a) Maximal effect in a fluorescence polarization assay measuring displacement of a fluorescently labeled Bak 
peptide from a GST-Bcl-xl fusion protein. 
Apart from the natural product and the derived acetonide 12, a congener 29 produced by 
hydrolysis of the hemiacetal, as well as a piperidone ketal 30 were subjected to biological 
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testing (scheme 15). Except for the hydrolysis product, all compounds were found to exhibit 
a significant effect on Bcl-xl[35] and displayed cytotoxicities within the same range. However, 
there seems to be no clear evidence for the correlation of enzyme inhibition and cytotoxic 
effects (table 1).[34]  
Recent systematic biochemical studies of the kendomycin-proteasome interactions in wild-
type and mutant yeast 20S proteasome in vitro and in vivo indicated a novel mechanism that 
is still not fully understood.[28, 32, 34] The 20S proteasome core particle (CP) is an enzyme with 
multicatalytic activity that, in general, promotes protein turnover in cells. The catalytically 
active sites of the proteasome are defined by the N-terminal threonines in the 1, 2, and 
5 subunits at the inner cavity of a barrel-like structure. Although a large number of CP 
inhibitors (such as bortezomib[36] or carfilzomib[37]) emerged from synthetic and natural 
sources, their activity is compromised by side effects and toxicity by off-target binding.[38] 
These drugs share a common mode of action, namely locking the substrate binding channel 
and inducing a conformational change of the active site of the protein and a subsequent 
covalent bond formation with Thr1.  
With this information, Groll and coworkers[39] set out to search for CP inhibitors of natural 
origin with hitherto unknown mode of action. An investigation of several compounds that 
were reported as active inhibitors before, only kendomycin passed the first tests. The ansa-
compound displayed a reproducible in vitro proteasome inhibition of y1 (24.0%), y2 
(23.5%) and y5 (15.3%) catalytic activities at 200 M in the presence of sodium dodecyl 
sulfate (SDS). This observation was consistent with earlier studies indicating that the CP of 
leukemic monocyte lymphoma cells (IC50 = 0.8 M) were targets of kendomycin, as the 
natural product reduced the proteasome activity to 25% in the presence of small amounts of 
SDS.[32] Furthermore, detailed investigations of the proteasome-ligand complex revealed a 
significant proteasomal 5 inhibitory activity at a reported IC50 value of 67.9 M. However, 
in the absence of SDS, kendomycin was noneffective. Detergents such as SDS are frequently 
used in in vitro assays to open the proteolytic chamber of the CP in order to promote 
substrate binding and product release. Therefore, it was assumed that a CP mutant (3N) 
that is lacking the first nine N-terminal amino acids and thus diplaying a permanently open 
gate structure would render SDS unnecessary. Surprisingly, kendomycin´s inhibitory activity 
was found to be attributed to small amounts of the detergent and unrelated to the substrate 
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binding channel. These findings indicated that a non-conventional binding mode must be 
operative.  
Furthermore, crystals of the proteasome-kendomycin complex were diffracted. The 
obtained data supported the previous conclusion, as the natural product was identified on 
the surface rather than in the binding pocket. Interestingly, kendomycin (10) was found to 
be covalently bound to the reactive methide at C20 via 2His141N. After mutagenesis of 
sections of the binding pocket (2-H141A), the ligand was absent, even though inhibition of 
5 activity was undiminished. Moreover, HeLa cells (derived from cervical cancer cells) were 
incubated with kendomycin and it was observed that the viability curve superimposes the 
IC50 curve, leading to the conclusion that the detected IC50 values in vivo cannot be 
attributed to impairment of the proteasome activity, but rather to the highly cytotoxic 
properties of kendomycin.  
In conclusion, the correct target of kendomycin (10) could not yet be identified, even when 
complementary and orthogonal assay techniques were applied in concert.[39a, 40] A 
polypharmacological mode of action was suggested to be responsible for the rapid 
kendomycin-mediated apoptosis.[28, 32, 34]  
3.2. Preceding Synthetic Studies 
18 years after its first isolation, (−)-kendomycin (10) remains an attractive target for 
synthetic organic chemists. The structural features of this unique ansamycin compound have 
attracted no less than eight different research groups so far. Six total syntheses (Lee,[41] 
Smith,[42] Panek,[43] Mulzer (2x),[44] Saikawa and Nakata[45]), two formal syntheses 
(Rychnovsky)[46] and several fragment syntheses (Mulzer,[47] Arimoto,[48] Panek,[49] White,[50] 
Williams[51]) were published prior to our work, and one total synthesis was reported briefly 
thereafter by Arimoto and Uemura.[52] A survey of the synthetic efforts preceding this PhD 
thesis is presented here. For the sake of brevity, emphasis is put on the key transformations 
and fragments. Synthetic elaborations published after the completion of this project will not 
be discussed.  
Many synthetic approaches mimic a biogenetic pathway with regard to the ansa-chain. 
Therefore, the majority of the reported syntheses resorted to similar fragment 
disconnections. Hence, a highly functionalized aromatic unit was commonly linked to a more 
or less advanced polyketide chain. Interestingly, synthetic efforts towards the latter relied 
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essentially on auxiliary-assisted aldol and alkylation chemistry. Moreover, the challenging 
macrocyclization to the all-carbon 18-membered ring and formation of the densely 
substituted tetrahydropyranyl unit were late stage transformations in all reported syntheses. 
Oxidation to the quinoid motif was carried out in the final steps in order to avoid issues that 
could potentially arise from the highly electrophilic C20 methide.  
 
Scheme 16: Overview of previous retrosynthetic disconnections in completed and uncompleted syntheses.  
Scheme 16 indicates that certain disconnections were more often selected for 
macrocyclization than others. A frequent choice was the ring-closing olefin metathesis (RCM) 
at the C13-C14 double bond.[53] This disconnection was attempted early on by Mulzer et 
al.[47d] and later on by the research groups of Smith[42] and Arimoto.[54] However, these 
approaches either failed to give the macrocycle or led to the undesired (Z)-olefin which had 
to be inverted to the (E)-olefin via several additional steps. In another approach, which was 
designed to circumvent this problem, the disconnection at the nonstereogenic C10-C11 bond 
was selected for RCM. In this case, the resulting double had to be reduced by hydrogenation 
(scheme 16).[44b, 55]  
In general, disconnections for macrocyclization placed adjacent to the chromophore have 
been more successful, as in the examples of Panek[43] (Barbier reaction), Arimoto[52] (Tsuji-
Trost etherification) and Lee[41] (glycosidation). On one occasion, the aromatic core was built 
up de novo by Saikawa and Nakata[45] (Dötz benzannulation), as the macrocyclic framework 
was closed. Rychnovsky et al.[46a] employed a Prins cyclization, thus constructing the 
tetrahydropyran and the macrocycle at the same time. The above syntheses featured widely 
varying efficiency.  
Formal Total Synthesis of (−)-Kendomycin 17 
 
3.2.1. Early Studies and Total Syntheses by Mulzer and Coworkers 
 
Scheme 17: A distinct atropisomerism about the C-glycosidic bond was observed for the substrate depicted 
above; NOEs are depicted for R1 = H.
[47a]
  
Mulzer´s strategy to form the ansa chain was especially influential on later endeavors. An 
interesting aspect first observed by Mulzer et al. was the rotational limitation about the C-
glycosidic C4a-C5 bond in two acyclic intermediates 31 and 32 that had the tetrahydropyran 
next to the arene already in place. In both compounds, rotation about the C4a-C5 single 
bond was restricted. In case of 31, temperature dependant NMR studies revealed an 
equilibrium of two atropisomers with broadened signals at ambient temperature that could 
be resolved into separate sharp signals at −40 °C. In the case of the brominated compound 
32, two separable rotamers were observed, showing that an increased rotational barrier 
might exist.[47a] This phenomenon would resurface in some of the succeeding syntheses. 
 
Scheme 18: Initial disconnection approach by Mulzer and coworkers.  
The initial synthetic plan of Mulzer and coworkers was centered on a RCM at the C13-C14 
olefinic bond (scheme 18). Anticipating the complications in the key macrocyclization step 
that could arise from the above mentioned atropisomerism, several substrates were 
prepared. Dienes containing the tetrahydropyran moiety and a dioxole protecting group on 
the arenes 36 and 37 gave only complex mixtures under metathesis conditions. 
Modifications that were assumed to decrease the rigidity about the C4a-C5 bond, such as 
acyclic protecting groups on the aromatic core (38, 39 and 40), as well as derivatives 
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containing a free (41 or protected 42 and 43) benzylic alcohol in place of the rigid THP ring 
were examined. However, all attempts to achieve ring closure led to dimerization and 
oligomerization. Since the open-chain representatives 41-43 gave the same result as the 
THP-containing substrates, an underlying negative impact of the planar and rigid benzofuran 
unit was presumed.[47d]  
 
Scheme 19: Dienes surveyed for the RCM at C13-C14 by Mulzer. Substrates existed as various mixtures of 
atropisomers.  
Nevertheless, the macrocyclization at the C13-C14 double bond was achieved in a later 
approach utilizing an intramolecular Horner-Wadsworth-Emmons olefination (scheme 18). 
While the designed key transformation proceed smoothly, deoxygenation at C15 resulted in 
significant isomerization of the double bond under various conditions.[44b]  
3.2.2. Mulzer´s Total Syntheses of (−)-Kendoymcin by RCM and Photo-Fries Reaction 
 
Scheme 20: RCM and macrolactonization/photo-Fries route by Mulzer et al.
[44a]
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The Mulzer group later reported two total syntheses of kendomycin (10) predicated on a 
different retrosynthetic analysis.[44a] RCM was planned at the C10-C11 bond of diene 44, 
followed by selective hydrogenation. The precursor was assembled by deprotonation and 
nucleophilic addition of benzofuran 46 to aldehyde 45. Furthmore, the C-glycosidic bond at 
C4a-C5 was chosen for the first disconnection. In this case, the macrocycle was built up by 
macrolactonization to give a metacyclophane, followed by ortho-Fries rearrangement, which 
adjusted the correct substitution pattern of the arene.  
Route A  The synthesis of the northwestern fragment started with an Evans syn-aldol 
reaction[56] of acrolein 50, followed by an anti-selective reduction with sodium 
triacetoxyborhydride[57] and hydrolytic cleavage of the auxiliary to give -lactone 51. 1,3-Diol 
protection as an acetonide followed by a reduction/oxidation sequence furnished aldehyde 
45. The eastern counterpart was prepared starting from aryl bromide 53 with a copper-
mediated epoxide opening of diastereomeric 52. An oxidation/condensation sequence then 
provided the benzofuran. The free phenol at C4 was reprotected as a MOM-ether. Further 
elaboration of the fragment was accomplished by silyl-ether cleavage, stepwise oxidation of 
the primary alcohol to the carboxylic acid 54 and esterification with alcohol 55. The obtained 
intermediate was rearranged using an Ireland-Claisen protocol[58] to the extended alkene 46. 
 
Scheme 21: Synthesis of the northwestern and eastern fragment of Mulzer´s C10-C11 RCM approach. 
Conditions: a) Sn(OTf)2; b) Me4NBH(OAc)3; c) LiOH, H2O2; d) Me2C(OMe)2, CSA; e) LiAlH4; f) py∙SO3, DMSO; g) 
Mg, CuI; h) (COCl)2, DMSO, Et3N; i) TfOH, toluene, ; j) MOMCl, NaH; k) TBAF; l) IBX; m) NaClO2; n) EDCI∙HCl, 
DMAP, 55; o) LDA, TBSCl, ; p) LiAlH4, q) MsCl; r) LiAlH4.
[44a]
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Scheme 22: Mulzer´s total synthesis of (−)-kendomycin (10) by RCM. Conditions: a) n-BuLi, TMEDA; b) HCl (3 N), 
MeOH; c) Grubb´s II catalyst C7;
[59]
 d) N2(COOK)2, AcOH; e) DDQ; f) 1% HCl, MeCN.
[44a]
  
The RCM precursor was synthesized by ortho-lithiation of benzofuran 46 and addition to 
aldehyde 45. Notably, this is one of the rare examples in which the single remaining position 
on the arene was functionalized by deprotonation. Attempts at utilizing substrates without 
the benzofuran motif failed. The ensuing RCM proceeded successfully (62% yield) even with 
the tetrahydropyran in place. This was somewhat unexpected as similar substrates such as 
38 did not undergo RCM, presumably due to atropisomerism that sequestered the diene in 
an unreactive conformation. The newly formed double bond at C10-C11 was reduced in the 
next step. This total synthesis was finally concluded with an oxidation of the arene to the 
ortho-quinone and a 1,6-addition of H2O, following the biomimetic pathway.
[44a]  
Route B  In a second approach, Mulzer et al. placed the disconnection at the C-glycosidic 
bond. Therefore, the required acyclic precursor 47 was assembled as depicted below 
(scheme 20). Alcohol 58 and carboxylic acid 59 were known intermediates from previous 
studies (see 3.2.2.). Esterification of these fragments under Steglich conditions was followed 
by a sequence of Ireland-Claisen rearrangment/reduction of the resulting acid. Then, 
deoxygenative manipulations were analogously conducted as before. The Ireland-Claisen 
route effectively crafted the northern part of the alkyl chain and avoids the difficulties 
associated with either the RCAM or HWE disconnection at C13-C14. However, a major 
drawback of this procedure was the laborious deoxygenation that involved three extra steps 
on an advanced intermediate. The lower part of the northwestern fragment was then 
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elaborated by silyl-ether cleavage and IBX-oxidation followed by a syn-aldol/anti-reduction 
and hydrolytic cleavage of the auxiliary (cf. chapter 3.2.2.).  
 
Scheme 23: Mulzer´s formal total synthesis of kendomycin by lactonization/photo-Fries reaction. Conditions: a) 
EDCI, DMAP; b) LDA, TBSCl, ; c) LiAlH4; d) MsCl; e) LiAlH4; f) TBAF; g) IBX; h) 48, Sn(OTf)2; i) NMe4NBH(OAc)3; j) 
LiOH, H2O2; k) HCl; l) Me2C(OMe)2, CSA; m) LiOH; n) EDCI, DMAP, DMAP∙HCl; o) h (254 nm); p) NaBH4; then 
HCl; q) p-TsOH.
[44a]
  
Upon 1,3-diol protection, -lactone 60 was opened to the ester which was saponified before 
macrolactonization under modified Keck-conditions proceeded in moderate yield. The 
macrolactone 61 was irradiated to undergo an ortho-selective Fries rearrangement to 
ketone 62. This methodology seemed to be beneficial as macrocyclization and introduction 
of the sixth substituent on the chromophore were two hurdles overcome at once. 
Furthmore, installation of the tetrahydropyran was postponed until after the 
macrocyclization to avoid atropisomerism. Ketone 62 was eventually reduced and the THP-
moiety was formed upon acidic work-up. Compound 63 converges with the previously 
described route to kendomycin (10). In summary, the Mulzer group disclosed two successful 
synthetic approaches to (−)-kendomycin (10).  
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3.2.3. Lee´s Total Synthesis of (−)-Kendomycin by Glycosidation 
 
Scheme 24: Retrosynthetic analysis of (−)-kendomycin (10) by Lee et al.
[41]
  
In 2004, a few years after Mulzer et al. published the first fragment synthesis,[47a, 47c] Lee and 
coworkers were first to report a total synthesis of (−)-kendomycin (10). A glycosidation at 
the C4a-C5 bond was selected for ring closure, thus avoiding the trouble that could 
potentially arise from conformational restrictions about this bond. Further retrosynthetic 
analysis led to an alkyl-Suzuki cross-coupling of 64 and 65, two fragments of similar size that 
allowed for a convergent buildup of the macrocycle.  
 
Scheme 25: Lee´s synthesis of the northwestern and southeastern fragment of (−)-kendomycin (10). 
Conditions: a) LDA, LiCl; b) LiAlH(OEt)3; then TFA, HCl (1 N); c) CBr4, PPh3, Zn; d) n-BuLi, MeI; e) TBAF; f) DMP; g) 
Sn(OTf)2, 48, Et3N; h) NaBH(OAc)3, AcOH; i) DBU; j) cat. Pd(OAc)2, PCy3, n-Bu3SnH; then I2; k) TBSCl, imidazole; l) 
DIBAl-H; m) PPh3∙HBr; n) 71, DCC, DMAP, Et3N, ; o) Pd/C, H2; p) I2, PPh3, imidazole.  
The synthesis of the western unit 64 started with a Myers´ alkylation of amide 66 with iodide 
67. After cleavage of the chiral auxiliary, the resulting aldehyde was elaborated into the 
corresponding alkyne. Removal of the silyl-ether followed by Dess-Martin oxidation resulted 
in aldehyde 68 that was subjected to a syn-aldol reaction with -ketoimide 48. A 
diastereoselective hydride reduction to the 1,3-anti-diol and treatment with base 
constructed the -lactone moiety. The alkyne was first transformed into an alkenyl stannane 
that was reacted with molecular iodine to give the alkenyl iodide 64. The synthetic path for 
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the eastern fragment commenced with known 1,4-hydroquinone 69 that readily underwent 
selective monosilylation of the less-hindered phenol group. After reduction of the aldehyde, 
the resulting benzylic alcohol was subsequently converted to phosphonium bromide 69. The 
remaining phenol was then esterified with carboxylic acid 71, and the resulting ester 
underwent an intramolecular Wittig reaction at elevated temperature to give the 
benzofuran. Consecutive hydrogenolytic cleavage of the benzyl ether and an Appel-type 
reaction completed the synthesis of fragment 65.  
 
Scheme 26: Macroglycosidation approach by Lee and coworkers. Conditions: a) 65, t-BuLi, 9-(MeO)-9-BBN, THF; 
cat. PdCl2(dppf), K3PO4 (3 M), 64; b) DIBAl-H,; then Ac2O, pyridine; c) TBAF; d) SnCl4, 4 Å MS; e) MeONa/MeOH; 
f) TESOTf, Et3N; g) IBX; h) aq. HF, MeCN.  
The synthesis of the macrocyclization precursor involved a sp2-sp3 cross-coupling variant of 
the Suzuki-Miyaura reaction using borate-complex 72 that was generated in situ from alkyl 
iodide 65 by lithium/halogen exchange and introduction of 9-(MeO)-9-BBN. Under Pd-
catalyzed conditions, coupling with alkenyl iodide 64 proceeded successfully. The -lactone 
was then elaborated into a glycosyl donor, paving the way for macrocyclization. However, 
direct C-glycosidation under Friedel-Crafts conditions failed. Instead, the TBS-ether at C4 was 
cleaved allowing for initial formation of an O-glycoside 74 that subsequently rearranged to 
the C-glycoside 75 in respectable yield. Finally, exposure to IBX triggered demethylation at 
C3 and oxidation to the ortho-quinone that subsequently underwent 1,6-addition of H2O 
across the benzofuran domain in the presence of aqueous hydrofluoric acid (scheme 26).  
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The natural product 10 was therefore constructed by a relatively short total synthesis in 20 
linear steps. This very elegant approach is accentuated by an efficient C-macroglycosidation 
as well as an Suzuki-Miyaura reaction at the C14-C15 bond, imparting the adjacent (E)-olefin 
in high stereochemical integrity.  
3.2.4. Contributions by the Arimoto Group 
 
Scheme 27: Early proposal for the tetrahydropyran synthesis by Arimoto and Uemura.
[48]
  
The initial synthetic forays by Arimoto and coworkers were published shortly after Lee 
reported the first total synthesis in 2004. As later results (2007) of Arimoto focus on a 
macrocyclization approach via RCM at the C13-C14 double bond[54] and as this strategy was 
discussed at length in chapter 3.2.2., merely the construction of the tetrahydopyran moiety 
will be outlined here.  
 
Scheme 28: Arimoto´s synthesis of the tetrahydropyran and construction of the hexasubstituted arene 81. 
Conditions: a) Ag2O; b) (CF3COO)IPh, K2CO3; c) Na2S2O3; d) allyl bromide, K2CO3, ; e) N,N-dimethylaniline, ; f) 
MeI, K2CO3, ; g) OsO4, NMO, ; h) NaIO4.
[48, 54] 
Compound 78 was a key intermediate in Arimoto´s early efforts to construct the aryl-
glycoside domain. The introduction of the stereogenic center at C5 was effected by an astute 
maneuver. The arene was devised to be oxidized to an ortho-quinone methide that would be 
predisposed for an intramolecular 1,4-addition of the free alcohol at C9. In fact, this plan 
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came to fruition when Ag2O was employed as oxidant to give tetrahydropyran 80 in 94% 
yield. Another interesting aspect of Arimoto´s strategy is the introduction of the sixth 
substituent of the arene by Claisen rearrangement. First, the methyl ether at C1 had to be 
removed. Notably methyl ethers had been used extensively[41-43, 46-47, 49-51] as phenol 
protecting groups due to their stability, even though this protecting group can cause severe 
trouble if cleavage has to be carried out on advanced intermediates that bear acid-labile 
groups. One solution to this challenge was a oxidation/reduction sequence that proceeded 
via a para-quinone. Then, allylation followed by Claisen rearrangement established the 
hexasubstituted aromatic ring. The terminal olefin was sequentially exposed to OsO4/NaIO4 
producing aldehyde 81. Although the described synthetic path did not result in a total 
synthesis, Arimoto et al. reported creative solutions to at least two of the major obstacles, 
that is the formation of the fully substituted THP unit and the installation of the sixth 
substituent on the arene.  
3.2.5. Smith´s Total Synthesis of (−)-Kendomycin by RCM 
 
Scheme 29: RCM-based retrosynthesis by Smith and coworkers.
[42]
  
Despite the discouraging literature precedents,[47d, 54] Smith et al. set out to attempt a RCM 
at the C13-C14 bond. Initially, the C4 hydroxyl group was protected as a bulky tert-
butyldimethylsilyl (TBS) ether which locked the desired synclinal rotamer. Thus, the two 
terminal olefins would be brought in closer proximity as needed for an effective RCM. 
Additionally, a sequential Petasis-Tebbe olefination/Petasis-Ferrier rearrangement was 
implemented in building up the cis-2,6-tetrahydrofuran domain.[42]  
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Scheme 30: Synthesis of the northwestern fragment 82 and arene 83 by Smith and coworkers. Conditions: a) 
O3; Me2S; b) 85, Et2BOTf, i-Pr2Net; c) LiOH, H2O2; d) m-CPBA, p-TsOH; e) K2CO3; f) HMTA, AcOH; g) Br2, K2CO3; h) 
TBSCl, i-Pr2NEt.
[42]
  
The forward synthesis of the northwestern fragment started from (+)--citronellene 86 
(scheme 30). Ozonolysis of the more electron-rich double bond followed by reductive work-
up yielded the corresponding aldehyde that was elaborated into the -hydroxy acid 82 by a 
boron-mediated syn-aldol reaction[56] with 85 and cleavage of the oxazolidinone. On the 
other hand, the fully functionalized arene 83 was constructed in five steps from commercial 
aldehyde 87. Baeyer-Villiger oxidation, hydrolysis of the phenol and ortho-formylation under 
Duff conditions[60] established intermediate 88 that was readily brominated. Finally, 
silylation of the hydroxyl group furnished 83.  
 
Scheme 31: Synthesis of the eastern fragment 84 by Smith et al. Conditions: a) NaI; b) 85, LDA; c) LiBH4; d) PPh3, 
I2, imidazole; e) 66, LDA, LiCl; f) LDA, BH3∙NH3; g) SO3∙pyridine, DMSO; h) CH2Br2, n-BuLi.
[42]
  
For the extension of aryl bromide 83, epoxide 84 was designed as adequate coupling 
partner. However as inconspicuous this segment might look, it turned out to be a tedious 
task to install the two stereogenic centers selectively. Notably, this problem was 
encountered by all parties who followed this synthetic plan. The route began with a 
Finkelstein reaction of chloride 89. The iodide then underwent an asymmetric alkylation to a 
chiral imide enolate derived from 85. Reductive cleavage then liberated alcohol 90, which 
was transformed into the corresponding iodide under Appel-type conditions. A second 
alkylation utilizing Myer´s amide 66 furnished the second stereogenic center in an anti-
relationship. Finally, epoxide 84 was provided by a BH3∙NH3 reduction/Parikh-Doering 
oxidation sequence followed by a Matteson epoxidation.[61]  
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Scheme 32: Fragment assembly and endgame by Smith. Conditions: a) i-PrOTMS, TMSOTf; b) Cp2TiMe2; c) 
Me2AlCl; d) LiHMDS, MeI; e) NaBH4; f) TBSOTf, 2,6-lutidine; g) t-BuLi, 84; then BF3OEt2; h) Grubb´s II catalyst 
C7
[59, 62]
; i) TESOTf, DMAP, 2,6-lutidine; j) OsO4, pyridine; k) MsCl, pyridine; l) BnNMe3OH, MeOH; m) WCl6, n-
BuLi; n) PPTS; o) DMP, pyridine; p) aq. HF, MeCN.
[42]
  
The joining of the prepared fragments began with condensation of aldehyde 83 and -
hydroxy acid 82 by converting the latter into the bis-TMS protected derivative. Exposure to 
the aldehyde in presence of TMSOTf then provided dioxanone 92. Smith et al. applied a 
Petasis-Tebbe methylenation[63] as method to install the tetrahydropyran unit. The formed 
enol acetal was then rearranged to the tetrahydropyranone 93 under Petasis-Ferrier 
conditions.[64] Formation of the kinetic enolate with LiHMDS resulted in a diastereoselective 
-methylation in the equatorial position, thus completing the substitution pattern around 
the THP-moiety. The ketone in 93 was diastereoselectively reduced and the resulting alcohol 
was TBS-protected. Introduction of the eastern alkyl chain was attained by lithium/halogen 
exchange of bromide 93 followed by a BF3∙OEt2-mediated epoxide opening of 84. The 
alcohol 95 was obtained in a 2:1 diastereomeric ratio. With diene 95 in hand the stage was 
set for the key RCM step that would establish the macrocycle. Surprisingly, application of 
Grubbs´ II generation catalyst C7[59, 62] led to full conversion of the major diastereomer (19S)-
97 to the macrocycle. However, the undesired (Z)-isomer was formed exclusively. 
Conversion to the (E)-olefin was only accomplished by a lengthy four-step sequence. The 
free alcohol at C19 was protected and the undesired (Z)-configured double bond cis-
dihydroxylated to give a single isomer of the diol that was selectively mesylated at the less 
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hindered C13 position. Treatment with benzyltrimethylammonium hydroxide gave the trans-
epoxide and liberated the C4 phenol from the TBS-group. Finally a Sharpless 
deoxygenation[65] procedure utilizing WCl6 and n-butyllithium yielded the required (E)-olefin 
98. Other attempts exploiting radical conditions for the equilibration of the double bond 
configuration or the Vedejs´ isomerization[66] by selectively opening a cis-epoxide failed and 
resulted in either migration of the double bond or decomposition of the material. The 
remaining oxidation/1,6-addition endgame essentially resembled that of Lee and 
coworkers[41] and concluded the second total synthesis of (−)-kendomycin (10) in 21 steps in 
the longest linear sequence.  
3.2.6. Contributions by the White Group  
 
Scheme 33: White et al.´s retrosynthetic sketch comprising a Dötz benzannulation and an iodoetherification to 
construct the THP-unit.
[50]
  
The White group was first to report a synthetic entry to the aryl-glycoside domain of (−)-
kendomycin (10) by developing a de novo synthesis of the aromatic core via a Dötz reaction. 
Furthermore, an iodoetherification was proposed to construct the tetrahydropyran unit 
(scheme 33). In the following, only the key transformations will be emphasized.  
In a forward sense, the Fischer alkenylchromium carbene 100 was reacted with the terminal 
alkyne of 101. The product of CO insertion was obtained as a single regioisomer. 
Methylation of the free phenol and electrophilic bromination at the C4a position followed by 
formylation furnished the fully substituted aromatic fragment 102. The aldehyde was used 
as a handle for the elongation of the western segment. A boron-mediated Masamune aldol 
reaction with propionate 103 gave the corresponding -hydroxyester. Silylation of the 
benzylic alcohol at C5, cleavage of the auxiliary under reductive conditions and Ley oxidation 
yielded an aldehyde that was then used as a substrate for a (−)-(Ipc)2BOMe-promoted Brown 
crotylation.[67] The subsequent protecting group replacement gave compound 99. Treatment 
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with iodine in the presence of NaHCO3 results in the formation of an iodonium intermediate 
that was opened by the C5-alcohol in a 6-exo-trig cyclization providing tetrahydropyran 98 in 
good yield. 
 
Scheme 34: Intermolecular Dötz benzannulation and iodoetherification by White et al. Conditions: a) ; b) MeI, 
K2CO3; c) NBS; d) t-BuLi, DMF; e) 103, Cy2BOTf, Et3N; f) TESOTf, i-Pr2NEt; g) DIBAl-H; h) TPAP, NMO; i) trans-2-
butene, n-BuLi, t-BuOK, (−)-(Ipc)2BOMe, BF3∙Et2O; then NaOH, H2O2; j) SEMCl, TBAI, 2,6-lutidine, DMAP; k) TBAF; 
l) I2, NaHCO3.  
Further studies of the White group demonstrated that the cyclization could also be triggered 
by alkoxymercuration.[55a] However, all attempts to either elaborate the obtained iodide or 
to oxidatively cleave the corresponding mercury species failed. Altogether, White et al. 
reported a fascinating entry to the aromatic core of (−)-kendomycin (10) by Dötz 
benzannulation. The pursued iodoetherification tactic was successful, yet, the further 
elaboration of the obtained iodide failed.  
3.2.7. Contributions to the Synthesis of the ansa-Chain by Williams and Coworkers 
 
Scheme 35: Williams´ approach to the ansa chain of (−)-kendomycin (10).
[51]
 
Interestingly, Williams and coworkers chose a linear entry to establish the polyketide chain 
of (−)-kendomycin (10) starting with the C15-C19 fragment. This approach differs clearly in 
30 Formal Total Synthesis of (−)-Kendomycin 
 
this aspect from the work of all competitors. An intramolecular variant of the Julia 
olefination was projected to close the macrocycle. Furthermore, the polyketide chain 104 
should be linked to the aromatic core by consecutive metalation/addition of aryl bromide 
105. This strategy was designed to avoid atropisomeric mixtures by late-stage introduction 
of the chromophore.  
 
Scheme 36: Williams´ synthesis of the ansa skeleton. Conditions: a) Mg, 108, CuBr∙SMe2, BF3∙Et2O; then 
oxazolidinone 111; b) LiBH4; c) (COCl)2, Et3N, DMSO; d) 112, K2CO3; e) cat. Cp2ZrCl2, AlMe3; f) 113; then (ent)-
111; g) LiBH4; h) TsCl, pyridine; i) NaCN, DMSO; j) DIBAl-H; k) 107, (−)-(Ipc)2BOTf, Et3N; l) Me4NBH(OAc)3; m) 2,2-
dimethoxypropane, PPTS. 
The forward route began with a diastereoselective 1,4-addition of the Yamamoto-type 
organocopper species derived from bromide 108 onto enoyl oxazolidinone 111. After 
cleavage of the auxiliary and Swern oxidation, the obtained aldehyde was elongated to the 
terminal alkyne 109 under Ohira-Bestmann conditions. The trisubstituted double bond was 
then constituted by Negishi´s carboalumination followed by transmetalation of aluminum to 
copper with 113 and subsequent conjugate addition to (ent)-111. Cleavage of the auxiliary 
and C1-homologation using a standard protocol provided the corresponding aldehyde. 
Ketone 107 was treated with Et3N and (−)-(Ipc)2BOTf to form the (Z)-enolate selectively 
before the previously described aldehyde was introduced. The Paterson aldol reaction[68] 
established the -hydroxyketone in good diastereoselectivity (dr 9:1), which was selectively 
reduced to the 1,3-anti-diol using triacetoxy borohydride. This synthetic route offers a 
concise access to the fully functionalized ansa chain 110.  
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3.2.8. Panek´s Total Synthesis of (−)-Kendomycin by an Intramolecular Barbier Reaction 
 
Scheme 37: Panek´s retrosynthetic projection based on an intramolecular Barbier reaction.
[43]
  
Panek and coworkers relied on a SmI2-mediated Barbier reaction as key transformation to 
construct the macrocycle. Moreover, the junction of the aryl and tetrahydropyranyl units 
was achieved by a Lewis acid-promoted formal [4+2]-cycloaddition of crotylsilane 116 and 
aldehyde 117. Notably, the quarternary crotylsilane 116 could be prepared by epoxide 
opening of the corresponding epoxysilane with an organocuprate.[49]  
 
Scheme 38: Panek´s SmI2-promoted Barbier macrocyclization approach. Conditions: a) TMSOTf; b) m-CPBA; c) 
K2CO3, MeOH; d) H2, PtO2, MeOH; e) TBSOTf, 2,6-lutidine; f) Br2, propylene oxide; g) Pd(PPh3)4, (n-Bu)3Sn(vinyl); 
h) O3; then NaBH4; i) MOMCl, 2,6-lutidine; j) DIBAl-H; k) n-BuLi, 123; l) Raney-Ni, H2, EtOH; m) (COCl)2, Et3N, 
DMSO; n) CBr4, Zn, PPh3; o) n-BuLi; then MeI; p) (n-Bu)3SnH, PCy3, Pd(OAc)2; q) NIS; r) t-BuLi, 115, ZnCl2, 
Pd(PPh3)4; s) MgBr2, EtSH; t) PPh3, Br2; u) CSA; v) (COCl)2, Et3N, DMSO; w) SmI2; x) TBAF; y) DMP; z) aq. HF, 
MeCN.
[49] 
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After the efficient preparation of dihydropyran 118 by the above mentioned formal [4+2]-
cycloaddition, a substrate-controlled epoxidation with m-CPBA gave the -epoxide. Epoxide 
opening under basic conditions led to double bond migration to the C8-C9 position (scheme 
38). Hydrogenation and silyl-protection delivered the tetrahydropyran which was ready for 
further chain elongation. However, functionalization of the aromatic domain was carried out 
first since the necessary conditions would have jeopardized the trisubstituted double bond 
at C13-C14 in later intermediates. Thus, the C20a position was brominated and subsequently 
converted to a styrene derivative 119 by Stille cross-coupling using tri-n-butylvinyltin. 
Ozonolysis with a reductive work-up gave the benzyl acohol that was finally masked as 
MOM-ether. Turning towards the western alkyl skeleton, Panek et al. placed reliable 
chemistry in their service. The methyl ester 119 was thus transformed into aldehyde 111, 
which represented the precursor for the key transformation. Panek´s approach towards the 
macrocyclization event resorted to a SmI2-promoted intramolecular Barbier reaction which 
gave the carbocycle 122 in moderate yield. After global deprotection, the endgame closely 
resembled the previously reported protocols. A total of 32 linear steps makes Panek´s 
synthetic strategy for (−)-kendomycin one of the longest.  
3.2.9. Two Formal Total Syntheses of (−)-Kendomycin by Rychnovsky and Coworkers 
 
Scheme 39: Theoretical disconnections by Rychnovsky et al.
[46]
  
The Rychnovsky group developed two formal syntheses of (−)-kendomycin (10). In the first 
instance, RCM in concert with an epoxide opening was proposed to introduce the eastern 
fragment. However, this design overlapped with results that Smith and coworkers[42] 
published prior to completion of Rychnovsky´s work. Thus, Rychnovsky´s first synthetic route 
ended in a formal synthesis at intermediates 84 and 94 previously used by Smith[42] (scheme 
39). In any case, it was demonstrated that a Prins cyclization could furnish the sterically 
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congested tetrahydropyran ring by a Lewis acid-mediated addition of the aldehyde 128 to 
the corresponding alkene 129.  
In their second synthetic approach, Rychnovsky et al. avoided the RCM en route to 10. The 
well-proven Prins reaction was instead chosen as the method of choice for macrocylization.  
 
Scheme 40: Synthesis of Smith´s intermediate 94 by Rychnovsky´s Prins cyclization strategy (Route A). 
Conditions: a) n-hexane; then NaOH, H2O2; b) BF3∙Et2O; c) DIBAl-H; d) Br2; e) TBSOTf, 2,6-lutidine; f) H2, Pd/C; g) 
2-NO2-C6H4-SeCN, PBu3; then H2O2.
[46]
  
Route A  Aldehyde 125 was advanced by allylation using Hoffmann´s borane 126, to give 
homoallylic alcohol 127. Treatment with aldehyde 128 in the presence of BF3∙Et2O furnished 
the desired tetrahydropyran via an oxonium intermediate. After reductive cleavage of the 
phenolic acetate, the sixth position of the arene was brominated. Furthermore, both free 
hydroxyl groups (at C4 and C7) were protected as tert-butyldimethylsilyl ethers before the 
alkyl-benzyl ether at C14 was cleaved hydrolytically. The liberated primary alcohol was 
transformed into a leaving group and eliminated to give the desired terminal alkene. In 
summary, Rychnovsky´s first approach gave a straightforward access to the critical THP-aryl 
moiety. A highly diastereoselective formation of two stereogenic centers in the course of the 
Prins reaction permitted the rapid fragment assembly.  
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Scheme 41: Formal total synthesis by Rychnovsky employing an intramolecular Prins cyclization (Route B). 
Conditions: a) t-BuLi, 9-(MeO)-9-BBN, THF, aq. K3PO4, PdCl2(dppf); b) TBAF; c) HMTA, H2O; d) PhSO2Cl, i-PrNEt2; 
e) AcOH, BF3∙Et2O; f) KOH, EtOH.
[46]
  
Route B  In their second and more sophisticated synthetic venture, Rychnovsky et al. relied 
on an alkyl-Suzuki cross-coupling for linking the western and eastern piece of (−)-
kendomycin (10). This strategy had been proven to be effective by Lee and coworkers[41] on 
similar substrates. Next, the silyl ether was cleaved and the free hydroxy-function at C4 
exerted an ortho-directing effect in the following aromatic formylation with hexamine[60] 
providing the Prins cyclization precursor 130. However, the Prins cyclization did not proceed. 
This outcome was somehow anticipated as earlier results showed that an electron-
withdrawing group on the phenol was mandatory to activate the aldehyde for electrophilic 
attack.[46b] After benzenesulfonylation, the BF3∙E2O-promoted Prins cyclization proceeded 
with remarkable efficiency in 81% yield, albeit 59% of the obtained material was the C7-
fluorinated macrocycle. Finally, hydrolysis of the sulfonyl and the acetate group gave the 
desired kendomycin skeleton in nearly quantitative yield together with the fluorinated 
congener. Compound 75 converged with the total synthesis of Lee et al.[41]  
3.2.10. Saikawa´s and Nakata´s Total Synthesis of (−)-Kendomycin by Dötz 
Benzannulation 
 
Scheme 42: Retrosynthetic map of (−)-kendomycin (10) including a Dötz benzannulation.
[45]
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Saikawa and Nakata published the sixth total synthesis of (−)-kendomycin (10) in 2010. Their 
efforts center around a ring-closing intramolecular Dötz benzannulation followed by a 
Claisen rearrangement as entry to the aryl-glycoside unit. The precursor bearing the 
required synthetic handles for the Dötz reaction was assembled by the previously used alkyl-
Suzuki cross-coupling at C14-C15.  
 
Scheme 43: Syntheses of the western and eastern fragment (133 and 135). Conditions: a) TESOTf, i-Pr2NEt; b) 
O3/O2; c) 139, n-BuLi, HMPA/THF; d) CSA, CH(OMe)3; e) N2H4∙H2O, aq. H2O2; f) DMP; g) CBr4, PPh3; h) n-BuLi; 
then MeI; i) Cp2ZrHCl; then I2; j) TBAF, AcOH,; k) DMP; l) 140; m) OsO4, NMO, H2O/t-BuOH/THF; n) PivCl, Et3N; 
o) PCC, NaOAc; p) Ph3PCH3Br, LiHMDS; q) TBAF; r) PPh3, I2, imidazole; s) DIBAl-H; t) TBSCl, imidazole.
[45]
  
The synthesis of the northwestern segment commenced with silylation of the known 
homoallylic alcohol 136.[69] Ozonolysis of the terminal olefin and nucleophilic addition of the 
lithiated acetylene 139 into the resulting aldehyde yielded alkyne 137. Reduction of the 
triple bond to the aliphatic chain using diimide preceeded elaboration of the northern 
terminus to the methyl-capped alkyne. The 1,3-diol was protected as an acetonide before 
hydrozirconation/iodination completed the fragment for the envisaged cross-coupling 
chemistry. After desilylation and Dess-Martin oxidation, treatment with lithium 
trimethylsilylacetylide resulted in the northwestern fragment 133. For the eastern unit, 
Saikawa et al. resorted to compound 141. Dihydroxylation, chemoselective pivaloylation of 
the formed primary alcohol and sequential oxidation of the secondary alcohol using Corey´s 
pyridinium chlorochromate,[70] followed by a Wittig olefination yielded intermediate 142 
with an exo methylene group. Desilylation, iodination and a protecting group 
interconversion provided alkyl iodide 135.  
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Scheme 44: Saikawa´s and Nakata´s Dötz benzannulation approach. Conditions: a) 135, t-BuLi, −78 °C, 9-(MeO)-
9-BBN, THF; then aq. K3PO4, PdCl2(dppf), 133; b) DMP; c) CSA; d) Et3SiH, BF3∙Et2O; e) TESOTf, 2,6-lutidine; f) 
TBAF; g) 134, AcBr; h) 50 °C, toluene; i) TBSOTf, 2,6-lutidine; j) Ac2O, DMAP, N,N-dimethylaniline, ; k) DIBAl-H; 
l) MOMCl, i-Pr2NEt, TBAI; m) OsO4, NMO, t-BuOH/THF/H2O; n) O3/O2; o) CS(imid)2, ; p) P(OEt)3; q) TBAF; r) IBX; 
s) SiO2; t) aq. HF, MeCN.
[45]
 
As expected, the two major fragments 133 and 135 could be successfully linked by an alkyl-
Suzuki reaction. Oxidation of the propargylic alcohol and transacetalization under acidic 
conditions constructed the -lactol ring which was reduced to the desired THP-ring. In the 
presence of acetic acid, the complex 134 forms the necessary acetoxychromium carbene 
species. Attack of alcohol 144 led to Dötz benzannulation through insertion of the terminal 
alkyne into the Fischer carbene complex followed by cyclization under CO-insertion between 
C3 and C4a, thus forming the resulting oxametacyclophane 132. The product was rearranged 
in a [3,3´]-sigmatropic fashion at elevated temperature. After construction of the ansa 
skeleton the superfluous exo methylene moiety in 145 was removed to liberate ketone 146. 
The still missing oxygen functionality on the arene was introduced after deprotection of the 
phenol at C4 by ortho-selective IBX oxidation giving rise to the ortho-quinone. Quinone 
methide formation occured smoothly during preparative thin layer chromatography (TLC) on 
silica. Desilylation gave the natural product. In summary, Saikawa and Nakata reported a 
highly convergent entry to the ansamycin 10. Concurrent macrocylization/benzannulation 
furnished the pentasubstituted arene and the critical aryl-glycoside pattern in a very elegant 
way. As a drawback of this strategy, the superfluous methylene unit in 145 had to be 
removed in a five-step detour that involved the protection of the alcohol at C4 and masking 
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of the internal olefin, ozonolysis of the exo double bond followed by regeneration of the 
C13-C14 double bond and deprotection of the hydroxyl group. In this way, the advanced 
material was depleted significantly.  
3.2.11. Conclusion 
Over the last one and a half decades, a variety of synthetic endeavors towards the intriguing 
cyclophanic polyketide (−)-kendomycin (10) have emerged. Mulzer et al. delivered the first 
and most comprehensive studies. Specifically, their early investigations concerning the 
densely substituted THP ring and the atropisomerism about the C4a-C5 bond observed for 
sterically congested substrates were seminal. The Lee group was first to report a total 
synthesis of kendomycin in 2004. Their glycosidation approach was highly efficient and 
elegant, raising the bar early on. Interestingly, RCM was invoked extensively as method of 
choice for macrocyclization (Mulzer, Smith, White and Arimoto), in which the trisubstituted 
double bond, as well as several other bonds were selected for the disconnection. Although 
olefin metathesis in general allowed access to the macrocyclic intermediates, the process 
was significantly compromised by the stereochemical outcome, as exclusively the undesired 
(Z)-olefin was formed at C13-C14. These results demonstrate that Grubbs catalysts[59] are 
reaching limitations when applied to sterically encumbered and strained macrolides and 
inherently (E)-selective olefin metathesis catalysts are so far unknown.[71]  
In conclusion (−)-kendomycin holds an exceptional macrolide structure which entails a 
number of synthetic challenges and triggered a broad spectrum of synthetic approaches that 
nourished the development and improvement of synthetic methodologies.  
3.3. Retrosynthetic Analysis of Kendomycin: The Key Steps 
It was in light of the previous synthetic work towards (−)-kendomycin (10) described in 3.2., 
that we envisaged a new approach emloying RCAM for the crucial macrocyclization event. As 
recent advances in catalyst design had led to a generation of highly active, functional group 
tolerant and more stable catalysts, (chapter 1.2.) we foresaw that  
(1) RCAM was an excellent tool to close the macrocycle, avoiding any complications 
deriving from isomer mixtures.  
(2) The cycloalkyne would be a valuable substrate for post-metathetic transformations.  
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In our retrosynthetic analysis, we chose to place the RCAM disconnection at the C19-C20 
bond, expecting that this strategy would give us a handle for the construction of the 
benzofuran-derived chromophore (scheme 45). It is known that ortho-hydroxyphenyl 
acetylenes undergo 5-endo-dig cyclizations under basic[46a] or Lewis acidic[17, 21j-l] conditions.  
 
Scheme 45: Our retrosynthetic considerations were based on RCAM and hydroalkoxylation.  
Flexible and sterically unshielded dialkynes of various chain lengths have been efficiently 
metathesized in the past using the highly-active molybdenum alkylidyne catalysts (C2-C5, 
chapter 1.2.).[7] In the kendomycin case, our proposed target structure for the RCAM product 
features an 18-membered cycloalkyne 147. The ring size itself was not expected to be a 
hurdle. However, limitations were anticipated due to the ortho-disubstituted aryl acetylene 
on the one hand and the -branched alkyne on the other hand that could obstruct substrate 
binding to the catalyst with its three bulky triphenylsilanolate ligands. Furthermore, the 
conformational isomerism about the C4a-C5 glycosidic bond might impede the projected 
ring closure. Thus, (−)-kendomycin (10) represents a sterically demanding target molecule 
that would put our RCAM catalysts to the test.  
3.4. Model Studies for the RCAM 
 
Scheme 46: Structure and retrosynthetic analysis of an RCAM model (149).  
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In order to assess the chances of the intended RCAM, preliminary studies were conducted 
on a model substrate. To this end, diyne 150 was selected as metathesis precursor. The 
compound was chosen to mimic the correct ring size of the macrocycle and the steric 
hindrance next to the reacting alkyne. Moreover, a total of three alkoxy-substituents would 
presumably render this alkyne electron-rich, similar to the fully functionalized diyne 148. 
Model compound 150 was to be prepared from three simple fragments by Suzuki cross-
coupling of alkenyl bromide 151 and iodide 153, followed by bromine/lithium exchange and 
nucleophilic addition to aldehyde 152.  
 
Scheme 47: Forward synthesis of the aliphatic chain for a model substrate. Conditions: a) TBSCl, imidazole, THF, 
rt, 88%; b) Cp2ZrHCl, THF, rt; then NBS, 0 °C to rt, 90% (151:155, 2.5:1); c) 153, t-BuLi, 9-(MeO)-9-BBN, THF, 
−78 °C to rt; then PdCl2(dppf)∙CH2Cl2, K3PO4, 151:155 (2.5:1), 50 °C, 80% (157a:157b, 8:1); d) TBAF, THF, rt, 83%; 
e) PPh3, imidazole, I2, MeCN/Et2O, 0 °C to rt, 99%.  
The preparation of the aliphatic chain was achieved in an efficient five step sequence. It 
starts with silylation of the known alcohol 154.[72] Hydrozirconation of the alkyne under 
conditions developed by Schwartz et al.[73] gave the alkenyl zirconium species that was 
trapped with N-bromosuccinimide (NBS). The resulting alkenyl bromide was obtained as a 
2.5:1 mixture of regioisomers. For the consequent cross-coupling, the known iodide 153[72] 
was converted to the ate-complex 156 via successive halogen/lithium exchange and 
transmetalation to boron, which readily underwent the alkyl-Suzuki coupling in presence of 
10 mol% of PdCl2(dppf). To our satisfaction, the major regioisomer reacted preferentially and 
the ratio was improved to 8:1 in the product mixture. The efficiency of this 9-(MeO)-9-BBN-
variant of the Suzuki cross-coupling had previously been used for numerous advanced and 
highly functionalized substrates.[41, 45-46, 74] Due to its robustness, this method was later also 
chosen for the fully elaborated polyketide fragment. Desilylation with TBAF and iodination in 
an Appel-type reaction with molecular iodine occurred smoothly, providing the model 
fragment 158 in excellent yield. The aromatic segment was prepared in a two-step protocol 
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from the commercially available aldehyde 159 (scheme 48). Electrophilic bromination with 
NBS followed by another variant of the Suzuki-Miyaura cross-coupling with sodium propyne 
and B(OMe)3 gave the desired arene 152.
[74]  
 
Scheme 48: Fragment assembly of diyne 150 and ring closure. Conditions: a) NBS, MeCN, 50 °C, 95%; b) sodium 
propyne, B(OMe)3, THF; then 160, PdCl2(dppf) (10 mol%), , 59%; c) 158, t-BuLi, Et2O, −78 °C; then 152, −78 °C 
to rt, 88%; d) DMP, CH2Cl2, 0 °C, 71%; e) for conditions see table 2.  
Alkyl iodide 158 was then subjected to halogen/lithium exchange. Treatment of the resulting 
intermediate with aldehyde 152 gave the benzylic alcohol in 88% yield. After Dess-Martin 
oxidation, the substrate 150 was ready for the upcoming RCAM. A small screening was 
conducted that allowed three of the alkyne metathesis catalysts toward ring-closure of 150 
to be compared (table 2). To our delight, the diyne participated well in the RCAM when 
treated with catalytic amounts of C5 in the presence of 5 Å molecular sieves. The macrocycle 
was formed at room temperature in 83% yield together with small amounts of an open 
dimer (table 2, entry 1). After decreasing the concentration to 0.001 M the monomeric 
cycloalkyne was obtained exclusively in 90% yield (table 2, entry 2). In comparison, catalyst 
C8, adorned with three trianisol silanolate ligands, generated the product in only moderate 
yield. However, the chromatographic separation of the polar silanol ligands from the desired 
product was easier in this case. The neutral alkylidyne complex C4 gave excellent results 
similar to C5 (table 2 entry 4). Thus, the ortho-disubstitution at the southern aryl alkyne did 
not constrain the coordination of the molybdenum species. In fact, all test reactions were 
exceedingly productive. Nevertheless, a potential influence of the tetrahydropyran ring on 
the steric and conformational situation of the substrate could not be evaluated with this 
model 150.  
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Table 2: Catalyst screening for the RCAM on model substrate 150.  
 
 
 
 
 
entry catalyst conditions yield (%) 
1 C5 (30 mol%) toluene (0.02 M), MS 5Å, 1.5 h, rt 83 (traces of open dimer) 
2 C5 (5+5+10 mol%) toluene (0.001 M), MS 5Å, 6 h, rt 90 
3 C8 (20 mol%) toluene (0.001 M), MS 5Å, 2 h, rt 71 
4 C4 (20 mol%) toluene (0.001 M), MS 5Å, 1 h, rt 92 
 
The promising outcome reassured us of the potential for a RCAM approach for the total 
synthesis of (−)-kendomycin (10). In the following section, our synthetic strategy will be 
discussed in detail.  
3.5. Retrosynthetic Analysis of (−)-Kendomycin: Fragment Assembly & Synthesis of a 
RCAM Precursor 
Building on the information gathered in the model studies, we then evaluated the 
preparation of possible fragments. A reasonable route was identified and is illustrated 
below.  
 
 
Scheme 49: Disconnection approach by lithiation/addition and alkyl-Suzuki cross-coupling. 
The construction of the quinone methide core was planned to proceed via a 1,6-addition and 
an oxidation to the ortho-quinone of the corresponding benzofuran 161, as previously 
reported.[41, 44] The retrosynthetic analysis begins with the macrocyclization by RCAM and a 
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noble metal-promoted hydroalkoxylation[75] to form the benzofuran 161, which represents a 
known late-stage intermediate[27] en route to 10. After careful consideration of the required 
fragments, a hexasubstituted arene 163 was proposed that would be linked to the 
polyketide chain via halogen/metal exchange and nucleophilic addition to aldehyde 162. This 
strategy would afford a direct and efficient fragment assembly; however, preparation of the 
hexasubstituted arene was deemed to be difficult.  
3.6. Forward Synthesis: The Lithiation/Addition Approach 
3.6.1. Synthesis of the Northwestern Polyketide Fragment 
 
Scheme 50: Retrosynthetic plan for the northwestern fragment 164. 
In pursuing an efficient synthesis of the three major fragments, the focus was laid on 
pragmatic and reliable chemistry. The northwestern polyketide fragment was considered as 
a product of two syn-aldol reactions of two propionate entities and the known aldehyde 
68.[41] The methyl-capped alkyne 166 was to be converted to the alkenyl iodide 164 by 
sequential hydrometalation and metal/iodine exchange. For aldehyde 68, several different 
options were considered. On one hand, simple ex chiral pool compounds might be used. For 
instance -(+)-citronellene (86) or (L)-(+)-lactic acid (167) could deliver the stereogenic 
center. On the other hand, cheap achiral starting materials such as methyl acrylate (168) and 
-valerolactone (169) could be converted to the desired chiral aldehyde via an asymmetric 
hydrogenation. We probed variants based on achiral starting materials first, as these would 
permit us to synthesize the aldehyde 68 in a few scalable steps. It was proposed that -
valerolactone 169 could either be directly converted to the ,-unsaturated lactone 172 or 
to the linear ,-unsaturated ester 171 after lactone opening. An asymmetric 1,4-reduction 
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would define the stereogenic center at the -position to the carbonyl, which could then be 
elaborated to the required alkyne.  
 
Scheme 51: Attempted synthesis of aldehyde 68 starting from -valerolactone (169). Conditions: a) NaH, THF, 
diethyl oxalate, EtOH; b) K2CO3, H2CO, rt, 82% over two steps; c) DOWEX® 50W X8, MeOH, reflux, 87%; d) 
TBSCl, imidazole, THF, 0 °C to rt, 95%.  
The -methylenation of simple -lactones was described by Tanaka and Yamashita in 
1978[76] and their protocol could be successfully reproduced. The two-step procedure 
proceeds presumably via the formation of a hydroxymethylene derivative by aldol-type 
condensation with formaldehyde that yielded under a deformylation/elimination-type 
process the exo-methylenated lactone 172 (scheme 51). All attempts to open this cyclic 
system to the methyl ester 173 resulted in decomposition. Furthermore, attempted direct 
asymmetric reduction of the exo double bond failed. Therefore, the order of steps was 
reversed. Methanolysis of the -lactone in the presence of an ion exchange resin and TBS-
protection of the primary alcohol provided methyl ester 175 in excellent yield. However, all 
attempts to introduce the methylene group on the acyclic substrate with the method 
described above for the -lactone or using Eschenmoser´s salt[77] were met with failure 
(scheme 51). However, -methylenated pentanoic diesters such as 176 (scheme 52) could 
be prepared by dimerization of inexpensive methyl acrylate 168 as reported by Jenner et 
al.[78]  
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Scheme 52: Synthetic approach based on dimerization of methyl acrylate and asymmetric hydrogenation. 
Conditions: a) n-Bu3P, hydroquinone, 50 °C, 23%; b) LiOH, THF/H2O (3:1), 0 °C, 85%; c) CSA, MeOH, rt, 88%.  
The phosphine-catalyzed Rauhut-Currier reaction[79] gave dimethyl diester 176 in 23% yield 
along with polymeric byproducts. Saponification of both ester groups and esterification with 
methanol catalyzed by camphersulfonic acid selectively furnished the monoester 177. 
However, the projected asymmetric hydrogenation using Noyori´s Ru-(S)-BINAP 
dicarboxylate system[80] resulted in decomposition of the material at various temperatures 
and hydrogen pressures.  
Turning towards chiral starting materials, our next synthetic advance was inspired by the 
work of the Breit group who described a zinc-catalyzed enantiospecific sp3-sp3 cross-coupling 
of -triflyl esters and Grignard reagents.[81] This methology starts from cheap (L)-(+)-lactic 
acid and features some advantages compared to variants that rely on chiral auxiliaries or 
chiral bases which are expensive and often difficult to prepare.  
The underlying principle of this transformation is the conversion of the hydroxyl group to a 
triflate leaving group followed by coupling with a Grignard reagent under complete inversion 
of the configuration. Therefore, triflate 181 was prepared in a literature-known four-step 
sequence from (L)-(+)-lactic acid (167).[82]  
 
Scheme 53: Synthesis of (S)-2-methylpentanoate (184) as key intermediate en route to aldehyde 68. 
Conditions: a) AcCl, AcOH, 0 °C to rt, 51%; b) t-BuOH, DMAP, DCC, CH2Cl2, 0 °C to rt, 78%; c) ethane-1,2-
diamine, cyclohexane, , 64%; d) 2,6-lutidine, Tf2O, CH2Cl2, 0 °C, 85%; e) isobutene, cat. H2SO4, CH2Cl2, rt, 75%; 
f) 183, Mg, THF, ; then ZnCl2 (5 mol%), THF, 0 °C; then 181, 66%.  
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Acetylation of the hydroxyl group preceded tert-butyl ester formation under Steglich 
conditions. Chemoselective cleavage of the acetate using ethylenediamine and triflation of 
the resulting free hydroxyl-group furnished 181. For the intended coupling, chloro-alcohol 
182 was identified as an adequate C3-source for the Grignard reagent. A tert-butyl group was 
chosen as suitable protecting group because it can be installed and removed with ease and it 
is also reasonably stable under the harsh conditions of the Grignard formation.[83] In fact, 
treatment of alcohol 182 with iso-butene and catalytic amounts of sulfuric acid triggered the 
tert-butyl ether formation in respectable yield. After formation of the corresponding 
Grignard reagent, a catalytic amount of ZnCl2 and 181 were added. The reaction proceeded 
under clean conversion in moderate 66% yield (scheme 53). Even upon careful 
considerations of the experimental setup, the yield could not be improved. Presumably, 
some magnesium species, as sideproducts from the Grignard formation, led to 
decomposition of the triflate coupling partner. Notably, the reaction failed when the t-butyl-
ether was replaced by a TBS-ether; the silyl group likely underwent a retro-[1,4]-Brook 
rearrangment[84] instead of giving the respective Grignard reagent. This scalable five-step 
sequence delivered several grams of ester 184. With this material in hand, the upcoming 
introduction of the methyl-capped alkyne was considered.  
Since RCAM has evolved into a powerful tool, there is a need for new methods that would 
allow access to the required methyl-capped acetylene substrates. It was in this context that 
the Fürstner group discovered a new method for the preparation of alkynes from lactones. 
The Wittig-type reaction of lactones with phopsphorus ylides to give the corresponding 
dichloro olefin 185 was a known process.[85] It was found that treatment of this dichloro 
species with lithium reagents (BuLi, MeLi) provoked a reductive alkylation to give internal 
acetylenes.[86] Furthermore, it was observed that the addition of catalytic amounts of 
Cu(acac)2 accelerated the reaction significantly.
[86b, 87]  
 
 
Scheme 54: Proposed mechanistic pathway for the reductive alkylation of dichloro olefin 185.
[87]
  
Alkyne formation is thought to start with metal/halogen exchange upon treatment of 185 
with methyllithium to generate vinylidene 186 and methyl chloride as side product.[87] 
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Another equivalent of methyllithium reacts with 186 to an alkenyllithium 187 that yields the 
alkyne 188 by reductive elimination.  
 
Scheme 55: Introduction of the methyl-capped alkyne via dichloro olefination. Conditions: a) TFA, CH2Cl2, rt, 
66%, 90%ee; b) CCl4, PPh3, THF, , 71%; c) MeLi, Et2O, Cu(acac)2 (10 mol%), rt, 92%; d) [Cu(MeCN)4]BF4 
(5 mol%), bipyridine (5 mol%), TEMPO (5 mol%), NMI (10 mol%), MeCN, rt, 96%.  
In an attempt to apply this methodology to kendomycin, the tert-butyl protecting groups on 
ester 184 were cleaved in the presence of TFA to furnish the -lactone 174 immediately. This 
compound could be stored at 5 °C for a few days but gradually degraded, presumably by 
polymerization. Treatment of 174 with CCl4 and PPh3 effected the dichloro olefination in 
acceptable yield. The resulting dichloro olefin 189 was opened to the desired alkyne 190 by 
addition of methyllithium and a catalytic amount of Cu(acac)2. The product 190 was 
obtained in excellent yield. The remaining oxidation to the aldehyde 68 was performed in 
virtually quantitative yield using a convenient protocol developed by Stahl and coworkers.[88] 
To our delight, the stereochemical integrity of the material was preserved throughout the 
sequence starting from (L)-(+)-lactic acid (167), with only minor erosion of the enantiomeric 
excess during the Breit-coupling.[81] This entry delivered chiral aldehyde 68 in multigram 
quantities in a good overall yield. However, the nine-step procedure seemed somewhat 
lengthy for this small fragment.  
 
Scheme 56: Alternative approach towards aldehyde 68 starting from (+)--citronellene (86). Conditions: a) O3, 
CH2Cl2, −78 °C; then Me2S; b) HC(OMe)3, K10 montmorrilonite, 75% over 2 steps; c) 4-dimethylaminopyridinium 
bromide perbromide, DMAP, CH2Cl2, 87%; d) LiHMDS, THF, 90%; e) n-BuLi, MeI, THF/DMPU; then aq. HCl, 95%.  
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In 2003, Fürstner et al. reported a synthesis of latrunculin B, in which aldehyde 68 had been 
prepared from -(+)-citronellene.[89] Specifically, aldehyde 68 could be prepared in a scalable 
five-step sequence that started with an ozonolysis of the more electron-rich double bond in 
86, reductive work-up and acetalization of the resulting aldehyde. Bromination provided 
dibromide 192 which was exposed to LiHMDS to give the terminal alkyne via a double 
elimination process. Treatment with n-butyllithium and methyl iodide gave the targeted 
aldehyde 68 upon acidic work-up. An overall yield of 56% seemed difficult to improve upon 
in terms of efficiency.  
 
Scheme 57: Synthesis of the C5-C14 fragment 166. Conditions: a) n-Bu2BOTf, Et3N, CH2Cl2, −78 °C, then 
propanal, 0 °C, 92%; b) SO3∙pyridine, DMSO, Et3N, CH2Cl2, −10 °C, 83%; c) Sn(OTf)2, Et3N, 68, CH2Cl2, −78 °C, 
57%; d) Me4NBH(OAc)3, MeCN/AcOH (1.7:1), −50 °C to −10 °C, 80%; e) LiOH, H2O2, THF/H2O (3:1), rt, 99%; f) 
2,2-dimethoxypropane, CSA, rt, 90%.  
The synthesis of the northwestern fragment continued with the preparation of known -
ketoimide 48 that was prepared via boron-mediated syn-aldol reaction[56b] of (ent)-85 with 
propanal and a Parikh-Doering oxidation[90] of the resulting -hydroxyimide. In accordance to 
Mulzer´s strategy[47d], a tin-aldol reaction of -ketoimide 48 and aldehyde 68 yielded 
compound 193 in acceptable yield. Using the highly diastereoselective Evans-Saksena 
reduction the 1,3-anti-diol was obtained[57a] which, upon hydrolytic cleavage of the Evans 
auxiliary, cyclized to the -lactone 194 in quantitative yield. Lee´s total synthesis featured 
this compound as a common intermediate.[41] However in our approach, the lactone 
formation was inconsequential as it was re-opened in the next step. Treatment of 194 with 
2,2-dimethoxypropane in the presence of a catalytic amount of CSA furnished the methyl 
ester and simultaneously installed the acetonide protecting group on the 1,3-anti-diol.  
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Scheme 58: Silylcupration and Si/I-exchange. Conditions: a) LiSiMe2Ph, CuCN, THF, −78 °C to 0 °C, 93%; b) NIS, 
2,6-lutidine, HFIP, 0 °C, 97%.  
For completion of the alkenyl iodide fragment 164, a hydrometalation and subsequent 
metal/halogen-exchange was required. Initial attempts were focused on a one-pot 
procedure using Schwartz´s reagent for hydrozirconation. However, the yields varied from 
40-60% depending on the batch of Cp2ZrHCl used. Since the freshly prepared zirconium 
reagent did not give a satisfactory result, we next tried a hydrostannylation with n-Bu3SnH 
but the alkenyl stannane was obtained in only moderate yield. A close literature survey 
revealed a silylcupration as described by Fleming et al. to be a viable alternative.[91] In 
accordance to the literature, the alkenyl silane was formed in high regioselectivity and 
silicon/iodine-exchange occurred almost quantitatively. This two-step procedure for the 
formation of the alkenyl iodide turned out to be a very reliable and robust operation. In 
conclusion, we developed an efficient eleven-step synthesis of the fragment 164 that 
delivered the material on a half-gram scale.  
3.6.2. Synthesis of the Eastern Fragment (C15-C19) 
The synthesis of the polyketide fragment 165 was developed and carried out by Dr. Peter 
Persich.[92] The strategy was based on the use of the ex chiral pool (R)-Roche ester (195) as 
starting material and a diastereoselective Myers alkylation[93] which would define the second 
stereogenic center (scheme 59).  
The forward path starts with a sequential tert-butylation of (R)-Roche ester (195), reduction 
of the ester and an Appel-type iodination. Subsequent alkylation of the Myers 
pseudoephedrine derivative 66[93] delivered amide 197 with high diastereoselectivity. 
Reductive cleavage of the auxiliary yielded the alcohol 198. 
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Scheme 59: Diastereoselective alkylation-based entry to the eastern polyketide fragment 165. Conditions: a) 
isobutene, H2SO4, CH2Cl2, rt, 92%; b) LiAlH4, THF, −78 °C, 80%; c) I2, PPh3, imidazole, Et2O/MeCN, rt, 88%; d) 66, 
LDA, LiCl, THF, −78 °C; then 196, −78 °C to 0 °C, 96%; e) LDA, BH3∙NH3, THF, 0 °C, 96%; f) TPAP, NMO, MS 4 Å, 
CH2Cl2, 0 °C to rt, 72%; g) CBr4, PPh3, Zn, CH2Cl2, rt, 68%; h) n-BuLi, MeI, THF, −78 °C to rt, 99%; i) TFA, CH2Cl2, rt; 
then KOH, MeOH/H2O, rt, 88%; j) I2, PPh3, imidazole, Et2O/MeCN, rt, 88%.
[92]
  
Initial studies for the construction of the methyl-capped alkyne focused on exploiting a 
dichloro olefination/reductive alkylation sequence as successfully applied in the synthesis of 
the northwestern fragment 164. However, considerable epimerization of the stereogenic 
center in -position was observed which rendered this entry ineffective for the eastern 
fragment of kendomycin (10). Instead, the internal acetylene 199 was introduced via an 
alternative route utilizing the well-established Corey-Fuchs reaction[94] preceded by a Ley-
Griffith oxidation.[95] 199 provided alkyl iodide 165 after acidic cleavage of the tert-butyl 
group and iodination.  
Thus, the eastern fragment 165 could be prepared on a multigram scale in high 
stereochemical purity.[96] 
3.6.3. Synthesis of the Aromatic Core 
3.6.3.1. Preliminary Considerations 
Parts of this chapter describe results obtained by Dr. Peter Persich or derive from a 
collaboration with Dr. Gaëlle Valot. Where applicable, this will be noted specifically.  
The necessary aromatic fragment (scheme 60) needs to feature: 
(1) a methyl-capped acetylene substituent in the 6-position for the desired RCAM,  
(2) a bromine-atom in 5-position as requisite for the lithiation/addition that would link 
to the polyketide fragment to 163  
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(3) a base-stable and acid-labile protecting groups at the 1- and 4-position that could 
easily be removed after RCAM 
 
Scheme 60: Design of the aromatic fragment 163.  
According to observations by Lee[41] and Mulzer,[44] the methyl ether in the 3-position 
seemed to act as a stabilizing anchor for the triphenolic motif and could be removed without 
difficulty in the course of the late-stage oxidation with IBX. Notably, a methyl ether at C1 had 
been removed successfully as well.[42] Our initial protecting group strategy relied on a methyl 
group at the C3 phenol and easily cleavable MOM-ethers at the C1 and C4 phenolic 
positions. 
In preliminary studies, a pentasubstituted arene 202 could be obtained by MOM-protection 
of the commercially available 1,4-diol 200. NBS-bromination was fully selective for the C6-
position as the overall directing effect of the triphenolic system renders this position most 
electron-rich. The introduction of the alkyne was then achieved in excellent yield by applying 
a trimethylborate-variant of the Suzuki-Miyaura cross-coupling.[74]  
 
Scheme 61: Synthesis of a pentasubstituted arene. Conditions: a) NaH, DMF, 0 °C to rt; then MOMCl, DMF, 0 °C 
to rt, 95%; b) NBS, MeCN, 0 °C, 68%; c) sodium propyne, B(OMe)3, THF; then 201, PdCl2(dppf)∙CH2Cl2, 65 °C, 
99%.  
However, subsequent functionalization of the C5-position failed because attempted direct 
bromination and deprotonation addressed the alkyne and the benzylic position faster than 
the desired aromatic position. This observation led to the conclusion that the bromine atom 
had to be introduced before the alkyne was installed.  
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3.6.3.2. Composition of the 1,3,4-Triphenolic Substitution Pattern by Baeyer-Villiger 
Oxidation[97] 
 
Scheme 62: Installation of the triphenolic motif in the presence of MOM-ether protecting groups. Conditions: 
a) NIS, AcOH, cat. H2SO4, rt, 96%; b) NaH, DMF, 0 °C to rt; then MOMCl, 0 °C to rt, 51%; c) BF3∙Et2O, rt to 70 °C; 
then Ac2O, rt to 80 °C, 84%; d) NIS, AcOH, cat. H2SO4, rt, 93%; e) MOMCl, DBU, acetone, , 60%; f) Pd(dba)2 
(10 mol%), t-BuXPhos (20 mol%), KOH, 1,4-dioxane/H2O (3:1), , 71%; g) Br2, t-BuNH2, CH2Cl2, −100 °C, 16%; h) 
NaH, DMF, 0 °C to rt; then MOMCl, 0 °C to rt; i) m-CPBA, NaHCO3, CH2Cl2, rt, 95% over two steps.  
In further studies, the synthesis of different 1,3,4-trihydroxybenzene derivatives was 
explored. The pivotal question was how the bromo-substituent at C5 could be introduced 
without affecting the substituents that were already in place. Furthermore, we decided that 
a halide or a carbonyl at C6 could serve as a handle to introduce the acetylene later on. In 
this context, 2-methylresorcinol 203 was identified as the universal starting material. Friedel-
Crafts acylation gave selectively the monoacylated compound 204 that was converted to 
ester 206 in high yield by MOM-diprotection and Bayer-Villiger oxidation. However, 
attempts to introduce an iodine-atom at C6 failed as both MOM-ethers were partially 
cleaved under the acidic conditions, giving a complex mixture. In contrast, iodination worked 
surprisingly well in case of the unprotected bisphenolic substrate 204. It occured exclusively 
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at the C6-position, which can be explained by the strong overall directing effect of the 
hydroxyl-groups. MOM-protection of 208 proceeded in acceptable yield. Unfortunately, a 
Baeyer-Villiger oxidation of the ketone worked neither with the bisphenolic compound 208 
nor the MOM-protected substrate 209. As an alternative elaboration of aryl iodide 209, we 
envisaged a hydroxylation at C6, which would offer two new synthetic perspectives: 
(1) The newly installed OH-group at C6 in 210 could be converted to a triflate later on 
and thus provide an option to install the alkyne by cross-coupling. 
(2) For reasons of symmetry, the substituents at C4 and C6 could be “formally 
exchanged” by re-defining the atom-numbering. Thus, the OH-group would be 
located at C4 thus completing the required triphenolic substitution pattern. 
Accordingly, the methyl ketone would become the substituent at C6 and could 
potentially be transformed to the gem-dihaloalkene and undergo a Fritsch-
Buttenberg-Wiechell[98] rearrangement to give 211.  
In fact, an I/OH-exchange was observed when aryl iodide 209 was treated with excess 
potassium hydroxide in presence of a Pd(dba)2 and a Buchwald ligand (t-BuXPhos).
[99] The 
product 210 was obtained in good yield when 20.0 equivalents of the hydroxide were used 
(compare entry 4 and 5, table 3). Other hydroxylation methods using copper-(I)-catalysts[100] 
or via borylation[101] failed for this substrate (entry 1,2 and 3, table 3).  
Table 3: Optimization of the Pd-catalyzed hydroxylation of aryl iodide 208.  
entry conditions result 
1 
CuI, 8-quinolinol-N-oxide, CsOH∙H2O, DMSO/H2O, 
100 °C[100b] 
no conversion 
2 
CuI, 1,10-phenanthroline, KOH, DMSO/H2O, 
100 °C[100a] 
no conversion 
3 
(Bpin)2, Pd(OAc)2, SPhos, K3PO4, 1,4-dioxane, 
80 °C[102] 
s.m. traces of 
protodeiodinationa) 
4 
Pd(dba)2, t-BuXPhos, 2.0 eq. KOH, 1,4-
dioxane/H2O, 80 °C
[101] 
full conversion: 
20% 210 & 58% deiodinationa) 
5 
Pd(dba)2, t-BuXPhos, 20.0 eq. KOH, 1,4-
dioxane/H2O, 80 °C 
71%b) 210 
a) GC-MS analysis; b) Isolated yield. 
Bromination of 210 seemed promising as a free OH-group at C4 should be able to direct the 
bromination to the ortho-position.[103] Yet, the halogenation was somewhat slow, whereas 
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MOM-cleavage occurred very fast in presence of NBS or Br2. Finally, the desired product 211 
was obtained when bromine was introduced as a very dilute precooled solution to the 
substrate at −100 °C. Nevertheless, the yield remained very poor (16%), and this approach 
was therefore abandoned.  
Based on the success in the hydroxylation of aryl iodide 208, we derived a strategy in which 
the symmetric diiodo compound 211 was subjected to the previously applied conditions 
(conditions of entry 5, table 3). However, the material decomposed to a complex mixture.  
3.6.3.3. A Trihydroxybenzene-Based Synthesis of the Aromatic Fragment[92]  
As the construction of trihydroxybenzene motif in combination with halogenation at C5 and 
C6 failed, starting materials were surveyed that already contained the trihydroxyl motif. The 
tetrasubstituted arenes 215 and 219 were considered as advanced starting points.[92] After 
methylation at the 2-position and protecting group manipulations, aldehyde 216 and ketone 
218 were subjected to different bromination conditions. To our surprise, the electrophilic 
attack occurred in both cases exclusively at C6 by substitution of the carbonyl group.  
Baeyer-Villiger oxidation and hydrolysis of 216 and 218 gave the common intermediate 217 
which was then tested in the bromination using different brominating reagents. However, 
the desired transformation did not take place and only MOM-cleavage was observed.[92]  
 
Scheme 63: Attempted synthesis of the hexafunctionalized aromatic core starting from the triphenolic 
derivatives 215 and 219. Conditions: a) HC(OMe)3, NH4Cl, EtOH; b) n-BuLi, TMEDA, MeI, THF, −78 °C, 53% over 
two steps; c) BBr3, CH2Cl2, rt; d) NaH, THF, 0 °C to rt; then MOMCl, 36% over two steps; e) m-CPBA, NaHCO3, 
CH2Cl2, rt; then KOH, MeOH, rt, 74% (216) and 90% (218); f) ethylene glycol, p-TsOH∙H2O, toluene, ; g) n-BuLi, 
TMEDA, THF, −78 °C to 0 °C; then MeI, 22% over two steps; h) LiCl, H2O, DMSO, 120 °C, 89%; g) KOH, MeOH, rt, 
74%.
[92]
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3.6.3.4. Strategies Towards the Southern Aromatic Core: Lessons Learned 
It was not entirely suprising that the synthesis of 163 was anything but trivial, and we 
probed numerous pathways to construct the depicted aromatic fragment (scheme 60). From 
one dead end to another, however, our understanding of the reactivity of the precursors 
grew. Finally, we came up with a detailed analysis of the failed attempts which can be 
summarized as shown in table 4.  
Table 4: Overview of failed functionalizations of the triphenolic core. 
entry objective result 
 
 
1 
 
 
 
 
 
The iodination at the 6-position does 
not work in presence of the labile 
MOM-ethers. 
2 
 
 
For iodination at the 6-position the 
para OH-groups at C1 and C4 have to 
be protected to prevent oxidation to 
the para-quinone.  
3 
 
 
The highly electron-rich arene is very 
reactive in electrophilic aromatic 
substitution reactions. The overall 
mesomeric effect of the hydroxyl-
groups directs electrophilic attacks to 
the C6-position. Even poor leaving 
groups are substituted.[92] 
4 
 
For bromination at C5, the OH-group at 
C4 has to be free in order to induce an 
ortho-directing effect; the hydroxyl-
groups at C1 and C3 have to be 
protected.  
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3.6.3.5. Synthesis of the Aromatic Fragment via a Selective Deprotection Strategy 
With these conclusions in mind we set out for an approach that would allow us to 
differentiate the hydroxyl group at C4 from those at C1 and C3, so that a bromine-atom 
could be introduced in an ortho-directed fashion as a sixth substituent. Furthermore, the 
introduction of methyl ethers on the C1 and C3 OH-groups should increase the stability of 
the relevant intermediates and prevent unwanted para- or ortho-quinone formation. This 
sequence also started with 2-methylresorcinol (203), which was first acylated under Friedel-
Crafts conditions and then methylated to give compound 228. Baeyer-Villiger oxidation of 
the ketone 228 was performed in good yield completing the triphenolic motif. To our delight 
the iodination at C6 - using NIS and catalytic amounts of sulfuric acid - gave 229 in excellent 
yields. In comparison to the attempted iodination of 206, no deprotection or any other side 
products were oberserved.  
The present protecting group set in 229 allowed for a selective deprotection at C4 which 
paved the way for functionalization at C5. In the event, the bromination with NBS in polar 
aprotic acetonitrile proceeded smoothly, providing the hexasubstituted arene 230 in 
satisfactory yield. As the phenolic group at C4 had to be protected for the following 
transformations, we decided to change the methyl ether to a MOM-ether, which would be 
easier to cleave at the end. For the deprotection, oxidative and Lewis acidic conditions were 
tested; however, the material decomposed in all cases.  
In order to explore the introduction of the alkyne we continued with 230. Thus, a MOM-
ether was installed at C4, giving compound 232 which was considered suitable for the 
introduction of the acetylene at C6. In earlier studies, a variant of the Suzuki-Miyaura cross-
coupling reaction with sodium propyne and trimethylborate was successfully applied to the 
pentasubstituted substrate 201. Subjecting the dihalo compound 232 to these conditions, 
good yields were only obtained when the bulky Buchwald ligand t-BuXPhos was present. The 
alkyne could alternatively be introduced by Sonogashira cross-coupling with TMS-protected 
acetylene at elevated temperature. The attempted Sonogashira-coupling with propyne 
failed. Again, the cleavage of the methyl-ether at C1 in 233 was investigated. However, the 
material seemed to be too sensitive to survive the required reaction conditions.[104]  
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Scheme 64: Installation of the triphenolic substitution pattern in the presence of methyl ether protecting 
groups. Conditions: a) BF3∙Et2O, rt to 70 °C; then Ac2O, rt to 80 °C, 84%; b) Me2SO4, K2CO4, acetone, rt, 93%; c) 
p-TsOH, m-CPBA, CH2Cl2, rt, 70%; d) AcOH, cat. H2SO4, NIS, rt; e) KOH, MeOH/H2O, rt, 87% over two steps; f) 
NBS, MeCN, −40 °C, 62%; g) NaH, THF, rt; then MOMCl, 0 °C to rt, 84%; h) PdCl2(PPh3)2 (20 mol%), Et3N, CuI, 
TMS-acetylene (6.0 eq.), 70 °C, 62% (for further details regarding the optimization of the cross-coupling 
reaction see experimental section); i) BBr3, CH2Cl2, −78 °C, 56%; j) B(OMe)3, propinyl sodium, t-BuXPhos, 
PdCl2(PPh3)2 (20 mol%), , 83%.
[104]
  
The hurdle of the methyl ether cleavage was considered too risky to be left until after the 
fragment assembly. Therefore, the protecting group strategy for the aryl component 163 
was revised once again:[96] 
The known 1,4-hydroquinone 200 was converted to the dibenzoate 234. Following the 
overall strategy described before, the iodination was conducted employing the established 
procedure which gave iodide 235 regioselectively in high yield. Under basic conditions, the 
sterically less hindered benzoate was hydrolyzed whereas the sterically more hindered 
benzoate at C1 remained intact. The structure of mono-benzoate 236 was confirmed by 2D-
NMR spetroscopy (scheme 65). The remaining benzoate in 236 was stable during an ortho-
directed bromination with NBS. Then, the benzoate at C1 was readily cleaved with DIBAl-H 
and the rather unstable dihalogenated 1,4-hydroquinone 238 was directly converted to the 
bis-MOM ether 239. Finally, the chemoselective cross-coupling reaction at the ortho-
disubstituted iodide was tested. Preceding investigations (scheme 64) indicated that this 
transformation would not be trivial; nevertheless, an extensive screening of catalysts, 
ligands and reagents revealed that the desired product 163 was formed in a mild Negishi-
coupling.[96]  
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Scheme 65: Revised route for the hexasubstituted arene 163. Conditions: a) BzCl, Et3N, THF, 0 °C, 89%; b) NIS, 
cat. H2SO4, AcOH, rt, 94%; c) KOH, MeOH, rt, 80%; d) NBS, MeCN, −10 °C, 49-81%; e) DIBAl-H, CH2Cl2, −78 °C; f) 
MOMCl, DBU, acetone, rt, 61% over two steps; g) BrMgCCCH3, ZnCl2, THF; then 239, Pd(PPh3)4 (2x20 mol%), , 
82%.
[96]
  
In conclusion, an efficient and reliable route to the desired aromatic fragment was achieved. 
The key requirements turned out to be a selective deprotection of a C4 benzoate. The 
resulting hydroxyl group at C4 was then used to direct the bromination to the C5-position, 
against the overall electronic effects of the triphenolic system which renders the C6-position 
most nucleophilic. With reasonable amounts of 163 in hand, its usefulness in the prospected 
transformations was evaluated.  
3.6.4. Further Model Studies Towards the Total Synthesis of Kendomycin 
In order to determine the utility of arene 163, the compound was subjected to several tests. 
The assessment started with the installation of the polyketide chain. To this end, aryl 
bromide 163 was treated with n-BuLi to induce a halogen/lithium-exchange and 
isobutyraldehyde or the corresponding Weinreb amide were subsequently added. The 
benzylic alcohol 240 was obtained in almost quantitative yield, whereas in case of the 
Weinreb amide, poor results were observed, presumably due to the greater steric hindrance 
around the carbonyl. Moreover, 163 was tested in an alkyne cross metathesis reaction with 
2-octyne. In the presence of the molybdenum alkylidyne catalyst C4 the cross metathesis 
product 243 was formed at elevated temperature in moderate yields. Thus, the alkyne site 
seemed to be accessible for the RCAM catalyst despite the two ortho substituents. At last, 
the MOM-ethers were removed under acidic conditions to test the hydroalkoxylation. In 
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fact, the benzofuran 242 was formed in good yield when 163 was exposed to catalytic 
amounts of PtCl2.
[96]  
 
Scheme 66: Model reactions with aromatic substrate 163. Conditions: a) n-BuLi, isobutyraldehyde, THF, −78 °C 
to 0 °C, 96%; b) n-BuLi, i-PrC(O)N(OMe)Me, THF, −78 °C to 0 °C, 37%; c) 2-octyne, C4 (18 mol%), MS 5 Å, rt to 
100 °C, 54%; d) p-TsOH∙H2O, MeOH, rt; e) PtCl2 (20 mol%), toluene, 82% over two steps.
[96]
  
Arene 163 passed all test reactions successfully, suggesting that the compound is a suitable 
choice for further synthetic manipulations en route to Kendomycin (10).  
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3.6.5. Fragment Assembly via Lithiation/Addition & RCAM Studies 
The assembly of the fragments started with the linkage of the polyketide fragments 164 and 
165 (scheme 67) via an alkyl-Suzuki cross-coupling[74] that furnished the polyketide chain in 
quantitative yield. The ester 244 was then converted to aldehyde 162 by a two-step 
procedure via the corresponding Weinreb amide. The use of the aldehyde 162 in the 
connection of the aryl fragments seemed a better choice, as yields were higher than with the 
Weinreb amide in the test reactions (scheme 66). Treatment of aryl bromide 163 with n-
butyllithium resulted in bromine/lithium exchange; upon addition of aldehyde 162, the diyne 
245 was formed in over 70% yield. Compound 245 served as starting material for the 
synthesis of several RCAM precursors.[92]  
 
Scheme 67: Assembly of the fragments by alkyl-Suzuki cross-coupling and a lithiation/addition reaction. 
Conditions: a) 165, t-BuLi, Et2O, −78 °C; then 9-(MeO)-9-BBN, THF, −78 °C to rt; then aq. K3PO4, PdCl2(dppf) 
(10 mol%), 164, DMF, rt, 99%; b) i-PrMgCl, HN(OMe)Me∙HCl, THF, −25 °C to rt, 78%; c) DIBAl-H, THF, −78 °C; d) 
163, n-BuLi, THF, −78 °C; then 162, −78 °C to rt, 70% over 2 steps.
[96]
  
The benzylic alcohol in diyne 245 was considered a possible source of troubles in the 
metathesis reaction, as the OH-group might coordinate to the catalyst. Thus, 245 was 
oxidized to the ketone 246, or protected with an acetate as in 247. Furthermore, it remained 
unclear if the acetonide would add extra rigidity to the polyketide chain that might impact 
on the outcome of the RCAM. Therefore, the acetonide-group was removed under acidic 
conditions to give tetrahydropyran 248. However the MOM-ethers were cleaved as well and 
two phenolic and the secondary alcohol on the THP had to be protected in two separate 
steps. Notably, the fully protected substrate 250 was obtained as a mixture of two 
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atropisomers. These simple modifications delivered six different substrates for the upcoming 
ring closure.[96]  
 
Scheme 68: Synthesis of different RCAM precursors 246-250. Conditions: a) DMP, CH2Cl2, rt, 97%; b) Ac2O, 
DMAP, pyridine, rt, 55%; c) HCl (2 N), MeOH, rt, 77%; d) MOMCl, i-Pr2EtN, CH2Cl2, rt, 73%; e) MOMCl, DBU, 
acetone, rt, 68%.
[96]
  
Next, diynes 245-250 were submitted to the RCAM conditions using our highly active alkyne 
metathesis catalysts C2, C3, C4 and C5. Remarkably, none of the substrates showed any 
reactivity in alkyne metathesis below 100 °C. Raising the temperature led to formation of the 
corresponding methoxybenzylidyne cross metathesis products (in case of 246 and 249) or 
open dimers 246, 247, 249 and 250 in which the alkyne of the alkyl chain reacted exclusively 
and the acetylene next to the arene appeared to be completely inert. In the case of 245, 
elimination of the alcohol was observed, whereas 248 did not undergo any metathesis 
reaction. Only the di-MOM protected substrate 249 reacted to the desired macrocycle in up 
to 62% yield when very harsh conditions were apllied using an increased catalyst loading (2 x 
30 mol%) of C4, reflux temperature and a high dilution (0.1 M). However, this result was 
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not well reproducible. The application of RCAM to this class of substrates was therefore 
considered impractical.[92]  
 
Scheme 69: Most promising substrate in the RCAM. Conditions: a) C4 (2 x 30 mol%), MS 5 Å, toluene, 
c = 0.1 M,, 18-62%.
[96]
  
The problems encountered in the alkyne metathesis of substrates 245-250 was rationalized 
by the vastly different reactivity of the two alkynes. As a consequence, the less-hindered 
acetylene at the polyketide chain reacted whereas the sterically more encumbered one at 
the arene did not.[96] However, the issue cannot solely be attributed to the two ortho-
substituents next to the alkyne since the model substrate 150 also bore the ortho-
disubstitution pattern and was metathesized without difficulty at ambient temperature. 
Rather, the rotational freedom about the aryl-glycosidic bond must determine whether a 
reactive conformation can be adopted. Interestingly, subtle structural changes appear to be 
responsible for the occurence of the atropisomerism. For example, the steric demand of the 
substituent at C4 is crucial because large protecting groups can presumably function as a 
steric lock for the rotation about the C4a-C5 bond.  
All in all, it must be assumed that the overall outcome of the RCAM reactions was a result of 
several steric effects.  
3.6.6.  Revision of the Aromatic Fragment: The Photo-Fries Approach 
Bypassing the problems arising from an ortho-disubstituted acetylene and the frequently 
recurring atropisomeric rigidity about the C-glycosidic bond that likely obstructed the RCAM, 
a revised route towards the macrocycle of kendomycin based on a pentasubstituted 
aromatic core 252 was pursued. Based on this strategy, the RCAM product would yield a 
metacyclophane. The construction of the hexasubstituted arene via a photo-Fries reaction 
was planned as a post-metathetic transformation. The diyne 252 should be assembled by 
esterification of phenol 254 and acid 253. The latter could be derived from the same methyl 
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ester 244 that had already been used in the preceding approach (chapter 3.6.5.). This 
underlines the flexibility of the strategy with regards to the polyketide fragment.  
 
Scheme 70: Retrosynthetic analysis based on an ortho-monosubstituted alkyne in the RCAM precursor.  
For the synthesis of the aromatic unit we sought to implement the previously used selective 
deprotection approach, as it was necessary to differentiate between the C1 and C4 hydroxy-
group in the esterification step with the polyketide chain 253. Furthermore, the introduction 
of the alkyne by cross-coupling was planned to occur after the connection of the fragments. 
The order of the steps was reasoned in the way that the selective deprotection would only 
work if the hydroxyl group at C1 is neighbored by a sterically shielding iodine-atom. 
Moreover, the cross-coupling reaction was expected to be impaired if an unprotected 
phenolic group was present. Therefore the aromatic fragment should bear an iodine-atom at 
C6 and the free OH-group at C4 for the esterification.  
 
Scheme 71: a) AcCl, Et3N, THF, −78 °C to rt, 90%; b) NIS, cat. H2SO4, AcOH, rt, 99%; c) K2CO3, MeOH, H2O, 0 °C, 
97%.  
The 1,4-hydroquinone 200 was therefore converted into the corresponding diacetate, which 
was then iodinated under the previously established conditions with NIS and a catalytic 
amount of sulfuric acid. Iodide 255 was isolated in basically quantitative yield. To our delight, 
a selective saponification of the C4 acetate proceeded under mild conditions in analogy to 
the benzoate case (chapter 3.6.3.5.). In this way, the required aromatic core was obtained in 
only three efficient steps in 86% overall yield.  
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3.6.7. RCAM, Gold-Catalyzed Hydroalkoxylation & Endgame 
For fragment assembly, the methyl ester 244 was saponified to acid 253, which was 
subsequently esterified with phenol 254 under Steglich conditions. Next, the yet missing 
alkyne was introduced by Suzuki-Miyaura cross-coupling, in which sodium propyne was 
transmetalated with trimethylborate. It was observed that the Pd-catalyzed reaction was 
promoted by Buchwald´s t-BuXPhos ligand. With less bulky ligands such as JohnPhos or 
triphenylphosphine, the reaction time was much longer (up to 16 h) and the yields only 
moderate.  
 
Scheme 72: Fragment assembly by esterification and introduction of the second alkyne. Conditions: a) LiOH, 
THF/MeOH/H2O, rt, 80%; b) 254, DMAP, DCC, CH2Cl2, 0 °C to rt, 77%; c) sodium propyne, B(OMe)3, THF, rt; then 
PdCl2(PPh3)2 (10 mol%), t-BuXPhos, THF, 70°C, 78%.  
In order to preserve the precious advanced material, initial studies towards the photo-Fries 
rearrangement were conducted on a model substrate 257. This was prepared in two steps 
from phenol 254 by esterification with isobutyric acid under Steglich conditions followed by 
the introduction of the alkyne at C6 by Suzuki cross-coupling (scheme 73).  
 
Scheme 73: Photo-Fries rearrangement on a model substrate. Conditions: a) DMAP, DCC, isobutyric acid, 
CH2Cl2, rt, 79%; b) sodium propyne, B(OMe)3, THF, rt; then PdCl2(PPh3)2 (10 mol%), t-BuXPhos, THF, 70 °C, 85%, 
c) h (450 W, medium pressure mercury gas lamp), EtOH, −20 °C, 78%.  
The photo-Fries reaction[105] is the photochemical version of the Fries reaction[106] that 
normally proceeds via formation of an acyl cation in the presence of Lewis acids such as AlX3, 
(X: Cl, Br or I), BF3, TiCl4 or SnCl4. The photo-Fries reaction is believed to proceed via 
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formation of an acyl-radical that is transferred to the ortho- or para-position. The 
aromaticity is regained by tautomerization of the product.  
 
Scheme 74: General mechanism of a photo-Fries rearrangement.
[105]
  
The setup for the photochemical reaction was based on a standard laboratory reactor that 
consisted of a vertically arranged set of an inner cooling well and an outer immersion well 
made of quartz. The UV lamp was inserted in a quartz tube that was positioned in the center 
of the reactor. On small scale, the reaction vessel was a short quartz tube that was attached 
to the quartz reactor. In our initial attempts, the model substrate 257 was irradiated at 
ambient temperature using a 125 W high pressure mercury gas lamp. Ethanol and 
cyclohexane were tested as solvents for their good permeability even for wavelengths as 
short as 204 nm.[107] However, only starting material was obtained in both cases even after 
48 h of irradiation. It was supposed that the intensity of the emitted light of the 125 W lamp 
might not be high enough. Therefore, a 450 W medium pressure mercury gas lamp entailing 
the same continuous spectrum in much higher intensity was used instead. For the change of 
the lamp however, the setup had to be altered. As the 450 W UV lamp was also a strong 
heat source, the whole reactor had to be additionally placed in an external cooling bath 
(−20 °C) (scheme 75). Under these conditions, clean conversion of ester 257 to the ketone 
258 was observed. The desired product was obtained in 78% yield along with traces of a 
byproduct 259 that was presumably the result of simple homolytic cleavage of the acyl 
group. The obtained results indicated that the transformation strongly depended on the light 
source and the setup. 
Diyne 252 was then irradiated using the setup mentioned above. However, applying 
different reaction temperatures, solvents and UV irradiation sources (125 W, 450 W UV 
lamps) merely gave the undesired phenol byproduct along with complex mixtures. We 
supposed that a macrocyclic ester would be a better substrate as the acyl radical could be 
transferred in an intramolecular fashion and a greater proximity of the two radical species 
would be enforced. 
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Scheme 75: Experimental setup of the photochemical transformation.  
Hence, the undesired simple cleavage of the acyl group should be less favored. Thus, we 
commenced to investigate the key feature of the synthesis: the ring-closing alkyne 
metathesis. To our delight, the macrocyclization proceeded efficiently under very mild 
conditions in 95% yield. Only 5 mol% of the reactive alkylidyne complex C4 were necessary 
to promote the RCAM even at ambient temperature. This result showcases the clear 
difference between diyne 252 and the previously used hexasubstituted substrates 245-250. 
The ring strain in cycloalkyne 267 is presumably higher than in the ortho-cyclophane 251. 
Nevertheless, this effect appears to be insignificant in comparison to the influence of steric 
bulk and the ensuing conformational rigidity of the ortho-disubstituted compounds 245-250.  
 
Scheme 76: Formation of the cycloalkyne 267 using molybdenum alkylidyne complex C4. Conditions: a) C4 
(5 mol%), MS 5 Å, toluene, rt, 95%.  
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The conformational constraint of the macrocycle was exploited for a conformational analysis 
and a review of the stereochemistry of the 1,3-diol. All atoms were assigned on the basis of 
2D NMR studies. The carbon shifts of the acetonide were closely examined as they correlate 
to the relative stereochemistry of the 1,3-diol. In 1990, Rychnovsky[108] and Evans[109] 
independently reported that for propionate-derived polyols the carbon resonances of the 
methyl-groups were found at 19 and 30 ppm for 1,3-syn diols and between 24-25 ppm for 
1,3-anti diols. In the depicted case, the carbon shifts were observed to be 25.2 and 
26.0 ppm, supporting the presence of an 1,3-anti diol. Furthermore, NOESY experiments 
displayed an interaction of the proton at C9 and at C6 with the axial CH3-group of the 
acetonide. This observation suggests a 1,3-diaxial relationship of these substituents. The 
coupling constants of the protons at C7/C8 indicate a 1,2-di-equatorial orientation and a 1,2-
syn relation for the protons at C8/C9. As a result, the relative configuration of all 
substituents around the six-membered ring was assigned.  
 
Scheme 77: NOE-experiments of the macrocyclic compound 267 confirmed the anti-relationship of the 1,3-diol.  
With cycloalkyne 267 in hand, we attempted the construction of the benzofuran, which 
represents the second key transformation in this synthesis. The acetate at C1 was 
hydrolyzed under mildly basic conditions which revealed the precursor for the desired 
heterocycle formation (scheme 78). Platinum-catalyzed hydroalkoxylations are known 
entries to benzofurans.[75a] However, treatment with PtCl2 did not deliver the cyclization 
product; even at elevated temperature the starting material was recovered. The cationic 
gold-complex [(PPh3)Au]OTf (entry 2 and 3, table 5) merely effected the cleavage of the acid 
labile acetonide group, which likely indicated the presence of traces of triflic acid. In order to 
cirmcumvent this problem, the corresponding tosylate species was tested. Yet, only small 
amounts of the desired product along with decomposition products were formed after a 
prolonged reaction time. Next, two gold tosylate complexes with Buchwald´s t-BuXPhos and 
JohnPhos ligands were prepared. The biarylmonophosphine ligands were expected to 
stabilize the AuI-complexes and render the cationic gold more carbophilic. Indeed, in the 
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presence of 10 mol% of [JohnPhosAu]OTs (C9) the desired benzofuran was generated 
quantitatively. The phosphine ligand had to be removed by HPLC separation to give the 
product in 79% yield (entry 4, table 5). In comparison, the use of the bulkier t-BuXPhos 
ligand gave only poor results (entry 5, table 5). Benzofuran 61 intercepts the total synthesis 
of kendomycin (10) reported by Mulzer et al.[44a]  
 
Scheme 78: Au
I
-catalyzed hydroalkoxylation. Conditions: a) K2CO3, MeOH, 0 °C, 86%; b) [Johnphos Au]OTs (C9), 
CH2Cl2, rt, 74%.  
Table 5: Investigation of the noble-metal-catalyzed hydroalkoxylation of 268.  
entry catalyst (mol%) conditions results 
1 PtCl2 (10) toluene, reflux sm recovered 
2 [(PPh3)Au]OTf (10) CH2Cl2, rt 
full conversion, cleavage of acetonide, 
further decomposition 
3 [(PPh3)Au]OTs (10) CH2Cl2, rt 
5% 61, very slow reaction, formation of 
further byproducts 
4 [JohnPhosAu]OTs (10) CH2Cl2, rt 
full conversion to 61 by 1H NMR, 79% 
isolated yield after HPLC separation 
5 [t-BuXPhosAu]OTs (10) CH2Cl2, rt 15% 61 after 2 d, slow decomposition 
 
For the completion of the synthesis the remaining transformations were conducted 
according to the literature.[41, 44a] Thus, we set out to approach the ring contraction. The 
setup that had been found successful for the model substrate 257 led to complete 
decomposition of the substrate if the 450 W unit was applied. Upon return to the original 
setup with the 125 W UV lamp, the reaction proceeded smoothly at ambient temperature to 
give the hexasubstituted aromatic core in 85% yield. The spectroscopic data of 61 and 62 
were in excellent agreement with those reported in the literature.[41, 44a] The remaining steps 
were repeated on very small scale in analogy to the known protocols.[44a]  
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Scheme 79: Photo-Fries rearrangement. Conditions: a) h (125 W, high pressure mercury gas lamp), 
cyclohexane, rt, 85%.  
Ketone 62 was reduced to the benzylic alcohol and upon treatment with hydrochloric acid, 
the acetonide was hydrolyzed and the tetrahydropyran 63 formed in 89% yield over the two 
transformations (scheme 80). Compound 63 was treated sequentially with DDQ and dilute 
hydrochloric acid to furnish the hemiacetal of kendomycin (10). The analytical and 
spectroscopic data of all known precursors matched the literature. However, the full 
characterization of the natural product was not attempted.  
 
Scheme 80: Formation of the tetrahydropyran and oxidative endgame. Conditions: a) NaBH4, MeOH, rt; then 
HCl (0.5 N); b) HCl (2.0 N), MeOH, rt, 89% over two steps; c) DDQ, CH2Cl2/H2O (10:1), rt; d) 1% HCl, MeCN.  
In summary, a highly convergent formal total synthesis of the macrocyclic natural product 
kendomycin (10) is described. In the course of our studies, it was demonstrated that the 
RCAM of sterically encumbered diynes 245-250 was impractical, even though the cross-
metathesis of an ortho-disubstituted arene 163 had been successful.[92] In contrast, the 
RCAM with a pentasubstituted arene proceeded smoothly to yield the metacyclophane 267 
that was converted to Mulzer´s benzofuran 61[44a] in a postmetathetic transformation with a 
highly carbophilic gold-catalyst C9. In analogy to literature precedent[44a], the construction of 
the fully functionalized aromatic core was achieved by a photo-Fries rearrangement.[110]  
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4. Total Synthesis of a 4-Pyrone Marine Natural Product 
4.1. Isolation & Structure 
Over the last decades, a few 4-pyrone-containing marine natural products have been 
isolated from different species such as algae and fungi: A predominant number of these 
compounds exhibit exotic structural motifs that are mostly accompanied by a versatile and 
powerful biological activity. In particular, some of the 2-alkoxy-substituted 4-pyrones were 
discovered to feature antiviral, antibacterial and cytotoxic properties.[111] These compounds 
have therefore attracted considerable attention of synthetic organic and medicinal chemists. 
In contrast to other depicted 2-alkoxy-4-pyrones, compound 11 has escaped total synthesis 
so far. We found the dibrominated, polyunsaturated framework synthetically most 
interesting. Because of the embedment of the exceptional pyrone motif into a macrocyclic 
skeleton, pyrone 11 was identified as an exquisite candidate for the application of RCAM and 
-acid catalysis. Therefore, we selected 11 to be the target of a total synthesis.  
 
Scheme 81: Natural products isolated from marine animals and algae that contain a 4-pyrone motif.
[111-112]
  
The marine metabolite 11 was first isolated by Kazlauskas and coworkers[112b] in 1982 from 
the red alga Phacellocarpus labillardieri that was originally collected at the southern 
Tasmanian coastline and re-isolated four years later at Flinders Reef (near Melbourne) by 
Fenical et al.[113] The sample gathered by Fenical was immediately freeze-dried after 
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collection. The raw material was then extracted and chromatographed on silica gel to give 
the dihalogenated 4-pyrone 11 in 0.7% yield based on dry algae.  
 
Scheme 82: 4- and 2-pyrone natural products isolated from the same algal origin.
[112b, 113]
  
Several structurally related 2- and 4-pyrone-containing macrolides were isolated from the 
same algae (scheme 82). Presumably, the reported compounds were the first ketene-acetal-
linked macrocycles extracted from natural sources. The 19- or 17-membered macrocyclic 
scaffolds are polyunsaturated, most of them displaying a 1,4-diene-6-yne. Moreover, the 
three representatives 11, 275 & 279 were found to be dihalogenated, displaying a 
brominated -pyrone and a homoallylic bromide function which presumably holds latent 
non-classical carbocation reactivity.[114] Furthermore, the five macrolides 273, 274, 276, 277, 
& 278 bear an uncommon enol-ether in the macrocyclic scaffold which links the 
polyunsaturated chain to the heterocycle. The relative and absolute configurations of the 
two stereogenic centers at C19 and C20 was not elucidated by the isolation teams. 
4.2. Biological Activity 
In 1982, Kazlauskas et al. reported a neuromuscular blocking activity of the crude 
dichloromethane extracts that stimulated some interest in this class of compounds.[112b] In 
general however, biological data of this unorthodox class of marine compounds are 
extremely scarce. In a broad survey of numerous algal metabolites, Mayer et al. observed a 
considerable inhibition of bee venom phospholipase A2 (PLA2) by 11 in the micromolar 
range.[115] In fact, their report was the first describing bee venom inhibition in an in vitro 
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system by pure compounds isolated from marine algae. The dibrominated enol-ether 11 
displayed a strong inhibitory activity with 93% inhibition at a 4.4 M concentration. Even 
though bee venom phospholipase itself might not appear to be the most fascinating target, 
it served as an initial model system. Phospholipases A2 are enzymes with a ubiquitous 
lipolytic activity and can be found in various cell types. These enzymes essentially hydrolyze 
the 2-acyl ester bond of 1,2-diacyl-sn-3 glycerophosphatides[116] liberating arachidonic acid 
and the corresponding lysophospholipid (scheme 83). Arachidonic acid is subsequently 
metabolized by further enzymatic processes to bioactive eicosanoids (e.g. prostaglandins, 
leucotrienes or thromboxanes). Therefore, PLA2 plays a major role in essential physiological 
processes such as phospholipid turnover or in the regulatory mechanism controlling 
inflammatory responses. The mode of action can either be direct or indirect; the latter refers 
to the subsequent biochemical transformations of arachidonic acid and lysophospholipids 
which are products of the primary process.  
 
Scheme 83: Release of arachidonic acid from glycerol. Further metabolization of the fatty acid to eicosanoids 
(e.g. prostaglandins, leucotrienes or thromboxanes).  
The crucial role of PLA2 in the above mentioned metabolisms has prompted many 
researchers to undertake substantial research on PLA2 inhibitors which could potentially 
render novel therapies for diseases that correlate with the enzyme activity such as septic 
shock, pancreatitis, rheumatoid arthritis etc. However, most of the previously examined 
candidates were limited in their in vitro potency and in vivo pharmacological activity.[115]  
Although, preliminary biological investigations of the 4-pyrone 11 were promising and 
indicated a potential for several therapeutic applications, further research has to show 
whether 11 and its congeners inhibit other PLA2 enzymes as well, especially mammalian 
types, and might therefore be relevant for future pharmacological studies.  
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4.3. Biosynthetic Hypothesis 
The coexistence of 2- and 4-pyrone-containing natural products in the same species of alga 
points to an acyclic enol of type 288 as the common intermediate. This 1,3-dicarbonyl could 
cyclize via enolization to 290 that tautomerizes to two different enol forms. These would be 
trapped by alkylation of the resulting hydroxyl-group as the 2-alkoxy-4-pyrone 293 or the 
corresponding 4-alkoxy-2-pyrone 292.[113]  
 
Scheme 84: Biosynthetic hypothesis by Fenical et al.
[113]
  
Although the chosen target 11 was re-isolated several times and the overall structure was 
repeatedly confirmed, the stereogenic center at the bromohydrin function (C19 and C20) 
remained unassigned. At the beginning of our synthetic venture, we selected the syn-
configured isomer which we believed more likely to possess the correct relative 
configuration.  
 
Scheme 85: Hypothesized biogenetic rationale for the bromohydrin in syn-11.  
The polyunsaturated chain is believed to derive from an omega-3 fatty acid derivative which 
carries an unusual acetylenic group and is basically extended by two acetyl units presumably 
via a polyketide pathway. In the depicted scenario, the hypothesized acyclic precursor would 
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initially form a 4-hydroxy-2-pyrone 295. The carboxyl group could undergo an intramolecular 
attack onto the most distal (Z)-alkene that is activated by a bromonium equivalent 
whereupon the heterocycle tautomerizes to the 2-alkoxy-4-pyrone. The resulting product 
would be syn-configured. The proposed pathway is consistent with the biosynthetic 
mechanism that is proposed for halogenations by haloperoxidases and O2-dependent 
halogenases.[117] The normally prevailing halogen anions (X−) are converted to more active 
halogenating species (e.g. of the type −OX) that promote C−X-bond formation. It is 
noteworthy that we are not able to decide whether the second bromine atom is introduced 
on the -ketoester stage or after the 4-pyrone cyclization since there are no biosynthetic 
references up to date. However, with these available biosynthetic notions in mind we 
advanced our synthetic plan and decided to address the syn-configured isomer first.  
4.4. An Overview of Methods for the Synthesis of 2- and 4-Pyrones 
4.4.1. Traditional Protocols 
Simple synthetic and natural 4-pyrone-containing compounds have been prepared using an 
array of methods that were mostly based on rather drastic conditions.[118] The first approach 
was reported by Wedekind and Häussermann in 1908.[118a] They observed the formation of 
trimeric condensation products from acid chlorides when treated with trimethylamine or 
pyridine as base. These ,-diketoacid chlorides were partially prevailing as their enol-
tautomers that could be cyclized in the presence of dilute sulfuric acid under loss of HCl 
(scheme 86).  
 
Scheme 86: Early reports of pyrone-derivatives by Wedekind and Häussermann.
[118a]
 Conditions: a) Et3N; b) 
H2SO4, quant over two steps.  
The observed pyronone 299 was presumably obtained as a mixture of two tautomeric forms: 
the 4-hydroxy-2-pyrone 300 and the 2-hydroxy-4-pyrone 301 (cf. chapter 4.2.). A clear 
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drawback of these methods is that acid-labile groups and sensitive stereogenic centers are 
compromised since strong acids and/or elevated temperatures are usually required to 
provide the 2-alkoxy-4-pyrone of the type 300. 
More selective and substantially milder methods for the synthesis of alkyl-substituted 4-
pyrones were reported by Yamamura and coworkers.[112c] Two procedures were described 
using either a mixture of DMSO and oxalyl chloride or alternatively Ph3P−CCl4 as Lewis-acidic 
reagents that activate one of the carbonyl groups of the enolized triketone 303 for attack of 
the enol oxygen. The elimination of H2O from the resulting dihydropyrone is presumably 
promoted by the electrophilic reagent as well (scheme 87).  
 
Scheme 87: Synthetic methods for the synthesis of 4-pyrone. Conditions: a) DMSO, (COCl)2, CH2Cl2, −30 °C, 
69%; b) PPh3, CCl4, THF, rt, 78%.
[112c]
  
Due to the fact that the 2- and 4-pyrones can easily undergo interconversion via a pyronone 
intermediate as previously mentioned, most syntheses of 2-methoxy-4-pyrone-derivatives 
were based on the methylation of the predominant 4-hydroxy-2-pyrones obtained from 
either ,-diketo anhydrides 307 or ,-diketo esters 306.[119] Standard methylating agents 
such as dimethyl sulfate,[119c, 120] methyl iodide[121] or trimethyloxonium tetrafluoroborate[122] 
have been employed, yet result in poor selectivity leading to mixtures of 2- and 4-pyrones. 
Beak and Lee[119f, 123] developed a method applying methyl fluorosulfonate which exhibits a 
remarkable preference for methylation of the oxygen at C2, albeit a large excess of the 
highly toxic reagent is required (scheme 88).  
Another protocol was published by De Paolis and coworkers in 2010.[124] Their strategy 
avoided the problem of chemoselective methylation by exploiting the desymmetrization of 
the symmetric and therefore readily available 2,6-dimethoxy-3,5-dimethyl-4-pyrone 
(311).[125] Conjugate addition of a nucleophile – for example an allyl tin species – and 
subsequent elimination of methoxide yielded the corresponding 2-methoxy-dimethyl-4-
pyrone derivative 312 (scheme 88). 
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Scheme 88: Literature examples for the synthesis of 2-alkoxy-4-pyrones. Conditions: a) DBU, C6H6, , 86%; b) 
MeOSO2F, CH2Cl2, rt, 89%; c) H2SO4/SO3, rt, 60%; d) n-Bu3Sn(allyl), n-BuLi, THF, , 65%.
[122-125]
  
Several different nucleophiles could be introduced in this way providing a broad substrate 
scope. Nevertheless, this method holds an inherent disadvantage, since one of the two 
alkoxy groups is sacrificed in the reaction. This fact renders the method useless for the 
preparation of compounds that bear a more complex alkoxy substituent, as it is the case for 
4-pyrone 11.  
4.4.2. Transition Metal Catalysis-Based Methods 
Within the last two decades, a few transition-metal-catalyzed methods were reported for 
the preparation of 2-pyrones. Interestingly, these protocols comprised cycloaddition and 
annulation reactions at which usually one or two of the carbonyl groups were replaced by 
alkynes as carbonyl equivalents. The triple bonds were activated by different carbophilic 
transition-metal catalysts – also referred to as -acid catalysts – for carbo- or 
alkoxymetalation reactions. Mild reaction conditions and therefore a broader scope speak 
for these catalyzed versions.  
In 1998, Larock[126] described a Pd-catalyzed cascade reaction of -iodopropenoates 313 and 
alkynes 314 (scheme 89). According to the proposed mechanism, the sequence starts with 
the oxidative addition of a alkenyl halide to palladium (0) to give a alkenylpalladium species 
315 that coordinates to the alkyne before undergoing an insertion that forms another 
alkenyl palladium species 316. After attack of the carbonyl oxygen onto the palladium, a 
seven-membered ring is formed that contracts to the 2-pyrone by reductive elimination. 
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Scheme 89: Transition metal-catalyzed methods for the formation of 2-pyrones. Conditions: a) Pd(OAc)2 
(5 mol%), Na2CO3, LiCl, DMF, 100 °C; b) [(p-CF3C6H4)3PAu]OTf (5 mol%), CH2Cl2, ; c) [Ph3PAu]Cl (5 mol%), 
AgOTf, CH2Cl2, rt; d) ZnBr2 (5-10 mol%), THF, rt. 
[126-127]
  
Furthermore, in the emerging field of -acid catalysis, gold (I) and platinum (II) have gained 
considerable importance, especially in the synthesis of heterocycles.[16a, 17a, 21a, 26a] The large 
gold cation is “soft” and polarizable, displaying a higher affinity to the -bond of the 
substrate than a proton (cf. chapter 1.2.). The carbophilicity of gold (I) has been employed by 
Pale et al.[127a] for the preparation of 2-pyrones from -alkynylpropiolactones 319 (scheme 
89). Presumably, formation of a -complex triggers a 1,3-oxygen shift. A two-component AuI-
catalyzed cascade reported by Schreiber and coworkers[127b, 128] is based on sequential 
activation of propiolic acid 323 and terminal acetylene derivative 324 to give alkenyl 
propiolate intermediate 325 that undergoes a 6-endo-cyclization yielding a cyclic oxonium 
species 326. Deprotonation and protodeauration give rise to the 2-pyrone derivatives 327 
(scheme 89). Another entry to this class of substrates was reported by Negishi et al.[127c] who 
managed to synthesize a small range of 2-pyrones from (Z)-enynoic acid derivatives 328 with 
catalytic amounts of ZnBr2.  
Among the reported examples (scheme 89) for the synthesis of 2-pyrones, gold (I)-catalysts 
seem to stand out as they can be easily modified by choice of the ancillary ligand. The 
Total Synthesis of a 4-Pyrone Natural Product 77 
 
exceptional -acidity displayed by the metal center often allowed the reactions to proceed 
at ambient temperature. However, to the best of the author´s knowledge, the noble-metal 
catalyzed direct synthesis of 4-pyrones has only been mentioned once in the literature (see 
chapter 4.4.3.).[129]  
4.5. Preceding Studies of the Fürstner Group on Macrocyclic Pyrone Derivatives 
Foregoing synthetic investigations[130] of the Fürstner group targeted the 4-alkoxy-2-pyrone 
natural product 276 that was isolated together with the dibrominated 2-alkoxy-4-pyrone 11. 
In a model study,[131] the metacyclophane skeleton of 338 – omitting further sites of 
unsaturation – was synthesized to test the two envisioned cyclizations (scheme 90). The 
unusual triple bond motif in the macrocyclic frame represents an obvious handle for RCAM. 
Moreover, a biomimetic approach for the construction of the 2-pyrone was chosen.[111a, 132] 
The required substrate was identified to be either ,-diketo ester 333 or 334 which were 
prepared from octynoic acid 330 by esterification and Claisen condensation with dianion 
332.[133]  
 
Scheme 90: Model studies for the synthesis of a 4-alkoxy-2-pyrone natural product by Fürstner et al. 
Conditions: a) TMSCHN2, pentane/MeOH, 85%; b) 332, TMEDA, THF; then n-BuLi, 0 °C, 58%; c) TFA, CH2Cl2; d) 
TMSCHN2, MeOH, 71% over two steps; e) TFA, CH2Cl2; f) Ac2O; g) DBU, toluene, ; h) 12-bromo-2-dodecyne, 
MeCN, 53% over two steps; i) K2CO3, cat. MeOH, 70% over three steps; j) 12-bromo-2-dodecyne, Et3N, MeCN, 
56% k) C1 (16 mol%), toluene, 80 °C, 84%.
[131]
  
The 2-pyrone was assembled via two routes: either from the free acid in the presence of 
acetic anhydride (Route A) or after a hydrolysis/esterification sequence to the methyl ester 
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334 in the presence of DBU (Route B). However, the question whether these conditions 
would be tolerated by the fully functionalized sidechains remained unanswered. The second 
alkyne was subsequently introduced by O-alkylation yielding the RCAM precursor 337 which 
smoothly underwent the formation of cycloalkyne 338 in the presence of catalytic amounts 
of Schrock´s tungsten alkylidyne complex C1. Thus, RCAM had proven to be a suitable tool 
for the construction of the 2-pyrone-containing macrocycle.[131]  
In another work, Fürstner et al.[129] reported the total synthesis of neurymenolide A (343, 
scheme 91), an algal metabolite that features similar structural elements as 4-pyrone 11 and 
2-pyrone 276. The 4-hydroxy-2-pyrone of 343 is embedded in a para-cyclophane scaffold 
that displays several non-conjugated unsaturated sites. These characteristics adumbrated 
the challenges that were encountered during the synthetic endeavor. Interestingly, some of 
the conclusions made during the course of this project were helpful for the projected 
synthesis of the 4-pyrone 11. The construction of the 4-alkoxy-2-pyrone 341 from a ,-
unsaturated -ketoester 339 was conducted using the [XPhosAu]NTf2 complex C10. Key to 
success was the cleavage of the tert-butyl group off the pyronium intermediate 340 to 
liberate the 2-pyrone.  
 
Scheme 91: Synthesis of the 4-alkoxy-2-pyrone neuromenolide A (343) by Fürstner et al. Conditions: a) C10 
(5 mol%), MeNO2/AcOH; b) Ac2O, Et3N, CH2Cl2, 0 °C, 73% over two steps; c) C11 (5 mol%), MS 5 Å, toluene, 88%; 
d) Lindlar catalyst, quinoline (cat.), H2 (1 atm), 84%; e) K2CO3, MeOH, 0 °C.
[129] 
 
Total Synthesis of a 4-Pyrone Natural Product 79 
 
The triple bond in conjugation to the carbonyl group can in fact be considered most 
electron-deficient which would – contrary to the experimental outcome – result in a 
decreased affinity to the electrophilic gold catalyst C10. It is believed that the catalyst is 
essentially able to interact with all six unsaturated sites; however, only one interaction is 
consequential. In a further exciting observation, the stereochemical integrity of the (Z)-
configured double bonds was found uncompromised under the mentioned conditions. After 
having constructed the heterocyclic core of neurymenolide A (343) the macrocycle was 
closed by RCAM using the molybdenum alkylidyne C11.[7, 13c] Finally, the total synthesis of 
343 was completed in two subsequent steps by semi-reduction of the alkyne and acetate 
cleavage (scheme 91).  
Fürstner et al. were also able to show that replacement of the tert-butyl group on the ester 
by a benzyl group could direct the reaction pathway towards the formation of the 2-hydroxy-
4-pyrone 346 (scheme 92).[129] The 4-pyrone was furnished with exceptional ease using only 
1 mol% of the [SPhosAu]NTf2 C12. Moreover, it was demonstrated for the tert-butylated 
substrates that -brominated -ketoesters 347 cyclize readily to the corresponding 4-
hydroxy-2-pyrone 348 (scheme 92).[129]  
 
Scheme 92: Gold-catalyzed 4-pyrone synthesis by Fürstner et al. Conditions: a) C12 (1 mol%), AcOH, 94%; b) 
C12 (1 mol%), HOAc, 82%.
[129]
  
The seminal achievements on synthesizing a 4-pyrone and a halogenated 2-pyrone 
prompted us to envisage the total synthesis of the marine metabolite 11. In addition, one 
successful RCAM was presented. Collectively, the precedents encouraged us to pursue a 
total synthesis comprising these key transformations.  
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4.6. Total Synthesis of a 4-Pyrone Natural Product 
4.6.1. Preliminary Considerations 
The compounds bearing the skipped diene/yne moiety were expected to be rather fragile as 
the energy barrier for the migration of the double bonds into conjugation was assumed to 
be low. Additionally, the internal alkyne on the rim of the macrocycle would require a 
differentiated synthetic approach to secure the selective construction of all sites of 
unsaturation side by side. Furthermore, the acetylenic unit in the lipophilic tether would 
serve as gateway for closing the polyunsaturated backbone. Of course, RCAM was the 
method of choice for this endeavor (scheme 93). 
The selective construction of a 2-alkoxy-4-pyrone should be triggered by a gold-catalyzed 
activation of an oxo-alkynoate. This acyclic precursor 349 would allow a disconnection at the 
ester function yielding two similarly sized fragments: the eastern -ketoacid fragment and 
the western alcohol fragment (scheme 93).  
 
Scheme 93: General disconnection analysis of syn-11.  
On the basis of the proposal for the relative configuration of the two stereogenic centers 
(chapter 4.2.), the syn-diastereomer of 11 was chosen as primary target for our synthetic 
efforts. Based on our hypothesis that the syn-bromohydrin presumably derived from an 
electrophilic activation of a (Z)-olefin by a bromonium equivalent, we planned to introduce 
the bromine atom at C19 by a nucleophilic substitution reaction of the corresponding 1,2-
anti-diol. Furthermore, the introduction of the bromine atom on the 4-pyrone had to be 
considered. The ketene-acetal side of the heterocycle appeared sufficiently electron-rich and 
the directing effect of the enol ether should render the C2-position reasonably reactive for a 
regioselective electrophilic bromination. However, compounds of the type 349 bear several 
delicate sites of unsaturation along the lipophilic chain and treatment with an electrophilic 
species should be exercised with extreme caution.  
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Having defined the key steps of the synthesis, the question regarding the order of these 
transformations – especially with respect to the installation of the bromine atoms – 
remained.  
It needs to be mentioned that some valuable groundwork of the projected total synthesis 
was compiled by coworkers of the Fürstner group. Dr. Tsutomu Fukuda[134] elaborated the 
initial synthetic strategy for the synthesis of -keto-acid fragment and the diol-fragment. 
Attempts to complete the synthesis of syn-11 were focused on the late-stage introduction of 
both bromine atoms. Furthermore, Dipl.-Chem. Gerit Pototschnig[135] contributed to this 
work by conducting model studies for the late-stage bromination on 1,2-anti-diol 
derivatives. The respective work will be referenced in the course of this chapter.  
4.6.2. Model Studies for the Electrophilic Bromination of the 4-Pyrone 
For the examination of a suitable strategy for the 4-pyrone synthesis, two different routes 
were considered. Because previous results documented that simple -halogenated oxo-
alkynoates can be cyclized to 4-pyrones,[129] an early bromination of the -ketoester 353 was 
taken into account (Route A). On the other hand, the late-stage bromination of the 4-pyrone 
moiety was evaluated. Therefore, reagents were to be tested on a simple 2-alkoxy-4-pyrone 
of the type 352, which could be obtained in one step from the corresponding -ketoester 
353 (Route B).  
 
Scheme 94: Route A: Cyclization of a brominated -ketoester 351. Route B: Bromination of the 4-pyrone 352.  
Bromination of -ketoester 354 was tested applying NBS as standard brominating reagent. 
The -brominated product 355 was isolated in 55% yield (scheme 95). However, efforts to 
remove the tert-butyl group failed since the reaction competed with an extremely fast 
decarboxylation to an -bromoketone. Reversing the order of the steps by cleaving the tert-
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butyl group prior to bromination also was met with failure as the labile -ketoacid 
decomposed under the bromination conditions. The limited options for its cleavage are a 
detriment of the tert-butyl group, as only concentrated TFA worked well. Alternatively, we 
set out to prepare the equivalent methyl ester 357 from 354 by cleavage of the tert-butyl 
group and subsequent methyl ester formation with trimethylsilyl diazomethane. Methyl 
ester 357 was then treated with one equivalent of NBS in the presence of an amine base.[136] 
In this case, an almost equimolar mixture of the monobrominated product 358, the 
dibrominated product 359 and the starting material 357 was obtained which could be 
separated by flash chromatography. Saponification of the monobrominated -ketoester 358 
was achieved with a moderate 52% yield. The compound 356 partially decomposed upon 
purification.  
 
Scheme 95: Investigation of the bromination of the -ketoesters 354 and 357. Conditions: a) NBS, 2,6-lutidine, 
acetone, 0 °C, 96%; b) TFA, CH2Cl2 (1:1), rt, 55%; c) TMSCH2N2, MeOH, CH2Cl2, 0 °C, 40-70%; d) NBS, 2,6-lutidine, 
acetone, 0 °C to rt, 358 (26%), 359 (21%), 357 (28%); e) NaOH, THF/MeOH/H2O (1:1:1), 0 °C to rt, 52%, f) 360, 
DMAP (10 mol%), DCC, CH2Cl2, 0 °C, 46%.  
Nevertheless, the little material was subjected to an esterification with alcohol fragment 
360. The experimental data indicated the formation of the desired ester 361 that was 
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directly treated with [SPhosAu]NTf2 C12 to test if the desired 2-alkoxy-3-bromo-4-pyrone 
362 would be formed. Unfortunately, the cyclization product was not observed even after 
extended reaction times upon increasing the catalyst loading. Therefore, this entry to the 3-
bromo-4-pyrone was abandoned.  
The late-stage bromination of the 4-pyrone seemed to be the only sensible alternative and a 
careful investigation would be worth all the effort. Therefore, the 2-methoxy-4-pyrone 363 
was prepared from the previously described methyl oxo-alkynoate 357 and served as a 
model substrate for testing a number of electrophilic brominating reagents (365a-j). The 
efficiency of these reagents was compared in a screening experiment. To this end, a solution 
of the 4-pyrone 363 in tetrahydrofuran was treated with one equivalent of the 
corresponding reagent and the NMR-spectroscopic data of the resulting mixture were 
compared. Reagents 365a-f caused several side reactions. However, in most cases moderate 
amounts of the desired 2-methoxy-3-bromo-4-pyrone 364 were observed among other 
polybrominated and degradation products. In contrast, reagents 365g-j led to a relatively 
clean formation of the desired brominated product with only trace impurities. In conclusion, 
the four reagents 365g-j were found to trigger a reasonably selective electrophilic 
bromination on the 3-position of the 4-pyrone.  
 
Scheme 96: Model studies for the electrophilic bromination of the 4-pyrone. Conditions: a) [SPhosAu]NTf2 C12 
(5 mol%), MeCN/AcOH (4:1), rt, 83%; b) [Br
+
] (365a-365i), THF, rt.  
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In further studies, the electrophilic bromination with NBS was tested on substrate 366[135] 
comprising a (Z)-olefin. In this case, the bromination proceeded well, but the single (Z)-
configured double bond in product 367 was isomerized to a significant extent. Lowering the 
temperature only stopped the bromination whereas the competing isomerization was still 
observed. It occurred to us that an even greater hurdle would be faced in case of the fully 
functionalized substrate which would offer ample opportunities for isomerization and 
further side reactions.  
 
Scheme 97: Studies of the electrophilic bromination on a model substrate.  
The results of our model studies suggested that serious difficulties were to be expected for 
the introduction of the second bromine atom. Yet, in absence of sensible alternatives, the 
bromination as the final step of the synthesis seemed inevitable.  
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4.6.3. Total Synthesis of a 4-Pyrone Natural Product: Retrosynthetic Analysis 
In the foregoing model studies, the cyclization of the -halogenated -ketoester 361 to the 
corresponding 4-pyrone failed (scheme 95); therefore, the installation of this bromine 
functionality was placed late in the planned synthetic strategy. For the introduction of the 
second bromine atom two alternative routes were identified:  
 
Scheme 98: Retrosynthetic analysis of syn-11.
[134]
  
Route A: The introduction of both bromine atoms was envisioned as the first 
retrosynthetic disconnection leading back to homoallylic alcohol anti-368. The 
ring-closing triple bond metathesis was projected after the formation of the 4-
pyrone from the ,-unsaturated -ketoester anti-369. This ester should be 
obtained from alcohol anti-371 and -ketoacid 370. 
Route B: Again, the installation of the bromine atom at the 4-pyrone was scheduled 
late-stage. The bromine atom in the side chain though was to be introduced 
to the alcohol fragment syn-372 before the construction of the macrocycle 
and the 4-pyrone moiety. 
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4.6.4. Synthesis of the Eastern -Ketoacid Fragment  
The -ketoacid 370 relates to a methyl alkynoate 376 via a Claisen condensation with tert-
butyl acetate 375. 
 
 
Scheme 99: Retrosynthetic analysis of -ketoacid 370.  
The preparation of the -ketoacid 370 was straightforward. It began with the silylation of 
1,7-octadiyne (377) to give the monosilylated compound 378 as major product along with 
the disilylated 379.[137] After methylation of the remaining terminal alkyne, the direct 
transformation to the methyl ester 376 was accomplished by subsequent treatment with 
methyllithium and chloroformate.[138] Finally, a -ketoester was formed by Claisen 
condensation of 376 with t-butyl acetate (375); the product was treated with TFA to give 
acid 370 (scheme 100). Notably, 370 was very sensitive and decomposed at ambient 
temperature within hours. Therefore, it had to be prepared promptly before the fragment 
coupling.  
 
Scheme 100: Synthesis of the -ketoacid 370 from 1,7-octadiyne (377). Conditions: a) LiHMDS, THF, −78 °C; 
then TMSCl, −78 °C to rt, 52% (378), 17% (379); b) n-BuLi, THF, −78 °C; then MeI, −78 °C to rt, 91%; c) MeLi, THF, 
−78 °C to 0 °C; then ClCO2Me, −78 °C to rt, 86%; d) t-BuOAc (375), LDA, THF, −78 °C; then 376, 87%; e) TFA, 
CH2Cl2, rt, 99%.
[134]
  
By this means, the C1-C10 fragment 370 was synthesized in five efficient steps in 35% overall 
yield. It could be shown that the sequence initially described by Dr. Fukuda is scalable to 
gram quantities.  
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4.6.5. Synthesis of the Western 1,2-Diol Fragment (Route A) 
The triply unsaturated alcohol anti-371 can be further disconnected by a Corey-Fuchs 
reaction that would introduce the methyl-capped alkyne. The diene anti-381 was traced 
back to the skipped diyne unit anti-385 by way of semihydrogenation.  
 
Scheme 101: Retrosynthetic analysis of the western 1,2-anti-diol fragment.  
The stereogenic centers in the targeted 1,2-anti diol 382 were to be defined by an 
asymmetric Katsuki-Sharpless epoxidation and a diastereoselective epoxide opening with a 
diacetylenic unit 385 and epoxide 383. The latter was prepared in three steps from 1,4-
pentadien-3-ol (384) which was epoxidized using 13 mol% of (+)-DIPT, 10 mol% of Ti(Oi-Pr)4 
and cumene hydroperoxide as oxidant. A close monitoring of the temperature during 
addition of the reagents was crucial for securing good yields. Alcohol 387 was then protected 
as tert-butylsilyl ether and the remaining terminal olefin was subsequently hydrogenated 
over palladium on charcoal to give the C18-C22 fragment 383 in excellent yield. Due to the 
simple and reliable protocols, the epoxide 383 was obtained in up to 7.6 grams by this route.  
 
Scheme 102: Synthesis of epoxide 383 by asymmetric epoxidation. Conditions: a) (+)-DIPT (13 mol%), Ti(Oi-Pr)4 
(10 mol%), cumene hydroperoxide, CH2Cl2, MS 4 Å, −35 °C, 82%; b) TBSCl, imidazole, DMF, 0 °C to rt, 90%; c) H2, 
Pd/C, EtOAc, rt, 95%.  
The synthesis of the skipped diyne 385 commenced with commercially available 3-butyn-1-ol 
(386). Protection of the primary alcohol as ethoxyethyl ether and a copper-(I)-mediated 
coupling with propargyl bromide established the skipped diyne in 82% yield (scheme 103). 
Next, epoxide 383 was to be opened selectively at the sterically less hindered side. For this 
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purpose, 385 was deprotonated at the terminal alkyne site and formation of a BF3-adduct 
was then followed by slow addition of epoxide 383 at −78 °C to give the homopropargylic 
alcohol anti-382. As an excess of three equivalents of diyne 385 was required to reach full 
conversion of the epoxide, the yield suffered from the formation of several byproducts that 
made the isolation of the delicate product somewhat laborious. Compounds 385 and anti-
382 proved to be extremely sensitive and decomposed noticeably within one day, even if 
stored at −20 °C. Directly after preparation, the skipped diyne anti-382 was reduced to the 
respective skipped diene anti-388 by using either a nickel boride catalyst[134] or Lindlar´s 
catalyst[135] for the chemoselective semihydrogenation. The diene anti-388 appeared to be 
slightly more stable as its precursor and could be stored in the freezer in a matrix of benzene 
glass. This procedure was employed for all subsequent intermediates since the skipped 
diene, specifically at the C13-C14 -system was observed to isomerize at ambient 
temperature to the thermodynamically more stable (E)-alkene.  
 
 
Scheme 103: Synthesis of the skipped diene/yne fragment anti-371. Conditions: a) ethyl vinyl ether,  
p-TsOH∙H2O, rt, 90%; b) EtMgBr, THF, 45 °C; then CuCl (5 mol%), 50 °C; then propargyl bromide, 60 °C, 82%; c) 
n-BuLi, Et2O, −78 °C; then BF3∙Et2O, −78 °C; then 383, −78 °C, 59%; d) H2 (1 atm), P-2 Ni, ethylenediamine, EtOH, 
rt, 74%; e) H2 (1 atm), Pd (5% on CaCO3, unpoisened, reduced), quinoline, CH2Cl2, rt, 87%; f) MOMCl, NaI,  
i-Pr2EtN, CH2Cl2, 35 °C, 90%; g) PPTS, MeOH, 30 °C, 90%; h) DMP, CH2Cl2, rt; i) PPh3, CBr4, THF, −78 °C 85% over 
two steps; j) n-BuLi, THF, −78 °C; then MeOTf, −78 °C, 79%; k) TBAF, AcOH, THF, 40 °C, 85%.  
The synthetic sequence was continued with orthogonal protection of the secondary alcohol 
as MOM-ether using standard conditions. The primary alcohol was then exposed to 
pyridinium p-toluenesulfonate to cleave the acetal group. Treatment of the alcohol anti-381 
with Dess-Martin periodinane (DMP) followed by a Corey-Fuchs reaction delivered the 
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methyl-capped alkyne anti-389 on gram-scale (scheme 103). For the selective removal of the 
TBS ether, the substrate was stirred for several days at 40 °C in the presence of excess 
TBAF.[134]  
4.6.6. Assembly of the Fragments and Formation of the Macrocycle (Route A) 
The esterification of anti-371 and the -ketoacid 370 under Steglich conditions employed 
DCC and a catalytic amount of DMAP. The oxo-alknyoate anti-369 was obtained in excellent 
yield. The material was a mixture of keto/enol tautomers and turned out to be less stable 
than the preceding alcohol fragment. Thus, -ketoester anti-369 was immediately engaged 
in the next step. The 4-pyrone anti-390 was formed under mild conditions as the exclusive 
product when exposed to 5 mol% of [SPhosAu]NTf2 (C12). Acetic acid was used as co-solvent 
as it was demonstrated that it would enhance the reaction rate by accelerating the 
protodeauration step. In this way, a potential diauration was essentially suppressed.[129] The 
projected RCAM proceeded smoothly with 10 mol% of ate-complex C11 giving the 
cycloalkyne anti-368 in 90% yield. At this stage, the synthetic efforts were directed toward 
the installation of the missing bromine atoms. The SN2 reaction at the side of the lipophilic 
backbone was studied first. Thus, the MOM-ether had to be removed. After an extensive 
screening of reagents that mostly caused decomposition of the fragile material, it was found 
that AlCl3 could cleave the ether without compromising the stereochemical integrity of the 
anti-diol or the non-conjugated (Z)-olefins. Interestingly, the deprotection was only 
successful if a large excess of anisol was added. Presumably, anisol ligates the metal center 
and thus tempers the Lewis acidity sufficiently for a clean reaction to take place. With the 
free alcohol anti-391 in hand, the bromination was investigated. The use of P(octyl)3 and 
CBr4, conditions previously reported by Crimmins
[139] and Murai[140] for the substitution of a 
secondary homoallylic alcohol by a bromide, failed in case of anti-391 (scheme 104). 
Moreover, the chloromesylate anti-392, which was expected to exhibit a reasonable leaving 
group ability, was subjected to the bromination conditions but this substrate also failed to 
give the corresponding brominated product.[134]  
In summary, all attempts to brominate the sidechain on the advanced intermediates were 
met with failure and the scarcity of the delicate advanced material did not allow for a 
broader screening of reaction conditions.[134]  
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Scheme 104: Fragment assembly and formation of the cycloalkyne anti-392 (Route A). Conditions: a) 370, 
DMAP, DCC, CH2Cl2, 0 °C, 90%; b) C12 (5 mol%), MeCN/AcOH (5:1), rt, 86%; c) C11 (5 mol%), toluene, MS 5 Å, rt, 
90%; d) AlCl3, ansiol, CH2Cl2, −78 °C to −50 °C, 90%; e) McCl, LiBr, THF, rt, 35%.
[134]
 
Finally, the discussed strategy was abandoned as it seemed too risky to leave this challenging 
transformation for the end of the synthesis. In the following, the bromination was pursued 
with an earlier intermediate that was available in bigger amounts.  
4.6.7. Revised Strategy for the Western Alcohol Fragment (Route B) 
In the revised approach, alcohol anti-393 was identified as appropriate substrate for the 
nucleophilic substitution reaction with a bromide. Two entries to compound anti-393 were 
considered . Firstly, the bis-protected anti-diol 389 could be converted to alcohol anti-393 by 
selective cleavage of the MOM-ether using dimethylboron bromide.[141]  
 
Scheme 105: Selective cleavage of the MOM-ether. Conditions: a) Me2BBr, CH2Cl2, −78 °C, 86%.  
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Secondly, a shorter alternative preparation of the skipped diene/yne was pursued, since the 
preceding approach for the synthesis of alcohol anti-393 was deemed somewhat lengthy 
with eleven steps in the linear sequence. It was presumed that the appending alkyne in anti-
393 could also be installed by a copper-mediated coupling of an allylic bromide anti-394 with 
a propynyl Grignard instead of by the previously employed Corey-Fuchs chemistry. This 
disconnection would lead back to a propargylic alcohol anti-395 that is by one carbon atom 
shorter than its equivalent in the previous retrosynthesis (scheme 101). Furthermore, the 
protection of the homoallylic alcohol might be avoided on this route.  
 
Scheme 106: Retrosynthetic analysis for the western alcohol fragment anti-372 (route B). 
The forward synthesis of the 1,2-anti-diol 393 started with the protection of the propargylic 
alcohol 397 as ethoxyethyl ether. The coupling with ethynylmagnesium bromide in the 
presence of catalytic amounts of copper (I) chloride furnished the skipped diyne 396. The 
lipophilic fragment was elaborated by BF3-mediated epoxide opening with 383. After 
cleavage of the acetal in almost quantitative yield, the diyne anti-395 was subjected to 
semihydrogenation. We resorted to nickel boride in methanol for the chemoselective 
reduction as these conditions had been established before.[134] Strict monitoring of the 
reaction mixture allowed us to isolate the diene in 79% yield along with only trace amounts 
of over-reduced byproducts. Next, the primary alcohol was converted to the corresponding 
bromide anti-398 under Appel conditions. The desired product was obtained in excellent 
yield, provided that the temperature was kept at 0 °C. The resulting highly sensitive allylic 
bromide anti-398 was immediately submitted to the next step.  
Our motivation to try the direct coupling of anti-398 with a propynyl Grignard was inspired 
by preliminary studies in our group.[129] To our delight, the projected copper-mediated 
coupling of anti-398 proceeded surprisingly well. The formation of an undesired SN2´product 
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was not observed at −15 °C. In conclusion, alcohol anti-393 was formed in 29% overall yield 
via an efficient and scalable eight-step sequence from 1,4-pentadien-3-ol 384.  
 
Scheme 107: Revised synthesis and bromination of the 1,2-diol anti-393. Conditions: a) ethyl vinyl ether,  
p-TsOH∙H2O (10 mol%), 0 °C, 84%; b) EtMgBr, THF, 45 °C; then CuCl (5 mol%), propargyl bromide, 60 °C, 68%; c) 
n-BuLi, THF, −78 °C; then BF3∙OEt2; then 383, −78 °C, 72%; d) PPTS, MeOH, 30 °C, 98%; e) H2 (1 atm), P2-Ni 
(25 mol%), EtOH, 79%; f) CBr4, PPh3, CH2Cl2, 0 °C, 91%; g) propynylmagnesium bromide, CuI (50 mol%), THF, 
−15 °C to −10 °C, 81%; h) CBr4, PPh3, toluene, 65 °C, syn-399 (60%), syn-400 (~12%), 401 (~11%).  
Having anti-diol 393 in hand, we next scrutinized the bromination with PPh3 and CBr4. At 
ambient temperature, merely the isomerization of the double bonds was triggered. 
Interestingly, the desired product was formed when the temperature was elevated. 
However, a complex mixture of isomerization and elimination products was obtained. 
Considerate optimization finally led to a reliable protocol for the bromination. The starting 
material and the reagents were mixed at 0 °C and the solution was directly placed in a pre-
heated oil bath. It was found that a temperature of 65 °C was necessary for the reaction to 
proceed. Additionally, the reaction time was kept as short as possible to reduce the amount 
of byproducts. In this way, bromide syn-399 was isolated in reproducible 60% yield along 
with around 12% of the isomerized (Z),(E)-configured bromide syn-400 and 11% of the 
elimination product 401 (scheme 107).  
The same delicacy of the material was observed throughout the synthesis. Therefore, 
compound 396 and its successors were treated with utmost care by storing the material only 
for a short time and keeping all intermediates that contain a skipped diyne or diene/yne 
motif at −20 °C in benzene glass. 
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4.6.8. Completion of the Total Synthesis of syn-11 (Route B) 
With the brominated fragment syn-399 and acid 370 in hand, we approached the remaining 
steps of the synthesis again. At first, the alcohol function in syn-399 was unmasked for the 
upcoming esterification. Hydrofluoric acid buffered with pyridine was found to cleave the 
silyl ether at 0 °C without compromising the stereochemical integrity of the material. The 
obtained alcohol syn-372 was then esterified with 370 using the previously established 
conditions. -Ketoester syn-374 was obtained in good yield as mixture of keto/enol-
tautomers. The ester was found to be extremely unstable and was therefore immediately 
subjected to the [AuI]-catalyzed cyclization. The 4-pyrone syn-402 was furnished in the 
presence of acetic acid by 3 mol% of C12 in 97% yield. Hence, the way was cleared for the 
macrocyclization by RCAM using molybdenum alkylidyne C4[13c] which furnished the 
macrocycle syn-373 with ease.  
 
Scheme 108: Fragment assembly and completion of the total synthesis of syn-11. Conditions: a) HF∙pyridine, 
THF, 0 °C, 83%; b) 370, DCC, DMAP (30 mol%), CH2Cl2, 0 °C, 70%; c) C12 (3 mol%), MeCN/AcOH (4:1), 97%; d) C4 
(5 mol%), MS 5 Å, toluene, rt, 82%; e) NBS, THF, rt, 40%.  
At this stage, the first bromine atom had been successfully installed in the homoallylic 
position of the lipophilic tether. By careful handling of the isolated brominated 
intermediates and close monitoring of the reactants during the transformations, it was 
possible to arrive at the monobrominated cycloalkyne syn-373 (scheme 108).  
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Finally, we ventured to try the electrophilic bromination of delicate syn-373. To our delight, 
the dibrominated compound could be obtained, when freshly recrystallized NBS was added 
in one portion to a solution of syn-373 in THF. Again, it was observed that the reaction 
proceeded much cleaner at ambient temperature than at 0 °C. Yet, the (Z)/(E)-isomerization 
took place to a certain degree. Under close monitoring, we were contented with receiving 
the product syn-11 in well reproducible 40% yield. In this way, ten milligrams of syn-11 were 
prepared that allow for further evaluation of the biological properties.  
                                           
Picture 109: Structure of syn-11 in the solid state. Co-crystallized MeCN was removed for simplicity. The 
complete crystallographic data can be found in the appendix.  
Crystals of syn-11 could be grown.[112b] The X-ray data confirmed the proposed configuration 
at the stereogenic centers. Apart from the essentially linear alkyne (177.8° and 179.6°), it can 
be seen that the two (Z)-alkenes are not in plane but contorted. This fact likely explains why 
a migration of the alkenes into conjugation was never observed. Furthermore, an overlap of 
the -sytem of the acetylenic bond with the -system of the vicinal alkene could explain the 
preferential (E)/(Z)-isomerization at the C13-C14 double bond. Surprisingly, the dihedral 
angle (179.1°) of the protons at the bromohydrin junction shows an antiperiplanar 
orientation which indicates that the conformation in the solid state differs considerably from 
the one in solution where the coupling constant (3JH,H = 4.6 Hz) of the respective protons 
suggests a synclinal orientation (cf. appendix).  
Finally, the obtained analytical and spectroscopic data were compared to the literature. It 
must be noted that the reported NMR data were not very detailed, as only the median was 
given for the multiplets and the coupling constants were rounded to one digit after the 
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comma. However, the 13C NMR data of syn-11 agree very well with the reported data of the 
natural product (see table 14 in the appendix). The 1H NMR data match too, except for the 
shifts of the vinyl protons as well as the proton at C20 which differ by 0.07 – 0.27 ppm. For 
the protons at the stereogenic centers at C19 and C20, a coupling constant of 3JH,H = 4.6 Hz 
was observed which is in line with the 5 Hz reported for the natural product. The overall 
match of the data sets was therefore sufficient to propose syn-11 to represent the marine 
metabolite which is in accordance to our biosynthetic hypothesis. For further validation, we 
decided to prepare anti-11 since our synthetic route allowed its preparation by a few 
modifications starting from the advanced intermediate anti-393 (chapter 4.7.1.).  
4.7. Total Synthesis of anti-11  
The anti-configured diastereomer of 11 was prepared in analogy to syn-11. For the sake of 
brevity and convenience the inversion of the stereogenic center at C19 was achieved by an 
oxidation/reduction sequence. Alcohol anti-393 was treated with DMP to give the 
corresponding ketone which was reduced to alcohol syn-393 in a diastereoselective fashion 
using (S)-(−)-2-methyl-CBS-oxazaborolidine (403) and catecholborane as hydride source.[142] 
Eventually, the product was obtained in 82% yield with excellent diastereoselectivity. The 
obtained alcohol syn-393 was then subjected to the same bromination conditions as 
described for the anti-diastereomer to give the SN2-product anti-399 in acceptable yield.  
 
Scheme 110: Twofold inversion of the 1,2-anti diol (393) to 1,2-anti configured bromide 399. Conditions: a) 
DMP, CH2Cl2, 0 °C to rt; b) (S)-(−)-2-methyl-CBS-oxazaborolidine (403), toluene, rt; then catecholborane, −78 °C, 
81% over two steps; c) CBr4, PPh3, toluene, 65 °C, 55%.  
Next, the TBS-ether was removed, the resulting alcohol anti-372 was esterified with acid 370 
and the corresponding -ketoester was treated with [SPhosAu]NTf2 (C12) to form the 2-
alkoxy-4-pyrone anti-402. The dibrominated cycloalkyne anti-11 was established by 
treatment of anti-402 with 5 mol% of the molybdenum alkylidyne complex C4 and 
subsequent NBS-bromination. The previously established procedures worked very well on 
the diastereomeric compounds and the yields varied only marginally.  
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Notably, during earlier studies concerning the 2-pyrone model 276 (chapter 4.5.) an 
alternative entry to alcohol fragment anti-393. This entry would win in the overall step 
count.[143] 
 
Scheme 111: Fragment assembly, key cyclizations and late-stage bromination. Conditions: a) HF∙pyridine, THF, 
0 °C to rt, 55%; b) 370, DCC, DMAP (30 mol%), CH2Cl2, 0 °C, 78%; c) C12 (3 mol%), MeCN/AcOH (5:1), rt, 84%; d) 
C4 (5 mol%), MS 5 Å, toluene, rt, 80%; e) NBS, THF, rt, 40%.  
The spectroscopic data of anti-11 deviated distinctly from the data of natural 11 (see table 
15 in the appendix). Therefore, the unique algal metabolite 11 was confirmed to feature a 
relative syn-configuration[144] which is consistent with our biosynthetic proposal (chapter 
4.2.).  
4.8. Structure Elucidation and Conclusion 
 
Scheme 112: Observed coupling constants and the corresponding Newman projections of synthetic compounds 
syn-11 & anti-11.  
In summary, the 4-pyrone marine metabolite syn-11 was prepared by a 14-step total 
synthesis in 3.2% overall yield. All materials passed through were found to be highly delicate. 
This fact made the use of mild and efficient methods absolutely necessary. Therefore, we 
employed a -acidic gold-catalyst for the construction of the 2-alkyoxy-4-pyrone. 
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Furthermore, the formation of the cycloalkyne was achieved by ring-closing alkyne 
metathesis using our molybdenum alkylidyne catalyst. Both transformations were highly 
chemo- and regioselective and furnished the corresponding products at ambient 
temperature. Our results therefore demonstrate that gold-catalysis and RCAM are not only 
extremely efficient but even highly compatible with a fragile skipped diene/yne motif.  
The anti-configured diastereomer anti-11 was prepared by a diastereoselective inversion of 
configuration of an advanced intermediate. The comparison of the reported NMR data to 
the data of the synthetic stereoisomers syn-11 and anti-11 revealed the relative 
configuration of the natural 4-pyrone.  
A virtually perfect fit of the carbon shifts and the characteristic coupling constant of the 
protons at C19-C20 in case of the syn-isomer and significant deviations in case of anti-11 
render the assignment of the relative configuration unambiguous. Furthermore, the X-ray 
diffraction of syn-11 confirmed the proposed relative stereochemistry.[145]  
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5. Summary & Conclusions 
The objective of this thesis were two total syntheses based on the combined application of 
ring-closing alkyne metathesis (RCAM) and -acid catalysis as key methodologies. RCAM has 
been spotlighted in recent synthetic endeavors to be a highly effective tool for the 
construction of macrocyclic natural products.[7] However, the obtained cycloalkyne motifs 
have been mainly engaged in semihydrogenations.[146] To date, only few examples are 
known that describe postmetathetic transformations leading to heterocyclic motifs, and thus 
leaving ample opportunities for further exploration. Complex heterocyclic fragments, whose 
derivation from an alkyne is not obvious, could potentially be established in this way. In the 
course of this thesis, the use of -acid catalysts, particularly gold-catalysts, was identified as 
a potent strategy for the activation and the consequent functionalization of alkynes in 
general and cycloalkynes in particular. With this duet of methods in mind, the antibiotic 
macrolide (−)-kendomycin (10) and the polyunsaturated brominated marine natural product 
11 were selected as targets for total synthesis (scheme 113). Both compounds were chosen 
for their potentially interesting biological profiles and their unique structural features. 
 
Scheme 113: Natural products selected for total syntheses.  
Kendomycin (10) is a highly versatile bacterial metabolite which displays a broad antibiotic 
and strong cytotoxic activity. Apart from its impressive biological profile, kendomycin 
features intriguing structural motifs such as a unique quinone methide chromophore with a 
linkage to a highly substituted tetrahydropyran and a polyketide scaffold completing the 16-
membered carbocycle. The macrocyclic rim is decorated with nine stereogenic centers. 
These biological and structural properties have motivated a number of synthetic organic 
chemists to pursue a total synthesis of kendomycin.  
The objective of this work was the development of a novel synthetic route for kendomycin 
(10) enabled by the two above mentioned key processes.  
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Scheme 114: Disconnection approach by lithiation/addition (route A) and esterification/photo-Fries 
rearrangement (route B).  
Our strategy was based on two highly convergent synthetic routes that were traced back to 
a polyketide chain 162 or 253 and the aromatic fragments 163 or 254.  The design rendered 
the building blocks highly flexible: the polyketide chains 162 and 253 (scheme 114) could be 
used in route A and B by simple derivatization of a common methyl ester progenitor. The 
syntheses of the two aromatic fragments 163 and 254 were based on a selective 
deprotection approach of the phenol at C4 which paved the way for the installation of the 
correct substitution pattern.  
On route A, a number of potential substrates for the RCAM were prepared. However, the 
reaction was found to be unfeasible. This outcome was attributed to two effects: the steric 
hindrance at the ortho-disubstituted aryl alkynes and presumably a rotational limitation 
about the C-glycosidic bond which could lock the two diynes in an unreactive conformation 
(scheme 115). Thus, route A was abandoned.[96] A brief summary of the successful route B 
will be given in the following.  
 
Scheme 115: Substrates that failed to give the RCAM product.  
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Methyl ester 244 was prepared from aldehyde 68 which could be obtained from either (L)-
(+)-lactic acid or -citronellene (scheme 116). Compound 68 participated in a syn-aldol 
reaction with -ketoimide 48 to give the aldol 193. Further transformations that were 
derived from literature precedents[41, 44a, 147] yielded alkyne 166, which was converted to an 
alkenyl iodide 164 by a highly efficient silylcupration/iodination sequence. The coupling 
partner 165 for an alkyl-Suzuki cross-coupling was prepared from (R)-(−)-Roche ester 195 in 
a few robust operations.[96]  
 
Scheme 116: Synthesis of the polyketide chain 244.  
Methyl ester 244 was saponified, linked to the arene 254 and the resulting ester adorned 
with an acetylene unit at the aromatic core (scheme 117). Diyne 252 represents the 
substrate for the envisioned RCAM. The triple bond metathesis with C4 proceeded under 
mild conditions furnishing the metacyclophane 267. The benzofuran moiety was formed by 
hydroalkoxylation of the cycloalkyne using an electrophilic gold-catalyst that was able to 
overcome the inherent ring strain. Benzofuran 61 intercepts the total synthesis of 
kendomycin (10) by Mulzer et al.[44a, 147] Using a photo-Fries rearrangement, the correct 
connectivity of the all-carbon macrocycle was put in place. Eventually, the completion of the 
synthesis was achieved according to the literature protocol.[44a, 147]  
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Scheme 117: Fragment assembly, RCAM and construction of the benzofuran moiety by -acid catalysis.  
With 22 steps in the longest linear sequence, this synthesis represents one of the shortest 
entries to the densely substituted polyketide 10 (cf. table 6).[110] An overall yield of 2.0% over 
the longest linear sequence highlights the efficiency of this entry.  
Table 6: Synthetic approaches and their efficiency by comparison.  
 
 
 
 
 
 
 
 
a) Longest linear sequence; b) Formal total synthesis. 
In the further course of this PhD thesis, a total synthesis of the highly unusual 
polyunsaturated marine natural product 11 was pursued. In contrast to the previously 
discussed compound 10, this target did not gather much attention after its isolation.[112b, 113]  
Total Syntheses Macrocylization event llsa 
Overall 
yield 
Lee (2004) Macro-glycosidation 20 2.0% 
Smith (2006) RCM 21 0.5% 
Panek (2008) Barbier reaction 32 1.5% 
Rychnovsky (2008) Prins cyclization 20 – b 
Mulzer (1. 2009) RCM 23 1.0% 
Mulzer (2. 2009) 
Lactonization/ 
Photo-Fries 
29 0.4% 
Saikawa (2010) Dötz benzannulation 32 0.2% 
Our work (2014) RCAM/gold-catalysis 22 2.0% 
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4-Pyrone 11 is a marine metabolite of algal origin. Initial examination of the biological 
properties revealed a promising inhibitory activity of 93% for bee venom phospholipase A2. 
The structural features of this marine natural product are a unique brominated 2-alkoxy-4-
pyrone that is linked by a ketene acetal to the lipophilic tether; a skipped diene/yne motif 
decorates the macrocycle. Furthermore, a homoallylic bromine augurs for a latent non-
classical carbon cation reactivity. These structural attributes all forecast the delicacy of the 
natural product and its precusors. The relative stereochemistry of 11 was not assigned by 
the isolation teams and had to be elucidated.  
The 4-pyrone 11 was thought to have its biogenetic origin likely from a polyunsaturated fatty 
acid. In accordance with the literature, we assumed the stereogenic bromohydrin entity to 
derive from the attack of a nucleophile (the pyrone or its precursor) onto a (Z)-alkene which 
is activated by a bromonium cation equivalent.[117a] Therefore, we deliberately chose syn-11 
as our prime target at the outset of the projected synthesis. 
The unusual 2-alkoxy-3-bromo-4-pyrone, embedded in the rim of the macrolide structure, 
was identified as a motif to be installed through a gold-catalyzed cycloisomerization. The 
cycloalkyne represented an obvious target for the application of RCAM. With regard to the 
sensitivity of the material, the installation of the bromine atoms was considered a major 
challenge.  
 
Scheme 118: Retrosynthetic disconnections of the marine metabolite syn-11.  
Building on prior intelligence,[134-135] -ketoester syn-374 was chosen as the key intermediate 
in the ultimately successful approach. It was derived from the previously described acid 370 
and a revised alcohol fragment syn-399 (scheme 119). The synthetic route started with the 
formation of a skipped diyne 385 that was engaged in an epoxide opening with 383.[134] 
Next, the methyl-capped alkyne was introduced via copper-mediated coupling of an allyl 
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bromide with a propynyl Grignard. The bromination at the homoallylic position could be 
achieved in a SN2-type reaction under Appel conditions. After deprotection of syn-399, the 
alcohol and the acid fragment 370 were finally linked by esterification giving the -ketoester 
syn-374. Using the previously established conditions,[134] the gold-catalyzed 
cycloisomerization followed by RCAM provided the macrocyclic 4-pyrone derivative syn-373. 
Finally, syn-11 was obtained by electrophilic bromination. The delicacy of the synthetic 
material was manifest throughout the entire synthesis, and utmost care had to be taken in 
handling and storing of virtually all compounds during the entire synthesis. The analytical 
data of the natural product and syn-11 were in very good agreement. 
 
Scheme 119: Fragment assembly & synthesis of syn-11.  
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In order to eliminate any uncertainties concerning the relative configuration, the anti-
configured diastereomer was prepared starting from alcohol anti-393 (scheme 120). 
Bromide anti-399 was obtained after inversion of the corresponding stereocenter and an 
Appel-type bromination. Subsequent conversion of anti-399 to anti-11 was conducted in 
analogy to the synthesis of syn-11 via -acid catalyzed 4-pyrone formation, RCAM and 
electrophilic bromination.  
The NMR data of anti-11 showed major deviations from the data of the isolated material 
which supported the initial biosynthetic hypothesis, according to which a syn-configuration 
was suspected.  
 
Scheme 120: Synthesis of anti-11.  
In conclusion, a formal total synthesis of the densely functionalized and synthetically 
challenging kendomycin (10) was successfully completed. A diverse portfolio of reactions, 
transition-metal catalyzed transformations in particular, were applied and improved along 
the way. Once again, RCAM has proven to be a valuable synthetic tool for the synthesis of 
highly complex compounds such as the sterically demanding orthocyclophane in 
kendomycin. Limitations were only met with substrates containing ortho-di-substituted aryl 
alkynes. The price to be paid to avoid this obstacle was a detour via a metacyclophane 
derivative, which underwent RCAM in high yield. The all-carbon skeleton of the macrocycle 
was set in place by a photo-Fries shift. Finally the benzofuran motif was established 
employing a gold-catalyst which smoothly mediated the reaction and allowed the ring strain 
to be overcome.  
Furthermore, a 14-step total synthesis of the exceptionally delicate marine natural product 
syn-11 was described. In the course of this work, a 2-alkoxy-4-pyrone was prepared by a 
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gold-catalyzed cycloisomerization reaction. It was demonstrated that this methodology is 
advancing to a level of maturity and reliability that should further encourage 
implementation in synthetic planning, even as a late-stage transformation. Moreover, 
formation of the cycloalkyne by RCAM proceeded with great efficiency, showcasing the 
compatibility of this method with very sensitive functional groups such as skipped dienes or 
enynes. Finally, after preparation of syn- and anti-11, the correct relative stereochemistry 
was identified to be syn, supporting our intitial proposal for the biosynthetic origin of the 
bromohydrin moiety.  
 
106 Experimental Procedures 
 
6. Experimental Procedures 
6.1. General Experimental Details 
All reactions were carried out under argon in flame-dried glassware unless H2O was used as 
solvent. The following solvents were purified by distillation over the drying agents indicated 
and were transferred under Ar: THF, Et2O (Mg/anthracene), CH2Cl2, DMSO (CaH2), pentane, 
hexane, toluene (Na/K), MeOH (Mg, stored over MS 3 Å), DMF (MS 4 Å), DMSO (distilled 
over CaH2, stored over MS 4 Å). 1,4-Dioxane, DMF, MeCN, Et3N and pyridine were dried by 
an adsorption solvent purification system based on molecular sieves. DBU, diisopropylamine 
(CaH2), (n-Bu)2BOTf, propanal, B(OMe)3 and acetyl chloride were distilled under argon prior 
to use. NBS and NIS were freshly recrystallized from H2O prior to use. All other commercially 
available compounds (Aldrich, Alfa Aesar, Fluka, TCI, Lancaster) were used as received. The 
following compounds were prepared according to the cited protocol by myself or within the 
department of Prof. Fürstner: Cp2ZrHCl,
[148] Me2BBr,
[141, 149] Dess-Martin periodinane,[150] 
LiSiMe2Ph,
[91] oxazolidinone 403,[56a] C4 (neutral-complex),[13b] C5 (ate-complex),[13b] 
[JohnPhosAu]OTs C9[151] and [SPhosAu]NTf2 C12.
[151-152]  
Compounds and fragments 163, 165, 217 and 245 – 251 were prepared by Dr. Peter 
Persich.[96] The syntheses of 370, anti-371, 383 and anti-391 were initially described by Dr. 
Tsutomu Fukuda.[134]  
Thin layer chromatography (TLC) was performed on Macherey-Nagel precoated plates 
(POLYGRAM®SIL/UV254). Detection was achieved under UV light (254 nm) and by staining 
with either cerium ammonium nitriate (CAN), basic KMnO4 or acidic vanilin solution. Flash 
chromatography was performed with Merck silica gel 60 (40–63 μm) or Florisil (60-100 
mesh). The analytical measurements by gas chromatography were conducted with a Hewlett 
Packard HP 6890 device with a HP 5973 (GC/MS) detector. Analytical and preparative high 
pressure liquid chromatography (HPLC) was performed in parts in cooperations with 
Roswitha Leichtweiß. The measurements and separations of samples were executed with 
devices LCMS-2010 and LCMS-2020 (Shimadzu). Analysis of samples was effected by a diode 
array detector and mass spectroscopic analysis. X-ray diffraction was performed in the 
department “Chemische Kristallographie” in the Max-Planck-Institut für Kohlenforschung 
under the guidance of Prof. Christian W. Lehmann. Measurements were conducted using a 
Bruker-AXS X8 Proteum Diffractometer.  
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NMR spectra were recorded on Bruker DPX 300, AMX 300, AV 400, AV 500 or AVIII 600 
spectrometer in the solvents indicated; chemical shifts (δ) are given in ppm relative to TMS, 
coupling constants (J) in Hz. The solvent signals were used as references and the chemical 
shifts converted to the TMS scale (CDCl3: δH 7.24 ppm, δC 77.0 ppm; CD2Cl2: 
δH5.32 ppm, δC53.8 ppm; C6D6: δH7.15 ppm, δC128.0 ppm; [D6]-DMSO: 
δH2.50 ppm, δC39.52 ppm). Multiplets are indicated by the following abbreviations: s: 
singlet, d: doublet, t: triplet, q: quartet, quint: quintet, hept: heptet, m: multiplet. The 
abbreviation “br” indicates a broad signal. 13C NMR were recorded in [1H]-decoupled mode 
and the values of the chemical shifts are rounded to one digit after the decimal point. All 
spectra from the 500 MHz and 600 MHz spectrometers were acquired by the NMR 
department under guidance of Dr. Christophe Farès at the Max-Plank-Institut für 
Kohlenforschung. The assignments are based upon 1D and 2D spectra recorded using the 
following pulse sequences from the Bruker standard pulse program library: DEPT; COSY 
(cosygpqf and cosydqtp); HSQC (hsqcedetgpsisp2.2) optimized for 1JC,H = 145 Hz; HMBC 
(hmbcetgpl3nd) for correlations via nJC,H; HSQC-TOCSY (invietgsml) using an MLEV17 mixing 
time of 120 ms; NOESY (noesygpph). The IR spectra were recorded on the Spectrum One 
(Perkin-Elmer) spectrometer and the Alpha Platinum ATR (Bruker) at room temperature, 
wavenumbers (?̃?) are given in cm1. Mass spectrometric samples were measured by the 
department for mass spectrometry at the Max-Planck-Institut für Kohlenforschung. The 
following equipment was used: MS (EI): Finnigan MAT 8200 (70 eV), ESI-MS: ESQ3000 
(Bruker), accurate mass determinations: Bruker APEX III FT-MS (7 T magnet) or Mat 95 
(Finnigan). Optical rotations were measured with a Perkin-Elmer Model 343 polarimeter at a 
wavelength of 589 nm; they are given as specific optical rotations with exact temperature, 
concentration (c/(10 mg/mL)) and solvent.  
 
6.2. Formal Total Synthesis of Kendomycin 
6.2.1. Synthesis of a Model for the Ring-Closing Alkyne Metathesis  
Silyl Ether 404.  Alkynol 154 (2.00 g, 13.0 mmol) was dissolved in THF (4 mL) and the solution 
stirred at 0 °C. Subsequently, a solution of TBSCl in THF (7.78 mL, 
15.6 mmol, 2.0 M) and imidazole (2.21 g, 32.4 mmol) were added. 
The mixture was then allowed to warm to ambient temperature and the reaction was 
monitored by thin layer chromatography. After 4 h the mixture was diluted with EtOAc and 
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the organic phase was washed with H2O (3 x 5 mL) and brine (5 mL). The organic layer was 
dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by 
flash chromatography (SiO2, pentane 100%  pentane/EtOAc, 8/2) to yield the desired silyl 
ether 404 as a colorless oil (3.07 g, 88%).  1H NMR (400 MHz, CDCl3):  = 3.59 (t, 2H, 
J = 6.5 Hz), 2.13 – 2.08 (m, 2H), 1.77 (t, 3H, J = 2.4 Hz), 1.53 – 1.43 (m, 4H), 1.40 – 1.29 (m, 
6H), 0.89 (s, 9H), 0.04 ppm (s, 6H); 13C NMR (100 MHz, CDCl3):  = 79.5, 75.5, 63.4, 33.0, 29.2, 
29.1, 29.0, 26.1 (3C), 25.9, 18.9, 18.5, 3.3, 5.1 ppm (2C); IR (film): ?̃? =  2929, 2857, 1471, 
1463, 1387, 1361, 1254, 1098, 1005, 938, 832, 812, 773, 712, 661 cm-1; GC-MS: tR 
(70_20) = 8.4 min; MS (EI) m/z (%): 267 (12), 211 (35), 135 (52), 109 (32), 75 (100); HRMS 
(ESI): m/z: calcd. for C16H32OSiNa [M+Na
+]: 291.2117, found 291.2115.  
 
Alkenyl Bromides 151 and 155.  Cp2ZrHCl (2.97 g, 11.6 mmol) was added to a solution of 
alkyne 404 (3.71 g, 13.0 mmol) in THF 
(25 mL). After stirring for 2 h, the white 
suspension turned slightly red and NBS (3.02 g, 17.0 mmol) was added slowly as a solution in 
THF (20 mL). The mixture was stirred for 3 h at ambient temperature and the color changed 
from red to yellow. For work-up, the solvent was removed and the crude material was 
purified by flash chromatography (SiO2, hexanes 100%). The title compound was isolated as 
a mixture of regioisomers (4.08 g, 90%, 151:155 = 2.5:1).  1H NMR (400 MHz, CDCl3):  = 5.83 
(tq, 1H, J = 7.6, 1.3 Hz), 3.59 (t, 2H, J = 6.6 Hz), 2.20 (d, 3H, J = 1.3 Hz), 2.00 (dt, 2H, J = 7.7, 
7.6 Hz), 1.55 – 1.46 (m, 4H), 1.38 – 1.29 ppm (m, 6H); 13C NMR (100 MHz, CDCl3):  =  132.6, 
119.2, 63.4, 33.0, 29.8, 29.4, 29.2, 29.1, 28.7, 26.1 (3C), 25.9, 25.3, −5.1 ppm (2C); IR (film): 
?̃? =  2927, 2855, 1717, 1649, 1430, 1377, 1121, 1056, 817, 723 cm-1; GC-MS: tR 
(70_20) = 8.4 min; m/z (%): 349 (10), 291 (15), 169 (22), 137 (32), 109 (27), 95 (100), 81 (77); 
MS (EI) m/z (%): 293 (5), 291 (5), 167 (5), 139 (7), 137 (27), 109 (13), 96 (8), 95 (100), 81 (89), 
75 (24), 73 (12), 69 (16), 67 (22), 55 (33), 53 (8), 41 (13); HRMS (CI): m/z: calcd. for 
C16H34OBrSi [M+H
+]: 349.1560, found 349.1562.  
 
Silyl Ether 157a and 157b.   A solution of alkyl iodide 153 (400 mg, 1.80 mmol) in Et2O 
(6.6 mL) was cooled to −78 °C before t-butyllithium (2.17 mL, 3.69 mmol, 1.7 M) was added 
and the solution was stirred for 10 min. Subsequently, 9-MeO-9-BBN (5.40 mL, 5.40 mmol) 
and THF (6.6 mL) were added dropwise. After stirring for 30 min at −78 °C, the white slurry 
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was allowed to warm to ambient temperature and 
stirring was continued for 2 h. After formation of 
the borate species[153] the alkenyl bromide was 
added as a mixture of regioisomers (151 and 155) (588 mg, 1.69 mmol) in DMF (7 mL). K3PO4 
(1.91 g, 9.00 mmol) and PdCl2(dppf)∙CH2Cl2 (66 mg, 5 mol%) were then subsequently 
introduced. The mixture was stirred for 15 min at ambient temperature and then for 1 h at 
50 °C. For work-up, the reaction mixture was filtered through a pad of Celite, the filtrate was 
evaporated under reduced pressure and the residue was purified by flash chromatography 
(SiO2, hexanes 100%  hexanes/EtOAc, 95/5) to afford the desired title compound as a 
mixture of regiosiomers (492 mg, 80%, 157a:157b = 8:1).  1H NMR (400 MHz, CDCl3):  = 5.12 
(tq, 1H, J = 7.3, 1.3 Hz), 3.59 (t, 2H, J = 6.6 Hz), 2.00 – 1.94 (m, 4H), 1.77 (t, 3H, J = 2.6 Hz), 
1.58 – 1.57 (m, 3H), 1.53 – 1.42 (m, 6H), 1.34 – 1.27 (m, 10H), 0.89 (s, 9H), 0.04 ppm (s, 6H); 
13C NMR (100 MHz, CDCl3):  =  134.2, 125.0, 79.5, 75.5, 63.5, 39.3, 33.1, 30.0, 29.6, 29.5, 
29.0, 28.8, 28.1, 27.3, 26.1 (3C), 26.0, 18.8, 16.0, 3.6, 5.1 ppm (2C); IR (film): ?̃? =  2857, 1712, 
1462, 1361, 1251, 1219, 1152, 1094, 1006, 938, 866, 834, 779, 671 cm-1; GC-MS: tR 
(70_20) = 8.4 min; MS (EI) m/z (%): 364 (11), 307 (35), 149 (26), 119 (12), 75 (100). 
 
Alcohol 405.  A solution of TBAF in THF (4.30 mL, 4.29 mmol, 1.0 M) was added dropwise to 
silyl ethers 157a and 157b (8:1) (390 mg, 1.07 mmol) in THF (10 mL). The 
pale yellow solution was stirred for 1 h before H2O was added. The 
aqueous phase was extracted with EtOAc and the combined organic 
phases were dried over MgSO4 and concentrated. The residue was purified by flash 
chromatography (SiO2, pentane/EtOAc, 4/1) to give alcohol 405 as a colorless oil (268 mg, 
83%).  1H NMR (400 MHz, CDCl3):  = 5.10 (tq, 1H, J = 7.2, 1.2 Hz), 3.80 (br s, 1H), 3.62 (t, 2H, 
J = 6.9 Hz), 2.14 – 2.08 (m, 2H), 1.99 – 1.93 (m, 4H), 1.77 (t, 3H, J = 2.5 Hz), 1.58 – 1.55 (m, 
3H), 1.55 – 1.52 (m, 2H), 1.46 – 1.41 (m, 4H), 1.36 – 1.28 ppm (m, 8H); 13C NMR (100 MHz, 
CDCl3):  = 143.4, 124.4, 79.0, 75.0, 62.7, 38.8, 32.4, 29.0, 28.9, 28.3, 27.5, 26.8, 25.4, 25.3, 
18.3, 15.4, 3.1 ppm; IR (film): ?̃? = 2934, 1733, 1478, 1390, 1233, 1155, 1092, 1065, 1044, 
965 cm-1; GC-MS: tR (70_20) = 10.5 min; MS (EI) m/z (%): 250 (29), 235 (14), 221 (11), 163 
(19), 150 (19), 149 (100), 147 (11), 136 (39), 135 (76), 133 (14), 123 (21), 122 (24), 121 (74), 
119 (19), 109 (21), 108 (24), 107 (94), 95 (60), 93 (92), 91 (29), 83 (13), 81 (69), 67 (56), 55 
(80).  
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Iodide 158.   PPh3 (236 mg, 0.90 mmol), imidazole (62.0 mg, 0.90 mmol) and iodine (228 mg, 
0.90 mmol) were added to a solution of alcohol 405 (150 mg, 0.60 mmol) 
in MeCN/Et2O (1:2, 6 mL) at 0 °C. The mixture was allowed to warm to 
ambient temperature and was stirred for 2 h. For work-up, the mixture 
was filtered through a pad of Celite which was rinsed with hexanes/EtOAc (7:3). The organic 
phase was washed with Na2S2O3 solution and brine, dried over Na2SO4, and the solvent was 
evaporated. The crude material was purified by flash chromatography (SiO2, pentane 100%) 
to afford iodide 158 as a single isomer (214 mg, 99%).  1H NMR (400 MHz, CDCl3):  = 5.10 
(tq, 1H, J = 7.1, 1.2 Hz), 3.18 (t, 2H, J = 7.1 Hz), 2.14 – 2.09 (m, 2H), 2.00 – 1.94 (m, 4H), 1.85 – 
1.78 (m, 2H), 1.78 (t, 3H, J = 2.6 Hz), 1.57 (br s, 3H), 1.47 – 1.42 (m, 4H), 1.40 – 1.34 (m, 2H), 
1.33 – 1.28 ppm (m, 6H); 13C NMR (100 MHz, CDCl3):  = 134.9, 124.8, 79.5, 75.5, 39.3, 30.6, 
29.9, 29.2, 28.7, 28.6, 27.9, 27.5, 27.2, 18.8, 16.0, 7.6, 3.7 ppm; IR (film): ?̃? =  3074, 2946, 
2830, 2547, 1768, 1688, 1596, 1573, 1471, 1417, 1372, 1291, 1261, 1214, 1176, 1137, 1074, 
1060, 1001, 896, 849, 821, 807, 747, 718 cm-1; MS (EI) m/z (%): 360 (27), 345 (25), 331 (17), 
163 (11), 150 (15), 149 (100), 136 (38), 135 (51), 122 (12), 121 (50), 108 (14), 107 (57), 95 
(28), 94 (10), 93 (54), 81 (37), 79 (31), 69 (12), 67 (28), 55 (15), 53 (17), 41 (29); HRMS (EI): 
m/z: calcd. for C17H29I [M
+]: 360.1312, found 360.1314.  
 
Bromide 160.  Commercially available 3,4,5-trimethoxybenzaldehyde (159) (1.88 g, 
6.85 mmol) was dissolved in MeCN (20 mL) and the solution treated with NBS 
(1.34 g, 7.54 mmol). After stirring for 1 h at ambient temperature the reaction 
mixture was concentrated and the crude material subjected to flash 
chromatography (SiO2, pentane/EtOAc, 85/15) to afford aryl bromide 160 as a colorless 
crystalline solid (1.79 g, 95%).  1H NMR (400 MHz, CDCl3):  = 10.29 (s, 1H), 7.30 (s, 1H), 3.98 
(s, 3H), 3.91 (s, 3H), 3.90 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 191.3, 153.1, 150.8, 
148.8, 128.8, 115.8, 107.5, 61.4, 61.3, 56.4 ppm; IR (film): ?̃? = 3349, 3080, 3001, 2940, 2864, 
1738, 1684, 1577, 1562, 1470, 1448, 1425, 1403, 1381, 1325, 1284, 1241, 1196, 1103, 1043, 
1000, 858, 816, 773, 725, 643, 584, 522, 410 cm-1; GC-MS: tR (70_20) = 9.6 min; MS (EI) m/z 
(%): 276 (39), 274 (40), 261 (10), 259 (10), 197 (11), 196 (100), 181 (50), 125 (24), 110 (17), 
95 (10), 93 (13); HRMS (EI): m/z: calcd. for C10H11O4Br [M
+]: 273.9840, found 273.9841.  
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Alkyne 152.  Trimethylborate (1.30 mL, 11.5 mmol) was slowly added to a suspension of 
sodium propyne (722 mg, 11.5 mmol) in THF (75 mL) until a clear solution was 
produced that was stirred for 10 min at ambient temperature before 
PdCl2(ddpf)∙CH2Cl2 (559 mg, 10 mol%) and aryl bromide 160 (1.79 g, 
7.64 mmol) were added. The dark red mixture was refluxed for 5 h. After 
completion of the reaction, the yellow solution was filtered through a pad of Celite, 
concentrated and the residue purified by flash chromatography (SiO2, hexanes/EtOAc, 7/3) 
to yield aryl alkyne 152 as a yellow oil (1.06 g, 59%).  1H NMR (400 MHz, CDCl3):  = 10.40 (s, 
1H), 7.21 (s, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.90 (s, 3H), 2.16 ppm (s, 3H); 13C NMR (100 MHz, 
CDCl3):  = 191.3, 154.6, 153.4, 147.7, 132.2, 116.8, 105.0, 96.3, 70.9, 61.5, 61.3, 56.3, 
5.9 ppm; IR (film): ?̃? = 2991, 2935, 2861, 1685, 1584, 1482, 1459, 1430, 1408, 1390, 1329, 
1295, 1264, 1222, 1182, 1191, 1136, 1084, 1049, 988, 966, 920, 839, 754, 689 cm-1; MS (EI) 
m/z (%): 234 (90), 233 (32), 220 (12), 219 (100), 204 (12), 203 (17), 189 (14), 188 (17), 176 
(22), 175 (16), 173 (14), 161 (16), 148 (17), 144 (10), 133 (10), 115 (10), 105 (11), 103 (11), 91 
(11); HRMS (ESI): m/z: calcd. for C13H24O4Na [M+Na
+]: 257.0786, found 257.0784.  
 
Alcohol 406.  At −78 °C t-butyllithium (70 L, 0.12 mmol, 1.7 M) was added to a solution of 
alkyl iodide 158 (42 mg, 0.12 mmol) in Et2O (0.95 mL). After 10 min at 
−78 °C, a solution of aldehyde 152 (18 mg, 78 mol) in Et2O (0.25 mL) was 
added dropwise. After further 15 min at −78 °C, the solution was allowed 
to warm to rt and stirring was continued for 20 min. The reaction was 
quenched by addition of aqueous HCl (2 mL, 2.0 M) and H2O (3 mL) and the 
aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phases were 
dried over Na2SO4 and concentrated, and the crude material was purified by flash 
chromatography (SiO2, hexanes/EtOAc, 7/3) to afford the title compound 406 as a colorless 
oil (32 mg, 88%).  1H NMR (400 MHz, CD3OD):  = 6.93 (s, 1H), 5.14 (tq, 1H, J = 7.2, 1.3 Hz), 
5.07 (dd, 1H, J = 8.1, 4.7 Hz), 5.00 (br, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.81 (s, 3H), 2.12 – 2.07 
(m, 2H), 2.11 (s, 3H), 2.04 – 1.98 (m, 4H), 1.74 (t, 3H, J = 2.6 Hz), 1.74 – 1.68 (m, 2H), 1.61 – 
1.59 (m, 3H), 1.51 – 1.42 (m, 4H), 1.40 – 1.32 ppm (m, 10H); 13C NMR (100 MHz, CD3OD): 
 = 155.5, 154.7, 145.6, 141.9, 135.8, 126.0, 105.7, 94.0, 79.7, 74.1, 73.3, 72.2, 61.6, 61.4, 
56.6, 56.4, 40.2, 39.7, 37.5, 30.9, 30.5, 30.3, 29.7, 28.8, 28.1, 26.9, 19.3, 15.9, 4.3, 3.1 ppm; 
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IR (film): ?̃? = 2924, 2854, 1460, 1331, 1253, 1066, 837, 782, 723, 699, 646, 565, 495 cm-1; MS 
(ESIpos) m/z (%): 491 (M+Na+, 100).  
 
Diyne 150.  Compound 406 (38 mg, 80 mol) was dissolved in CH2Cl2 (1.3 mL) and the 
solution was treated with Dess-Martin periodinane (51 mg, 0.12 mmol) at 
0 °C. After 1 h, the reaction was quenched by addition of an aqueous 
solution of NaHCO3/Na2S2O3 (1:1). The phases were separated, the 
aqueous phase was extracted with CH2Cl2, the organic layers were washed 
with brine, dried over MgSO4 and the solvent was evaporated. The residue 
was purified by flash chromatography (SiO2, hexanes/EtOAc, 7/3) to give ketone 150 as a 
colorless oil (27 mg, 71%).  1H NMR (400 MHz, CD2Cl2):  = 6.87 (s, 1H), 5.13 (tq, 1H, J = 7.2, 
1.1 Hz), 3.90 (s, 3H), 3.86 (s, 6H), 3.05 (t, 2H, J = 7.5 Hz), 2.13 – 2.08 (m, 2H), 2.11 (s, 3H), 2.02 
– 1.95 (m, 4H), 1.75 (t, 3H, J = 2.5 Hz), 1.69 – 1.63 (m, 2H), 1.58 (s, 3H), 1.57 – 1.52 (m, 2H), 
1.47 – 1.40 (m, 4H), 1.38 – 1.28 ppm (m, 6H); 13C NMR (100 MHz, CD2Cl2):  = 204.0, 155.7, 
153.7, 145.2, 139.0, 135.3, 125.4, 110.4, 107.6, 95.1, 79.7, 75.7, 74.5, 61.6, 61.4, 56.6, 42.9, 
39.7, 30.5, 30.3, 30.0, 29.8, 29.3, 28.4, 27.7, 25.1, 19.1, 16.1, 5.1, 3.7 ppm; IR (film): ?̃? = 2926, 
2854, 1732, 1591, 1488, 1461, 1332, 1236, 1196, 1128, 1015, 796 cm-1; MS (ESIpos) m/z (%): 
489 (M+Na+, 100). 
 
Cycloalkyne 149.  Diyne 150 (15 mg, 32 mol) was stirred with MS 5 Å (100 mg) in toluene 
(32 mL) for 30 min before a solution of alkylidyne C4 (8.7 mg, 20 mol%) in 
toluene (1 mL) was added. After stirring for 1 h at ambient temperature, 
the reaction was completed and the mixture was filtered through a pad of 
Celite. The solvent was evaporated and the residue was purified by 
preparative thin layer chromatography (SiO2, hexanes/MTBE, 7/3) to 
afford cycloalkyne 149 as a colorless oil (12 mg, 92%).  1H NMR (400 MHz, CD2Cl2):  = 6.83 
(s, 1H), 5.13 (tq, 1H, J = 7.4, 1.2 Hz), 3.89 (s, 3H), 3.85 (s, 6H), 2.96 (t, 2H, J = 7.5 Hz), 2.46 – 
2.42 (m, 2H), 2.07 – 2.01 (m, 4H), 1.67 – 1.60 (m, 2H), 1.46 – 1.42 (m, 2H), 1.41 – 1.33 (m, 
4H), 1.31 – 1.26 ppm (m, 6H); 13C NMR (100 MHz, CD2Cl2):  = 203.9, 155.8, 153.5, 145.0, 
139.1, 134.8, 126.5, 107.1, 99.3, 88.8, 74.7, 61.6, 61.4, 56.6, 42.8, 39.6, 30.3, 29.4, 28.7, 28.4, 
28.1, 27.6, 27.3, 24.2, 20.7, 15.8 ppm; IR (film): ?̃? = 3068, 3048, 2928, 2854, 1704, 1608, 
1589, 1513, 1486, 1463, 1428, 1284, 1247, 1172, 1117, 1028, 997, 832, 710, 698 cm-1; MS 
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(ESIpos) m/z (%): 435 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C26H36O4Na [M+Na
+]: 
435.2509, found 435.2506.  
 
6.2.2. Early Approaches to the C9−C14-Fragment 
Lactone 172.  -Valerolactone (169) (122 mg, 1.22 mmol) and diethyl oxalate (1.60 mL, 
11.7 mmol) were dissolved in THF (8.5 mL) and the solution was cooled to 0 °C 
before it was added to a suspension of NaH (48 mg, 2.0 mmol) in THF (6.4 mL) at 
0 °C. Ethanol (320 L) was then added and the reaction mixture was allowed to warm to 
ambient temperature. After 4 h, the mixture was cooled to 0 °C and a solution of K2CO3 
(693 mg, 5.02 mmol) in H2O (1.0 mL) followed by paraformaldehyde (1.24 mL, 16.7 mmol, 
37%) was added. After 15 min, the mixture was allowed to warm to 5 °C before brine (5 mL) 
was added. The aqueous phase was extracted with MTBE, the organic layers were washed 
with brine, dried over MgSO4 and concentrated. The crude material was purified by flash 
chromatography (SiO2, pentane/EtOAc, 3/2) to afford title compound 172 as a colorless oil 
(112 mg, 82%).  1H NMR (400 MHz, CDCl3):  = 6.38 (q, 1H, J = 1.9 Hz), 5.52 (q, 1H, J = 1.9 Hz), 
4.40 – 4.31 (t, 2H, J = 6.1 Hz), 2.63 (ddt, 2H, J = 8.1, 6.1, 3.1 Hz), 1.98 – 1.84 ppm (m, 2H). IR 
(film): ?̃? = 2935, 1796, 1737, 1470, 1446, 1368, 1277, 1212, 1178, 1152, 1124, 1074, 1042, 
1028, 1000, 961, 859, 788, 740, 706 cm-1; GC-MS: tR (70_20) = 4.9 min; MS (EI) m/z (%): 112 
(90), 84 (100), 67 (24), 54 (98).  
 
Alcohol 407 and Silyl Ether 175.  DOWEX® 50Wx8 (14 mg) was added to a solution of -
valerolactone (169) (1.00 g, 10.0 mmol) in methanol 
(52 mL). The mixture was stirred at reflux 
temperature for 4 h before it was filtered through a 
pad of Celite and the solvent was evaporated. The obtained colorless oil was subjected to 
the next step without further purification.  
Alcohol 407 (1.16 g, 10.0 mmol) was dissolved in THF (20 mL) and the solution was cooled to 
0 °C before TBSCl (1.96 g, 13.0 mmol) and imidazole (1.70 g, 25.0 mmol) were added. After 
warming to rt, the mixture was stirred for 4 h. The yellow suspension was filtered trough a 
pad of Celite to remove imidazole and salts. Then the sovent was removed under reduced 
pressure. The crude material was purified by flash chromatography (SiO2, hexanes/EtOAc, 
9/1) to afford TBS-ether 175 as a colorless oil (2.34 g, 95% over 2 steps).  1H NMR (400 MHz, 
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CDCl3):  = 3.63 (s, 3H), 3.58 (t, 2H, J = 6.3 Hz), 2.30 (t, 2H, J = 7.5 Hz), 1.72 – 1.59 (m, 2H), 
1.56 – 1.44 (m, 2H), 0.85 (s, 9H), 0.00 ppm (s, 6H); 13C NMR (100 MHz, CDCl3):  = 174.2, 
62.7, 51.6, 33.9, 32.2, 26.0 (3C), 21.5, 18.5, −5.3 ppm (2C); IR (film): ?̃? = 2953, 2930, 2858, 
1741, 1472, 1463, 1436, 1388, 1361, 1250, 1198, 1164, 1093, 1006, 972, 938, 872, 833, 773, 
715, 661 cm-1; MS (EI) m/z (%): 245 (1), 215 (10), 191 (3), 189 (59), 158 (8), 157 (64), 115 
(12), 113 (12), 101 (7), 90 (8), 89 (100), 75 (26), 73 (25), 59 (15), 55 (13); HRMS (ESIpos): m/z: 
calcd. for C12H26O3SiNa [M+Na
+]: 269.1543, found 269.1543. 
 
Diester 176.  In a pressure tube methyl acrylate (168) (0.96 g, 11.2 mmol) was treated with 
n-Bu3P (0.14 mL, 5 mol%) and hydroquinone (25 mg, 2 mol%). The 
mixture was stirred for 24 h at 50 °C in the sealed tube. The resulting 
yellow solution was poured into aqueous HCl (4.0 M) to remove the phosphine and the 
aqueous phase was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were 
washed with aqueous NaHCO3 (15 mL), H2O (15 ml) and brine (10 mL), dried over MgSO4 and 
concentrated to afford the title compound 176 as a colorless oil (441 mg, 23%).  1H NMR 
(400 MHz, CDCl3):  = 5.95 (d, 1H, J = 1.2 Hz), 5.39 (d, 1H, J = 1.2 Hz), 3.53 (s, 3H), 3.44 (s, 3H), 
2.48 – 2.36 (m, 2H), 2.31 ppm (dd, 2H, J = 8.0, 1.0 Hz).; IR (film): ?̃? = 2954, 1720, 1631, 1436, 
1378, 1332, 1307, 1256, 1196, 1159, 1139, 1048, 990, 954, 884, 832, 818, 759, 688 cm-1; GC-
MS: tR (70_20) = 5.5 min; MS (EI) m/z (%): 172 (5), 140 (78), 125 (2), 112 (100), 97 (16), 81 
(35).  
 
Diacid 408.  A solution of LiOH∙H2O (645 mg, 15.4 mmol) in H2O (1.0 mL) was added to 
diester 176 (441 mg, 2.56 mmol) in THF (3.0 mL) at 0 °C. After 24 h the 
reaction mixture was acidified with aqueous HCl (2.0 M), extracted with 
EtOAc (3 x 20 mL) and dried over MgSO4. The solvent was evaporated to yield diacid 408 as a 
colorless crystalline solid (315 mg, 85%).  1H NMR (400 MHz, CD3OD):  = 12.41 (br s, 1H), 
10.02 (br, 1H), 6.18 (s, 1H), 5.60 (s, 1H), 2.61 – 2.55 (m, 2H), 2.50 – 2.46 ppm (m, 2H); 
13C NMR (100 MHz, CD3OD):  = 175.1, 168.7, 139.1, 125.5, 32.6, 26.9 ppm. 
 
Methyl Ester 177.  A solution of compound 408 (275 mg, 1.91 mmol) in methanol (5.5 mL) 
was treated with camphorsulfonic acid (89 mg, 0.38 mmol). After stirring 
for 1 h, the mixture was filtered through a pad of Celite and the solvent 
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was evaporated. The residue was purified by flash chromatography (SiO2, pentane/EtOAc, 
1/1) to give monoester 177 as a colorless oil (266 mg, 88%).  1H NMR (400 MHz, CD3OD): 
 = 6.17 – 6.16 (m, 1H), 5.63 (d, 1H, J = 1.3 Hz), 5.33 (br, 1H), 3.64 (s, 3H), 2.61 – 2.56 (m, 2H), 
2.54 – 2.50 ppm (m, 2H); 13C NMR (100 MHz, CD3OD):  = 174.8, 169.7, 140.8, 126.4, 52.1, 
33.8, 28.3 ppm; IR (film): ?̃? = 2954, 2356, 2267, 2076, 1735, 1690, 1629, 1438, 1360, 1272, 
1198, 1171, 1027, 985, 951, 887, 824, 752, 683 cm-1; MS (neg. ESI) m/z (%): 157 (M−H+, 100). 
 
tert-Butyl Ether 183.  A solution of 3-chloropropan-1-ol (182) (25.0 mL, 299 mmol) in CH2Cl2 
(625 mL) was treated dropwise with sulfuric acid (1.60 mL, 30.0 mmol). 
Iisobutene was bubbled through the vigorously stirred solution until it was 
saturated. After 2 h, the reaction was completed and saturated aqueous NaHCO3 was added 
to the mixture until gas formation ceased. The phases were then separated and the aqueous 
phase was extracted with CH2Cl2 (2 x 80 mL). The combined organic phases were dried over 
Na2SO4 and the solvent was evaporated. The crude material was distilled (64 – 
67 °C/44 mbar) to give the title compound 183 as a colorless oil (44.7 g, 99%).  1H NMR 
(400 MHz, CDCl3):  = 3.64 (t, 2H, J = 6.3 Hz), 3.48 (t, 2H, J = 5.8 Hz), 1.95 (tt, 2H, J = 6.3, 
5.8 Hz), 1.18 ppm (s, 9H); 13C NMR (100 MHz, CDCl3):  = 80.4, 65.1, 41.2, 32.4, 28.1 ppm 
(3C); MS (EI) m/z (%): 135 (11), 115 (23), 93 (100), 57 (46), 48 (17); HRMS (EI): m/z: calcd. for 
C7H15OCl [M
+]: 150.0811, found 150.0810. 
 
tert-Butyl Ester 184.  Magnesium pellets (1.94 g, 79.8 mmol) were activated with 1,2-
dibromoethane (one drop) before a small amount of the solution of 
chloride 183 (100 mg, 0.67 mmol) in THF (1.0 mL) was added. After 
Grignard formation was initiated, the remaining substrate 183 (11.8 g, 78.7 mmol) was 
added as a solution in THF (39 mL) via dropping funnel to the refluxing mixture. After 2 h, the 
Grignard formation was completed and the mixture was allowed to cool to ambient 
temperature. In a separate flask a solution of ZnCl2 in THF (2.0 mL, 1.0 M) was prepared at 
0 °C before triflate 181[81-82] (11.2 g, 40.1 mmol) was added, followed by the freshly prepared 
solution of the Grignard reagent (40 mL, 1.9 M). After stirring for 2 h at 0 °C, the triflate was 
consumed and the reaction was quenched with saturated aqueous NH4Cl (25 mL). The 
aqueous phase was extracted with CH2Cl2 (3 x 50 mL), the combined organic layers were 
dried over MgSO4 and the solvent was evaporated. The crude material was purified by flash 
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chromatography (SiO2, pentane/EtOAc, 4/1) to yield the coupling product 184 as a colorless 
oil (6.47 g, 66%).  1H NMR (400 MHz, CDCl3):  = 3.32 (tt, 2H, J = 5.7, 2.8 Hz), 2.35 – 2.27 (m, 
1H), 1.66 – 1.49 (m, 2H), 1.54 – 1.40 (m, 2H), 1.43 (s, 9H), 1.17 (s, 9H), 1.10 ppm (d, 3H, 
J = 7.0 Hz); 13C NMR (100 MHz, CDCl3):  = 176.4, 79.9, 72.6, 61.5, 40.4, 30.6, 28.5, 28.2 (3C), 
27.7 (3C), 17.3 ppm; IR (film): ?̃? = 2973, 1728, 1459, 1391, 1363, 1256, 1149, 1079, 849, 
749 cm-1; MS (EI) m/z (%): 171 (1), 131 (22), 115 (100), 103 (4), 97 (7), 69 (14), 57 (67), 56 
(19), 55 (12), 41 (32); HRMS (ESI): m/z: calcd. for C14H28O3Na [M+Na
+]: 267.1928, found 
267.1931. 

-Lactone 174.  A solution of tert-butyl ester 184 (4.89 g, 18.8 mmol) in CH2Cl2 (40 mL) was 
treated with trifluoroacetic acid (8.0 mL, 100 mmol) at 0 °C. The mixture was 
allowed to warm to ambient temperature. After 16 h, the reaction was quenched 
by addition of saturated aqueous NaHCO3. The mixture was extracted with CH2Cl2 (3 x 
30 mL), the organic phases were dried over MgSO4 and concentrated. The residue was 
purified by column chromatography (SiO2, pentane/Et2O, 1/1) to yield -lactone 174  as a 
colorless oil (1.41 g, 66%, 90% ee).  [𝛼]D
20 = +59 (c = 1.07, CHCl3); 
1H NMR (400 MHz, CDCl3): 
 = 4.24 – 4.14 (m, 2H), 2.02 – 1.94 (m, 1H), 1.78 (tt, 2H, J = 6.8, 5.9 Hz), 1.46 – 1.36 (m, 1H), 
1.11 ppm (d, 3H, J = 6.9 H); 13C NMR (100 MHz, CDCl3):  = 175.2, 68.3, 34.3, 26.8, 21.8, 
16.4 ppm; IR (film): ?̃? = 2971, 2938, 2876, 1726, 1461, 1380, 1362, 1326, 1241, 1197, 1151, 
1083, 1061, 1027, 1012, 943, 917, 730 cm-1; MS (EI) m/z (%): 114 (30), 70 (21), 56 (43), 55 
(100), 41 (37), 39 (19); HRMS (EI): m/z: calcd. for C6H10O2 [M
+]: 114.0680, found 114.0681. 
 
Dichloro Olefin 189.  A solution of -lactone 174 (1.41 g, 12.4 mmol) and PPh3 (12.9 g, 
49.6 mmol) in THF (250 mL) was prepared. A solution of CCl4 (29.2 mL, 
301 mmol) in THF (50 mL) was added over 4 h to the refluxing mixture. Upon 
complete addition, the reaction mixture was stirred for 15 min and then 
allowed to cool to ambient temperature before H2O (250 mL) was added. The aqueous 
phase was extracted with CH2Cl2 (3 x 150 mL), the organic layers were washed with 
saturated aqueous NaHCO3 (150 mL), dried over MgSO4 and concentrated to ca. 20 mL. 
Pentane (100 mL) was added to the residue under vigorous stirring to give a white 
precipitate that was removed by filtration. This procedure was repeated three times. Then, 
the solvent was evaporated and the crude material was purified by flash chromatography 
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(SiO2, pentane 100%  pentane/Et2O, 49/1) to give the dichloro olefin 189 as a colorless oil 
(1.59 g, 71%).  [𝛼]D
20 = +125 (c = 0.96, CHCl3); 
1H NMR (400 MHz, C6D6):  = 3.75 (ddt, 1H, 
J = 10.9, 5.1, 1.9 Hz), 3.17 (ddd, 1H, J = 13.3, 10.9, 2.8 Hz), 2.80 (tt, 1H, J = 7.2, 5.1 Hz), 1.53 – 
1.41 (m, 1H), 1,21 (tdd, 1H, J = 13.3, 5.4, 4.2 Hz), 1.08 – 1.02 (m, 1H), 0.92 (d, 3H, J = 7.2 Hz), 
0.74 – 0.68 ppm (m, 1H); 13C NMR (100 MHz, C6D6):  = 154.4, 104.6, 70.3, 29.5, 28.2, 19.9, 
17.3 ppm; IR (film): ?̃? = 2939, 2871, 1731, 1623, 1375, 1274, 1249, 1178, 1134, 1072, 1010, 
953, 920, 882 cm-1; MS (EI) m/z(%): 184 (15), 182 (47), 180 (73), 165 (24), 145 (27), 139 (54), 
110 (52), 70 (79), 55 (100), 27 (20); HRMS (EI): m/z: calcd. for C7H10OCl2 [M
+]: 180.0109, 
found 180.0111.  
 
Alkynol 190.  A solution of dichloro olefin 189 (1.27 g, 6.99 mmol) in Et2O (4 mL) and 
Cu(acac)2 (183 mg, 10 mol%) were subsequently added to a solution of 
methyllithium (13.1 mL, 21.0 mmol, 1.6 M) in Et2O (60 mL). After stirring 
for 14 h, the reaction was complete and excess methyllithium was quenched by addition of 
H2O (100 mL). The aqueous phase was extracted with Et2O (3 x 150 mL), the organic layers 
were dried over MgSO4 and the solvent was evaporated. The crude material was purified by 
flash chromatography (SiO2, pentane/Et2O, 1/1) to give the title compound as a colorless oil 
(829 mg, 92%, 90% ee).  [𝛼]D
20 = +37 (c = 1.05, CHCl3); 
1H NMR (400 MHz, CDCl3):  = 4.10 (br 
s, 1H), 3.58 (t, 2H, J = 6.6 Hz), 2.37 – 2.29 (m, 1H), 1.72 (d, 3H, J = 2.4 Hz), 1.70 – 1.53 (m, 2H), 
1.46 – 1.31 (m, 2H), 1.08 ppm (d, 3H, J = 6.9 Hz); 13C NMR (100 MHz, CDCl3):  = 83.6, 75.9, 
62.7, 35.5, 30.6, 25.8, 21.5, 3.4 ppm; IR (film): ?̃? = 3340, 2922, 2870, 1452, 1376, 1339, 1055, 
983, 896 cm-1; MS (EI) m/z (%): 111 (9), 93 (11), 91 (16), 84 (11), 83 (14), 82 (87), 80 (12), 79 
(23), 77 (23), 69 (17), 67 (100), 65 (26), 55 (15), 53 (12), 39 (14); HRMS (EI): m/z: calcd. for 
C8H14O [M
+]: 126.1045, found 126.1045.  
 
Aldehyde 68.  Alcohol 190 (1.64 g, 13.0 mmol) was dissolved in MeCN (65 mL). 
[Cu(MeCN)4]BF4 (204 mg, 5 mol%), bipyridine (101 mg, 5 mol%), TEMPO 
(101 mg, 5 mol%) and N-methyl imidazole (107 mg, 10 mol%) were 
added. The initial red color of the reaction solution had changed to dark green when the 
reaction was completed. The mixture was filtered through a pad of Celite and the solvent 
was evaporated. The residue was purified by flash chromatography (SiO2, pentane/Et2O, 9/1) 
to yield the title compound as a colorless oil (1.54 g, 96%, 90% ee).  1H NMR (400 MHz, 
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CDCl3):  = 9.77 (s, 1H), 2.65 –2.50 (m, 2H), 2.44 – 2.41 (m, 1H), 1.81 – 1.73 (m, 1H), 1.76 (s, 
3H), 1.63 (tdd, 1H, J = 14.3, 8.2, 6.2 Hz), 1.12 ppm (d, 3H, J = 7.0 Hz); 13C NMR (100 MHz. 
CDCl3):  = 202.0, 82.1, 76.5, 41.6, 29.0, 25.2, 21.0, 3.0 ppm; IR (film): ?̃? = 2971, 2922, 1723, 
1454, 1376, 1335, 1259, 1021, 800 cm-1; MS (EI) m/z (%): 96 (10), 82 (100), 81 (25), 80 (42), 
79 (62), 77 (18), 67 (63), 65 (29), 55 (14), 53 (18), 41 (43), 39 (24); HRMS (ESI): m/z: calcd. for 
C8H13O [M+H
+]: 125.0965, found 125.0966.  
 
6.2.3. Synthesis of the Northwestern Fragment  
-Hydroxyimide 409.  A solution of (n-Bu)2BOTf (29.4 mL, 29.4 mmol, 1.0 M in CH2Cl2) was 
added via syringe over a period of 10 min to a solution of compound (ent)-
86 (5.80 g, 24.9 mmol) in CH2Cl2 (47 mL) at −78 °C. Then Et3N (4.49 mL, 
32.4 mmol) was added dropwise over 15 min. The mixture was briefly 
allowed to warm to ambient temperature. After cooling to 0 °C, freshly 
distilled propanal (2.35 ml, 32.4 mmol) was added dropwise. After another 3.5 h, the 
reaction was quenched by addition of H2O (28 mL), MeOH (74 mL) and H2O2 (28 mL, 30% 
wt). The mixture was stirred for 2.5 h and concentrated to a slurry, and the aqueous phase 
was extracted with EtOAc (3 x 90 mL). The organic layers were dried over MgSO4 and 
concentrated. The crude material was purified by flash chromatography (SiO2, 
pentane/EtOAc, 7/3) to afford the title compound as a colorless solid (6.66 g, 92%). 
[𝛼]D
23 = −36.5 (c = 1.07, CHCl3) 
1H NMR (400 MHz, CDCl3):  = 7.28 – 7.19 (m, 3H), 7.14 – 7.12 
(m, 2H), 4.64 (ddt, 1H, J = 9.4, 7.4, 3.3 Hz), 4.18 – 4.10 (m, 2H), 3.79 (ddd, 1H, J = 8.1, 5.1, 
2.8 Hz), 3.72 (qd, 1H, J = 7.0, 2.7 Hz), 3.18 (dd, 1H, J = 13.4, 3.4 Hz), 2.79 (s, 1H), 2.72 (dd, 1H, 
J = 13.4, 9.4 Hz), 1.56 – 1.40 (m, 2H), 1.18 (d, 3H, J = 7.0 Hz), 0.91 ppm (t, 3H, J = 7.4 Hz); 
13C NMR (100 MHz, CDCl3):  = 177.2, 155.7, 134.7, 129.1 (2C), 128.6 (2C), 127.1, 72.7, 65.9, 
54.8, 41.3, 37.5, 26.4, 10.1, 9.9 ppm; IR (film): ?̃? = 3524, 2975, 2937, 2880, 1755, 1697, 1478, 
1456, 1373, 1346, 1326, 1264, 1208, 1185, 1115, 1098, 1069, 1055, 983, 969, 928, 764, 750, 
706, 696 cm-1; MS (EI) m/z (%): 291 (42), 273 (17), 245 (12), 244 (74), 233 (38), 178 (63), 158 
(15), 142 (13), 134 (36), 133 (23), 118 (16), 117 (68), 116 (33), 115 (70), 97 (33), 96 (11), 92 
(27), 91 (57), 86 (100), 85 (11), 69 (27), 65 (14), 59 (23), 57 (38), 56 (17), 45 (14), 42 (14), 41 
(13), 31 (16), 29 (16); HRMS (ESI): m/z: calcd. for C16H21NO4Na [M+Na
+]: 314.1362, found 
314.1363. The analytical and spectroscopic data are in agreement with those reported in the 
literature.[56a, 154] 
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-Ketoimide 48.  -Hydroxyimide 409 (5.49 g, 18.8 mmol) was dissolved in CH2Cl2/DMSO 
(108 mL, 1:1) and the solution was cooled to −15 °C. Et3N (8.03 mL, 
57.1 mmol) was added in one portion, then a solution of SO3∙py (9.09 g, 
57.1 mmol) in DMSO (81 mL) was slowly added via a dropping funnel. The 
reaction mixture was stirred for 3 h. Aqueous KHSO4 (250 mL, 1.0 M) was 
added and the aqueous phase was extracted with Et2O (3 x 200 mL). The combined organic 
layers were washed with saturated aqueous NaHCO3 (40 mL) and brine (30 mL), dried over 
MgSO4 and concentrated. The crude material was purified by flash chromatography (SiO2, 
pentane/MTBE, 1/1) to afford the title compound 48 as a crystalline colorless solid (4.55 g, 
83%). [𝛼]D
23 = −129 (c = 1.38, CHCl3), 
1H NMR (400 MHz, CDCl3):  = 7.35 – 7.27 (m, 3H), 
7.20 – 7.16 (m, 2H), 4.73 (ddt, 1H, J = 9.5, 7.8, 3.2 Hz), 4.60 (q, 1H, J = 7.3 Hz), 4.26 – 4.13 (m, 
2H), 3.30 (dd, 1H, J = 13.4, 3.6 Hz), 2.77 (dd, 1H, J = 13.4, 9.5 Hz), 2.64 (dq, 2H, J = 11.0, 
7.3 Hz), 1.43 (d, 3H, J = 7.3 Hz), 1.06 ppm (t, 3H, J = 7.3 Hz); 13C NMR (100 MHz, CDCl3): 
 = 208.0, 170.1, 153.8, 135.1, 129.3 (2C), 128.9 (2C), 127.3, 66.4, 55.2, 52.6, 37.9, 34.0, 12.8, 
7.5 ppm; IR (film): ?̃? = 2981, 1766, 1713, 1696, 1451, 1386, 1352, 1337, 1280, 1247, 1223, 
1215, 1179, 1120, 1070, 1049, 994, 958, 908, 763, 750, 705, 686 cm-1; MS (EI) m/z (%): 289 
(20), 260 (32), 233 (20), 178 (12), 142 (29), 134 (21), 133 (18), 117 (59), 116 (21), 113 (51), 91 
(28), 57 (100), 56 (15), 29 (22); HRMS (ESI): m/z: calcd. for C16H19NO4Na [M+Na
+]: 312.1205, 
found 312.1206. The analytical and spectroscopic data are in agreement with those reported 
in the literature.[155] 
 
Aldol 193.  Sn(OTf)2 (4.36 g, 10.5 mmol) was dispersed in CH2Cl2 (20 mL). The mixture was 
cooled to −20 °C. Upon addition of Et3N (1.46 mL, 10.5 mmol) the 
colorless suspension turned pale yellow. Then a solution of -
ketoimide 48 (2.86 g, 9.89 mmol) in CH2Cl2 (10 mL) was added 
dropwise and the resulting mixture was stirred for 1 h at −20 °C before it was cooled to 
−78 °C and a solution of aldehyde 68 (766 mg, 6.18 mmol) in CH2Cl2 (10 mL) was added 
dropwise. Upon completion of the reaction, the mixture was diluted with CH2Cl2 (100 mL) 
and poured into a cooled (0 °C) aqueous solution of NaHSO4 (150 mL, 1.0 M). The resulting 
mixture was vigorously stirred for 20 min. The aqueous phase was extracted with CH2Cl2 (3 x 
100 mL), the combined organic phases were washed with saturated aqueous NaHCO3 
(40 mL), dried over MgSO4 and concentrated. The crude material was purified by flash 
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chromatography (SiO2, pentane/MTBE, 1/1) to afford the title compound as a colorless sticky 
oil (1.46 g, 57%).[156] [𝛼]D
23 = −48.0 (c = 1.00, CHCl3), 
1H NMR (400 MHz, CDCl3):  = 7.35 – 
7.32 (m, 2H), 7.30 – 7.28 (m, 1H), 7.21 – 7.19 (m, 2H), 4.87 (q, 1H, J = 7.3 Hz), 4.76 (ddt, 1H, 
J = 9.7, 8.0, 3.1 Hz), 4.27 (t, 1H, J = 8.0 Hz), 4.19 (dd, 1H, J = 9.1, 2.9 Hz), 3.94 (ddd, 1H, J = 9.0, 
4.1, 2.7 Hz), 3.31 (dd, 1H, J = 13.4, 3.4 Hz), 2.83 – 2.76 (m, 2H), 2.49 (br, 1H), 2.44 – 2.39 (m, 
1H), 1.78 (d, 3H, J = 2.3 Hz), 1.72 – 1.66 (m, 1H), 1.60 – 1.52 (m, 1H), 1.49 (d, 3H, J = 7.3 Hz), 
1.47 – 1.40 (m, 2H), 1.25 (d, 3H, J = 7.2 Hz), 1.14 ppm (d, 3H, J = 6.8 Hz); 13C NMR (100 MHz, 
CDCl3):  = 212.1, 170.3, 153.6, 135.0, 129.4 (2C), 129.0 (2C), 127.4, 83.3, 76.0, 70.9, 66.5, 
55.3, 51.9, 48.4, 37.9, 33.4, 31.6, 25.6, 21.4, 12.9, 10.0, 3.5 ppm; IR (film): ?̃? = 2970, 2940, 
1775, 1711, 1690, 1454, 1357, 1289, 1212, 1115, 1077, 1049, 998, 923, 761, 742, 702 cm-1; 
MS (EI) m/z (%): 344 (13), 289 (34), 260 (53), 233 (46), 178 (56), 177 (11), 167 (25), 142 (12), 
135 (12), 134 (34), 133 (23), 125 (16), 123 (15), 118 (10), 117 (62), 116 (17), 113 (17), 112 
(100), 107 (11), 93 (11), 92 (29), 91 (45), 86 (24), 83 (26), 82 (15), 80 (16), 79 (13), 67 (18), 65 
(10), 56 (24), 55 (32); HRMS (ESI): m/z: calcd. for C24H31NO5Na [M+Na
+]: 436.2098, found 
436.2094. The analytical and spectroscopic data are in agreement with those reported in the 
literature.[41] 
 
1,3-Diol 410.  A solution of compound 193 (1.46 g, 3.53 mmol) in MeCN (44 mL) was added 
to a solution of Me4NBH(OAc)3 (4.64 g, 17.7 mmol) in MeCN 
(70 mL) and AcOH (39 mL) via a dropping funnel at −50 °C. The 
mixture was allowed to warm to −10 °C. After stirring for 1 h, the 
reaction mixture was poured into a mixture of saturated aqueous Rochelle salt (350 mL) and 
CH2Cl2 (350 mL) (1:1) at 0 °C. Under vigorous stirring, saturated aqueous NaHCO3 followed by 
solid NaHCO3 were added until gas evolution ceased. The aqueous phase was extracted with 
CH2Cl2 (4 x 200 mL), the last batch was stirred with the aqueous phase for 5 min. The 
combined organic layers were washed with brine, dried over MgSO4 and concentrated. The 
residue was purified by flash chromatography (SiO2, pentane/EtOAc, 1/1) to afford the title 
compound as a colorless foam (1.16 g, 80%). [𝛼]D
23 = −5.0 (c = 0.93, CHCl3), 
1H NMR 
(400 MHz, CDCl3):  = 7.36 – 7.28 (m, 3H), 7.21 – 7.19 (m, 2H), 4.71 (ddt, 1H, J = 9.4, 7.6, 
3.2 Hz), 4.27 – 4.19 (m, 2H), 4.00 (dd, 1H, J = 9.1, 2.5 Hz), 3.90 (qd, 1H, J = 7.0, 2.5 Hz), 3.82 
(dt, 1H, J = 9.7, 2.8 Hz), 3.65 (br, 1H), 3.25 (dd, 1H, J = 13.4, 3.4 Hz), 2.80 (dd, 1H, J = 13.4, 
9.4 Hz), 2.47 – 2.35 (m, 1H), 1.87 (dqd, 1H, J = 9.4, 7.1, 2.5 Hz), 1.78 (d, 3H, J = 2.3 Hz), 1.70 –
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 1.42 (m, 5H), 1.28 (d, 3H, J = 7.0 Hz), 1.14 (d, 3H, J = 7.0 Hz), 0.87 ppm (d, 3H, J = 7.0 Hz); 
13C NMR (100 MHz, CDCl3):  = 177.7, 152.5, 134.6, 129.1 (2C), 128.6 (2C), 127.1, 83.3, 75.6, 
73.4, 73.2, 65.9, 54.7, 39.2, 38.9, 37.5, 33.6, 30.2, 25.4, 21.1, 11.4, 9.8, 3.2 ppm; IR (film): 
?̃? = 2970, 2919, 1779, 1697, 1455, 1387, 1210, 1106, 1045, 1015, 972, 762, 702 cm-1; MS 
(pos. ESI) m/z (%): 438 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C24H33NO5Na [M+Na
+]: 438. 
2254, found 438.2251. The analytical and spectroscopic data are in agreement with those 
reported in the literature.[41] 
 
-Lactone 194.  Diol 410 (878 mg, 2.13 mmol) was dissolved in THF/H2O (21 mL, 3:1) and the 
solution was cooled to 0 °C. The mixture was treated with H2O2 (0.85 mL, 30% 
wt) and LiOH (143 mg, 3.41 mmol). The resulting mixture was stirred at 
ambient temperature for 2 h until TLC control indicated full conversion of the 
diol 410. The mixture was acidified with aqueous HCl (2.0 mL, 1.0 M) and 
stirred for 5 min before the aqueous phase was extracted with Et2O (3 x 
60 mL). The combined organic phases were dried over MgSO4 and concentrated. The crude 
material was purified by flash chromatography (SiO2, pentane/EtOAc, 7/3  1/1) to afford -
lactone 194 as a colorless oil (512 mg, 99%). [𝛼]D
23 = +95.2 (c = 0.75, CHCl3), 
1H NMR 
(400 MHz, CDCl3):  = 3.80 (ddd, 1H, J = 8.7, 5.0, 2.4 Hz), 3.36 (dd, 1H, J = 10.4, 4.3 Hz), 2.47 –
 2.35 (m, 2H), 2.16 (br, 1H), 1.98 (dddd, 1H, J = 13.1, 10.2, 8.6, 4.4 Hz), 1.72 – 1.58 (m, 2H), 
1.68 (d, 3H, J = 2.4 Hz), 1.52 – 1.33 (m, 2H), 1.47 (d, 3H, J = 7.1 Hz), 1.22 (d, 3H, J = 6.9 Hz), 
0.81 ppm (d, 3H, J = 7.1 Hz); 13C NMR (100 MHz, CDCl3):  = 173.3, 83.6, 79.4, 76.8, 74.0, 
40.4, 37.8, 33.4, 30.6, 26.3, 21.9, 14.7, 4.7, 3.6 ppm; IR (film): ?̃? = 2941, 1766, 1713, 1696, 
1475, 1464, 1451, 1386, 1353, 1337, 1280, 1247, 1223, 1214, 1179, 1120, 1085, 1070, 1049, 
1032, 994, 973, 958, 908, 857, 825, 763, 750, 705, 686 cm-1; MS (EI) m/z (%): 152 (11), 151 
(45), 147 (11), 137 (10), 136 (17), 135 (23), 133 (11), 131 (12), 130 (12), 125 (50), 124 (17), 
123 (35), 122 (12), 121 (40), 119 (20), 113 (49), 112 (16), 111 (10), 109 (56), 108 (31), 107 
(81), 106 (12), 105 (34), 103 (15), 98 (42), 97 (21), 96 (32), 95 (48 ), 94 (17), 93 (74), 91 (53), 
87 (16), 86 (12), 85 (77), 83 (22), 82 (81), 81 (49), 80 (93), 79 (90), 77 (31), 69 (43), 68 (26), 67 
(100), 66 (15), 65 (28), 59 (13), 58 (35), 57 (69), 56 (31), 55 (72), 53 (27), 44 (19), 43 (44), 41 
(67), 39 (27), 29 (21); HRMS (ESI): m/z: calcd. for C14H22NO3Na [M+Na
+]: 261.1459, found 
261.1461. The analytical and spectroscopic data are in agreement with those reported in the 
literature.[41]  
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Methyl Ester 166.  Camphorsulfonic acid (49 mg, 10 mol%) was added to a solution of -
lactone 194 (512 mg, 2.11 mmol) in 2,2-dimethoxypropane (26 mL) and the 
reaction mixture was stirred at ambient temperature overnight. The 
mixture was diluted with Et2O (50 mL), treated with saturated aqueous 
NaHCO3 and the aqueous phase was extracted with Et2O (3 x 50 mL). The 
combined organic phases were washed with brine (40 mL), dried over MgSO4 and 
concentrated. The residue was purified by flash chromatography (SiO2, pentane/Et2O, 7/3) 
to afford methyl ester 166 as a colorless oil (589 mg, 90%).[44a, 147] [𝛼]D
20 = −1.86 (c = 0.59, 
CHCl3), 
1H NMR (400 MHz, CDCl3):  = 3.76 (dt, 1H, J = 9.4, 4.4 Hz), 3.69 (s, 3H), 3.63 (dd, 1H, 
J = 7.7, 5.0 Hz), 2.60 – 2.54 (m, 1H), 2.43 – 2.37 (m, 1H), 1.87 – 1.82 (m, 1H), 1.79 (d, 3H, 
J = 2.3 Hz), 1.62 – 1.49 (m, 2H), 1.44 – 1.35 (m, 2H), 1.31 (s, 3H), 1.29 (s, 3H), 1.20 (d, 3H, 
J = 7.0 Hz), 1.13 (d, 3H, J = 6.9 Hz), 0.84 ppm (d, 3H, J = 6.8 Hz); 13C NMR (100 MHz, CDCl3): 
 = 174.6, 100.2, 83.2, 75.4, 75.0, 68.7, 51.3, 42.6, 36.5, 33.0, 27.8, 25.3, 24.6, 23.3, 20.9, 
11.7, 11.1, 3.2 ppm; IR (film): ?̃? = 2983, 2937, 2877, 1738, 1456, 1434, 1379, 1224, 1198, 
1166, 1126, 1090, 1018, 985, 954, 876, 855, 838 cm-1; MS (pos. ESI) m/z (%): 333 (M+Na+, 
100); HRMS (ESI): m/z: calcd. for C18H30NO4Na [M+Na
+]: 333.2037, found 333.2036.  
 
Alkenyl Silane 411.  A solution of freshly prepared LiSiMe2Ph
[91] (6.70 mL, 2.01 mmol) in THF 
(5.1 mL) was added to CuCN (180 mg, 2.01 mmol) at 0 °C. After 30 min 
of stirring, the mixture was cooled to −78 °C and a solution of alkyne 
166 (406 mg, 1.34 mmol) in THF (1.0 mL) was added dropwise. After 
30 min, the reaction mixture was allowed to warm to 0 °C and 
saturated aqueous NH4Cl (20 mL) was added. The aqueous phase was extracted with CH2Cl2 
(3 x 50 mL). The combined organic layers were dried over MgSO4 and concentrated. The 
crude material was purified by flash chromatography (SiO2, pentane 100%  pentane/EtOAc 
30/1) to afford the title compound as a colorless oil (557 mg, 93%). [𝛼]D
23 = −18.0 (c = 0.52, 
CHCl3), 
1H NMR (400 MHz, CDCl3):  = 7.50 – 7.47 (m, 2H), 7.34 – 7.32 (m, 3H), 5.58 (d, 1H, 
J = 9.4 Hz), 3.74 – 3.69 (m, 1H), 3.69 (s, 3H), 3.62 (dd, 1H, J = 7.8, 5.0 Hz), 2.63 – 2.53 (m, 2H), 
1.84 – 1.75 (m, 1H), 1.64 (d, 3H, J = 1.7 Hz), 1.47 – 1.34 (m, 2H), 1.31 (s, 3H), 1.30 (s, 3H), 
1.28 – 1.25 (m, 2H), 1.19 (d, 3H, J = 6.9 Hz), 0.95 (d, 3H, J = 6.6 Hz), 0.81 (d, 3H, J = 6.8 Hz), 
0.32 (s, 3H), 0.31 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 175.1, 147.8, 139.1, 134.1 (2C), 
132.2, 128.9, 127.8 (2C), 100.7, 75.5, 69.4, 51.8, 43.1, 36.9, 33.3, 32.5, 28.5, 25.2, 23.8, 20.8, 
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15.1, 12.1, 11.6, −3.1, −3.3 ppm; IR (film): ?̃? = 2986, 2953, 1739, 1618, 1456, 1428, 1379, 
1320, 1290, 1247, 1224, 1200, 1173, 1200, 1173, 1109, 1055, 1020, 999, 985, 968, 956, 926, 
880, 831, 811, 772, 746, 729, 699 cm-1; MS (EI) m/z (%): 245 (14), 137 (23), 136 (14), 135 
(100), 128 (19), 127 (13), 121 (13), 75 (11), 73 (15); HRMS (ESI): m/z: calcd. for C26H42O4SiNa 
[M+Na+]: 469.2748, found 469.2745.  
 
Alkenyl Iodide 164.  A solution of alkenyl silane 411 (472 mg, 1.06 mmol) in HFIP[157] (11 mL) 
was treated at 0 °C with 2,6-lutidine (0.50 mL, 4.3 mmol) and NIS (358 mg, 
1.59 mmol) and the resulting mixture was stirred for 30 min at 0 °C. Then, 
saturated aqueous Na2S2O5 (30 mL) was added to quench the reaction. The 
aqueous phase was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic phases were dried over MgSO4 and concentrated. The residue was purified by flash 
chromatography (SiO2, pentane100%  pentane/EtOAc, 20/1) to afford alkenyl iodide 164 
as a colorless oil (458 mg, 97%). [𝛼]D
23 = +11.5 (c = 1.08, CHCl3), 
1H NMR (400 MHz, C6D6): 
 = 5.97 (d, 1H, J = 10.0 Hz), 3.80 (dd, 1H, J = 7.7, 4.8 Hz), 3.67 (dt, 1H, J = 9.1, 4.2 Hz), 3.38 (s, 
3H), 2.49 (qd, 1H, J = 6.9, 4.4 Hz), 2.20 – 2.15 (m, 1H), 2.14 (s, 3H), 1.75 – 1.66 (m, 1H), 1.45 –
 1.32 (m, 2H), 1.34 (s, 3H), 1.29 (d, 3H, J = 6.7 Hz), 1.29 (s, 3H), 1.13 – 1.00 (m, 2H), 0.75 (d, 
3H, J = 6.8 Hz), 0.75 ppm (d, 3H, J = 6.8 Hz); 13C NMR (100 MHz, C6D6):  = 174.2, 147.4, 
100.7, 92.9, 75.8, 69.3, 51.3, 43.4, 37.7, 35.8, 33.4, 28.6, 27.8, 25.3, 23.9, 20.3, 12.3, 
11.8 ppm; IR (film): ?̃? = 2984, 2946, 1737, 1635, 1456, 1434, 1378, 1358, 1325, 1290, 1224, 
1198, 1169, 1135, 1090, 1035, 1019, 986, 955, 878, 858, 839, 808, 765, 699 cm-1; MS (EI) m/z 
(%): 380 (31), 293 (14), 253 (43), 235 (17), 208 (31), 195 (51), 183 (15), 175 (13), 147 (16), 
137 (28), 129 (31), 128 (100), 125 (69), 113 (34), 107 (21), 97 (39), 96 (11), 95 (37), 83 (23), 
82 (11), 81 (49), 79 (11), 69 (80), 68 (26), 67 (40), 59 (34), 55 (42), 53 (12), 43 (46), 41 (43), 29 
(12); HRMS (ESI): m/z: calcd. for C18H31O4INa [M+Na
+]: 461.1160, found 461.1160.  
 
6.2.4. Strategies Towards the Aromatic Core 
MOM-Ether 412.  A solution of 2-methoxy-3-methylbenzene-1,4-diol (200) (1.01 g, 
6.56 mmol) in DMF (3.4 mL) was added dropwise to a suspension of NaH 
(441 mg, 18.3 mmol) in DMF (2.7 mL) at 0 °C. The mixture was allowed 
to warm to ambient temperature over 1 h. After cooling to 0 °C, a 
solution of (chloromethyl)methyl ether (1.39 mL, 18.3 mmol) in DMF (1.4 mL) was added 
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dropwise. After warming to rt, the mixture was stirred for 14 h. For work-up, aqueous NH3 
was added and the aqueous phase was extracted with CH2Cl2 (3 x 15 mL). The extracts were 
combined, washed with water (10 mL) and brine (10 mL), dried over Na2SO4, and 
concentrated. The crude material was purified by flash chromatography (SiO2, 
pentane/EtOAc, 6/3) to yield the title compound 412 as a colorless oil (1.51 g, 95%).  1H NMR 
(400 MHz, CD3OD):  = 6.89 (d, 1H, J = 9.0 Hz), 6.76 (d, 1H, J = 9.0 Hz), 5.13 (s, 2H), 5.12 (s, 
2H), 3.78 (s, 3H), 3.48 (s, 3H), 3.45 (s, 3H), 2.14 ppm (s, 3H); 13C NMR (100 MHz, CD3OD): 
 = 152.5, 150.4, 146.5, 123.0, 116.0, 111.1, 97.1, 96.3, 60.8, 56.4, 56.2, 9.3 ppm; IR (film): 
?̃? = 2934, 2900, 2825, 1594, 1484, 1402, 1272, 1245, 1224, 1206, 1150, 1101, 1089, 1062, 
1040, 1009, 985, 940, 919, 802, 766, 714 cm-1; MS (EI) m/z (%): 242 (29), 197 (11), 45 (100); 
HRMS (ESI): m/z: calcd. for C12H18O5Na [M+Na
+]: 265.1048, found 265.1046.  
 
Aryl Bromide 201.  A solution of compound 412 (1.51 g, 6.24 mmol) in MeCN (60 mL) was 
cooled to −10 °C and treated with NBS (1.14 g, 6.43 mmol). The mixture 
was then warmed to 0 °C and stirring was continued for 4 h. The solvent 
was removed and the residue was purified by flash chromatography 
(SiO2, pentane/MTBE, 8/2) to give aryl bromide 201 as a pale yellow oil (1.37 g, 68%).  
1H NMR (400 MHz, CD3OD):  = 7.22 (s, 1H), 5.16 (s, 2H), 5.00 (s, 2H), 3.80 (s, 3H), 3.60 (s, 
3H), 3.45 (s, 3H), 2.25 ppm (s, 3H); 13C NMR (100 MHz, CD3OD):  = 149.7, 149.5, 148.8, 
119.4, 116.0, 111.2, 100.9, 97.7, 60.8, 58.2, 56.6, 11.0 ppm; IR (film): ?̃? = 3373, 2942, 2829, 
1651, 1588, 1473, 1376, 1287, 1233, 1205, 1151, 1081, 1036, 992, 954, 923, 840, 791, 778, 
752, 724, 692, 666 cm-1; GC-MS: tR (70_20) = 10.1 min; MS (EI) m/z (%): 322 (7), 290 (1), 209 
(2), 195 (5), 45 (100). 
 
Alkyne 202.  A suspension of sodium propyne (310 mg, 0.966 mmol) in THF (10 mL) was 
prepared. Trimethylborate (568 L, 5.00 mmol) was slowly added and 
the resulting solution was stirred for 30 min before PdCl2(dppf)∙CH2Cl2 
(91 mg, 10 mol%) and aryl bromide 201 (400 mg, 1.25 mmoL) were 
added. After refluxing for 12 h, the reaction mixture was cooled to 
ambient temperature and H2O (10 mL) was added. The aqueous phase was extracted with 
MTBE (3 x 50 mL), the organic phases were dried over Na2SO4 and evaporated. The residue 
was purified by flash chromatography (SiO2, pentane/MTBE, 8/2) to afford the title 
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compound 202 as a colorless oil (270 mg, 99%).  1H NMR (400 MHz, CD3OD):  = 6.97 (s, 1H), 
5.14 (s, 2H), 5.10 (s, 2H), 3.79 (s, 3H), 3.57 (s, 3H), 3.48 (s, 3H), 2.18 (s, 3H), 2.04 ppm (s, 3H); 
13C NMR (100 MHz, CD3OD):  = 153.4, 150.1, 147.6, 127.2, 119.5, 114.2, 100.4, 96.6, 89.9, 
79.2, 60.9, 57.9, 56.5, 10.3, 4.0 ppm; MS (EI) m/z (%): 280 (13), 250 (6), 235 (100), 205 (32), 
175 (10), 138 (5), 83 (5); HRMS (ESI): m/z: calcd. for C15H20O5Na [M+Na
+]: 303.1206, found 
303.1203.  
 
Ketone 204.  2-Methylresorcinol (203) (5.00 g, 40.3 mmol) was added dropwise to BF3∙Et2O 
(12.3 mL, 96.7 mmol). The mixture was stirred at 70 °C until a clear red 
solution was obtained. After cooling to ambient temperature, acetic 
anhydride (4.16 mL, 44.3 mmol) was added over 30 min under occasional 
cooling of the reaction vessel (exothermic reaction!). After complete addition, the mixture 
was heated to 80 °C. After 6 h, the orange suspension was allowed to cool to ambient 
temperature. Next, ice water was slowly added. The aqueous phase was extracted with Et2O 
(3 x 100 mL) and the extracts were concentrated. The crude material was recrystallized from 
boiling methanol/H2O (1:1, 250 mL) to yield the desired compound 204 as beige needles 
(5.59 g, 84%).  1H NMR (400 MHz, CD3OD):  = 12.93 (s, 1H), 8.33 (s, 1H), 7.58 (d, 1H, 
J = 8.9 Hz), 6.40 (d, 1H, J = 8.9 Hz), 2.53 (s, 3H), 2.05 ppm (s, 3H); 13C NMR (100 MHz, CD3OD): 
 = 204.4, 164.0, 163.9, 131.1, 114.0, 112.2, 107.9, 26.1, 7.5 ppm; IR (film): ?̃? = 3160, 2924, 
1613, 1591, 1493, 1429, 1374, 1304, 1271, 1177, 1130, 1090, 1014, 994, 931, 866, 805, 766, 
750, 721 cm-1; MS (EI) m/z (%): 166 (37), 152 (9), 151 (100), 95 (5), 77 (4); HRMS (ESIneg): 
m/z: calcd. for C9H9O3 [M−H
+]: 165.0557, found 165.0557. 
 
MOM-Ether 205.  A solution of compound 204 (5.00 g, 30.1 mmol) in DMF (43 mL) was 
treated with NaH (2.89 g, 120.5 mmol, 60%) in small portions at 0 °C. The 
ice bath was removed and the mixture was allowed to stir for 30 min at 
ambient temperature before it was cooled to 0 °C and 
(chloromethyl)methyl ether (5.72 mL, 75.3 mmol) was added. The resulting yellow 
suspension was stirred for 14 h at rt. For work-up, H2O (15 mL) was added and the aqueous 
phase was extracted with EtOAc (2 x 150 mL) and CH2Cl2 (2 x 150 mL), the organic phases 
were dried over MgSO4 and concentrated. The crude material was purified by flash 
chromatography (SiO2, hexanes/EtOAc, 3/1) to give the title compound 205 as an orange oil 
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(4.95 g, 65%).  1H NMR (400 MHz, CDCl3):  = 7.48 (d, 1H, J = 8.5 Hz), 6.89 (d, 1H, J = 8.5 Hz), 
5.23 (s, 2H), 4.96 (s, 2H), 3.52 (s, 3H), 3.48 (s, 3H), 2.57 (s, 3H), 2.21 ppm (s, 3H); 13C NMR 
(100 MHz, CDCl3):  = 199.5, 159.3, 156.1, 128.5, 127.6, 121.7, 109.4, 101.1, 94.4, 58.0, 56.4, 
30.2, 9.8 ppm; GC-MS: tR (70_20) = 9.7 min; MS (EI) m/z (%): 254 (92), 239 (14), 223 (43), 211 
(35), 192 (77), 180 (100), 163 (74), 149 (36), 136 (19). 
 
Aryl Iodide 208.  A solution of ketone 204 (3.00 g, 18.1 mmol) in acetic acid (30 mL) was 
treated with NIS (4.45 g, 19.9 mmol) and sulfuric acid (0.30 mL). After 30 min 
the mixture was filtered through a pad of SiO2 which was washed with 
hexanes/EtOAc (2 x 50 mL, 4:1). The filtrate was evaporated to afford the 
title compound 208 as a brown crystalline solid (4.99 g, 93%).  1H NMR (400 MHz, DMSO-d6): 
 = 12.96 (s, 1H), 10.25 (br s, 1H), 8.10 (s, 1H), 2.56 (s, 3H), 2.08 ppm (s, 3H); 13C NMR 
(100 MHz, DMSO-d6):  = 202.9, 161.8, 160.4, 138.6, 115.0, 111.6, 75.3, 26.4, 9.0 ppm; MS 
(EI) m/z (%): 292 (77), 278 (9), 277 (100), 221 (4), 150 (7); HRMS (ESIneg): m/z: calcd. for 
C9H8O3I [M−H
+]: 290.9523, found 290.9524. 
 
Aryl Iodide 209.  1,8-Diazabicyclo[5.4.0]undec-7-en (1.28 mL, 8.56 mmol) was added to a 
solution of compound 208 (1.00 g, 3.42 mmol) in acetone (22 mL). 
(Chloromethyl)methyl ether (0.65 mL, 8.56 mmol) was then added 
dropwise and the reaction solution was stirred at reflux temperature for 
1 h. For work-up, the slurry was filtered through a pad of Celite and the filtrate was 
evaporated. The residue was purified by flash chromatography (SiO2, hexanes/EtOAc, 4/1) to 
yield compound 209 as a pale yellow oil (778 mg, 60%).  1H NMR (400 MHz, CDCl3):  = 7.04 
(s, 1H), 5.04 (s, 2H), 4.88 (s, 2H), 3.62 (s, 3H), 3.48 (s, 3H), 2.54 (s, 3H), 2.20 ppm (s, 3H); 
13C NMR (100 MHz, CDCl3):  = 200.2, 147.9, 147.6, 145.3, 130.8, 126.4, 114.6, 101.1, 99.3, 
57.8, 57.5, 30.3, 10.7 ppm; MS (EI) m/z (%): 380 (7), 348 (2), 318 (1), 304 (13), 45 (100); 
HRMS (ESI): m/z: calcd. for C13H17O5INa [M+Na
+]: 403.0013, found 403.0013. 
 
Phenol 210.  Aryl iodide 209 (150 mg, 0.396 mmol), KOH (446 mg, 7.92 mmol) and  
t-BuXPhos (33 mg, 20 mol%) were added to a solution of 1,4-dioxane 
(2.93 mL) and H2O (0.97 mL) and the mixture was degassed for 5 min by 
bubbling a stream of argon through. Pd(dba)2 (23 mg, 10 mol%) was 
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introduced and the reaction mixture was stirred for 6 h at reflux temperature. For work-up, 
the dark brown mixture was acidified by dropwise addition of aqueous HCl (1.0 M), the 
aqueous phase was extracted with EtOAc (3 x 50 mL), the organic phases were dried over 
MgSO4 and evaporated. The crude material was purified by flash chromatography (SiO2, 
pentane/EtOAc, 8/3) to give phenol 210 as a yellow oil (63 mg, 60%).  1H NMR (400 MHz, 
CDCl3):  = 7.34 (br s, 1H), 7.04 (s, 1H), 5.04 (s, 2H), 4.88 (s, 2H), 3.62 (s, 3H), 3.48 (s, 3H), 
2.54 (s, 3H), 2.20 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 200.2, 147.9, 147.6, 145.3, 
130.8, 126.4, 114.6, 101.1, 99.3, 57.8, 57.5, 30.3, 10.7 ppm; IR (film): ?̃? = 3319, 2933, 1676, 
1589, 1428, 1395, 1357, 1336, 1265, 1216, 1199, 1155, 1041, 955, 917, 809, 762, 699 cm-1; 
GC-MS: tR (70_20) = 10.5 min; MS (EI) m/z (%): 270 (9), 194 (12), 179 (4), 164 (4), 45 (100); 
HRMS (ESIpos): m/z: calcd. for C13H18O6Na [M+Na
+]: 293.0996, found 293.0996. 
 
Aryl Bromide 211.  A solution of t-BuNH2 (7.8 L, 74 mol) and bromine (1.9 L, 37 mol) in 
toluene (0.2 mL) was cooled to −100 °C. Phenol 210 (10 mg, 37 mol) was 
dissolved in toluene (0.2 mL) and the solution was also cooled to −100 °C 
before the basic bromine solution was slowly introduced. After 30 min, 
the mixture was diluted with CH2Cl2 (1 mL) and H2O (1 mL). Aqueous HCl (1.0 M) was added 
dropwise until the mixture was acidic. The aqueous phase was extracted with CH2Cl2 (3 x 
8 mL), the combined organic phases were washed with aqueous Na2S2O3 solution, dried over 
MgSO4 and evaporated. The crude material was purified by flash chromatography (SiO2, 
pentane 100%  pentane/EtOAc, 7/3) to afford aryl bromide 211 as a colorless oil (2.1 mg, 
16%).  1H NMR (400 MHz, CDCl3):  = 8.91 (br, 1H), 5.17 (s, 2H), 4.91 (s, 2H), 3.52 (s, 3H), 3.50 
(s, 3H), 2.55 (s, 3H), 2.02 ppm (s, 3H); GC-MS: tR (70_20) = 10.5 min; MS (EI) m/z (%): 349 (1), 
313 (12), 285 (23), 242 (100), 207 (14), 177 (14).  
 
Diiodide 212.  A solution of 2-methylbenzene-1,3-diol (203) (400 mg, 3.23 mmol) in acetic 
acid (5.6 mL) was treated with NIS (1.52 g, 6.77 mmol) and sulfuric acid 
(0.11 mL, 2.07 mmol). After 30 min, the reaction mixture was filtered through 
a pad of Celite which was rinsed with hexanes/EtOAc (20 mL, 10:1). The 
solvent was evaporated and the residue was purified by flash chromatography (SiO2, 
hexanes/EtOAc, 10/1) to give diiodide 212 as a pale yellow solid (1.17 g, 96%).  1H NMR (400 
MHz, CDCl3):  = 7.72 (s, 1H), 5.27 (s, 2H), 2.27 ppm (s, 3H); 
13C NMR (100 MHz, CDCl3): 
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 = 154.3, 140.9 (2C), 112.0, 75.9 (2C), 11.1 ppm; IR (film): ?̃? = 3495, 3468, 3425, 2923, 2854, 
1704, 1569, 1438, 1420, 1325, 1312, 1269, 1235, 1207, 1132, 1054, 855, 788, 716 cm-1; MS 
(EI) m/z (%): 376 (100), 249 (10), 221 (5), 122 (12), 94 (11), 66 (12), 65 (14), 39 (17); HRMS 
(EI): m/z: calcd. for C7H6O2I2 [M
+]: 375.8454, found 375.8457. 
 
Diiodide 213.  A solution of compound 212 (1.23 g, 3.00 mmol) in DMF (4.3 mL) was cooled 
to 0 °C before NaH (264 mg, 6.59 mmol, 60%) was added in small portions. 
The mixture was stirred for 20 min at ambient temperature before it was 
cooled to 0 °C and (chloromethyl)methyl ether (523 L, 6.89 mmol) was 
introduced dropwise. The reaction mixture was warmed to ambient temperature and stirred 
for 20 min. The reaction was quenched with H2O (2 mL) and the aqueous phase was 
extracted with EtOAc (3 x 20 mL), the organic phases were washed with brine (10 mL), dried 
over MgSO4 and evaporated. The crude material was purified by flash chromatography (SiO2, 
pentane/EtOAc, 4/1) to yield compound 213 as a colorless oil (712 mg, 51%).  1H NMR 
(400 MHz, CDCl3):  = 8.10 (s, 1H), 5.17 (s, 2H), 5.03 (s, 2H), 3.67 (s, 3H), 3.46 (s, 3H), 
2.25 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 157.6 (2C), 144.7, 128.8, 100.2 (2C), 88.1 
(2C), 58.3 (2C), 10.8 ppm; IR (film): ?̃? = 2934, 2902, 2826, 1713, 1574, 1461, 1423, 1387, 
1257, 1228, 1202, 1185, 1153, 1102, 1077, 1047, 992, 955, 921, 880, 833, 798, 745 cm-1; MS 
(EI) m/z (%): 464 (18), 418 (2), 388 (3), 358 (1), 337 (9), 45 (100); HRMS (ESIpos): m/z: calcd. 
for C11H14O4I2Na [M+Na
+]: 486.8875, found 486.8874. 
 
Ketone 228.  Compound 204 (5.00 g, 30.1 mmol) was dissolved in acetone (60 mL) and 
dimethyl sulfate (6.20 mL, 75.2 mmol) and K2CO3 (12.5 g, 90.3 mmol) were 
added to the solution. The mixture was stirred for 17 h at rt. For work-up, 
the mixture was filtered through a pad of Celite to remove K2CO3, then 
aqueous NH3 (10 mL, 24%) was added to remove excess dimethyl sulfate. The aqueous 
phase was extracted with MTBE (3 x 60 mL), the combined organic phases were washed with 
H2O (20 mL), HCl (20 mL, 1.0 M) and brine (20 mL), dried over MgSO4 and evaporated. The 
crude material was purified by flash chromatography (SiO2, pentane/EtOAc, 9/1) to yield the 
desired compound 228 as a pale yellow oil (5.44 g, 93%).  1H NMR (400 MHz, CDCl3):  = 7.60 
(d, 1H, J = 8.2 Hz), 6.67 (d, 1H, J = 8.2 Hz), 3.86 (s, 3H), 3.74 (s, 3H), 2.60 (s, 3H), 2.16 ppm (s, 
3H); 13C NMR (100 MHz, CDCl3):  = 198.5, 161.8, 129.4, 128.6, 125.3, 105.5, 101.4, 61.5, 
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55.4, 29.9, 8.5 ppm; GC-MS: tR (70_20) = 8.1 min; MS (EI) m/z (%): 194 (13), 179 (100), 136 
(11), 91 (9).  
 
Acetate 413.  A solution of ketone 228 (5.00 g, 25.8 mmol) and p-toluenesulfonic acid 
(250 mg, 6 mol%) in CH2Cl2 (12 mL) was treated with a solution of m-CPBA 
(12.7 g, 51.5 mmol) in CH2Cl2 (12 mL). The mixture was allowed to warm 
to ambient temperature and was stirred for 14 h. Saturated aqueous 
NaHCO3 was then added and the aqueous phase was extracted with CH2Cl2 (3 x 50 mL), the 
organic phases were evaporated and the resulting residue was again washed with saturated 
aqueous NaHCO3 to remove benzoic acid. After the solvent was removed, the residue was 
diluted with Et2O (10 mL) and the mixture passed through a pad of MgSO4. The filtrate was 
concentrated and the crude material was purified by flash chromatography (SiO2, 
hexanes/EtOAc, 4/1) to yield the title compound 413 as an orange oil (3.76 g, 70%).  1H NMR 
(400 MHz, CDCl3):  = 6.85 (d, 1H, J = 8.9 Hz), 6.58 (d, 1H, J = 8.9 Hz), 3.79 (s, 3H), 3.74 (s, 3H), 
2.31 (s, 3H), 2.15 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 169.4, 156.0, 137.2, 133.3, 
129.8, 119.3, 105.2, 60.4, 55.4, 20.4, 8.8 ppm; IR (film): ?̃? = 2942, 2839, 1760, 1713, 1630, 
1597, 1483, 1418, 1367, 1302, 1275, 1244, 1222, 1197, 1158, 1105, 1022, 1003, 980, 918, 
885, 802, 771, 741, 718, 696 cm-1; MS (EI) m/z (%): 210 (15), 169 (10), 168 (100), 158 (11), 
156 (33), 153 (42), 141 (15), 139 (48), 125 (10), 111 (15); HRMS (ESI): m/z: calcd. for 
C11H14O4Na [M+Na
+]: 233.0784, found 233.0784.  
 
Aryl Iodide 229 and Phenol 414.  NIS (6.10 g, 27.1 mmol) and sulfuric acid (0.63 mL, 
11.8 mmol) were added to a solution of compound 413 
(4.74 g, 22.6 mmol) in acetic acid (45 mL). After stirring for 
30 min, the suspension was filtered through a pad of Celite. 
H2O (25 mL) was added, the aqueous phase was extracted 
with MTBE (3 x 80 mL) and the organic phases were washed with aqueous Na2S2O3 solution 
(20 mL), dried over Na2SO4 and concentrated. The yellow oil was subjected to the next step 
without further purification.  
A solution of acetate 229 (6.84 g, 20.3 mmol) in MeOH (23 mL) was treated with a solution 
of KOH (2.27 g, 40.6 mmol) in MeOH/H2O (6 mL, 10:1) and the resulting mixture was stirred 
for 2 h. For work-up, H2O (60 mL) and aqueous HCl (35 mL, 2.0 M) were added. The aqueous 
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phase was extracted with MTBE (3 x 100 mL), the organic phases were washed with brine 
(50 mL), dried over MgSO4 and evaporated. The residue was purified by flash 
chromatography (SiO2, hexanes/EtOAc, 4/1) to afford the product 414 as a pale orange oil 
(6.17 g, 87%, over 2 steps).  1H NMR (400 MHz, CDCl3):  = 7.24 (s, 1H), 5.50 (br s, 1H), 3.77 
(s, 3H), 3.72 (s, 3H), 2.28 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 151.5, 145.9, 145.8, 
124.8, 121.8, 84.9, 60.5, 60.2, 10.4 ppm; IR (film): ?̃? = 3375, 2937, 2834, 1704, 1580, 1471, 
1451, 1403, 1359, 1336, 1279, 1229, 1193, 1163, 1030, 990, 881, 847, 774, 718, 701, 675, 
629, 530, 510 cm-1; MS (EI) m/z (%): 294 (100), 279 (52), 251 (9); HRMS (ESI): m/z: calcd. for 
C9H10O3I [M−H
+]: 292.9681, found 292.9680. 
 
Aryl Bromide 230.  Compound 414 (1.00 g, 3.40 mmol) was dissolved in MeCN (34 mL) and 
the solution was cooled to −40 °C before NBS (680 mg, 3.82 mmol) was 
added portionwise. After 2 h, the solvent was removed and the residue was 
purified by flash chromatography (SiO2, toluene/EtOAc, 9/1) to afford the 
desired aryl bromide 230 as a sticky yellow oil (790 mg, 62%).  1H NMR (400 MHz, CDCl3): 
 = 5.87 (s, 1H), 3.80 (s, 3H), 3.70 (s, 3H), 2.24 ppm (s, 3H); 13C NMR (100 MHz, CDCl3): 
 = 152.5, 146.3, 143.6, 124.6, 113.7, 93.6, 60.4, 60.2, 10.5 ppm; IR (film): ?̃? = 3408, 2939, 
2836, 1567, 1450, 1403, 1275, 1225, 1193, 1178, 1090, 1039, 986, 897, 843, 801, 775, 759, 
733, 675 cm-1; GC-MS: tR (70_20) = 10.6 min; MS (EI) m/z (%): 375 (17), 374 (98), 373 (19), 
372 (100), 359 (48), 357 (47), 293 (10), 232 (13), 230 (11), 197 (22), 99 (36), 83 (13), 56 (29), 
53 (11); HRMS (ESIneg): m/z: calcd. for C9H9O3BrI [M−H
+]: 370.8787, found 370.8785.  
 
MOM-Ether 232.  NaH (11 mg, 0.45 mmol) was added portionwise to a solution of phenol 
230 (188 mg, 0.412 mmol) in THF (1.5 mL). After stirring for 30 min, the 
reaction mixture was cooled to 0 °C and (chloromethyl)methyl ether 
(34 mL, 0.45 mmol) was introduced. The mixture was allowed to warm to 
rt and was stirred for 14 h. The reaction was quenched by addition of H2O (2 mL), the 
aqueous phase was extracted with MTBE (3 x 10 mL), the organic phases were washed with 
brine (4 mL), dried over MgSO4 and evaporated. The crude material was purified by flash 
chromatography (SiO2, pentane/EtOAc, 4/1) to yield the MOM-ether 232 as a colorless oil 
(147 mg, 84%).  1H NMR (400 MHz, CDCl3):  = 5.12 (s, 2H), 3.80 (s, 3H), 3.72 (s, 3H), 3.65 (s, 
3H), 2.23 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 155.8, 152.7, 144.5, 125.5, 122.3, 98.8, 
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95.3, 60.1, 60.0, 57.9, 10.5 ppm; IR (film): ?̃? = 2933, 2852, 1447, 1412, 1390, 1374, 1286, 
1229, 1206, 1159, 1103, 1025, 1025, 995, 927, 899, 814, 794, 773 cm-1; MS (EI) m/z (%): 418 
(13), 416 (13), 373 (9), 371 (9), 338 (13), 337 (100), 210 (8); HRMS (ESIpos): m/z: calcd. for 
C11H14O4BrINa [M+Na
+]: 438.9013, found 438.9013. 
 
Table 7: Representative conditions for the alkynylation of 232 by cross-coupling. 
 
 
entry catalyst conditions yield 
1 10 mol% PdCl2(dppf) B(OMe)3, THF, 1.5 equiv NaCCCH3, 7 h, 70 °C - 
2 100 mol% PdCl2(PPh3)2 Et3N, CuI, THF, 6.0 equiv HCCTMS, 14 h, rt 95% 
3 20 mol% PdCl2(PPh3)2 Et3N, CuI, THF, 6.0 equiv HCCTMS, 24 h, 70 °C 62% 
4 20 mol% PdCl2(PPh3)2 Et3N, CuI, THF, 6.0 equiv 1-hexyne, 16 h, 65 °C - 
5 20 mol% PdCl2(P(o-tol)3)2 Et3N, CuI, THF, 6.0 equiv 1-hexyne, 16 h, 65 °C - 
6 100 mol% PdCl2(PPh3)2 Et3N, CuI, THF, 20.0 equiv propyne 2 d, rt 5% 
 
 
TMS-Acetylene 233.  PdCl2(PPh3)2 (17 mg, 24 mol), CuI (14 mg, 72 mol) and Et3N (46 L, 
0.33 mmol) were added to a solution of aryl iodide 232 (10 mg, 24 mol) 
in THF (0.25 mL). After 10 min, trimethylsilylacetylene (10 L, 72 mol) 
was slowly added to give a brown solution. After stirring for 24 h at 70 °C, 
the mixture was filtered through a pad of Celite and the filtrate was 
evaporated. The crude material was purified by flash chromatography (SiO2, pentane/EtOAc, 
15/1) to afford the title compound 233 as a colorless oil (5.0 mg, 62%).  1H NMR (400 MHz, 
CDCl3):  = 5.11 (s, 2H), 3.86 (s, 3H), 3.80 (s, 3H), 3.66 (s, 3H), 2.14 (s, 3H), 0.23 ppm (s, 9H); 
13C NMR (100 MHz, CDCl3):  = 175.8, 153.1, 144.4, 125.6, 118.8, 116.0, 107.7, 103.4, 99.3, 
99.1, 60.6, 58.2, 9.49, 1.01 ppm (3C); IR (film): ?̃? = 2958, 2931, 2156, 1733, 1573, 1455, 1400, 
1385, 1249, 1210, 1161, 1125, 1094, 1041, 999, 932, 843, 797, 760, 700 cm-1; MS (EI) m/z 
(%): 388 (18), 386 (18), 343 (13), 341 (12), 308 (21), 307 (80), 284 (16), 279 (14), 219 (13), 73 
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(49), 45 (100); HRMS (ESI): m/z: calcd. for C16H23O4BrSiNa [M+Na
+]: 409.0442, found 
409.0441.  
 
Alkyne 163.  Trimethylborate (34 L, 0.30 mmol) was added to a suspension of propynyl 
sodium (19 mg, 0.30 mmol) in THF (0.5 mL) and the mixture was stirred 
until a clear solution was obtained. t-BuXPhos (20 mg, 40 mol%), 
PdCl2(PPh3)2 (17 mg, 20 mol%) and iodide 232 (50 mg, 0.12 mmol) were 
added and the orange solution was stirred at reflux temperature. After 
3 h, the dark brown mixture was filtered through a pad of Celite and the filtrate was 
concentrated. The residue was purified by flash chromatography (SiO2, toluene/EtOAc, 19/1) 
to yield the title compound 163 as a colorless oil (33 mg, 83%).  1H NMR (400 MHz, CDCl3): 
 = 5.12 (s, 2H), 3.83 (s, 3H), 3.80 (s, 3H), 3.66 (s, 3H), 2.16 (s, 3H), 2.14 ppm (s, 3H); 13C NMR 
(100 MHz, CDCl3):  = 156.8, 151.9, 143.9, 125.1, 117.8, 98.7, 95.2, 88.7, 74.3, 60.3, 60.1, 
55.8, 9.1, 4.3 ppm; MS (EI) m/z (%): 330 (18), 328 (18), 285 (17), 283 (17), 257 (13), 255 (15), 
249 (100), 219 (15), 161 (17), 45 (50); HRMS (ESI): m/z: calcd. for C14H17O4BrNa [M+Na
+]: 
351.0202, found 351.0203.  
 
6.2.5. Synthesis of the Aromatic Core – Final Route 
Diacetate 415.  Diol 200 (2.50 g, 16.2 mmol) was dissolved in THF (125 mL) and the solution 
was cooled to −78 °C before Et3N (11.2 mL, 81.1 mmol) was added in one 
portion. Acetyl chloride (2.36 mL, 33.3 mmol) was added dropwise. After 
complete addition, the mixture was allowed to slowly warm to 0 °C over 1 h. 
The reaction was quenched by addition of saturated aqueous NaHCO3 (100 mL) and H2O 
(50 mL) and the aqueous phase was extracted with MTBE (3 x 200 mL). The organic phases 
were dried over MgSO4 and concentrated. The crude material was purified by flash 
chromatography (SiO2, pentane/EtOAc, 7/3) to afford diacetate 415 as a pale yellow oil 
(3.47 g, 90%). 1H NMR (400 MHz, CDCl3):  = 6.90 (d, 1H, J = 8.7 Hz), 6.79 (d, 1H, J = 8.7 Hz), 
3.74 (s, 3H), 2.28 (s, 3H), 2.26 (s, 3H), 2.09 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 168.6, 
168.6, 150.3, 147.2, 141.2, 125.2, 120.1, 117.2, 60.4, 20.3, 20.3, 9.5 ppm; IR (film): ?̃? = 1757, 
1613, 1583, 1477, 1420, 1370, 1276, 1237, 1210, 1180, 1145, 1073, 1027, 1008, 980, 916, 
897, 829, 797, 739, 657 cm-1; MS (EI) m/z (%): 196 (15), 154 (100), 139 (22), 43 (19); HRMS 
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(ESI): m/z: calcd. for C12H14O5Na [M+Na
+]: 261.0737, found 261.0733. The analytical and 
spectroscopic data are in agreement with those reported in the literature.[46a] 
 
Aryl Iodide 255.  Diacetate 415 (2.74 g, 7.53 mmol) was dissolved in acetic acid (23 mL) and 
the solution was treated with H2SO4 (0.32 mL, 50 mol%) before NIS (2.88 g, 
12.8 mmol) was added in one portion. The orange solution was stirred for 
3 h and was then diluted with H2O (50 mL). The aqueous phase was 
extracted with EtOAc (3 x 70 mL) and the organic phases were concentrated. The crude 
material was purified by flash chromatography (SiO2, pentane/EtOAc, 4/1) to afford the title 
compound as a yellow solid (2.73 g, 99%). 1H NMR (400 MHz, CDCl3):  = 7.39 (s, 1H), 3.75 (s, 
3H), 2.37 (s, 3H), 2.31 (s, 3H), 2.13 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 168.3, 167.5, 
150.6, 148.1, 141.7, 129.6, 126.7, 83.2, 60.6, 20.6, 20.3, 10.7 ppm; IR (film): ?̃? = 2941, 1763, 
1468, 1423, 1408, 1367, 1285, 1228, 1166, 1086, 1031, 1007, 992, 919, 894, 872, 800, 
681 cm-1; MS (EI) m/z (%): 364 (14), 322 (23), 280 (100), 265 (20), 43 (26); HRMS (ESI): m/z: 
calcd. for C12H13O5Na [M+Na
+]: 386.9689, found 386.9700. The analytical and spectroscopic 
data are in agreement with those reported in the literature.[46a] 
 
Phenol 254.  Compound 255 (1.00 g, 2.75 mmol) was dissolved in MeOH (40 mL) and the 
solution was cooled to 0 °C before a solution of K2CO3 (1.52 g, 11.0 mmol) in 
H2O (5 mL) was added under stirring. The reaction was quenched after 3 h 
by addition of saturated aqueous NH4Cl (25 mL) and the aqueous phase was 
extracted with EtOAc (3 x 100 mL). The organic phases were dried over Na2SO4 and 
concentrated to afford the title compound as a yellow oil (859 mg, 97%). 1H NMR (400 MHz, 
CDCl3):  = 7.27 (s, 1H), 5.56 (s, 1H), 3.77 (s, 3H), 2.36 (s, 3H), 2.14 ppm (s, 3H); 
13C NMR 
(100 MHz, CDCl3):  = 168.7, 147.7, 146.1, 143.6, 125.4, 122.4, 84.8, 61.2, 21.1, 11.2 ppm; IR 
(film): ?̃? = 1753, 1712, 1581, 1472, 1423, 1368, 1336, 1284, 1180, 1079, 1030, 1008, 989, 
917, 873, 847, 794, 757, 727, 707, 668 cm-1; MS (EI) m/z (%): 322 (15), 280 (100), 265 (40); 
HRMS (ESI): m/z: calcd. for C10H11O4INa [M+Na
+]: 344.9597, found 344.9594.  
 
Propionate 416 and Alkyne 257.  A solution of isobutyric acid (135 L, 1.46 mmol), phenol 
254 (376 mg, 1.17 mmol) and DMAP (14 mg, 10 mol%) in CH2Cl2 (2.3 mL) was cooled to 0 °C 
and treated with DCC (241 mg, 1.17 mmol). After 30 min, the slurry was filtered through a 
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pad of SiO2 and the filtrate was evaporated. The crude material was 
purified by flash chromatography (SiO2, pentane/EtOAc, 4/1) to afford 
compound 416 (312 mg, 79%) as a colorless oil that was subjected to the 
next step without characterization.  
 
A solution of propynyl sodium (67 mg, 1.1 mmol) in degassed THF 
(9.0 mL) was treated with trimethylborate (123 L, 1.08 mmol) and the 
resulting solution was stirred for 10 min before t-BuXPhos (92 mg, 
40 mol%), PdCl2(PPh3)2 (78 mg, 20 mol%) and aryl iodide 416 (212 mg, 
0.541 mmol) were successively added. The orange reaction mixture was 
stirred at reflux temperature for 1.5 h. For work-up, the mixture was filtered through a pad 
of Celite and the filtrate was concentrated. The residue was purified by flash 
chromatography (SiO2, pentane/EtOAc, 8/1) to give the title compound 257 as a yellow oil 
(140 mg, 85%).  1H NMR (400 MHz, CDCl3):  = 6.99 (s, 1H), 3.74 (s, 3H), 2.82 (hept, 1H, 
J = 7.0 Hz), 2.34 (s, 3H), 2.09 (s, 3H), 2.02 (s, 3H), 1.32 ppm (d, 6H, J = 7.0 Hz); 13C NMR 
(100 MHz, CDCl3):  = 174.5, 168.1, 150.0, 148.3, 141.0, 125.6, 123.7, 113.6, 90.0, 73.8, 60.7, 
33.7, 20.2, 18.6 (2x), 9.7, 4.0 ppm; IR (film): ?̃? = 2975, 2936, 1759, 1480, 1427, 1368, 1339, 
1247, 1207, 1177, 1107, 1089, 1072, 1048, 1008, 995, 909, 880, 816, 747, 691 cm-1; MS (EI) 
m/z (%): 304 (16), 234 (13), 193 (12), 192 (100), 177 (13), 43 (18); HRMS (ESI): m/z: calcd. for 
C17H20O5Na [M+Na
+]: 327.1204, found 327.1203.  
 
Ketone 258.  In a quartz tube (30 cm x 1.2 cm), a solution of diester 257 (25 mg, 82 mol) in 
ethanol (15 mL) was degassed by bubbling argon through it via canula for 
30 min. The quartz tube was then sealed and positioned next to a quartz 
photo reactor (double-walled vessel with water cooling). A Hanovia 450 W 
medium pressure mercury gas lamp was put inside the quartz apparatus. 
The inner void containing the lamp was filled with argon and sealed with a plug of cotton to 
avoid ozone formation. The stirred solution was irradiated for 2 h causing a color change 
from colorless to pale orange. The solvent was removed and the crude material was purified 
by flash chromatography (SiO2, pentane/EtOAc, 8/2) to yield the desired compound as a 
yellow oil (19 mg, 73%).  1H NMR (400 MHz, CDCl3):  = 12.38 (s, 1H), 4.32 (sept, 1H, 
J = 6.9 Hz), 3.88 (s, 3H), 2.34 (s, 3H), 2.12 (s, 3H), 2.11 (s, 3H), 1.21 ppm (d, 6H, J = 6.9 Hz); 
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13C NMR (100 MHz, CDCl3):  = 212.6, 169.1, 154.3, 147.4, 144.8, 131.8, 119.3, 112.3, 97.2, 
74.6, 60.6, 38.3, 20.7, 19.6 (2C), 10.6, 4.9 ppm; MS (EI) m/z (%): 304 (64), 289 (13), 286 (14), 
262 (40), 261 (26), 248 (12), 247 (70), 244 (26), 234 (14), 229 (24), 220 (14), 219 (100), 204 
(14), 192 (43), 177 (12), 91 (13), 83 (10); HRMS (ESI): m/z: calcd. for C17H20O5Na [M+Na
+]: 
327.1206, found 327.1203.  
 
Methyl Ester 244.  tert-Butyllithium (2.64 mL, 4.48 mmol, 1.70 M in pentane) was added to a 
solution of alkyl iodide 165 (560 mg, 2.24 mmol) in Et2O (6.6 mL) at 
−78 °C. After stirring for 5 min, a solution of 9-MeO-9-BBN (5.39 mL, 
5.39 mmol, 1.0 M in THF) and THF (0.5 mL) was added. After another 
10 min, the mixture was allowed to warm to ambient temperature 
over 1 h. Then, a mixture of aqueous K3PO4 (0.87 mL, 2.61 mmol, 3.0 M), alkenyl iodide 164 
(394 mg, 0.897 mmol) and PdCl2(dppf)∙CH2Cl2 (64 mg, 10 mol%) in DMF (9.0 mL) was added 
and stirring was continued for 1 h. The reaction was quenched by addition of saturated 
aqueous NH4Cl and the aqueous phase was extracted with MTBE (3 x 50 mL). The combined 
organic phases were washed with brine (30 mL), dried over MgSO4 and concentrated. The 
crude material was purified by flash chromatography (SiO2, pentane 100%  
pentane/EtOAc, 30/1) to afford the title compound as a colorless oil (388 mg, quant.). 
[𝛼]D
20 = +0.94 (c = 1.00, CH2Cl2), 
1H NMR (600 MHz, C6D6):  =  5.00 (d, 1H, J = 9.4 Hz), 3.84 
(dd, 1H, J = 7.3, 4.8 Hz), 3.80 (dt, 1H, J = 9.6, 4.4 Hz), 3.38 (s, 3H), 2.55 – 2.49 (m, 2H), 2.44 –
 2.37 (m, 1H); 2.14 (dd, 1H, J = 13.0, 5.3 Hz), 1.99 – 1.93 (m, 1H), 1.81 – 1.76 (m, 1H), 1.67 
(dd, 1H, J = 13.0, 9.0 Hz), 1.64 (d, 3H, J = 1.4 Hz), 1.63 – 1.57 (m, 1H), 1.59 (d, 3H, J = 2.4 Hz), 
1.50 – 1.42 (m, 2H), 1.36 (s, 3H), 1.34 (s, 3H), 1.33 – 1.27 (m, 2H), 1.31 (d, 3H, J = 7.0 Hz), 
1.24 – 1.18 (m, 1H), 1.16 (d, 3H, J = 6.8 Hz), 1.02 (d, 3H, J = 6.6 Hz), 0.90 (d, 3H, J = 6.6 Hz), 
0.84 ppm (d, 3H, J = 6.8 Hz); 13C NMR (150 MHz, C6D6):  = 174.2, 133.3, 132.8, 100.7, 84.2, 
75.8, 75.7, 69.5, 51.1, 47.5, 45.3, 43.3, 37.3, 34.5, 32.8, 29.1, 29.1, 25.2, 24.2, 23.8, 21.9, 
21.7, 20.2, 16.2, 12.3, 11.7, 3.4 ppm; IR (film): ?̃? = 2952, 2920, 1740, 1455, 1435, 1379, 1328, 
1291, 1225, 1196, 1167, 1087, 1056, 1020, 955, 877, 837, 809, 756 cm-1; MS (EI) m/z (%): 434 
(17), 376 (28), 289 (31), 249 (16), 248 (57), 233 (24), 219 (10), 206 (20), 205 (97), 191 (21), 
189 (44), 183 (27), 177 (15), 164 (15), 163 (37), 159 (36), 150 (18), 149 (44), 147 (28), 135 
(34), 134 (16), 133 (24), 129 (17), 128 (34), 127 (58), 126 (77), 125 (12), 124 (15), 123 (57), 
122 (27), 121 (100), 120 (14), 119 (35), 113 (13), 107 (48), 105 (16), 97 (11), 95 (32), 93 (19), 
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83 (11), 69 (70), 59 (25), 55 (22), 43 (32); HRMS (ESI): m/z: calcd. for C27H46NO4Na [M+Na
+]: 
457.3294, found 457.3297.  
 
Carboxylic Acid 253.  Methyl ester 244 (356 mg, 0.81 mmol) was dissolved in 
THF/MeOH/H2O (10 mL, 2:2:1). After addition of LiOH (195 mg, 
8.10 mmol), the solution was stirred for 16 h. CH2Cl2 (15 mL) was then 
added and the biphasic system was slightly acidified by dropwise 
addition of aqueous HCl (1.0 M). The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were 
dried over MgSO4 and concentrated. The residue was dried by azeotropic distillation with 
toluene (3 x 5 mL) to afford acid 253 as a colorless sticky oil (307 mg, 90%). [𝛼]D
23 = −0.20 
(c = 1.00, CH2Cl2), 
1H NMR (400 MHz, CDCl3):  = 10.0 (br, 1H), 4.86 (d, 1H, J = 8.3 Hz), 3.74 –
 3.65 (m, 2H), 2.60 (dq, 1H, J = 7.0, 3.7 Hz), 2.48 – 2.42 (m, 1H), 2.38 – 2.31 (m, 1H), 2.05 (dd, 
1H,  = 12.8, 5.0 Hz), 1.83 – 1.72 (m, 2H), 1.78 (d, 3H, J = 2.4 Hz), 1.68 – 1.60 (m, 1H), 1.56 (d, 
3H, J = 1.3 Hz), 1.48 – 1.39 (m, 1H), 1.32 (s, 3H), 1.31 (s, 3H), 1.30 – 1.22 (m, 5H), 1.20 (d, 3H, 
J = 7.0 Hz), 1.09 (d, 3H, J = 6.8 Hz), 0.92 (d, 3H, J = 6.6 Hz), 0.84 (d, 3H, J = 6.6 Hz), 0.80 ppm 
(d, 3H, J = 6.6 Hz); 13C NMR (100 MHz, CDCl3):  = 179.1, 132.3, 132.2, 100.5, 83.8, 74.9, 74.8, 
69.1, 47.0, 44.5, 42.4, 36.2, 33.4, 31.9, 28.3, 28.0, 24.6, 23.4, 23.3, 21.0, 21.0, 19.5, 15.7, 
11.8, 10.6, 3.1 ppm; IR (film): ?̃? = 2953, 2919, 1708, 1455, 1379, 1225, 1166, 1087, 1019, 
968, 928, 909, 877 cm-1; MS (EI) m/z (%): 362 (11), 289 (26), 248 (19), 233 (12), 227 (11), 220 
(13), 205 (17), 203 (10), 191 (16), 177 (12), 175 (12), 169 (23), 164 (15), 163 (24), 161 (18), 
151 (30), 150 (21), 149 (40), 147 (29), 137 (16), 136 (10), 135 (34), 134 (11), 133 (32), 127 
(39), 126 (100), 125 (16), 124 (13), 123 (51), 122 (27), 121 (62), 120 (12), 119 (28), 114 (22), 
111 (11), 110 (12), 109 (66), 108 (21), 107 (60), 105 (12), 97 (18), 96 (14), 95 (46), 93 (26), 91 
(12), 85 (15), 83 (24), 82 (26), 81 (37), 79 (15), 69 (88), 68 (13), 67 (66), 59 (63), 57 (15), 55 
(48), 43 (49), 41 (48); HRMS (ESI): m/z: calcd. for C26H44NO4Na [M+Na
+]: 443.3137, found 
43.3132.  
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6.2.6. Assembly of the Fragements 
Aryl Iodide 256.  A solution of acid 253 (219 mg, 0.500 mmol), phenol 254 (178 mg, 
0.550 mmol) and DMAP (21 mg, 33 mol%) in CH2Cl2 (1.0 mL) was 
prepared. EDCI∙HCl (102 mg, 0.500 mmol) was added at 0 °C and  
the mixture was allowed to warm to ambient temperature and 
was stirred overnight. The mixture was filtered through a pad of 
cotton and SiO2, the solvent was removed and the crude material 
was purified by flash chromatography (SiO2, pentane 100%  pentane/EtOAc, 10/1) to 
afford the title compound as a colorless oil (279 mg, 77%). [𝛼]D
20 = −6.4 (c = 0.50, CH2Cl2), 
1H NMR (400 MHz, CDCl3):  = 7.34 (s, 1H), 4.88 (d, 1H, J = 9.3 Hz), 3.82 – 3.75 (m, 2H), 3.74 
(s, 3H), 2.83 (qd, 1H, J = 7.0, 4.1 Hz), 2.48 – 2.40 (m, 1H), 2.38 – 2.32 (m, 1H), 2.36 (s, 3H), 
2.13 (s, 3H), 2.06 (dd, 1H, J = 13.0, 5.1 Hz), 1.94 – 1.87 (m, 1H), 1.83 – 1.74 (m, 1H), 1.78 (d, 
3H, J = 2.2 Hz), 1.67 – 1.61 (m, 1H), 1.57 (d, 3H, J = 1.1 Hz), 1.49 – 1.40 (m, 1H), 1.35 (s, 3H), 
1.33 (s, 3H), 1.33 (s, 3H), 1.31 – 1.23 (m, 5H), 1.09 (d, 3H, J = 6.8 Hz), 0.93 (d, 3H, J = 6.6 Hz), 
0.90 (s, 3H, J = 6.8 Hz), 0.81 ppm (d, 3H, J = 6.5 Hz); 13C NMR (100 MHz, CDCl3):  = 172.5, 
168.0, 151.2, 148.4, 142.3, 132.8, 132.6, 130.0, 127.1, 100.7, 84.3, 83.6, 75.4, 75.3, 69.4, 
61.1, 47.4, 45.0, 43.0, 36.6, 33.9, 32.4, 28.8, 28.6, 25.2, 24.0, 23.7, 21.5, 21.5, 21.0, 20.0, 
16.2, 12.3, 11.3, 11.2, 3.6 ppm; IR (film): ?̃? = 2952, 2920, 1768, 1468, 1426, 1370, 1328, 
1286, 1224, 1182, 1086, 1019, 968, 916, 873, 800, 753, 666 cm-1; MS (EI) m/z (%): 418 (22), 
403 (11), 345 (26), 322 (59), 280 (100), 195 (18), 191 (19), 189 (10), 163 (11), 151 (31), 147 
(10), 137 (12), 135 (29), 123 (32), 121 (35), 109 (49), 107 (32), 97 (10), 96 (40), 95 (32), 93 
(12), 83 (23), 81 (20), 69 (60), 67 (28), 55 (20), 43 (36), 41 (16); HRMS (ESI): m/z: calcd. for 
C36H53O7INa [M+Na
+]: 747.2729, found 747.2728.  
 
Diyne 252.  Trimethylborate (110 L, 0.969 mmol) was added to a slurry of sodium propyne 
(60 mg, 0.97 mmol) in THF (6.4 mL). The mixture was stirred for 
10 min until a clear solution had formed. t-BuXPhos (33 mg, 
20 mol%), PdCl2(PPh3)2 (27 mg, 10 mol%) and iodide 256 (279 mg, 
0.386 mmol) were added and the reaction mixture was stirred at 
reflux temperature for 2 h. The resulting black mixture was filtered 
through a pad of Celite and the filtrate was concentrated. The 
brown residue was subjected to flash chromatography (SiO2, pentane/EtOAc, 1/0  10/1) to 
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afford diyne 252 as a colorless oil (192 mg, 78%). [𝛼]D
20 = −5.1 (c = 0.57, CHCl3), 
1H NMR 
(600 MHz, CDCl3):  = 6.96 (s, 1H), 4.88 (d, 1H, J = 9.5 Hz), 3.80 (dd, 1H, J = 7.5, 4.4 Hz), 3.76 
(dt, 1H, J = 8.5, 4.6 Hz), 3.75 (s, 3H), 2.83 (dq, 1H, J = 7.1, 4.4 Hz), 2.46 – 2.43 (m, 1H), 2.39 –
 2.34 (m, 1H), 2.34 (s, 3H), 2.09 (s, 3H), 2.06 (dd, 1H, J = 13.0, 5.3 Hz), 2.02 (s, 3H), 1.91 (ddq, 
1H, J = 7.4, 6.8, 4.6 Hz), 1.81 – 1.76 (m, 1H), 1.79 (d, 3H, J = 2.3 Hz), 1.64 (ddd, 1H, J = 13.0, 
8.9, 0.7 Hz), 1.58 (d, 3H, J = 1.1 Hz), 1.49 – 1.43 (m, 1H), 1.36 (s, 3H), 1.35 (d, 3H, J = 7.0 Hz), 
1.33 (s, 3H), 1.32 – 1.25 (m, 5H), 1.10 (d, 3H, J = 6.8 Hz), 0.93 (d, 3H, J = 6.6 Hz), 0.90 (d, 3H, 
J = 6.8 Hz), 0.82 ppm (d, 3H, J = 6.6 Hz); 13C NMR (150 MHz, CDCl3):  = 172.6, 168.6, 150.5, 
148.8, 141.4, 132.9, 132.7, 126.2, 124.2, 114.1, 100.8, 90.4, 84.8, 75.4, 75.4, 74.3, 69.5, 61.2, 
47.5, 45.0, 43.2, 36.8, 34.0, 32.5, 28.8, 28.7, 25.3, 24.1, 23.8, 21.5, 21.5, 20.7, 20.0, 16.2, 
12.4, 11.5, 10.2, 4.6, 3.6 ppm; IR (film): ?̃? = 2919, 2280, 1768, 1481, 1455, 1379, 1341, 1330, 
1247, 1225, 1207, 1186, 1108, 1074, 1022, 966, 912, 879, 812, 739, 703 cm-1; MS (EI) 
m/z (%): 330 (19), 235 (12), 234 (70), 193 (14), 192 (100), 151 (13), 149 (12), 135 (14), 123 
(14), 121 (17), 109 (24), 107 (16), 95 (16), 83 (11), 69 (28), 67 (15), 55 (11), 43 (13); HRMS 
(ESI): m/z: calcd. for C39H56O7Na [M
++Na]: 659.3924, found 659.3918.  
 
Cycloalkyne 267.  5 Å molecular sieves (370 mg, 2 mg/mol) were dispersed in freshly 
distilled toluene (93 mL). Diyne 252 (120 mg, 0.185 mmol) was 
azeotropically dried with toluene (3 x 3 mL) and was added as a 
solution in freshly distilled toluene (1 mL). The mixture was stirred 
for 30 min before a solution of complex C4 was added (9.4 mg, 
5.0 mol%, in 250 L toluene). The resulting pale orange mixture 
was stirred for 1 h. For work-up, the mixture was filtered through a pad of silica which was 
rinsed with EtOAc. The crude material was purified by flash chromatography (SiO2, 
pentane/EtOAc, 20/1) to afford the title compound as a colorless sticky oil (102 mg, 95%). 
For characterization purposes, trace impurities of the silanol ligand were removed by HPLC 
(150 mm, Kromasil, Ø 30 mm, MeOH/H2O = 90:10, 35 mL/min, 308 K, 6.3 MPa). The impurity 
could also be removed by flash chromatography after the next transformation. [𝛼]D
23 = +2.3 
(c = 0.57, CHCl3), 
1H NMR (600 MHz, CDCl3):  = 6.86 (s, 1H), 4.93 (d, 1H, J = 9.0 Hz), 3.91 (td, 
1H, J = 7.1, 3.6 Hz), 3.76 (s, 3H), 3.51 (dd, 1H, J = 7.9, 5.3 Hz), 3.07 (dq, 1H, J = 7.9, 7.0 Hz), 
2.85 – 2.79 (m, 1H), 2.48 – 2.43 (m, 1H), 2.34 (s, 3H), 2.13 – 2.10 (m, 1H), 2.10 (s, 3H), 1.99 –
 1.94 (m, 1H), 1.92 (ddq, 1H, J = 6.8, 5.3, 3.5 Hz), 1.66 (d, 3H, J = 0.8 Hz), 1.52 (dd, 1H, 
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J = 14.0, 9.8 Hz), 1.47 – 1.42 (m, 2H), 1.41 – 1.39 (m, 1H), 1.39 (s, 6H), 1.38 (d, 3H, J = 7.0 Hz), 
1.34 – 1.24 (m, 3H), 1.22 (d, 3H, J = 6.8 Hz), 0.96 (d, 3H, J = 6.7 Hz), 0.95 (d, 3H, J = 6.8 Hz), 
0.92 ppm (d, 3H, J = 6.6 Hz); 13C NMR (150 MHz, CDCl3):  = 172.5, 168.5, 150.7, 148.2, 141.0, 
133.3, 131.1, 126.3, 124.7, 114.3, 100.5, 99.2, 78.2, 76.3, 68.7, 61.1, 44.6, 44.5, 44.4, 35.5, 
32.5, 31.6, 30.1, 27.1, 25.9, 25.3, 24.7, 21.5, 21.2, 20.7, 20.4, 18.3, 15.1, 13.0, 10.2 ppm; IR 
(film): ?̃? = 2930, 1767, 1589, 1482, 1456, 1428, 1371, 1318, 1247, 1224, 1207, 1186, 1116, 
1065, 997, 934, 851, 740, 709, 699 cm-1; MS (ESIpos) m/z (%): 605 (M+Na+, 100); HRMS (ESI): 
m/z: calcd. for C35H50O7Na [M+Na
+]: 605.3453, found 605.3449.  
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Table 8: 
1
H and 
13
C NMR data of cycloalkyne 267; numbering 
scheme as shown in the insert. 
 
 
  
1
H NMR (600 MHz, CDCl3) 
13
C NMR (150 MHz, CDCl3) 
No.   (ppm) Integral Splitting COSY J (Hz)  (ppm) HMBC 
1 - - - - - 148.2 4a, 21, 22 
2 - - - - - 126.3 22 
3 - - - - - 150.7 4a, 22, 23 
4 - - - - - 141.0 4a, 22 
5 -- - - - - 172.5 6, 7, 24 
6 3.07 1H dq 7, 24 7.9, 7.0 44.6 7, 8, 24 
7 3.51 1H dd 8, 24 7.9, 5.3 78.2 6, 8, 24, 27 
8 1.92 1H ddq 7, 9, 27 6.8, 5.3, 3.5 35.5 6, 7, 10, 27 
9 3.91 1H td 8, 10a, 10b 7.1, 3.6 68.7 7, 10, 11, 27 
10 1.47 – 1.39 2H m 9, 11a, 11b - 27.1 9, 11, 12 
11 1.34 – 1.24 2H m 10, 11b, 12 - 32.5 9, 10, 12, 13, 28, 29 
12 2.48 – 2.43 1H m 11, 13, 28 - 31.6 10, 11, 13, 28, 29 
13 4.93 1H d 12, 15a, 29 9.0 131.1 12, 14, 15, 29 
14 - - - - - 133.3 12, 15, 29 
15a 2.13 – 2.10 1H m 13, 15b, 16 - 44.4 
44.4 
13, 17, 29, 30 
15b 1.52 1H dd 15a, 16 14.0, 9.8 
16 1.99 – 1.94 1H m 15a, 15b, 17a, 17b, 30 - 30.1 15, 17, 18, 30 
17a 1.41 – 1.39 1H m 16, 17b, 18 - 
44.5 15, 18, 30, 31 
17b 1.34 – 1.24 1H m 16, 17a, 18 - 
18 2.85 – 2.79 1H m 17a, 17b, 31 - 24.7 17, 31 
19 - - - - - 99.2 17, 18, 31 
20 - - - - - 76.3 4a, 17, 18, 22 
21 2.34 3H s - - 20.7 - 
22 2.10 3H s 4a - 10.2 - 
23 3.76 3H s - - 61.1 - 
24 1.38 3H d 6 7.0 15.1 6, 7 
25 - - - - - 100.5 7, 9, 26a, 26b 
26a 
1.39 6H 
s - - 25.9 26b 
26b  - - 25.3 26a 
27 0.95 3H d 8 6.8 13.0 7, 8, 9 
28 0.96 3H d 12 6.7 20.4 11, 12, 13, 29 
29 1.66 3H d 13 0.8 18.3 13, 15 
30 0.92 3H d 16 6.6 21.2 15, 17 
31 1.22 3H d 18 6.8 21.5 17, 18 
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Phenol 268.  Macrocycle 267 (100 mg, 0.172 mmol) was dissolved in MeOH (8.6 mL) and the 
solution was cooled to 0 °C before a solution of  K2CO3 (47 mg, 
0.34 mmol) in H2O (0.2 mL) was added. The resulting mixture was 
stirred for 1.5 h at 0 °C. After completion of the reaction, the 
mixture was filtered through a small pad of silica which was washed 
with EtOAc. The solvent was removed and the crude material was 
purified by flash chromatography (SiO2, petane 100%  pentane/EtOAc, 10/1) to afford the 
title compound as a colorless sticky oil (73 mg, 86%). [𝛼]D
20 = −31.8 (c = 1.71, CHCl3), 
1H NMR 
(500 MHz, CDCl3):  = 6.73 (s, 1H), 5.69 (s, 1H), 4.95 (d, 1H, J = 9.0 Hz), 3.90 (td, 1H, J = 7.4, 
3.5 Hz), 3.75 (s, 3H), 3.53 (dd, 1H, J = 7.7, 5.1 Hz), 3.07 (dq, 1H, J = 7.1, 6.9 Hz), 2.92 – 2.84 
(m, 1H), 2.48 – 2.40 (m, 1H), 2.18 (s, 3H), 2.18 – 2.15 (m, 1H), 2.01 – 1.97 (m, 1H), 1.95 – 1.90 
(m, 1H), 1.66 (d, 3H, J = 1.3 Hz), 1.52 – 1.41 (m, 4H), 1.39 (s, 6H), 1.37 (d, 3H, J = 7.1 Hz), 
1.34 – 1.28 (m, 2H), 1.26 (d, 3H, J = 6.9 Hz), 1.24 – 1.20 (m, 1H), 0.97 – 0.93 ppm (m, 9H); 
13C NMR (125 MHz, CDCl3):  = 173.1, 153.2, 151.4, 136.6, 133.1, 131.0, 122.8, 118.9, 105.5, 
101.9, 100.4, 78.3, 75.3, 68.7, 61.0, 44.4 (2C), 44.1, 34.9, 32.5, 31.7, 30.0, 27.3, 26.0, 25.5, 
24.8, 21.7, 21.2, 20.4, 18.5, 15.0, 13.0, 9.5 ppm; IR (film): ?̃? = 2931, 1756, 1713, 1483, 1454, 
1423, 1377, 1317, 1251, 1220, 1159, 1111, 1095, 1023, 998, 881, 861, 798, 755, 663 cm-1; 
MS (pos. ESI) m/z (%): 563 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C33H48O6Na [M+Na
+]: 
563.3346, found 563.3343.  
 
Benzofuran 61.  A solution of [JohnphosAu]OTs (C9) (8.7 mg, 10 mol%) in CH2Cl2 (1.3 mL) 
was added to a freshly prepared solution of phenol 268 (70 mg, 
0.13 mmol) in CH2Cl2 (1.0 mL). The resulting mixture was stirred at 
ambient temperature for 14 h. The mixture was filtered through a 
pad of SiO2. Evaporation of the filtrate and purification of the 
residue by flash chromatography (SiO2, pentane 100%  pentane/EtOAc, 9/1) afforded 
benzofuran 61 as a pale yellow oil (63 mg, 79%) that was further subjected to HPLC 
purification to remove trace impurities of the phosphine ligand. [𝛼]D
20 = −27.1 (c = 0.35, 
CH2Cl2), 
1H NMR (600 MHz, CDCl3):  = 7.04 (s, 1H), 6.20 (s, 1H), 4.42 (d, 1H, J = 9.1 Hz), 3.80 
(s, 3H), 3.77 (ddd, 1H, J = 9.4, 5.4, 3.4 Hz), 3.58 (dd, 1H, J = 9.9, 9.9 Hz), 3.14 – 3.10 (m, 1H), 
3.05 (dq, 1H, J = 7.1, 4.5 Hz), 2.45 (s, 3H), 2.25 – 2.20 (m, 1H), 1.98 (d, 1H, J = 15.6 Hz), 1.91 
(ddq, 1H, J = 6.9, 5.4, 3.4 Hz), 1.61 – 1.55 (m, 1H), 1.51 (s, 3H), 1.49 – 1.45 (m, 1H), 1.44 (s, 
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3H), 1.43 – 1.41 (m, 1H), 1.41 (s, 3H), 1.38 (d, 3H, J = 6.9 Hz), 1.35 – 1.33 (m, 1H), 1.33 (d, 3H, 
J = 7.1 Hz), 1.31 – 1.25 (m, 2H), 1.00 – 0.94 (m, 1H), 0.91 – 0.84 (m, 1H), 0.89 (d, 3H, 
J = 6.9 Hz), 0.82 (d, 3H, J = 6.4 Hz), 0.79 ppm (d, 3H, J = 6.7 Hz); 13C NMR (150 MHz, CDCl3): 
 = 172.8, 163.0, 151.6, 146.8, 140.4, 131.5, 129.4, 123.7, 115.7, 110.1, 102.9, 100.8, 78.4, 
69.7, 61.7, 44.1, 42.8, 42.5, 33.8, 33.7, 32.3, 31.6, 28.3, 28.1, 26.9, 24.5, 21.6, 20.2, 19.2, 
19.1, 14.4, 13.1, 9.4 ppm; IR (film): ?̃? = 2930, 2872, 1758, 1604, 1456, 1417, 1377, 1324, 
1226, 1194, 1108, 1024, 1002, 931, 861 cm-1; MS (pos. ESI) m/z (%): 563 (M+Na+, 100); HRMS 
(ESI): m/z: calcd. for C33H48O6Na [M+Na
+]: 563.3346, found 563.3343. The analytical and 
spectroscopic data are in agreement with those reported in the literature.[44a] 
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Table 9: 
1
H and 
13
C NMR data of benzofuran 61; numbering scheme as 
shown in the insert. 
 
 
  
1
H NMR (600 MHz, CDCl3) 
13
C NMR (150 MHz, CDCl3) 
No.   (ppm) Integral Splitting COSY J (Hz)  (ppm) HMBC 
1 - - - - - 151.6 4a, 20, 21 
2 - - - - - 115.7 4a, 21 
3 - - - - - 146.8 4a, 21, 22 
4 - - - - - 140.4 4a 
5 - - - - - 172.8 5, 6, 23 
6 3.05 1H dq 7, 23 7,1, 4.5 44.1 7, 8, 23 
7 3.58 1H dd 5, 8 9.9, 9.9 78.4 6, 8, 9, 23, 26 
8 1.91 1H ddq 7, 9, 26 6.9, 5.4, 3.4 33.7 6, 7, 9, 10, 26 
9 3.77 1H ddd 8, 10a, 10b 9.4, 5.4, 3.4 69.7 7, 10, 11, 26 
10a 1.43 – 1-41 1H m 9, 10b, 11a, 11b - 
28.1 9, 11, 12 
10b 1.31 – 1.25 1H m 9, 10a, 11a, 11b - 
11a 1.00 – 0.94 1H m 10a, 10b, 11b, 12 - 
33.8 9, 10, 12, 13, 27 
11b 0.91 – 0.84 1H m 10a, 10b, 11a, 12 - 
12 2.25 – 2.20 1H m 11a, 11b, 13, 27 - 32.3 10, 11, 13, 27, 28 
13 4.42 1H d 12, 15a, 28 9.1 129.4 11, 12, 15, 27, 28 
14 - - - - - 131.5 12, 15, 28 
15a 1.98 1H d 13, 15b, 16, 28 15.6 
42.5 13, 17, 28, 29 
15b 1.35 – 1.33 1H m 15a, 16 - 
16 1.31 – 1.27 1H m 15a, 15b, 17a, 17b, 29 - 28.3 15, 17, 18, 29 
17a 1.61 – 1.55 1H m 16, 17b, 18 - 
42.8 15, 18, 29, 30 
17b 1.49 – 1.45 1H m 16, 17a, 18 - 
18 3.14 – 3.10 1H m 17a, 17b, 30 - 31.6 17, 20, 30 
19 - - - - - 163.0 4a, 17, 18, 20, 30 
20 6.20 1H s - - 102.9 4a, 18 
21 2.45 3H s 4a - 9.4 20 
22 3.80 3H s - - 61.7 21 
23 1.33 3H d 6 7.1 14.4 6, 7 
24 - - - - - 100.8 7, 9, 25a, 25b 
25a 1.44 3H s - - 26.9 25b 
25b 1.41 3H s - - 24.5 25a 
26 0.89 3H d 8 6.9 13.1 7, 8, 9 
27 0.79 3H d 12 6.7 20.2 11, 12, 13 
28 1.51 3H s 13, 15a - 19.1 13, 15 
29 0.82 3H d 16 6.4 21.6 15, 17 
30 1.39 3H d 18 6.9 19.2 18, 20 
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Photo-Fries Product 62.  In a quartz tube (30 cm x 1.2 cm) a solution of benzofuran 61 
(37 mg, 68 mol) in cyclohexane (15 mL) was degassed by bubbling 
argon through it via canula for 30 min. The quartz tube was sealed and 
positioned next to a quartz photo reactor (double-walled vessel with 
water cooling at high flow). A Heraeus 125 W high pressure mercury gas 
lamp was put inside the quartz apparatus. The inner void containing the 
lamp was filled with argon and sealed with a plug of cotton to avoid ozone formation. Under 
stirring, the pale yellow solution was irradiated for 3-5 h. The solvent was removed and the 
residue was purified by flash chromatography (SiO2, pentane/EtOAc, 9/1) to afford ketone 
62 as a bright yellow oil (31 mg, 85%). [𝛼]D
23 = −50.4 (c = 0.30, CH2Cl2), 
1H NMR (500 MHz, 
CDCl3):  = 13.74 (s, 1H), 6.77 (s, 1H), 4.67 (d, 1H, J = 9.4 Hz), 3.90 (s, 3H), 3.89 – 3.82 (m, 2H), 
3.60 (dd, 1H, J = 8.7, 6.7 Hz), 3.12 – 3.05 (m, 1H), 2.52 – 2.46 (m, 1H), 2.50 (s, 3H), 2.30 (d, 
1H, J = 14.5 Hz), 1.84 – 1.78 (m, 1H), 1.70 (d, 3H, J = 1.3 Hz), 1.60 (td, 1H, J = 6.9, 4.2 Hz), 1.49 
(dd, 1H, J = 5.0, 0.4 Hz), 1.47 – 1.44 (m, 2H), 1.43 – 1.30 (m, 1H), 1.39 – 1.18 (m, 2H), 1.37 (s, 
3H), 1.36 (d, 3H, J = 6.0 Hz), 1.35 (s, 3H), 1.34 (d, 3H, J = 6.3 Hz), 1.18 – 1.10 (m, 1H), 0.83 (d, 
3H, J = 6.7 Hz), 0.82 (d, 3H, J = 6.2 Hz), 0.71 ppm (d, 3H, J = 6.7 Hz); 13C NMR (125 MHz, 
CDCl3):  = 208.1, 163.7, 156.3, 147.2, 143.5, 132.5, 129.2, 125.2, 121.9, 110.6, 103.8, 100.3, 
78.2, 68.4, 60.6, 47.2, 43.8, 43.6, 37.0, 32.1, 31.7, 31.2, 30.2, 26.9, 25.9, 24.4, 21.5, 20.9, 
20.0, 19.5, 15.7, 12.5, 10.0 ppm; IR (film): ?̃? = 2928, 1612, 1454, 1401, 1378, 1311, 1263, 
1226, 1162, 1084, 1014, 991, 939, 809, 722 cm-1; MS (pos. ESI) m/z (%): 563 (M+Na+, 100); 
HRMS (ESI): m/z: calcd. for C33H48O6Na [M+Na
+]: 563.3347, found 563.3343. The analytical 
and spectroscopic data are in agreement with those reported in the literature.[44a] 
 
Tetrahydropyran 63.  NaBH4 (4.9 mg, 0.13 mmol) was added to a solution of ketone 62 
(17 mg, 32 mol) in MeOH (0.64 mL) which caused an immediate color 
change from yellow to colorless. After 10 min, the reaction was 
quenched by the dropwise addition of aqueous HCl (0.33 mL, 0.5 M) and 
the mixture was stirred for 5 min before it was diluted and the aqueous 
phase was extracted with CH2Cl2 (3 x 120 mL). The combined organic 
phases were dried over MgSO4 and concentrated. The crude material was applied in the next 
step without further purification.  
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The residue was dissolved in MeOH (0.2 mL) and the solution was treated with four drops of 
HCl (2.0 M). The mixture was stirred at ambient temperature overnight before it was diluted 
with H2O (5 mL) and the aqueous phase was extracted with EtOAc (3 x 15 mL). The organic 
phases were dried over MgSO4 and concentrated. The residue was purified by flash 
chromatography (SiO2, pentane/EtOAc, 3/2) to afford tetrahydropyran 63 as a colorless oil 
(14 mg, 89%). [𝛼]D
23 = +16.3 (c = 0.17, CHCl3), 
1H NMR (500 MHz, CDCl3):  = 6.55 (s, 1H), 5.53 
(s, 1H), 4.60 (d, 1H, J = 9.8 Hz), 4.54 (d, 1H, J = 10.1 Hz), 3.83 (s, 3H), 3.66 – 3.62 (m, 1H), 3.44 
(ddd, 1H, J = 11.3, 2.3, 1.5 Hz), 3.11 – 3.03 (m, 1H), 2.46 – 2.43 (m, 1H), 2.45 (s, 3H), 2.25 –
 2.19 (m, 1H), 1.93 – 1.88 (m, 1H), 1.84 – 1.76 (m, 1H), 1.62 (s, 3H), 1.61 – 1.56 (m, 1H), 1.51 
(d, 1H, J = 5.3 Hz), 1.48 – 1.41 (m, 2H), 1.38 (d, 3H, J = 6.9 Hz), 1.33 – 1.18 (m, 5H), 1.03 (d, 
3H, J = 6.8 Hz), 0.90 (d, 3H, J = 6.6 Hz), 0.81 (d, 3H, J = 6.6 Hz), 0.76 ppm (d, 3H, J = 6.4 Hz); 
13C NMR (125 MHz, CDCl3):  = 159.7, 148.2, 141.7, 141.5, 131.5, 129.0, 122.2, 115.7, 112.5, 
104.8, 77.8, 77.4, 77.3, 61.4, 43.8, 41.8, 39.6, 38.7, 33.7, 32.5, 31.5, 31.2, 27.5, 21.8, 21.0, 
19.6, 18.7, 12.8, 9.4, 6.6 ppm; IR (film): ?̃? = 2925, 1454, 1404, 1383, 1324, 1216, 1106, 1055, 
998, 974, 922, 852, 808 cm-1; MS (EI) m/z (%): 485 (32), 484 (100), 466 (18), 456 (17), 245 
(29); HRMS (ESI): m/z: calcd. for C30H44O5Na [M+Na
+]: 507.3082, found 507.3081. The 
analytical and spectroscopic data are in agreement with those reported in the literature.[44a] 
 
6.3. Synthesis of a 4-Pyrone Natural Product 
6.3.1.  Preparation of Model Compounds 
Methyl Ester 357.  A solution of-ketoacid 354 (1.10 g, 5.32 mmol) in CH2Cl2 (31 mL) was 
cooled to 0 °C before methanol (0.58 mL) and (trimethylsilyl)-
diazomethane (2.29 mL, 14.4 mmol) were added. After stirring for 4 h, 
the reaction was quenched by addition of concentrated acetic acid 
(5 mL). H2O (10 mL) was then added and the mixture was stirred for 10 min before the 
aqueous phase was extracted with EtOAc (3 x 50 mL). The combined organic phases were 
washed with H2O (20 mL) and brine (20 mL), dried over Na2SO4 and concentrated. The crude 
material was purified by flash chromatography (SiO2, pentane/EtOAc, 9/1) to give-
ketoester 357 as a pale yellow oil (890 mg, 40-70%).  1H NMR (400 MHz, CDCl3, mixture of 
keto/enol tautomers):  = 11.77 (s, 0.18H), 5.25 (s, 0.18H), 3.72 (s, 2.20H), 3.70 (s, 0.62H), 
3.54 (s, 1.64H), 2.37 (t, 2H, J = 7.0 Hz), 2.15 – 2.09 (m, 2H), 1.73 (t, 3H, J = 2.6 Hz), 1.69 – 1.62 
(m, 2H), 1.57 – 1.50 ppm (m, 2H); 13C NMR (100 MHz, CDCl3, mixture of keto (k)/enol (e) 
146 Experimental Procedures 
 
tautomers):  = 178.7 (k), 172.6 (e), 166.6 (k), 155.8 (e), 96.6 (k), 95.9 (e), 80.5 (k), 78.5 (e), 
78.3 (k), 76.2 (k), 76.0 (e), 75.7 (e), 52.5 (k), 51.5 (e), 51.2 (k), 28.1 (e), 28.0 (k), 27.0 (e), 26.6 
(k), 18.9 (e), 18.7 (k), 18.2 (e), 18.2 (k), 3.5 ppm (k/e); IR (film): ?̃? = 2950, 2922, 2863, 2213, 
1744, 1676, 1611, 1439, 1325, 1249, 1170, 1142, 1015, 806, 757, 689, 558 cm-1; MS (EI) m/z 
(%): 220 (3), 219 (13), 205 (10), 177 (54), 162 (12), 161 (31), 160 (9), 147 (13), 146 (40), 145 
(14), 131 (13), 119 (39), 118 (24), 117 (61), 115 (21), 105 (22), 104 (16), 103 (19), 101 (15), 93 
(12), 92 (13), 91 (100), 79 (50), 77 (44), 69 (22), 67 (17), 66 (32), 65 (27), 59 (30), 57 (11), 55 
(16), 53 (56), 51 (33), 43 (31), 39 (51), 31 (17); HRMS (ESI): m/z: calcd. for C13H16O3BrNa 
[M+Na+]: 321.0096, found 321.0097.  
 
-Bromo--ketoester 358.  Compound 357 (79 mg, 0.36 mmol) was dissolved in acetone 
(2.4 mL) and the solution was cooled to 0 °C. NBS (70 mg, 0.39 mmol) 
was added in one portion and the mixture was allowed to warm to 
ambient temperature. After 3 h, the reaction was filtered through a pad 
of Celite and the filtrate was evaporated. The residue was purified by flash chromatography 
(SiO2, hexanes/toluene, 1/1) to yield the monobrominated compound 358 (28 mg, 26%) 
along with the dibrominated 359 (29 mg, 21%) and recovered starting material 357 (25 mg, 
31%).  1H NMR (400 MHz, CDCl3, mixture of keto/enol tautomers):  = 12.23 (s, 0.21H), 4.90 
(s, 0.79H), 3.86 (s, 0.63H), 3.85 (s, 2.37H), 2.47 (t, 2H, J = 7.0 Hz), 2.19 – 2.15 (m, 2H), 1.77 (t, 
3H, J = 2.6 Hz), 1.75 – 1.68 (m, 2H), 1.63 – 1.56 ppm (m, 2H); 13C NMR (100 MHz, CDCl3, 
mixture of keto (k)/enol (e) tautomers):  = 173.8 (k), 169.1 (e), 164.1 (k), 154.2 (e), 102.5 
(e), 99.6 (k), 77.7 (e), 77.4 (k), 77.2 (k), 75.5 (k), 75.3 (e), 74.9 (e), 53.2 (k), 52.5 (e), 50.4 (e), 
49.4 (k), 27.2 (e), 27.1 (k), 26.0 (e), 25.7 (k), 18.5 (e), 18.1 (k), 17.4 (e), 17.4 (k), 2.7 ppm (k/e); 
IR (film): ?̃? = 2952, 2922, 2212, 1745, 1677, 1580, 1438, 1261, 1142, 1016, 798, 545 cm-1; MS 
(EI) m/z (%): 299 (2), 297 (2), 284 (3), 282 (3), 220 (8), 219 (49), 204 (34), 187 (34), 160 (9), 
159 (28), 147 (20), 131 (18), 119 (65), 118 (10), 117 (29), 115 (17), 105 (12), 104 (14), 103 
(15), 93 (12), 91 (100), 79 (32), 77 (28), 69 (13), 66 (15), 65 (15), 53 (32); HRMS (ESI): m/z: 
calcd. for C13H15O3Na [M+Na
+]: 243.0993, found 243.0992.  
1H NMR (400 MHz, CDCl3):  = 3.92 (s, 3H), 2.51 (t, 2H, J = 6.9 Hz), 2.20 – 
2.14 (m, 2H), 1.77 (t, 3H, J = 2.5 Hz), 1.76 – 1.70 (m, 2H), 1.64 – 1.57 ppm 
(m, 2H); 13C NMR (100 MHz, CDCl3):  = 169.9, 162.9, 101.6, 77.4, 75.5, 
74.5, 58.4, 54.5, 27.1, 25.6, 18.2, 17.4, 2.7 ppm; MS (EI) m/z (%): 299 (13), 297 (12), 284 (28), 
Experimental Procedures 147 
 
282 (30), 267 (8), 265 (7), 147 (19), 129 (11), 119 (66), 117 (22), 115 (14), 104 (12), 103 (14), 
93 (10), 92 (8), 91 (100), 79 (34), 77 (31), 66 (13), 65 (15), 53 (26); HRMS (ESI): m/z: calcd. for 
C13H14O3Br2Na [M+Na
+]: 398.9202, found 398.9202.  
 
2-Methyl-4-pyrone 363.  -Ketoester 357 (100 mg, 0.45 mmol) was dissolved in acetic acid 
(2.2 mL) and [SPhosAu]NTf2 (40 mg, 10 mol%) was added to the 
solution. The mixture was stirred for 18 h before the solvent was 
removed. and the crude material was purified by flash 
chromatography (SiO2, CH2Cl2/Et2O, 2/1) to yield the 4-pyrone 363 as a colorless solid 
(89 mg, 89%).  1H NMR (400 MHz, CDCl3):  = 6.00 (d, 1H, J = 1.9 Hz), 5.46 (d, 1H, J = 1.9 Hz), 
3.86 (s, 3H), 2.51 – 2.47 (m, 2H), 2.19 – 2.15 (m, 2H), 1.77 (t, 3H, J = 2.5 Hz), 1.76 – 1.70 (m, 
2H), 1.58 – 1.48 ppm (m, 2H); 13C NMR (100 MHz, CDCl3):  = 179.0, 163.3, 159.7, 111.8, 
89.9, 79.9, 76.0, 56.2, 33.4, 30.1, 23.4, 19.0, 3.9 ppm; MS (pos. ESI) m/z (%): 220 (8), 205 
(11), 188 (2), 181 (16), 153 (25), 125 (100), 95 (21), 80 (11), 53 (44), 48 (67), 37 (11).  
 
Exemplary Procedure for the Electrophilic Bromination of a model 4-Pyrone Substrate 
3-Bromo-4-pyrone 364.  A solution of 4-pyrone 363 (10 mg, 45 mol) in THF (0.5 mL) was 
treated with NBS (8.0 mg, 45 mol) in one portion. The mixture 
was stirred until the starting material was completely consumed 
(15 min). The mixture was filtered through a pad of Celite, the 
solvent was removed and the residue was purified by flash chromatography (SiO2, 
CH2Cl2/Et2O, 5/1) to give the title compound as a pale yellow solid (9.4 mg, 71%).  
1H NMR 
(400 MHz, CDCl3):  = 6.14 (s, 1H), 4.08 (s, 3H), 2.56 – 2.52 (m, 2H), 2.20 – 2.14 (m, 2H), 1.79 
– 1.72 (m, 2H), 1.75 (t, 3H, J = 2.5 Hz), 1.56 – 1.49 ppm (m, 2H); 13C NMR (100 MHz, CDCl3): 
 = 175.5, 163.0, 162.7, 111.4, 90.3, 78.2, 76.5, 56.8, 32.1, 28.0, 25.5, 18.4, 3.5 ppm; IR (film): 
~  = 2940, 1775, 1706, 1656, 1562, 1460, 1430, 1335, 1291, 1175, 1097, 1014, 974, 922, 849, 
816, 737, 631, 572 cm−1; MS (pos. ESI) m/z (%): 282 (1), 266 (15), 219 (8), 217 (9), 204 (25), 
202 (19), 149 (100), 67 (25), 53 (27), 37 (19); HRMS (ESIpos): m/z: calcd. for C13H15O3BrNa 
[M+H+]: 321.0097, found: 321.0096.  
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6.3.2. Synthesis of the -Ketoester Fragment 
Silyl Ether 378.  A LiHMDS solution was prepared by dropwise addition of a hexane solution 
of n-BuLi (60.8 mL, 97.2 mmol, 1.60 M), to a solution of HMDS (20.3 mL, 
97.2 mmol) in THF (50 mL) at –78 C. Then, the mixture was allowed to warm 
to 0 C over 0.5 h. The resulting LiHMDS solution was cooled to –78 C and was transferred 
by cannula to a solution of 1,7-octadiyne (377) (12.9 mL, 97.2 mmol) in THF (135 mL) at –
78 C. After stirring for 0.5 h, chlorotrimethylsilane (12.3 mL, 97.2 mmol) was added 
dropwise. The reaction mixture was stirred for 10 min and was then allowed to warm to 
ambient temperature. After stirring for additional 2 h, the reaction was quenched with water 
(200 mL). The aqueous phase was extracted with pentane (3 x 100 mL) and the extracts were 
combined, washed with aqueous HCl (200 mL, 1.0 M), water (200 mL) and brine (100 mL), 
dried over MgSO4, and concentrated. The crude material was distilled with a Vigreux column 
(bp 75 – 78.5 C, 7 mbar) to give silyl ether 378 (9.10 g, 52%) as colorless oil.  1H NMR 
(400 MHz, CDCl3):  = 2.28 – 2.18 (m, 4H), 1.94 (t, 1H, J = 2.7 Hz), 1.67 – 1.59 (m, 4H), 
0.14 ppm (s, 9H); 13C NMR (100 MHz, CDCl3):  = 107.0, 84.9, 84.3, 68.6, 27.7, 27.6, 19.5, 
18.1, 0.3 ppm (3C); IR (film): ~  = 3305, 2949, 2174, 1249, 837, 758, 697 cm−1; MS (EI) m/z 
(%): 163 (47), 145 (16), 135 (72), 119 (10), 109 (20), 95 (14), 83 (33), 73 (93), 69 (12), 59 
(100), 55 (12), 43 (25); HRMS (EI): m/z: calcd. for C11H19Si [M
 +]: 179.1256, found: 179.1254.  
The 1H NMR data are identical to the previously reported.[137a] 
The distillation residue was re-distilled using a Kugelrohr apparatus (100 – 
120 C/0.09 mbar) to give the disilylated product 379 as a colorless oil (4.07 g, 
17%).  1H NMR (400 MHz, CDCl3):  = 2.28 – 2.18 (m, 4H), 1.65 – 1.56 (m, 4H), 0.13 ppm (s, 
18H); 13C NMR (100 MHz, CDCl3):  = 107.1 (2C), 84.8 (2C), 27.8 (2C), 19.5 (2C), 0.3 ppm (6C); 
IR (film): ~  = 2957, 2174, 1248, 835, 757, 697 cm−1; MS (EI): m/z (%) 162 (29), 147 (13), 73 
(100), 67 (4), 59 (21); HRMS (EI): m/z: calcd. for C14H26Si2 [M
+]: 250.1573, found: 250.1571. 
The 1H and 13C NMR data are identical to the reported previously.[137b] 
 
Diyne 380.  A solution of n-butyllithium (39.9 mL, 63.9 mmol, 1.60 M in hexane) was added 
dropwise to a solution of 378 (7.60 g, 42.6 mmol,) in THF (200 mL) at –78 C. 
After 1 h, iodomethane (5.30 mL, 85.2 mmol) was added dropwise. The 
reaction mixture was then allowed to warm to ambient temperature and was stirred for 
additional 2 h before it was cooled to 0 C. The reaction was quenched with water (30 mL), 
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the aqueous phase was extracted with pentane (3 x 100 mL) and the extracts were 
combined, washed successively with water (30 mL) and brine (30 mL), dried over Na2SO4, 
and concentrated. The crude material was purified by distillation (119 – 125 C/20 mbar) to 
give the desired product 380 as a colorless oil (7.42 g, 91%).  1H NMR (400 MHz, CDCl3): 
 = 2.22 (t, 2H, J = 6.9 Hz), 2.17 – 2.10 (m, 2H), 1.76 (t, 3H, J = 2.5 Hz), 1.65 – 1.51 (m, 4H), 
0.13 ppm (s, 9H); 13C NMR (100 MHz, CDCl3):  = 107.3, 84.7, 78.9, 75.8, 28.3, 27.9, 19.6, 
18.4, 3.6, 0.3 ppm (3C); IR (film): ~  = 2946, 2174, 1248, 837, 758, 697 cm−1; MS (EI) m/z (%): 
177 (18), 149 (21), 135 (11), 118 (17), 97 (16), 83 (13), 73 (100), 67 (6), 59 (40), 43 (10); 
HRMS (CI): m/z: calcd. for C12H21Si [M+H
+]: 193.1413, found: 193.1411. The NMR data are 
identical to the previously reported.[138]  
 
Methyl Ester 376.  A solution of MeLi (23.7 mL, 37.9 mmol, 1.60 M in Et2O) was added to a 
solution of 380 (3.65 g, 19.0 mmol) in THF (73 mL) at –78 C. After stirring 
for 10 min, the reaction mixture was allowed to warm to 0 C, was stirred 
for additional 6 h. The mixture was cooled to –78 C before methyl 
chloroformate (3.70 mL, 47.9 mmol) was added dropwise. After 0.5 h, the reaction mixture 
was allowed to warm to 0 C, and the reaction was quenched with saturated aqueous 
NaHCO3 (50 mL). The aqueous phase was extracted with MTBE (3 x 150 mL) and the extracts 
were combined, washed with water (50 mL) and brine (50 mL), dried over Na2SO4, and 
concentrated. The residue was purified by flash chromatography (SiO2, hexanes/EtOAc, 
20/1) to give 376 as a colorless oil (2.90 g, 86%).  1H NMR (400 MHz, CDCl3):  = 3.73 (s, 3H), 
2.34 (t, 2H, J = 7.0 Hz), 2.18 – 2.10 (m, 2H), 1.75 (t, 3H, J = 2.4 Hz), 1.72 – 1.62 (m, 2H), 1.62 – 
1.52 ppm (m, 2H); 13C NMR (100 MHz, CDCl3):  = 154.3, 89.5, 78.4, 76.2, 73.1, 52.6, 28.0, 
26.7, 18.3, 18.3, 3.5 ppm; IR (film): ~  = 2951, 2235, 1712, 1434, 1248, 1076, 751 cm−1; MS 
(EI) m/z (%): 177 (15), 163 (14), 149 (15), 135 (22), 131 (6), 119 (53), 117 (54), 105 (23), 91 
(100), 79 (59), 66 (31), 59 (13), 53 (57), 41 (48), 27 (33); HRMS (CI): m/z: calcd. for C11H15O2 
[M+H+]: 179.1072, found: 179.1074. The analytical data are identical to the previously 
reported.[138] 

-Ketoester 354.  A LDA solution was freshly prepared by dropwise addition of  
n-butyllithium (6.57 mL, 10.5 mmol, 1.60 M) to a stirred solution of diisopropylamine 
(1.48 mL, 10.5 mmol) in THF (15 mL) at –78 C, followed by warming to 0 C over 5 min. The 
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obtained LDA solution was cooled to –78 C and t-butyl acetate 
(1.41 mL, 10.5 mmol) was added neat. After stirring for 0.5 h, a solution 
of 376 (950 mg, 5.33 mmol) in THF (15 mL) was added dropwise. The 
reaction mixture was stirred for 2 h at –78 C and was then poured into saturated aqueous 
NH4Cl (5.0 mL). The aqueous phase was extracted with MTBE (3 x 50 mL) and the extracts 
were combined, washed with water (15 mL) and brine (15 mL), dried over Na2SO4, and 
concentrated. The residue was purified by flash chromatography (SiO2, hexanes/EtOAc, 
20/1) to give 354 as a yellow oil (166 mg, 87%).  1H NMR (400 MHz, CDCl3, mixture of 
keto/enol tautomers):  = 12.01 (s, 0.18H), 5.20 (s, 0.18), 3.45 (s, 1.38), 2.43 – 2.35 (m, 2H), 
2.20 – 2.11 (m, 2H), 1.77 (br s, 3H), 1.74 – 1.64 (m, 2H), 1.64 – 1.53 (m, 2H), 1.47 ppm (s, 9H); 
13C NMR (100 MHz, CDCl3):  = 179.6, 165.5, 98.0, 95.9, 82.3, 78.4, 76.3, 52.9, 28.4, 28.1 (3C), 
26.8, 18.8, 18.3, 3.6 ppm; IR (film): ~  = 2933, 2213, 1732, 1677, 1610, 1393, 1368, 1323, 
1254, 1135, 956, 837, 732 cm−1; MS (EI) m/z (%): 205 (13), 189 (14), 177 (37), 161 (15), 146 
(32), 119 (21), 91 (25), 57 (100), 53 (11), 41 (28), 29 (11); HRMS (ESI): m/z: calcd. for 
C16H22NaO3 [M+Na
+]: 285.1461, found: 285.1461. 
 
-Ketoacid 370.  TFA (5.0 mL) was added to a solution of 354 (1.00 g, 3.81 mmol) in CH2Cl2 
(5.0 mL). After stirring for 0.5 h, the reaction mixture was concentrated 
and the obtained brown oil was purified by flash chromatography (SiO2, 
hexanes/EtOAc, 5/1  EtOAc 100%) to give 370 as a purple/brown solid 
(777 mg, 99%). This compound was highly sensitive and could only be stored for a few days 
in a freezer. It was therefore submitted to the next step without further purification.  
1H NMR (400 MHz, CDCl3, mixture of keto/enol tautomers):  = 11.56 (br s, 0.33H), 5.32 (s, 
0.33H), 3.63 (s, 1.28H), 2.42 (t, 2H, J = 6.9 Hz), 2.20 – 2.11 (m, 2H), 1.76 (t, 3H, J = 2.5 Hz), 
1.74 – 1.63 (m, 2H), 1.63 – 1.52 ppm (m, 2H); IR (film): ~  = 2936, 2214, 1650, 1574, 1455, 
1252, 1183, 1040, 965, 901, 804, 721, 689 cm−1; MS (EI) m/z (%): 161 (18), 147 (50), 119 (51), 
105 (17), 91 (66), 77 (26), 65 (16), 53 (35), 43 (100), 27 (23); HRMS (ESIneg): m/z: calcd. for 
C12H13O3 [M−H
+]: 205.0870, found: 205.0872. 
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6.3.3. Synthesis of the Epoxide 
Epoxide 387.  A mixture of powdered MS 4 Å (2.00 g) and CH2Cl2 (60 mL) was cooled to –
35 °C before titanium tetraisopropoxide (1.76 mL, 10 mol%) and (+)-diisopropyl 
(L)-tartrate (1.62 mL, 7.73 mmol) were added successively. After stirring for 3 h 
at –35 °C, 1,4-pentadien-3-ol (384) (5.78 mL, 59.4 mmol) was added dropwise followed by 
cumene hydroperoxide (17.6 mL, 119 mmol). The reaction mixture was stirred for 38 h at  
–35 °C. The reaction was quenched by addition of saturated aqueous Na2SO4 (5.0 mL) and 
the mixture was diluted with MTBE (50 mL). After stirring for 3 h at ambient temperature, 
the resulting slurry was filtered through a pad of Celite and the yellow filtrate was 
concentrated. Excess cumene alcohol and cumene hydroperoxide were removed by flash 
chromatography (SiO2, hexanes/MTBE, 5/1) to give the desired epoxide 387 as a colorless oil 
(4.87 g, 82%).  23D][  = +68.8 (c = 0.73, CHCl3); 
1H NMR (400 MHz, CDCl3):  = 5.83 (ddd, 1H, 
J = 17.2, 10.5, 6.2 Hz), 5.38 (dt, 1H, J = 17.2, 1.3 Hz), 5.25 (dt, 1H, J = 10.5, 1.3 Hz), 4.34 – 4.28 
(m, 1H), 3.08 (dt, 1H, J = 4.0, 3.0 Hz), 2.79 (dd, 1H, J = 5.0, 3.0 Hz), 2.74 (dd, 1H, J = 5.0, 
4.0 Hz), 2.23 ppm (d, 1H, J = 3.0 Hz); 13C NMR (100 MHz, CDCl3):  = 135.6, 117.7, 70.3, 54.0, 
43.6 ppm; IR (film): ~  = 3417, 2997, 1427, 1251, 1024, 972, 930, 885, 832, 793, 756 cm−1; 
MS (EI) m/z (%): 69 (22), 57 (100), 55 (24), 43 (29), 31 (18), 29 (55), 27 (29); HRMS (CI): m/z: 
calcd. for C5H9O2 [M+H
+]: 101.0603, found: 101.0602. The spectral data are identical to the 
previously reported.[158] 
 
TBS-Ether 417.  TBSCl (6.96 g, 46.2 mmol) was added to a solution of 387 (4.20 g, 42.0 mmol) 
and imidazole (6.00 g, 88.2 mmol) in DMF (42 mL) at 0 °C. After stirring for 1 h 
at 0 °C, the reaction mixture was diluted with MTBE (300 mL) and the organic 
phase was washed with water (4 x 100  mL) and brine (100 mL), dried over Na2SO4, and 
concentrated. The residue was purified by flash chromatography (SiO2, hexanes/MTBE, 10/1) 
to give 417 as a colorless oil (8.09 g, 90%).  23D][  = +1.90 (c = 0.73, CHCl3); 
1H NMR (400 MHz, 
CDCl3):  = 5.88 (ddd, 1H, J = 17.2, 10.4, 5.5 Hz), 5.32 (dt, 1H, J = 17.2, 1.5 Hz), 5.18 (dt, 1H, 
J = 10.4, 1.5 Hz), 4.12 (ddt, 1H, J = 5.5, 4.0, 1.5 Hz), 2.94 (td, 1H, J = 3.9, 3.1 Hz), 2.70 – 2.69 
(m, 2H), 0.89 (s, 9H), 0.06 (s, 3H), 0.05 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 137.6, 
116.0, 72.6, 54.6, 44.4, 25.9 (3C), 18.4, −4.6, −4.7 ppm; IR (film): ~  = 2956, 2930, 2857, 
1472, 1250, 1119, 1079, 1033, 1000, 926, 834, 774, 673 cm−1; MS (EI) m/z (%): 171 (11), 157 
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(18), 127 (100), 101 (32), 75 (71), 59 (23), 45 (13); HRMS (ESI): m/z: calcd. for C11H22NaO2Si 
[M+Na+]: 237.1281, found: 237.1283. 
 
Epoxide 383.  A mixture of 417 (8.00 g, 37.3 mmol), palladium on charcoal (10% Pd basis, 
400 mg) and EtOAc (80 mL) was vigorously stirred under hydrogen atmosphere 
for 2 h. The mixture was filtered through a pad of Celite and the resulting 
filtrate was concentrated. The residue was distilled using a Kugelrohr apparatus (90 – 
105 C/9 mbar) to give 383 as a colorless oil (7.65 g, 95%).  23D][  = +13.0 (c = 0.730, CHCl3); 
1H NMR (400 MHz, CDCl3):  = 3.51 (dt, 1H, J = 6.6 Hz), 2.86 (ddd, 1H, J = 4.6, 3.9, 2.6 Hz), 
2.69 (dd, 1H, J = 5.5, 3.9 Hz), 2.65 (dd, 1H, J = 5.0, 2.6 Hz), 1.71 – 1.49 (m, 2H), 0.96 (t, 3H, 
J = 7.5 Hz), 0.88 (s, 9H), 0.043 (s, 3H), 0.041 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 72.5, 
54.6, 44.9, 28.3, 26.0 (3C), 18.3, 9.4, −4.3, −4.7 ppm; IR (film): ~ = 2957, 2930, 2857, 1463, 
1251, 1110, 1074, 1017, 994, 833, 773 cm−1; MS (EI) m/z (%): 173 (4), 159 (29), 129 (44), 117 
(33), 101 (48), 89 (11), 75 (100), 59 (22); HRMS (ESI): m/z: calcd. for C11H24NaO2Si [M+Na
+]: 
239.1438, found: 239.1438. The spectral data are identical to the previously reported.[159] 
 
6.3.4. Synthesis of the Skipped Diene/Yne Fragment 
Alkyne 418.  3-Butyn-1-ol (386) (25.0 g, 357 mmol) was added dropwise to a solution of  
p-TsOH·H2O (67.8 mg, 10 mol%) in ethyl vinyl ether (68 mL) at 0 C. After stirring 
for 5 h at 0 C, the reaction was quenched by addition of saturated aqueous 
Na2CO3 (7.1 mL) and excess Na2CO3. The suspension was filtered through a frit and the 
filtrate was concentrated. The residue was distilled through a Vigreux column (68 – 73 C/42 
mbar) to give the ethoxyethyl ether 418 as a colorless oil (45.6 g, 90%).  1H NMR (400 MHz, 
CDCl3):  = 4.74 (q, 1H, J = 5.4 Hz), 3.72 – 3.62 (m, 2H), 3.62 – 3.44 (m, 2H), 2.45 (dt, 2H, 
J = 6.9, 2.5 Hz), 1.97 (t, 1H, J = 2.5 Hz), 1.31 (d, 3H, J = 5.4 Hz), 1.20 ppm (t, 3H, J = 7.1 Hz); 
13C NMR (100 MHz, CDCl3):  = 99.7, 81.6, 69.3, 63.0, 61.1, 20.2, 19.9, 15.4 ppm; MS (EI) 
m/z (%): 127 (14), 97 (11), 73 (90), 67 (60), 53 (57), 43 (100), 40 (22), 29 (36); HRMS (CI): m/z: 
calcd. for C8H15O2 [M+H
+]: 143.1072, found: 143.1071.  The analytical data are identical to 
the previously reported.[160] 
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Skipped Diyne 385.  4-(1-Ethoxyethoxy)but-1-yne (418) (20.0 mL, 129 mmol) was added 
dropwise to a solution of EtMgBr (47 mL, 140 mmol, 3.0 M) in THF (160 mL) at 
45 C. After stirring for 0.5 h at 45 C, copper(I) chloride (641 mg, 5 mol%) was 
added and the temperature was raised to and kept at 50 °C for 0.5 h. A 
solution of propargyl bromide (16.6 mL, 149 mmol, 80% in toluene) was added dropwise and 
the temperature was increased to 60 °C. After 1.5 h, the reaction mixture was cooled to 0 °C 
and poured into a solution of KCN (2.59 g) and NH4Cl (19.7 g) in water (130 mL). The aqueous 
phase was extracted with MTBE (3 x 250 mL) and the extracts were combined, washed with 
water (100 mL) and brine (100 mL), dried over Na2SO4, and concentrated. The crude material 
was purified by distillation using a Vigreux column (30 – 41 C/5 mbar) to give the desired 
product 385 as a pale yellow oil (19.1 g, 82%). The skipped diyne is very sensitive and must 
be stored under argon in the freezer.  1H NMR (400 MHz, CDCl3):  = 4.69 (q, 1H, J = 5.4 Hz), 
3.68 – 3.57 (m, 2H), 3.55 – 3.41 (m, 2H), 3.11 (q, 2H, J = 2.5 Hz), 2.40 (tt, 2H, J = 7.0, 2.5 Hz), 
2.02 (t, 1H, J = 2.5 Hz), 1.27 (d, 3H, J = 5.4 Hz), 1.16 ppm (t, 3H, J = 7.1 Hz); 13C NMR 
(100 MHz, CDCl3):  = 99.6, 78.6, 78.1, 74.3, 68.6, 63.1, 61.0, 20.4, 19.8, 15.3, 9.6 ppm; MS 
(EI) m/z (%): 105 (12), 91 (38), 79 (18), 72 (81), 65 (33), 51 (11), 43 (100), 39 (14), 29 (26); 
HRMS (CI): m/z: calcd. for C11H17O2 [M+H
+]: 181.1229, found: 181.1227. 
 
Alcohol anti-382.  A hexane solution of n-butyllithium (65.0 mL, 104 mmol, 1.60 M) was 
added dropwise to a solution of the skipped diyne 385 (18.7 g, 104 mmol) in 
Et2O (120 mL) at –78 C. After stirring for 0.5 h, BF3·OEt2 (12.8 mL, 104 mmol) 
was added dropwise and the mixture was stirred for 5 min at –78 C. A 
solution of the epoxide 383 (7.50 g, 34.7 mmol) in Et2O (4.0 mL) was added. 
After stirring for 0.5 h at –78 C, the mixture was poured into saturated 
aqueous NaHCO3 (120 mL). The aqueous phase was extracted with MTBE (3 x 250 mL) and 
the extracts were combined, washed with water (50 mL) and brine (50 mL), dried over 
Na2SO4 and concentrated. The crude material was purified by flash chromatography (SiO2, 
hexanes/EtOAc, 20/1 containing 1% Et3N) to give anti-382 as a pale yellow oil (8.12 g, 59%) 
that was submitted to the semihydrogenation without delay.  23D][  = +14.2 (c = 1.71, CHCl3); 
1H NMR (400 MHz, CDCl3):  = 4.71 (q, 1H, J = 5.3 Hz), 3.71 – 3.59 (m, 4H), 3.57 – 3.42 (m, 
2H), 3.12 (br s, 2H), 2.47 – 2.35 (m, 4H), 2.16 (br s, 1H), 1.63 – 1.40 (m, 2H), 1.30 (d, 3H, 
J = 5.3 Hz), 1.19 (t, 3H, J = 7.1 Hz), 0.90 (t, 3H, J = 7.5 Hz), 0.88 (s, 9H), 0.07 (s, 3H), 0.07 ppm 
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(s, 3H); 13C NMR (100 MHz, CDCl3):  = 99.6, 77.5, 77.0, 76.7, 75.4, 75.2, 72.2, 63.3, 61.0, 26.0 
(3C), 24.7, 22.8, 20.5, 19.9, 18.2, 15.4, 10.0, 9.4, −4.3, −4.4 ppm; IR (film): ~  = 3491, 2930, 
2858, 1463, 1380, 1253, 1132, 1086, 1055, 1003, 939, 834, 774, 668 cm−1; MS (EI) m/z (%): 
293 (12), 173 (51), 145 (13), 73 (100), 45 (21); HRMS (ESI): m/z: calcd. for C22H40NaO4Si 
[M+Na+]: 419.2588, found: 419.2586.  
 
Skipped Diene anti-388.  Quinoline (14.1 mL, 119 mmol,) and palladium (3.04 g, 5% on 
CaCO3, unpoisoned, reduced) were added to a solution of diyne anti-
382 (6.30 g, 15.9 mmol) in CH2Cl2 (46 mL). The heterogenous mixture 
was saturated with hydrogen using a balloon and stirred under 
hydrogen atmosphere for 2.5 h. The suspension was filtered through 
a pad of Celite and the filtrate was concentrated. The residue was purified by flash 
chromatography (SiO2, hexanes/EtOAc, 20/1 containing 1% Et3N) to give anti-388 as a pale 
yellow oil (5.42 g, 87%).  23D][  = +5.2 (c = 1.22, CHCl3); 
1H NMR (400 MHz, CDCl3):  = 5.55 – 
5.37 (m, 4H), 4.69 (q, 1H, J = 5.3 Hz), 3.69 – 3.53 (m, 4H), 3.53 – 3.38 (m, 2H), 2.83 (t, 2H, 
J = 5.5 Hz), 2.38 – 2.31 (m, 2H), 2.29 – 2.16 (m, 2H), 2.08 (d, 1H, J = 3.3 Hz), 1.61 – 1.41 (m, 
2H), 1.30 (d, 3H, J = 5.3 Hz), 1.20 (t, 3H, J = 7.1 Hz), 0.91 (t, 3H, J = 7.1 Hz), 0.91 (s, 9H), 
0.08 ppm (s, 6H); 13C NMR (100 MHz, CDCl3):  = 130.6, 129.7, 126.5, 126.2, 99.6, 76.2, 74.0, 
64.7, 60.9, 30.1, 28.3, 26.1, 26.0 (3C), 24.2, 20.0, 18.2, 15.5, 10.1, −4.3, −4.3 ppm; IR (film): 
~  = 3500, 2930, 2858, 1463, 1379, 1253, 1132, 1084, 1059, 1004, 940, 834, 774, 731 cm−1; 
MS (EI) m/z (%): 355 (1), 336 (1), 297 (6), 271 (1), 253 (6), 173 (36), 145 (17), 107 (10), 73 
(100), 45 (22); HRMS (ESI): m/z: calcd. for C22H44NaO4Si [M+Na
+]: 423.2901, found: 423.2903. 
 
MOM-Ether anti-419.  To a solution of alcohol anti-388 (4.90 g, 12.2 mmol) in CH2Cl2 
(180 mL) were added successively (i-Pr)2NEt (32.0 mL, 183 mmol), 
(chloromethyl)methyl ether (8.36 mL, 110 mmol) and sodium 
iodide (6.60 g, 44.0 mmol). The mixture was stirred at 35 C for 
14 h. After cooling to ambient temperature, aqueous NH3 was 
added and the aqueous phase was extracted with CH2Cl2 (3 x 200 mL). The extracts were 
combined, washed successively with water (50 mL) and brine (50 mL), dried over Na2SO4, 
and concentrated. The residue was purified by flash chromatography (SiO2, hexanes/EtOAc, 
30/1 containing 1% Et3N) to give anti-419 as a colorless oil (4.88 g, 90%).  
23
D][  = +14.2 
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(c = 1.28, CHCl3); 
1H NMR (400 MHz, CDCl3):  = 5.52 – 5.37 (m, 4H), 4.72 (d, 1H, J = 6.7 Hz), 
4.69 (q, 1H, J = 5.3 Hz), 4.62 (d, 1H, J = 6.7 Hz), 3.70 – 3.53 (m, 4H), 3.53 – 3.37 (m, 2H), 3.36 
(s, 3H), 2.82 (t, 2H, J = 5.7 Hz), 2.39 – 2.22 (m, 4H), 1.60 – 1.41 (m, 2H), 1.30 (d, 3H, 
J = 5.3 Hz), 1.20 (t, 3H, J = 7.1 Hz), 0.92 (t, 3H, J = 7.4 Hz), 0.90 (s, 9H), 0.06 (s, 3H), 0.05 ppm 
(s, 3H); 13C NMR (100 MHz, CDCl3):  = 129.9, 129.6, 126.9, 126.3, 99.6, 96.0, 80.0, 75.6, 64.7, 
60.9, 55.8, 28.8, 28.2, 26.1 (3C), 26.0, 25.7, 20.0, 18.3, 15.5, 10.4, −4.1, −4.5 ppm; IR (film): 
~  = 2930, 2885, 1463, 1378, 1252, 1134, 1099, 1035, 918, 834, 773 cm−1; MS (EI) m/z (%): 
209 (1), 173 (42), 145 (26), 89 (13), 73 (100), 59 (4), 45 (34); HRMS (ESI): m/z: calcd. for 
C24H48NaO5Si [M+Na
+]: 467.3163, found: 467.3162. 
 
Alcohol anti-381.  Pyridinium p-toluenesulfonate (2.71 g, 10.8 mmol) was added to a 
solution of anti-419 (4.80 g, 10.8 mmol) in MeOH (410 mL). The 
reaction mixture was stirred for 2 h at 30 C. Saturated aqueous 
NaHCO3 was added, the mixture was concentrated to remove 
MeOH, and the residue was extracted with EtOAc (3 x 250 mL). The 
extracts were combined, washed with water (50 mL) and brine (50 mL), dried over Na2SO4, 
and concentrated. The crude material was purified by flash chromatography (SiO2, 
hexanes/EtOAc, 5/1) to give anti-381 as a colorless oil (3.62 g, 90%).  23D][  = +15.2 (c = 1.17, 
CHCl3); 
1H NMR (400 MHz, CDCl3):  = 5.59 – 5.36 (m, 4H), 4.72 (d, 1H, J = 6.7 Hz), 4.62 (d, 1H, 
J = 6.7 Hz), 3.68 – 3.53 (m, 4H), 3.37 (s, 3H), 2.84 (t, 2H, J = 6.5 Hz), 2.39 – 2.22 (m, 4H), 1.62 
– 1.41 (m, 3H), 0.92 (t, 3H, J = 7.5 Hz), 0.90 (s, 9H), 0.07 (s, 3H), 0.05 ppm (s, 3H); 13C NMR 
(100 MHz, CDCl3):  = 131.1, 129.5, 127.0, 125.8, 96.0, 80.0, 75.6, 62.4, 55.8, 31.1, 28.8, 26.1 
(3C), 26.1, 25.7, 18.3, 10.4, −4.1, −4.5 ppm; IR (film): ~  = 3359, 2929, 2857, 1463, 1252, 
1142, 1101, 1035, 917, 833, 773 cm−1; MS (EI) m/z (%): 283 (17), 173 (100), 145 (84), 115 
(22), 89 (47), 73 (67), 59 (14), 45 (71); HRMS (ESI): m/z: calcd. for C20H40NaO4Si [M+Na
+]: 
395.2588, found: 395.2588. 
 
Aldehyde anti-420.  Dess-Martin periodinane (6.01 g, 14.2 mmol) was added to a solution of 
alcohol anti-381 (3.30 g, 8.86 mmol) in CH2Cl2 (200 mL) at 0 C. After 
stirring for 10 min at 0 C, the mixture was allowed to warm to 
ambient temperature and was stirred for additional 2 h. As a part of 
the alcohol remained, more Dess-Martin reagent (6.01 g, 14.2 mmol) 
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was added to the mixture and stirring was continued for 2 h. A mixture of saturated aqueous 
NaHCO3 (18.3 mL) and saturated aqueous Na2SO3 (18.3 mL) was added and the resulting 
heterogeneous mixture was stirred vigorously for 15 min. The aqueous phase was extracted 
with CH2Cl2 (3 x 150 mL) and the extracts were combined, washed with saturated aqueous 
NH4Cl (50 mL) and brine (50 mL), dried over Na2SO4, and concentrated to give aldehyde anti-
420 which was used in the next step without further purification.  23D][  = +13.3 (c = 1.02, 
CHCl3); 
1H NMR (400 MHz, C6D6):   = 9.24 (s, 1H), 5.62 – 5.48 (m, 2H), 5.48 – 5.31 (m, 2H), 
4.69 (d, 1H, J = 6.7 Hz), 4.54 (d, 1H, J = 6.7 Hz), 3.71 – 3.60 (m, 2H), 3.23 (s, 3H), 2.70 (m, 3H,), 
2.53 – 2.40 (m, 1H), 2.36 – 2.24 (m, 1H), 1.69 – 1.57 (m, 1H), 1.48 – 1.27 (m, 2H), 1.02 (s, 9H), 
0.93 (t, 3H, J = 7.4 Hz), 0.16 (s, 3H), 0.09 ppm (s, 3H); 13C NMR (100 MHz, C6D6):  = 197.4, 
132.6, 128.8, 127.9, 119.5, 96.0, 79.8, 76.1, 55.5, 42.5, 28.7, 26.5, 26.4, 26.2 (3C), 18.5, 10.6, 
−4.0, −4.4 ppm; IR (film): ~  = 2929, 2856, 1727, 1463, 1252, 1142, 1100, 1034, 916, 834, 
773 cm−1; MS (EI) m/z (%): 173 (66), 145 (38), 117 (30), 89 (48), 73 (77), 59 (17), 45 (100); 
HRMS (ESI): m/z: calcd. for C20H38NaO4Si [M+Na
+]: 393.2432, found: 393.2429. 
 
Dibromide anti-421.  CBr4 (5.88 g, 17.7 mmol) was added to a solution of PPh3 (9.30 g, 
35.4 mmol) in CH2Cl2 (120 mL) at 0 C. After stirring for 0.5 h at 
0 C, the mixture was cooled to –78 C before a solution of 
aldehyde anti-420 in CH2Cl2 (35 mL) was added dropwise. After 
stirring for 0.5 h at –78 C, hexane (100 mL) was added to the 
vigorously stirred mixture. The suspension was filtered through a pad of Celite which was 
washed with an cold (0 °C) mixture of hexanes/MTBE (100 mL, 4:1) and the filtrate was 
concentrated. The residue was dissolved in a mixture of hexane/MTBE (50 mL, 4:1), the 
resulting suspension was filtered through a pad of Celite, and the filtrate was concentrated 
again. The residue was purified by flash chromatography (SiO2, hexanes/toluene, 10/1  
hexanes/EtOAc, 30/1) to give anti-421 as a colorless oil (3.95 g, 85% over 2 steps).  23D][  = 
+11.8 (c = 1.11, CHCl3); 
1H NMR (400 MHz, C6D6):  = 6.07 (t, 1H, J = 7.3 Hz), 5.60 (dtt, 1H, J = 
10.7, 7.4, 1.7 Hz), 5.43 (dtt, 1H, J = 10.5, 8.7, 1.6 Hz), 5.39 (dtt, 1H, J = 10.6, 8.8, 1.5 Hz), 5.13 
(dtt, 1H, J = 10.5, 7.3, 1.6 Hz), 4.70 (d, 1H, J = 6.7 Hz), 4.56 (d, 1H, J = 6.7 Hz), 3.71 – 3.62 (m, 
2H), 2.79 (m, 2H), 2.64 (tt, 2H, J = 7.3, 0.7 Hz), 2.54 – 2.43 (m, 1H), 2.38 – 2.29 (m, 1H), 1.70 – 
1.58 (m, 1H), 1.48 – 1.37 (m, 1H), 1.02 (s, 9H), 0.94 (t, 3H, J = 7.5 Hz), 0.17 (s, 3H), 0.10 ppm 
(s, 3H); 13C NMR (100 MHz, C6D6):  = 137.0, 130.5, 129.1, 127.9, 124.4, 96.0, 89.8, 79.9, 
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76.1, 55.5, 31.6, 28.9, 28.8, 26.5, 26.3 (3C), 18.5, 10.6, −3.9, −4.4 ppm; IR (film): ~  = 2929, 
2856, 1462, 1251, 1142, 1100, 1035, 917, 833, 773 cm−1; MS (EI) m/z (%): 437 (22), 407 (1), 
173 (100), 145 (73), 119 (28), 89 (50), 73 (59), 45 (74); HRMS (ESI): m/z: calcd. for 
C21H38Br2NaO3Si [M+Na
+]: 547.0849, found: 547.0850. 
 
Alkyne anti-389.  A hexane solution of n-butyllithium (7.84 mL, 12.5 mmol, 1.60 M) was 
added dropwise to a solution of dibromide anti-421 (3.30 g, 
6.27 mmol) in THF (188 mL) at –78 C. After stirring for 0.5 h at  
–78 C, MeOTf (3.55 mL, 31.3 mmol) was added dropwise and the 
mixture was stirred for an additional 0.5 h at –78 C. A mixture of 
THF and phosphate buffer (100 mL, pH 7, 1:1) was then carefully added carefully via the cold 
walls of the flask at –78 C. The frozen mixture was shaken in the cooling bath to ensure 
good mixing with the organic phases. The mixture was then allowed to warm to ambient 
temperature and the aqueous phase was extracted with MTBE (3 x 100 mL). The extracts 
were washed with saturated aqueous NaHCO3 (30 mL), water (30 mL) and brine (30 mL). The 
organic phase was dried over Na2SO4 and concentrated. The crude material was purified by 
flash chromatography (SiO2, hexanes/toluene, 7/3  toluene 100%) to give anti-389 as a 
colorless oil (2.02 g, 79%).  23D][  = +14.9 (c = 1.00, CHCl3); 
1H NMR (400 MHz, CDCl3):  = 5.54 
– 5.37 (m, 4H), 4.72 (d, 1H, J = 6.7 Hz), 4.62 (d, 1H, J = 6.7 Hz), 3.63 (ddd, 1H, J = 7.3, 4.4, 
2.9 Hz), 3.57 (ddd, 1H, J = 7.3, 5.3, 2.9 Hz), 3.36 (s, 3H), 2.93 – 2.88 (m, 2H), 2.83 – 2.79 (m, 
2H), 2.37 – 2.22 (m, 2H), 1.78 (t, 3H, J = 2.6 Hz), 1.62 – 1.41 (m, 2H), 0.92 (t, 3H, J = 7.5 Hz), 
0.90 (s, 9H), 0.07 (s, 3H), 0.05 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 129.3, 129.1, 
127.3, 125.5, 96.0, 79.9, 77.4, 75.6, 75.6, 55.8, 28.9, 28.7, 26.1 (3C), 25.8, 18.3, 17.3, 10.4, 
3.6, −4.1, −4.5 ppm; IR (film): ~  = 2928, 2857, 1463, 1252, 1142, 1100, 1034, 917, 833, 
773 cm−1; MS (EI) m/z (%): 291 (18), 173 (99), 145 (100), 133 (24), 117 (29), 89 (60), 73 (84), 
59 (19), 45 (79); HRMS (ESI): m/z: calcd. for C22H40NaO3Si [M+Na
+]: 403.2639, found: 
403.2636. 
 
Alcohol anti-393.  A solution of MOM-ether anti-389 (1.28 g, 3.35 mmol) in CH2Cl2 (367 mL) 
was cooled to −78 °C before a freshly prepared solution of Me2BBr
[149b] (5.7 mL, 5.7 mmol, 
1.0 M in CH2Cl2) was slowly added via the cold walls of the flask. The colorless mixture was 
stirred for 40 min at −78 °C. After completion of the reaction, the cold solution was 
158 Experimental Procedures 
 
transferred by canula into a vigorously stirred mixture of 
THF/H2O/NaHCO3 (300 mL, 1:1:1). The resulting suspension was 
stirred for 15 min before the aqueous phase was extracted with CH2Cl2 
(3 x 100 mL), the organic phases were dried over Na2SO4 and 
concentrated. The crude material was purified by flash chromatography (SiO2, 
pentane/EtOAc, 50/1  30/1) to afford alcohol anti-393 as a colorless oil (970 mg, 86%). For 
characterization purposes an aliquot of the obtained material were purified by HPLC (UFLC 
SHIMADZU; Kromasil 100-5C18, 150 x 30 mm; 35 °C, 74 bar, 35 mL/min, 
methanol/H2O = 85/15).  [𝛼]D
20 = +2.5 (c = 0.50, CHCl3), 
1H NMR (600 MHz, C6D6):  = 5.56 
(dtt, 1H, J = 10.4, 7.0, 1.7 Hz), 5.50 (dtt, 1H, J = 10.7, 7.0, 1.4 Hz), 5.49 (dtt, 1H, J = 10.7, 6.9, 
1.3 Hz), 5.41 (dtt, 1H, J = 10.5, 7.3, 1.7 Hz), 3.58 (dt, 1H, J = 8.5, 4.3 Hz), 3.54 (dt, 1H, J = 7.3, 
4.2 Hz), 2.91 (ddqt, 2H, J = 7.0, 2.6, 1.9, 0.8 Hz), 2.79 (m, 2H), 2.34 – 2.23 (m, 2H), 1.77 (br s, 
1H), 1.64 (dq, 1H, J = 13.9, 7.4 Hz), 1.55 (t, 3H, J = 2.6 Hz), 1.40 (ddq, 1H, J = 14.0, 7.4, 4.3 Hz), 
0.96 (s, 9H), 0.91 (t, 3H, J = 7.5 Hz), 0.07 (s, 3H), 0.06 ppm (s, 3H); 13C NMR (150 MHz, C6D6): 
 = 130.2, 129.2, 127.0, 126.1, 77.6, 76.8, 75.7, 73.9, 30.6, 26.1 (3C), 26.0, 25.1, 18.4, 17.7, 
10.1, 3.4, −4.2, −4.3 ppm; IR (film): ?̃? = 2956, 2928, 2857, 1463, 1388, 1361, 1253, 1080, 
1005, 939, 909, 834, 792, 774, 730, 671 cm-1; MS (ESIpos) m/z (%): 359 (M+Na+, 100); HRMS 
(ESI): m/z: calcd. for C20H36O2SiNa [M+Na
+]: 359.2377, found 359.2377.  
 
6.3.5. Revised Synthesis of the Skipped Diene/Yne Fragment 
Alkyne 422.  Propargyl alcohol (397) (30.0 mL, 515 mmol) was added dropwise to a solution 
of p-TsOH·H2O (98.0 mg, 0.1 mol%) in ethyl vinyl ether (74.0 mL) at 0 C. After 
stirring for 5 h at 0 C, the reaction was quenched with saturated aqueous 
Na2CO3 (10 mL) and excess of solid Na2CO3 was added to the resulting mixture. The 
suspension was filtered through a frit and the filtrate was concentrated. The crude product 
was distilled through a Vigreux column (58 – 64 C/50 mbar) to give the ethoxyethyl ether 
422 as a colorless oil (55.6 g, 84%).  1H NMR (400 MHz, CDCl3):  = 4.85 (q, 1H, J = 5.4 Hz), 
4.20 (d, 2H, J = 2.4 Hz), 3.65 (dq, 7.1, J = 9.4, 7.1 Hz), 3.51 (dq, 1H, J = 9.4, 7.1 Hz), 2.39 (t, 1H, 
J = 2.4 Hz), 1.33 (d, 3H, J = 5.4 Hz), 1.20 ppm (t, 3H, J = 7.1 Hz); 13C NMR (100 MHz, CDCl3): 
 = 98.8, 80.2, 73.9, 60.9, 52.6, 19.8, 15.4 ppm; IR (film): ~  = 2979, 2933, 2900, 1445, 1385, 
1339, 1267, 1128, 1084, 1052, 1036, 991, 946, 927, 852, 823, 659, 631, 500 cm−1; MS (EI): 
m/z (%) 113 (87), 85 (29), 83 (95), 73 (100), 57 (31), 55 (33), 45 (99), 43 (94),39 (95), 29 (61); 
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HRMS (CI): m/z: calcd. for C7H13O2 [M+H
+]: 129.0916, found: 129.0915. The 1H and 13C NMR 
data are identical to the previously reported.[161] 
 
Skipped Diyne 396.  A solution of EtMgBr (39.6 mL, 119 mmol, 3.0 M in Et2O) was diluted 
with THF (120 mL) and warmed to 45 C. 3-(1-Ethoxyethoxy)prop-1-yne (422) 
(15.0 mL, 110 mmol) was added dropwise to the mixture at 45 C. After stirring 
for 0.5 h at 45 C, copper(I) chloride (546 mg, 5.00 mol%) was added and the 
temperature raised to and kept at 50 °C for 0.5 h. A solution of propargyl bromide (14.1 mL, 
127 mmol, 80% in toluene) was added dropwise and the temperature was increased to 
60 °C. After 1.5 h, the reaction mixture was cooled to ambient temperature and then poured 
into a solution of KCN (1.94 g) and NH4Cl (14.8 g) in water (97.8 mL). The aqueous phase was 
extracted with MTBE (3 x 150 mL) and the extracts were combined, washed successively 
with water (50 mL) and brine (50 mL), dried over Na2SO4 and concentrated. The crude 
product was purified by distillation (53 – 55 C/0.07 mbar) to give the desired product 396 as 
a pale yellow oil (12.4 g, 68%) which was very sensitive to air and must be stored under 
argon in a freezer.  1H NMR (400 MHz, CDCl3):  = 4.82 (q, 1H, J = 5.4 Hz), 4.18 (dt, 2H, J = 2.2, 
1.1 Hz), 3.64 (dq, 1H, J = 9.4, 7.1 Hz), 3.50 (dq, 1H, J = 9.4, 7.1 Hz), 3.21 – 3.18 (m, 2H), 2.05 
(t, 1H, J = 2.8 Hz), 1.31 (d, 3H, J = 5.4 Hz), 1.19 ppm (t, 3H, J = 7.1 Hz); 13C NMR (100 MHz, 
CDCl3):  = 98.7, 79.2, 77.9, 77.2, 69.1, 60.8, 53.1, 19.8, 15.4, 9.8 ppm; IR (film): 
~  = 3295, 
2979, 2900, 1445, 1385, 1338, 1311, 1124, 1083, 1053, 1028, 979, 945, 927, 854 cm−1; MS 
(EI) m/z (%): 151 (20), 121 (25), 93 (10), 77 (100), 73 (53), 65 (7), 51 (39), 45 (57); HRMS (CI): 
m/z: calcd. for C10H15O2 [M+H
+]: 167.1072, found: 167.1073. 
 
Alcohol anti-395.  A hexane solution of n-butyllithium (2.60 mL, 4.16 mmol, 1.5 M) was 
added dropwise to a solution of the skipped diyne 396 (691 mg, 4.16 mmol) in 
THF (40 mL) at –78 C. After stirring for 0.5 h, BF3·OEt2 (513 L, 4.16 mmol) 
was added dropwise and the mixture was stirred for 5 min at –78 C. A 
solution of epoxide 383 (300 mg, 1.39 mmol) in THF (4.0 mL) was added to the 
reaction mixture which was stirred for 0.5 h at –78 C and subsequently 
poured into saturated aqueous NaHCO3 (40 mL). The aqueous phase was extracted with 
MTBE (3 x 50 mL) and the extracts were combined, washed with water (20 mL) and brine 
(20 mL), dried over Na2SO4, and concentrated. The crude product was purified by flash 
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chromatography (SiO2, hexane/EtOAc, 10/1 containing 1% Et3N) to give anti-395 as a yellow 
oil (381 mg, 72%).  23D][ = +16.4 (c = 1.55, CHCl3); 
1H NMR (400 MHz, CDCl3):  = 4.82 (q, 1H, 
J = 5.3 Hz), 4.18 (q, 2H, J = 2.2 Hz), 3.73 – 3.59 (m, 3H), 3.50 (dq, 1H, J = 9.4, 7.1 Hz), 3.19 (tt, 
2H, J = 2.2, 2.2 Hz), 2.40 – 2.35 (m, 2H), 2.17 (br s, 1H), 1.63 – 1.40 (m, 2H), 1.32 (d, 3H, 
J = 5.3 Hz), 1.19 (t, 3H, J = 7.1 Hz), 0.90 (t, 3H, J = 7.4 Hz), 0.89 (s, 9H), 0.07 (s, 3H), 0.07 ppm 
(s, 3H); 13C NMR (100 MHz, CDCl3):  = 98.7, 80.3, 76.6, 75.9, 75.2, 72.1, 60.7, 53.1, 46.3, 26.0 
(3C), 24.7, 22.8, 19.8, 18.2, 15.4, 10.1, 9.4, −4.3, −4.4 ppm; IR (film): ~  = 3481, 2930, 2858, 
1463, 1384, 1253, 1128, 1084, 1055, 1030, 1004, 928, 834, 774, 668 cm−1; MS (EI) m/z (%): 
279 (13), 235 (21), 173 (61), 145 (24), 115 (9), 91 (7), 73 (100), 45 (26); HRMS (ESI): m/z: 
calcd. for C21H38NaO4Si [M+Na
+]: 405.2432, found: 405.2428.   
 
Diol anti-423.  PPTS (509 mg, 2.03 mmol) was added to a solution of anti-395 (775 mg, 
2.03 mmol) in MeOH (100 mL). The reaction mixture was stirred for 1 h, 
before saturated aqueous NaHCO3 was added. The mixture was concentrated 
to remove MeOH, and the residue was extracted with EtOAc (3 x 50 mL). The 
extracts were combined, washed with water (40 mL) and brine (40 mL), dried 
over Na2SO4, and concentrated. The crude material was purified by flash 
chromatography (SiO2, hexane/EtOAc, 2/1 containing 1% Et3N) to give anti-423 as a yellow 
oil (615 mg, 98%).  1H NMR (400 MHz, CDCl3):  = 4.25 (t, 2H, J = 2.2 Hz), 3.74 – 3.64 (m, 2H), 
3.20 (tt, 2H, J = 2.3, 2.3 Hz), 2.41 – 2.36 (m, 2H), 1.64 – 1.39 (m, 2H), 0.91 (t, 3H, J = 7.5 Hz), 
0.89 (s, 9H), 0.08 (s, 3H), 0.08 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 80.5, 78.7, 77.6, 
75.8, 75.2, 72.2, 51.4, 26.0 (3C), 24.6, 22.8, 18.2, 10.1, 9.5, −4.3, −4.4 ppm; IR (film): 
~  = 3361, 2929, 2857, 1463, 1252, 1068, 1003, 834, 773, 668 cm−1; MS (EI) m/z (%): 235 
(21), 187 (11), 174 (14), 173 (100), 145 (53), 133 (14), 117 (19), 115 (27), 105 (13), 91 (16), 77 
(12), 75 (98), 73 (82), 57 (23); HRMS (ESI): m/z: calcd. for C17H30O3SiNa [M+Na
+]: 333.1854, 
found: 333.1856.  
 
Skipped Diene anti-424.  An solution of NaBH4 (495 L, 25 mol%, 1.0 M IN EtOH) was added 
to a solution of Ni(OAc)2·4H2O (138 mg, 25 mol%) in EtOH (0.7 mL). After 
the evolution of hydrogen had ceased, the resulting black suspension was 
cooled to –78 C and the flask was filled with hydrogen gas. EDA (106 L, 
1.58 mmol) and a solution of the skipped diyne anti-423 (615 mg, 
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1.98 mmol) in EtOH (0.5 mL) were added and the mixture was allowed to reach ambient 
temperature. After stirring for 7 h, the mixture was diluted with EtOAc. The resulting 
suspension was filtered through a pad of Celite and the filtrate was concentrated. The crude 
product was purified by flash chromatography (SiO2, hexane/EtOAc, 3/1 containing 1% Et3N) 
to give anti-424 as a pale yellow oil (489 mg, 79%).  23D][  = +2.2 (c = 1.80, CHCl3); 
1H NMR 
(400 MHz, CDCl3):  = 5.70 – 5.60 (m, 1H), 5.59 – 5.43 (m, 3H), 4.27 – 4.21 (m, 1H), 4.17 – 
4.08 (m, 1H), 3.65 – 3.54 (m, 2H), 2.99 – 2.92 (m, 1H), 2.84 – 2.74 (m, 1H), 2.32 – 2.16 (m, 
2H), 2.05 (br s, 2H), 1.64 – 1.40 (m, 2H), 0.90 (t, 3H, J = 7.4 Hz), 0.90 (s, 9H), 0.07 (s, 3H), 
0.07 ppm (s, 3H); 13C NMR (100 MHz, CDCl3):  = 130.7, 130.2, 128.8, 126.6, 76.1, 73.8, 58.4, 
30.3, 26.1, 26.0 (3C), 24.3, 18.2, 9.9, −4.2, −4.3 ppm; IR (film): ~  = 3361, 2929, 2857, 1463, 
1253, 1082, 1004, 834, 773, 755, 666 cm−1; MS (EI) m/z (%): 239 (12), 187 (21), 173 (80), 145 
(60), 133 (43), 115 (17), 93 (50), 75 (100), 67 (13), 57 (20), 41 (13); HRMS (ESI): m/z: calcd. for 
C17H34NaO3Si [M+Na
+]: 337.2169, found: 337.2166. 
 
Allyl Bromide anti-398.  A solution of PPh3 (84.3 mg, 0.322 mmol) in CH2Cl2 (1.5 mL) was 
added to a solution of anti-424 (77.8 mg, 0.247 mmol) and CBr4 (107 mg, 
0.322 mmol) in CH2Cl2 (3.5 mL) at 0 °C. After stirring for 0.5 h at 0 °C, the 
reaction was quenched by addition of saturated aqueous NH4Cl and the 
aqueous phase was extracted with MTBE (3 x 30 mL). The extracts were 
combined, washed with water (15 mL) and brine (15 mL), dried over Na2SO4, and 
concentrated, and the crude product was purified by flash chromatography (SiO2, 
hexane/EtOAc, 20/1) to give anti-398 as a colorless oil (85.3 mg, 91%).  23D][ = −3.4 (c = 1.05, 
CHCl3); 
1H NMR (400 MHz, CDCl3):  = 5.76 (dtt, 1H, J = 10.4, 8.4, 1.7 Hz), 5.61 – 5.47 (m, 3H), 
4.01 (dd, 2H, J = 8.3, 1.0 Hz), 3.66 – 3.57 (m, 2H), 2.92 (t, 2H, J = 6.6 Hz), 2.31 – 2.14 (m, 2H), 
2.06 (br s, 1H), 1.64 – 1.40 (m, 2H), 0.92 (t, 3H, J = 7.5 Hz), 0.91 (s, 9H), 0.09 (s, 3H), 0.08 ppm 
(s, 3H); 13C NMR (100 MHz, CDCl3):  = 133.7, 128.9, 127.4, 125.8, 76.3, 73.9, 30.1, 27.0, 26.0 
(3C), 25.6, 24.1, 18.3, 10.1, −4.2, −4.3 ppm; IR (film): ~  = 3567, 2930, 2857, 1463, 1253, 
1077, 1004, 834, 774, 754, 668 cm−1; HRMS (ESI): m/z: calcd. for C17H33BrNaO2Si [M+Na
+]: 
399.1326, found: 399.1329. 
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Alcohol anti-393.  1-Propynylmagnesium bromide (2.38 mL, 1.19 mmol, 0.5 M in THF) was 
added to a suspension of CuI (38 mg, 50 mol%) in THF (10 mL) at 
−15 C. The mixture was stirred for 0.5 h at −15 C, before a solution 
of bromide anti-398 (150 mg, 0.397 mmol) in THF (4.0 mL) was added 
dropwise. After stirring for 5 h at −10 C, the reaction was quenched 
with saturated aqueous NH4Cl and the mixture was warmed to ambient temperature before 
it was extracted with MTBE (3 x 15 mL). The extracts were combined, washed successively 
with water (5 mL) and brine (5 mL), dried over Na2SO4, and concentrated. The residue was 
purified by flash chromatography (SiO2, hexane/EtOAc, 30/1) to give anti-393 as colorless oil 
(108 mg, 81%). For characterization purposes an aliquot was purified by HPLC (UFLC 
SHIMADZU; Kromasil 100-5C18, 150 x 30 mm; 35 °C, 74 bar, 35 mL/min, 
methanol/H2O = 85/15).  [𝛼]D
20 = +2.5 (c = 0.50, CHCl3), 
1H NMR (600 MHz, C6D6):  = 5.56 
(dtt, 1H, J = 10.4, 7.0, 1.7 Hz), 5.50 (dtt, 1H, J = 10.7, 7.0, 1.4 Hz), 5.49 (dtt, 1H, J = 10.7, 6.9, 
1.3 Hz), 5.41 (dtt, 1H, J = 10.5, 7.3, 1.7 Hz), 3.58 (dt, 1H, J = 8.5, 4.3 Hz), 3.54 (dt, 1H, J = 7.3, 
4.2 Hz), 2.91 (ddqt, 2H, J = 7.0, 2.6, 1.9, 0.8 Hz), 2.79 (m, 2H), 2.34 – 2.23 (m, 2H), 1.77 (br s, 
1H), 1.64 (dq, 1H, J = 13.9, 7.4 Hz), 1.55 (t, 3H, J = 2.6 Hz), 1.40 (ddq, 1H, J = 14.0, 7.4, 4.3 Hz), 
0.96 (s, 9H), 0.91 (t, 3H, J = 7.5 Hz), 0.07 (s, 3H), 0.06 ppm (s, 3H); 13C NMR (150 MHz, C6D6): 
 = 130.2, 129.2, 127.0, 126.1, 77.6, 76.8, 75.7, 73.9, 30.6, 26.1 (3C), 26.0, 25.1, 18.4, 17.7, 
10.1, 3.4, −4.2, −4.3 ppm; IR (film): ~  = 2956, 2928, 2857, 1463, 1388, 1361, 1253, 1080, 
1005, 939, 909, 834, 792, 774, 730, 671 cm-1; MS (ESIpos) m/z (%): 359 (M+Na+, 100); HRMS 
(ESI): m/z: calcd. for C20H36O2SiNa [M+Na
+]: 359.2377, found 359.2377. 
 
Bromide syn-399.  PPh3 (1.96 g, 7.49 mmol) was added to a solution of alcohol anti-393 
(630 mg, 1.87 mmol) in toluene (62 mL) at 0 °C and the resulting 
mixture was stirred for 10 min before CBr4 (2.48 g, 7.49 mmol) was 
introduced. After stirring for another 10 min, the flask was placed into a 
pre-heated oilbath at 65 °C and stirring was continued for 1 h. After 
cooling to room temperature, the pale yellow suspension was filtered through a pad of 
Celite which was carefully rinsed with pentane/EtOAc (20:1). The combined filtrates were 
concentrated and purified by flash chromatography (SiO2, pentane/EtOAc, 200/1) to yield 
the bromide syn-399 as a pale yellow oil (445 mg, 60%). The material was very unstable and 
must be stored under argon in a freezer. For characterization purposes an aliquot was 
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purified by HPLC (UFLC SHIMADZU; Kromasil 100-5C18, 150 x 30 mm; 25 °C, 61 bar, 
35 mL/min, 210 nm, methanol/H2O = 95/5).  [𝛼]D
20 = −16.2 (c = 1.01, CHCl3); 
1H NMR 
(600 MHz, C6D6):  = 5.56 (ddt, 1H, J = 10.4, 7.0, 1.7 Hz), 5.53 (dddt, 1H, J = 10.7, 7.6, 6.2, 
1.4 Hz), 5.47 (ddt, 1H, J = 10.7, 7.0, 1.4 Hz), 5.39 (ddt, 1H, J = 10.5, 7.2, 1.7 Hz), 3.93 (dt, 1H, 
J = 10.1, 3.5 Hz), 3.63 (ddd, 1H, J = 7.7, 4.6, 3.3 Hz), 2.90 (ddqt, 2H, J = 7.0, 2.6, 1.9, 0.7 Hz), 
2.78 (dq, 1H, J = 16.0, 7.1 Hz), 2.75 (dq, 1H, J = 16.0, 7.1 Hz); 2.69 (dddd, 1H, J = 15.5, 6.4, 3.6, 
1.6 Hz), 2.61 (dddd, 1H, J = 15.2, 9.9, 7.5, 1.2 Hz), 1.89 (ddq, 1H, J = 13.6, 7.5, 4.6 Hz), 1.54 (t, 
3H, J = 2.6 Hz), 1.44 (dq, 1H, J = 13.7, 7.5 Hz), 0.95 (s, 9H), 0.81 (t, 3H, J = 7.4 Hz), 0.00 (s, 3H), 
−0.01 ppm (s, 3H); 13C NMR (150 MHz, C6D6):  = 130.1, 128.9, 127.5, 126.3, 77.5, 76.7, 75.8, 
59.4, 31.7, 26.3, 26.1, 26.0 (3C), 18.3, 17.7, 10.5, 3.4, −4.2, −4.3 ppm; IR (film): ?̃? = 2956, 
2929, 2857, 1462, 1382, 1361, 1254, 1094, 1048, 1005, 834, 794, 774, 726, 671 cm-1; MS 
(pos. ESI) m/z (%): 421 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C20H35OBrSiNa [M+Na
+]: 
421.1536, found 421.1533.  
 
Alcohol syn-372.  In a Teflon vial, a solution of syn-399 (432 mg, 1.08 mmol) in THF (18 mL) 
was carefully treated with HF∙pyridine (3.41 mL, 37.8 mmol, 70% HF) at  
0 °C. The resulting mixture was stirred for 5 h at 0 °C before it was 
diluted with EtOAc (10 mL) and H2O (5 mL). A saturated aqueous 
solution of NaHCO3 was added until the evolution of gas ceased. The 
mixture was extracted with EtOAc (3 x 30 mL), the combined organic phases were washed 
with brine (10 mL), dried over Na2SO4 and concentrated. The crude material was purified by 
flash chromatography (SiO2, pentane/EtOAc, 15/1) to yield the free alcohol syn-372 as a 
colorless oil (371 mg, 83%). The material was very unstable and should be immediately used 
in the next step. For characterization purposes an aliquot was purified by HPLC (UFLC 
SHIMADZU; Kromasil 100-5C18, 150 x 30 mm; 35 °C, 70 bar, 35 mL/min, 210 nm, 
methanol/H2O = 75/25).  [𝛼]D
20 = −18.6 (c = 0.56, CHCl3); 
1H NMR (600 MHz, C6D6):  = 5.53 
(dtt, 1H, J = 10.5, 7.0, 1.7 Hz), 5.42 (dtt, 1H, J = 10.7, 7.3, 1.6 Hz), 5.34 (dtt, 1H J = 10.4, 7.3, 
1.7 Hz), 5.30 (dtt, 1H, J = 10.7, 7.3, 1.7 Hz), 3.73 (ddd, 1H, J = 7.9, 6.3, 2.9 Hz), 3.10 (m, 1H), 
2.88 (ddqt, 2H, J = 7.0, 2.6, 1.8, 0.8 Hz), 2.70 (m, 2H), 2.60 (dddt, 1H, J = 15.0, 7.3, 6.3, 
1.5 Hz), 2.56 (dddt, 1H, J = 15.0, 7.9, 7.2, 1.5 Hz), 1.55 (t, 3H, J = 2.6 Hz), 1.38 (dq, 1H, 
J = 13.7, 7.4 Hz), 1.35 – 1.33 (m, 1H), 1.30 (ddq, 1H, J = 13.7, 7.4, 4.7 Hz), 0.79 ppm (t, 3H, 
J = 7.4 Hz); 13C NMR (150 MHz, C6D6):  = 130.6, 128.8, 126.8, 126.2, 77.6, 75.8, 74.2, 63.3, 
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34.0, 29.1, 26.0, 17.7, 10.2, 3.4 ppm; IR (film): ?̃? = 3436, 3020, 2964, 2920, 1710, 1424, 1375, 
1222, 1112, 1059, 969, 792, 681, 535, 482 cm-1; MS (EI) m/z (%): 187 (11), 147 (17), 145 (23), 
133 (24), 132 (10), 131 (42), 129 (10), 121 (18), 119 (34), 118 (15), 117 (40), 115 (11), 107 
(14), 106 (12), 105 (86), 93 (29), 92 (24), 91 (100), 85 (40), 81 (16), 79 (55), 78 (13), 77 (40), 
69 (19), 67 (24), 65 (14), 59 (32), 57 (85), 55 (22), 53 (20), 43 (12), 41 (39), 39 (17), 29 (20); 
HRMS (ESI): m/z: calcd. for C14H21OBrNa [M+Na
+]: 307.0667, found 307.0668.  

-Ketoester syn-374.  A solution of acid 370 (298 mg, 1.45 mmol) in CH2Cl2 (16 mL) was 
added to a solution of alcohol syn-372 (165 mg, 0.58 mmol) in 
CH2Cl2 (16 mL) at 0 C. DCC (298 mg, 1.45 mmol) was 
introduced to the mixture followed by DMAP (21 mg, 
30 mol%). The mixture was stirred for 0.5 h before it was 
diluted with MTBE (20 mL). The resulting suspension was 
filtered through a pad of Celite and the filtrate was concentrated. The residue was dissolved 
in a mixture of hexanes/MTBE (10 mL, 2:1) and the resulting suspension was filtered again 
through a pad of Celite. After evaporation of the filtrate, the crude product was purified by 
flash chromatography (SiO2, hexanes/EtOAc, 10/1  5/1) to give the highly unstable title 
compound syn-374 as a yellow oil (208 mg, 76%), which was directly used in the next step 
without further purification.  [𝛼]D
20 = −13.2 (c = 0.55, CHCl3). MS (ESIpos) m/z (%): 495 
(M+Na+, 100); HRMS (ESI): m/z: calcd. for C26H33O3BrNa [M+Na
+]: 495.1507, found 495.1505.  
 
4-Pyrone syn-402.  [SPhosAu]NTf2 (C12) (6.2 mg, 3 mol%) was added to a solution of -
ketoester syn-374 (110 mg, 0.23 mmol) in MeCN/AcOH (7.7 mL, 
5:1). The reaction mixture was stirred for 38 h at ambient 
temperature befiore it was concentrated. The crude product was 
purified by flash chromatography (SiO2, hexanes/EtOAc, 1/1  
EtOAc 100%) to give syn-402 as a colorless oil (105 mg, 97%). For 
characterization purposes an aliquot was purified by HPLC (UFLC 
SHIMADZU; Kromasil 100-5C18, 150 x 30 mm; 25 °C, 75 bar, 35 mL/min, 244 nm, 
methanol/H2O = 85/15).  [𝛼]D
20 = −41.9 (c = 0.44, CHCl3); 
1H NMR (600 MHz, C6D6):  = 5.95 
(dt, 1H, J = 1.8, 0.7 Hz), 5.63 (d, 1H, J = 1.9 Hz), 5.52 (dtt, 1H, J = 10.5, 7.0, 1.7 Hz), 5.41 (dtt, 
1H, J = 10.7, 7.4, 1.6 Hz), 5.28 (dtt, 1H, J = 10.5, 7.3, 1.8 Hz), 5.22 (dtt, 1H, J = 10.7, 7.1, 
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1.7 Hz), 4.01 (ddd, 1H, J = 7.2, 5.8, 3.5 Hz), 3.75 (ddd, 1H, J = 8.2, 5.9, 3.5 Hz), 2.84 (ddqt, 2H, 
J = 7.0, 1.8, 2.6, 0.8 Hz), 2.64 (dt, 1H, J = 15.8, 7.4 Hz), 2.60 (dt, 1H, J = 15.8, 7.3 Hz), 2.52 – 
2.47 (m, 2H), 1.91 (tq, 2H, J = 7.0, 2.6 Hz), 1.85 (dd, 2H, J = 7.4, 0.7 Hz), 1.61 (ddq, 1H, 
J = 14.2, 5.8, 7.5 Hz), 1.56 (t, 3H, J = 2.5 Hz), 1.55 (t, 3H, J = 2.6 Hz), 1.52 (dq, 1H, J = 14.2, 
7.3 Hz), 1.38 – 1.32 (m, 2H), 1.21 – 1.16 (m, 2H), 0.81 ppm (t, 3H, J = 7.5 Hz); 13C NMR 
(150 MHz, C6D6):  = 180.9, 166.8, 164.8, 131.2, 128.4, 126.4, 125.8, 112.8, 92.0, 82.5, 78.7, 
77.4, 76.2, 75.9, 54.3, 32.8, 32.3, 28.4, 25.9, 25.8, 24.7, 18.7, 17.6, 9.4, 3.4, 3.4 ppm; IR (film): 
?̃? = 2919, 1659, 1577, 1404, 1240, 1157, 928, 858, 679 cm-1; MS (EI) m/z (%): 393 (23), 208 
(13), 207 (100), 187 (32), 165 (25), 159 (16), 147 (16), 146 (12), 145 (47), 143 (12), 135 (11), 
132 (16), 131 (60), 129 (13), 123 (11), 119 (24), 118 (11), 117 (40), 111 (24), 109 (11), 107 
(18), 106 (10), 105 (57), 95 (31), 93 (36), 92 (13), 91 (64), 81 (45), 80 (12), 79 (51), 77 (20), 69 
(20), 55 (29), 53 (11), 43 (13), 41 (24); HRMS (ESI): m/z: calcd. for C26H33O3BrNa [M+Na
+]: 
495.1507, found 495.1505.  
 
Cycloalkyne syn-373.  A solution of syn-402 (30.0 mg, 63.0 mol) in toluene (60 mL) was 
stirred with activated MS 5 Å (powder, 440 mg) for 0.5 h before a 
solution of the molybdenum alkylidyne complex C4 (3.3 mg, 5 mol%, in 
50 L toluene) was added to the mixture. After stirring for 2 h at rt, the 
reaction mixture was filtered through a pad of Celite which was 
thoroughly rinsed with acetone. The filtrate was concentrated and the 
residue was purified by flash chromatography (SiO2, EtOAc 100%  EtOAc/acetone, 1/1) to 
give syn-373 as a colorless oil (21.7 mg, 52.0 mol, 82%). For characterization purposes an 
aliquot was purified by HPLC (UFLC SHIMADZU; Kromasil 100-5C18, 150 x 20 mm; 35 °C, 
55 bar, 25 mL/min, 240 nm, acetonitrile/H2O = 60/40).  [𝛼]D
20 = −42.1 (c = 1.05, CHCl3), 
1H NMR (600 MHz, C6D6):  = 5.87 (d, 1H, J = 1.8 Hz), 5.51 (d, 1H, J = 1.8 Hz), 5.48 – 5.45 (m, 
1H), 5.46 – 5.42 (m, 1H), 5.33 (dtt, 1H, J = 10.3, 6.9, 1.3 Hz), 5.20 (dtt, 1H, J = 10.7, 7.3, 
1.7 Hz), 3.75 (td, 1H, J = 6.8, 2.6 Hz), 3.63 (ddd, 1H, J = 9.5, 4.9, 2.6 Hz), 2.83 (dddt, 1H, 
J = 17.4, 8.0, 1.4, 2.1 Hz), 2.79 (dt, 1H, J = 16.3, 7.4 Hz), 2.73 (dt, 1H, J = 16.3, 6.9 Hz), 2.68 – 
2.64 (m, 1H), 2.54 (dddt, 1H, J = 15.1, 9.5, 7.2, 1.6 Hz), 2.44 (dddt, 1H, J = 15.1, 7.3, 4.9, 
1.6 Hz), 1.93 – 1.87 (m, 3H), 1.67 (dt, 1H, J = 14.2, 7.8 Hz), 1.65 – 1.55 (m, 2H), 1.44 – 1.37 
(m, 2H), 1.09 – 0.99 (m, 2H), 0.55 ppm (t, 3H, J = 7.5 Hz); 13C NMR (150 MHz, C6D6):  = 180.3, 
166.7, 164.5, 131.0, 129.9, 126.0, 125.2, 113.1, 91.5, 82.1, 79.3, 79.2, 54.4, 33.1, 32.6, 27.6, 
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26.2, 26.0, 24.9, 18.6, 17.3, 9.5 ppm; MS (pos. ESI) m/z (%): 441 (M+Na+, 100); HRMS (ESI): 
m/z: calcd. for C22H27O3BrNa [M+Na
+]: 441.1037, found 441.1036.  
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Table 10: 
1
H and 
13
C NMR data of macrocycle syn-373; numbering 
scheme as shown in the insert. 
 
 
  
 
1
H NMR (600 MHz, C6D6) 
13
C NMR (150 MHz, C6D6) 
No.   (ppm) Integral Splitting COSY J (Hz) 
 
(ppm) 
HMBC 
1 - - - - - 166.7 2, 20 
2 5.51 1H d 4 1.8 91.5 4 
3 - - - - - 180.3 2, 4 
4 5.87 1H d 2 1.8 113.1 2, 6a, 6b 
5 - - - - - 164.5 4, 6a, 6b 
6a 1.93 – 1.87 1H m 6b, 7 - 
32.6 4, 7, 8 
6b 1.67 1H dt 6a, 7 14.2, 7.8 
7 1.44 – 1.37 2H m 6a, 6b, 8 - 26.2 6a, 6b, 8, 9 
8 1.09 – 0.99 2H m 7, 9 - 27.6 6a, 6b, 7, 9 
9 1.90 – 1.87 2H m 8, 12a, 12b - 18.6 7, 8 
10 - - - - - 79.3 8, 9 
11 - - - - - 79.2 12a, 12b, 13, 14 
12a 2.83 1H dddt 9, 12b, 13 17.4, 8.0, 1.4, 2.1 
17.3 9, 13, 14 
12b 2.68 – 2.64 1H m 9, 12a, 13 - 
13 5.48 – 5.45 1H m 12a, 12b, 14 - 125.2 
9, 12a, 12b, 14, 15a, 
15b 
14 5.33 1H dtt 13, 15a, 15b 10.3, 6.9, 1.3 129.9 12a, 12b, 13, 15a, 15b 
15a 2.79 1H dt 14, 15b, 16 16.3, 7.4 
26.0 13, 14, 16, 17 
15b 2.73 1H dt 14, 15a, 16 16.3, 6.9 
16 5.46 – 5.42 1H m 15a, 15b, 17 - 131.0 
14, 15a, 15b, 17, 18a, 
18b 
17 5.20 1H dtt 
15a, 15b, 16, 18a, 
18b 
10.7, 7.3, 1.7 126.0 
15a, 15b, 16, 18a, 18b, 
19 
18a 2.54 1H dddt 17, 19 15.1, 9.5, 7.2, 1.6 
33.1 16, 17, 19, 20 
18b 2.44 1H dddt 17, 19 15.1, 7.3, 4.9, 1.6 
19 3.63 1H ddd 18a, 18b, 20 9.5, 4.9, 2.6 54.4 17, 18a, 18b, 20, 21 
20 3.75 1H td 19, 21 6.8, 2.6 82.1 18a, 18b, 19, 21, 22 
21 1.65 – 1.55 2H m 20, 22 - 24.9 19, 20, 22 
22 0.55 3H t 21 7.5 9.5 20, 21 
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syn-11.  NBS (4.2 mg, 2.4 mol) was added in solid form to a solution of syn-373 (11 mg, 
2.6 mol) in THF (1.1 mL) at 0 °C. The pale yellow solution was 
immediately allowed to warm to ambient temperature. The reaction 
was closely monitored by TLC (pentane/EtOAc, 1/1). After complete 
consumption of the starting material, the mixture was diluted with 
pentane and filtered through a pad of Celite, which was carefully rinsed 
with  pentane/EtOAc (1:1). The combined filtrates were concentrated and the residue was 
purified by flash chromatography (SiO2, pentane/EtOAc, 1/1  EtOAc 100%) to give syn-11 
as a colorless solid (5.3 mg, 40%). Crystals suitable for X-ray diffraction were grown from 
MeCN. For characterization purposes an aliquot was purified by HPLC (UFLC SHIMADZU; 
Kromasil 100-5C18, 150 x 20 mm; 35 °C, 50 bar, 20 mL/min, 264 nm, MeCN/H2O = 60/40).  
M.p. 105 – 108 °C; [𝛼]D
20 = −13.8 (c = 0.25, CHCl3). 
1H NMR (600 MHz, CDCl3):  = 6.13 (s, 1H), 
5.67 (dddt, 1H, J = 10.7, 7.6, 7.1, 1.4 Hz), 5.55 (dtt, 1H, J = 10.7, 7.1, 1.6 Hz), 5.51 – 5.45 (m, 
2H), 4.80 (ddd, 1H, J = 7.4, 5.4, 4.6 Hz), 4.14 (ddd, 1H, J = 8.3, 5.5, 4.6 Hz), 2.91 – 2.88 (m, 
2H), 2.90 – 2.78 (m, 2H), 2.73 (dddd, 1H, J = 15.1, 7.2, 5.4, 1.5 Hz), 2.72 (dddd, 1H, J = 15.2, 
8.3, 7.0, 1.5 Hz), 2.56 (ddd, 1H, J = 14.7, 8.5, 6.4 Hz), 2.53 (ddd, 1H, J = 14.6, 8.4, 6.9 Hz), 2.26 
– 2.24 (m, 2H), 1.96 (ddq, 1H, J = 14.3, 5.4, 7.5 Hz), 1.92 (dq, 1H, J = 14.3, 7.3 Hz), 1.83 (dtt, 
1H, J = 13.9, 8.5, 6.8 Hz), 1.79 (dtt, 1H, J = 13.7, 8.5, 6.8 Hz), 1.57 – 1.52 (m, 2H), 1.03 ppm (t, 
3H, J = 7.4 Hz); 13C NMR (150 MHz, CDCl3):  = 175.8, 163.1, 162.0, 130.8, 129.4, 125.9, 
125.0, 111.8, 92.2, 84.6, 79.2, 79.0, 55.1, 33.6, 32.7, 27.8, 26.5, 26.4, 26.1, 18.6, 17.4, 
9.7 ppm; IR (film): ?̃? = 2926, 1659, 1573, 1459, 1379, 1324, 1262, 1157, 1091, 1013, 975, 
918 cm-1; MS (EI) m/z (%): 506 (32), 505 (82), 420 (13), 419 (25), 417 (26), 338 (12), 337 (17), 
235 (19), 219 (29), 217 (28), 206 (21), 199 (20), 197 (20), 195 (21), 185 (38), 181 (23), 173 
(25), 171 (59), 169 (34), 159 (25), 157 (44), 145 (44), 143 (58), 141 (27), 133 (33), 131 (62), 
129 (87), 119 (32), 117 (81), 115 (29), 105 (57), 97 (22), 95 (33), 93 (38), 91 (100), 81 (42), 80 
(14), 79 (58), 69 (25), 67 (50), 55 (40); HRMS (ESI): m/z: calcd. for C22H26O3Br2Na [M+Na
+]: 
519.0138, found 519.0141.  
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Table 11: 
1
H and 
13
C NMR data of synthetic 4-pyrone syn-11; numbering 
scheme as shown in the insert. 
 
 
  
 
1
H NMR (600 MHz, CDCl3) 
13
C NMR (150 MHz, CDCl3) 
No.   (ppm) Integral Splitting COSY J (Hz)  (ppm) HMBC 
1 - - - - - 162.0 20 
2 - - - - - 92.2 4 
3 - - - - - 175.8 4 
4 6.13 1H s - - 111.8 6a, 6b 
5 - - - - - 163.1 4, 6a, 6b, 7a, 7b 
6a 2.56 1H ddd 6b, 7a, 7b 14.7, 8.5, 6.4 
32.7 4, 7a, 7b, 8 
6b 2.53 1H ddd 6a, 7a, 7b 14.6, 8.4, 6.9 
7a 1.83 1H dtt 6a, 6b, 7b, 8 13.9, 8.5, 6.8 
26.4 4, 6a, 6b, 8, 9 
7b 1.79 1H dtt 6a, 6b, 7a, 8 13.7, 8.5, 6.8 
8 1.57 – 1.52 2H m 7a, 7b, 9 - 27.8 6a, 6b, 7a, 7b, 9 
9 2.26 – 2.24 2H m 8, 12 - 18.6 7a, 7b, 8 
10 - - - - - 79.2 8, 9, 12 
11 - - - - - 79.0 9, 12, 13 
12 2.91 – 2.88 2H m 9, 13 - 17.4 13, 14 
13 5.51 – 5.45 1H m 12 - 125.0 12, 15 
14 5.51 – 5.45 1H m 15 - 129.4 12, 15, 16 
15 2.90 – 2.78 2H m 14, 16, 17 - 26.1 13, 14, 16, 17 
16 5.67 1H dddt 15, 17, 18a, 18b 10.7, 7.6, 7.1, 1.4 130.8 14, 15, 17, 18a, 18b 
17 5.55 1H dtt 15, 16, 18a, 18b 10.7, 7.1, 1.6 125.9 15, 16, 18a, 18b, 19 
18a 2.73 1H dddd 16, 17, 18b, 19 15.1, 7.2, 5.4, 1.5 
33.6 16, 17, 19, 20 
18b 2.72 1H dddd 16, 17, 18a, 19 15.2, 8.3, 7.0, 1.5 
19 4.14 1H ddd 18a, 18b, 20 8.3, 5.5, 4.6 55.1 17, 18a, 18b, 21a, 21b 
20 4.90 1H ddd 19, 21a, 21b 7.4, 5.4, 4.6 84.6 18a, 18b, 19, 21a, 21b, 22 
21a 1.96 1H ddq 20, 22 14.3, 5.4, 7.5 
26.5 19, 20, 22 
21b 1.92 1H dq 20, 22 14.3, 7.3 
22 1.03 3H t 21a, 21b 7.4 9.7 20, 21a, 21b 
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Ketone 425.  A solution of the Dess-Martin reagent (265 mg, 0.624 mmol) in CH2Cl2 (0.5 mL) 
was added to a solution of anti-393 (140 mg, 0.416 mmol) in dry CH2Cl2 
(8.7 mL) to 0 °C. The mixture was stirred for 10 min at 0 °C and for 2 h at 
ambient temperature before the reaction was quenched with a mixture 
of saturated aqueous NaHCO3 and saturated aqueous Na2SO3 (2 mL, 1:1). The resulting slurry 
was vigorously stirred for 5 min before the aqueous phase was extracted with EtOAc (3 x 
20 mL). The combined organic phases were dried over Na2SO4 and the solvent was removed 
under reduced pressure. Ketone 425 was immediately used in the next step without further 
purification (138 mg, 99%).  
 
Alcohol syn-393.  (S)-(−)- 1-Methyl-3,3-diphenyl-tetrahydropyrrolo(1,2-c)(1,3,2)oxazabor-
ole[142a] (403) ((S)-CBS-reagent, 343 mg, 1.24 mmol) in toluene (1.8 mL) 
was treated with a solution of ketone 425 (138 mg, 0.413 mmol) in 
toluene (8.0 mL). After cooling to −78 °C, a solution of catecholborane 
(149 mg, 1.24 mmol) in toluene (3.0 mL) was added via syringe pump 
over the course of 5 h. Once the addition was complete, the mixture was stirred for 12 h at 
−78 °C. The reaction was quenched with MeOH (2.0 mL) at this temperature and the 
resulting slurry stirred at ambient temperature for 1 h. The mixture was washed twice with 
NaOH (3.0 mL, 0.2 M) and the combined aqueous phases were extracted with EtOAc (3 x 
30 mL). The combined organic phases were washed with brine (20 mL), dried over Na2SO4 
and concentrated. The crude material was purified by flash chromatography (SiO2, 
pentane/EtOAc, 50/1  30/1) to yield alcohol syn-393 as a colorless oil (112 mg, 81%). For 
characterization purposes an aliquot was purified by HPLC (UFLC SHIMADZU; Kromasil 100-
5C18, 150 x 30 mm; 35 °C, 70 bar, 35 mL/min, 210 nm, MeOH/H2O = 85/15).  [𝛼]D
20 = −2.4 
(c = 0.40, CHCl3). 
1H NMR (600 MHz, C6D6):  = 5.61 (dtt, 1H, J = 10.8, 7.3, 1.6 Hz), 5.57 (dtt, 
1H, J = 10.5, 7.0, 1.8 Hz), 5.50 (dtt, 1H, J = 10.8, 7.3, 1.6 Hz), 5.43 (dtt, 1H, J = 10.5, 7.2, 
1.7 Hz), 3.54 (dt, 1H, J = 8.5, 4.1 Hz), 3.45 (dt, 1H, J = 5.8, 4.1 Hz), 2.92 (ddqt, 2H, J = 6.2, 2.6, 
1.8, 0.8 Hz), 2.89 – 2.77 (m, 2H), 2.31 – 2.27 (m, 1H), 2.25 – 2.20 (m, 1H), 1.97 (br s, 1H), 1.67 
(dq, 1H, J = 7.7, 6.0 Hz), 1.55 (t, 3H, J = 2.6 Hz), 1.44 – 1.37 (m, 1H), 0.94 (s, 9H), 0.86 (t, 3H, 
J = 7.5 Hz), 0.04 (s, 3H), 0.03 ppm (s, 3H); 13C NMR (150 MHz, C6D6):  = 129.6, 129.2, 127.2, 
126.1, 77.6, 76.5, 75.7, 72.8, 32.0, 26.6, 26.1, 26.1 (3C), 18.4, 17.7, 9.8, 3.4, −4.1, −4.4 ppm; 
IR (film): ?̃? = 2955, 2929, 2884, 2857, 1463, 1389, 1361, 1254, 1056, 1005, 939, 834, 774, 
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676 cm-1; MS (EI) m/z (%): 336 (1), 279 (8), 203 (25), 187 (44), 174 (14), 173 (91), 145 (32), 
134 (11), 133 (100), 131 (23), 119 (13), 117 (28), 115 (36), 93 (12), 91 (13), 75 (70), 73 (60); 
HRMS (ESI): m/z: calcd. for C20H36OSiNa [M+Na
+]: 359.2377, found 359.2377.  
 
Bromide anti-399.  PPh3 (341 mg, 1.30 mmol) was added to a solution of alcohol syn-393 
(97 mg, 0.288 mmol) in toluene (11 mL) at 0 °C and the resulting 
mixture was stirred for 10 min before CBr4 (431 mg, 1.30 mmol) was 
introduced. After stirring for 10 min, the flask was placed into a pre-
heated oilbath at 65 °C and the mixture stirred at this temperature for 
1 h. After cooling to rt, the pale yellow suspension was filtered through a pad of Celite, 
which was carefully rinsed with pentane/EtOAc (15 mL, 20:1). The combined filtrates were 
concentrated and the residue was purified by flash chromatography (SiO2, pentane/EtOAc, 
200/1) to yield the bromide anti-399 as a pale yellow oil (64 mg, 55%). The material was very 
unstable and must be stored under argon in a freezer. For characterization purposes an 
aliquot was purified by HPLC (UFLC SHIMADZU; Kromasil 100-5C18, 150 x 20 mm; 35 °C, 
53 bar, 20 mL/min, 210 nm, MeOH/H2O = 95/5).  [𝛼]D
20 = +9.0 (c = 0.30, CHCl3). 
1H NMR 
(600 MHz, C6D6):  = 5.56 (dtt, 1H, J = 10.5, 7.1, 1.7 Hz), 5.51 (dtt, 1H, J = 10.7, 6.7, 1.6 Hz), 
5.46 (dtt, 1H, J = 10.7, 7.0, 1.3 Hz), 5.39 (dtt, 1H, J = 10.5, 7.3, 1.7 Hz), 3.95 (ddd, 1H, J = 9.5, 
4.7, 4.3 Hz), 3.72 (dt, 1H, J = 5.2, 4.7 Hz), 2.90 (ddqt, 2H, J = 7.0, 1.8, 2.6, 0.8 Hz), 2.76 – 2.73 
(m, 2H), 2.68 (dddd, 1H, J = 15.3, 6.8, 4.2, 1.3 Hz), 2.56 (dddd, 1H, J = 15.5, 9.5, 6.8, 1.2 Hz), 
1.80 (ddq, 1H, J = 14.0, 6.2, 7.4 Hz), 1.54 (t, 3H, J = 2.6 Hz), 1.43 (ddq, 1H, J = 14.0, 4.6, 
7.4 Hz), 0.99 (s, 9H), 0.82 (t, 3H, J = 7.5 Hz), 0.10 (s, 3H), 0.03 ppm (s, 3H); 13C NMR (150 MHz, 
C6D6):  = 130.0, 128.9, 127.4, 126.3, 77.5, 76.7, 75.8, 59.5, 32.3, 27.5, 26.1 (3C), 26.0, 18.4, 
17.7, 9.1, 3.4, −4.2, −4.3 ppm; IR (film): ?̃? = 2959, 2928, 2856, 1462, 1258, 1091, 1014, 836, 
794, 777, 674 cm-1; MS (EI) m/z (%): 319 (11), 197 (70), 195 (71), 187 (24), 173 (39), 159 (38), 
145 (41), 139 (38), 137 (37), 135 (2), 133 (56), 131 (59), 119 (21), 117 (38), 115 (43), 107 (12), 
93 (30), 91 (71), 79 (36), 75 (68), 73 (100), 67 (26), 55 (28); HRMS (ESI): m/z: calcd. for 
C20H35OBrSiNa [
++Na+]: 421.1535, found 421.1533. 
 
Alcohol anti-372.  HF∙pyridine (0.20 mL, 2.22 mmol, 70% HF) was added dropwise to a 
solution of bromide anti-399 (47 mg, 0.12 mmol) in THF (1.0 mL) at 0 °C. The reaction 
mixture was then allowed to warm to ambient temperature and was stirred for 4 h before it 
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was  cooled to 0 °C and diluted with EtOAc (10 mL) and H2O (5 mL). 
Saturated aqueous NaHCO3 was added until the evolution of gas 
ceased. The mixture was extracted with EtOAc (3 x 20 mL), the organic 
phases were washed with brine (20 mL), dried over Na2SO4 and 
concentrated. The crude material was purified by flash chromatography (SiO2, 
pentane/EtOAc, 15/1) to yield alcohol anti-372 as a colorless oil (18.5 mg, 55%).  
[𝛼]D
20 = +19.2 (c = 0.10, CHCl3). 
1H NMR (600 MHz, C6D6):  = 5.55 (dtt, 1H, J = 10.5, 7.0, 
1.7 Hz), 5.45 – 5.39 (m, 2H), 5.35 (dtt, 1H, J = 10.5, 7.3, 1.8 Hz), 3.79 (dt, 1H, J = 9.4, 4.3 Hz), 
3.35 (dt, 1H, J = 8.7, 4.3 Hz), 2.88 – 2.85 (m, 2H), 2.69 – 2.66 (m, 2H), 2.56 – 2.51 (m, 1H), 
2.46 – 2.42 (m, 1H), 1.54 (t, 3H, J = 2.7 Hz), 1.41 – 1.40 (m, 1H), 1.38 – 1.35 (m, 2H), 0.82 ppm 
(t, 3H, J = 7.5 Hz); 13C NMR (150 MHz, C6D6):  = 130.1, 128.9, 127.1, 126.2, 77.5, 75.9, 75.8, 
62.5, 31.6, 27.0, 26.0, 17.7, 10.4, 3.4 ppm; IR (film): ?̃? = 2963, 2923, 2359, 1738, 1670, 1456, 
1259, 1013, 705, 681, 561, 432 cm-1; MS (EI) m/z (%): 187 (11), 147 (17), 145 (23), 133 (24), 
132 (10), 131 (42), 121 (18), 119 (34), 118 (15), 117 (40), 115 (11), 107 (14), 106 (12), 105 
(86), 93 (29), 91 (100), 85 (40), 81 (16), 79 (55), 77 (40), 59 (32), 57 (85), 41 (39); HRMS (ESI): 
m/z: calcd. for C14H21OBrNa [M+Na
+]: 307.0669, found 307.0668. 
 
-Ketoester anti-374.  A solution of acid 370 (16 mg, 77 mol) in CH2Cl2 (0.6 mL) was added 
to a solution of alcohol anti-372 (10 mg, 35 mol) in CH2Cl2 
(1.0 mL) at 0 C. DCC (16 mg, 77 mol) was then introduced at 
this temperature, followed after 5 min by DMAP (1.3 mg, 
30 mol%). The mixture was stirred for 15 min at 0 °C before it 
was diluted with MTBE (3 mL). The resulting suspension was 
filtered through a pad of Celite and the filtrate was concentrated. The residue was dissolved 
in a mixture of hexanes/MTBE (1 mL, 2:1) and the suspension was filtered through a pad of 
Celite. Evaporation of the filtrate followed by purification of the crude product by flash 
chromatography (SiO2, hexanes/EtOAc, 15/1  13/1) gave the highly unstable title 
compound as a yellow oil (13 mg, 78%, mixture of keto/enol tautomers) which was used 
directly in the next step without characterization. 
 
 
Experimental Procedures 173 
 
4-Pyrone anti-402.  [SPhosAu]NTf2 (C12) (0.4 mg, 3 mol%) was added to a solution of the -
ketoester anti-374 (10 mg, 21 mol) in MeCN/AcOH (1.5 mL, 5:1). 
The reaction mixture was stirred for 38 h at ambient temperature 
before all volatile materials were evaporated. Purification of the 
crude product by flash chromatography (SiO2, hexanes/ EtOAc, 
1/1  EtOAc 100%) gave anti-402 as a colorless oil (8.4 mg, 84%). 
For characterization purposes an aliquot was purified by HPLC 
(UFLC SHIMADZU; Kromasil 100-5C18, 150 x 20 mm; 35 °C, 55 bar, 20 mL/min, 228 nm, 
MeCN/H2O = 60/40).  [𝛼]D
20 = +13.6 (c = 0.09, CHCl3). 
1H NMR (600 MHz, C6D6):  = 5.92 (d, 
1H, J = 1.8 Hz), 5.59 (d, 1H, J = 1.8 Hz), 5.55 (dtt, 1H, J = 10.5, 6.9, 1.7 Hz), 5.42 (dtt, 1H, 
J = 10.7, 7.3, 1.4 Hz), 5.31 (dtt, 1H, J = 10.5, 7.3, 1.7 Hz), 5.27 (dtt, 1H, J = 10.7, 7.2, 1.8 Hz), 
4.09 (ddd, 1H, J = 9.1, 5.2, 3.6 Hz), 3.85 (dt, 1H, J = 8.5, 5.2 Hz), 2.86 (ddqt, 1H, J = 7.0, 1.6, 
2.5, 0.7 Hz), 2.64 – 2.59 (m, 2H), 2.48 – 2.37 (m, 2H), 1.92 (tq, 2H, J = 7.2, 2.6 Hz), 1.84 – 1.81 
(m, 2H), 1.58 – 1.56 (m, 2H), 1.57 (t, 3H, J = 2.5 Hz), 1.56 (t, 3H, J = 2.7 Hz), 1.35 – 1.31 (m, 
2H), 1.20 – 1.16 (m, 2H), 0.68 ppm (t, 3H, J = 7.4 Hz); 13C NMR (150 MHz, C6D6):  = 180.4, 
166.4, 164.4, 131.2, 128.5, 126.4, 125.7, 112.9, 92.1, 82.7, 78.7, 77.3, 76.2, 76.0, 53.9, 32.3, 
32.2, 28.4, 26.0, 25.8, 24.5, 18.7, 17.7, 9.1, 3.4, 3.4 ppm; IR (film): ?̃? =  3359, 2920, 2851, 
1661, 1632, 1578, 1411, 1247, 1086, 859, 800, 700 cm-1; MS (ESIpos) m/z (%): 495 (M+Na+, 
100); HRMS (ESI): m/z: calcd. for C26H33O3BrNa [M+Na
+]: 495.1506, found 495.1505. 
 
Cycloalkyne anti-373.  Activated MS 5 Å (powder, 70 mg) was added to a solution of anti-
402 (6.0 mg, 13 mol) in toluene (7.0 mL) and the resulting suspension 
was stirred for 0.5 h before a solution of the molybdenum alkylidyne 
complex C4 (0.7 mg, 5 mol%, in 50 L toluene) was introduced. After 
stirring for 2 h, the mixture was filtered through a pad of Celite, which 
was rinsed with EtOAc and the combined filtrates were concentrated. 
The crude product was purified by flash chromatography (SiO2, EtOAc 100%  
EtOAc/acetone, 1/1) to remove traces of the silanol ligands. The material was further 
purified by HPLC (UFLC SHIMADZU; Kromasil 100-5C18, 150 x 20 mm; 35 °C, 55 bar, 
20 mL/min, 240 nm, MeCN/H2O = 60/40) to yield anti-373 as a colorless oil (4.4 mg, 80%).  
[𝛼]D
20 = −7.5 (c = , CHCl3). 
1H NMR (600 MHz, C6D6):  = 5.88 (d, 1H, J = 1.8 Hz), 5.55 (d, 1H, 
J = 1.8 Hz), 5.48 (dtt, 1H, J = 10.3, 7.3, 1.7 Hz), 5.46 (dtt, 1H, J = 10.6, 7.1, 1.5 Hz), 5.37 (dtt, 
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1H, J = 10.6, 7.6, 1.7 Hz), 5.35 (dtt, 1H, J = 10.3, 7.1, 1.4 Hz), 4.14 (td, 1H, J = 6.7, 4.0 Hz), 3.70 
(ddd, 1H, J = 10.8, 5.0, 4.0 Hz), 2.79 – 2.76 (m, 4H), 2.58 – 2.53 (m, 1H), 2.50 – 2.45 (m, 1H), 
1.93 (tt, 2H, J = 6.5, 2.3 Hz), 1.83 (ddd, 1H, J = 14.7, 9.2, 5.7 Hz), 1.74 – 1.69 (m, 1H), 1.61 – 
1.54 (m, 1H), 1.49 – 1.43 (m, 2H), 1.39 – 1.34 (m, 1H), 1.07 – 1.01 (m, 2H), 0.63 ppm (t, 3H, 
J = 7.8 Hz); 13C NMR (150 MHz, C6D6):  = 180.3, 166.4, 164.2, 131.0, 129.9, 125.8, 125.3, 
113.2, 92.2, 83.0, 79.3, 79.2, 53.6, 32.6, 31.9, 27.7, 26.2, 26.0, 24.6, 18.6, 17.3, 8.5 ppm; IR 
(film): ?̃? =  2922, 2852, 1663, 1630, 1584, 1399, 1241, 1158, 928 cm-1; MS (ESIpos) m/z (%): 
443 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C22H27O3BrNa [M+Na
+]: 441.1037, found 
441.1036. 
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Table 12: 
1
H and 
13
C NMR data of macrocycle anti-373; numbering 
scheme as shown in the insert. 
 
 
  
 
1
H NMR (600 MHz, C6D6) 
13
C NMR (150 MHz, C6D6) 
No.   (ppm) Integral Splitting COSY J (Hz) 
 
(ppm) 
HMBC 
1 - - - - - 166.4 2, 20 
2 5.55 1H d 4 1.8 92.2 4 
3 - - - - - 180.3 2, 4 
4 5.88 1H d 2 1.8 113.2 2, 6a, 6b 
5 - - - - - 164.2 4, 6a, 6b 
6a 1.83 1H ddd 6b, 7 14.7, 9.2, 5.7 
31.9 4, 7, 8 
6b 1.74 – 1.69 1H m 6a, 7 - 
7a 1.49 – 1.43 1H m 6a, 6b, 8 - 
26.2 6a, 6b, 8, 9 
7b 1.39 – 1-43 1H m   
8 1.07 – 1.01 2H m 7, 9 - 27.7 6a, 6b, 7, 9 
9 1.93 2H tt 8, 12a, 12b 6.5, 2.3 18.6 7, 8 
10 - - - - - 79.3 8, 9 
11 - - - - - 79.2 12a, 12b, 13, 14 
12 2.79 – 2.76 2H m 9, 12b, 13 - 17.3 9, 13, 14 
13 5.48 1H dtt 12a, 12b, 14 10.3, 7.3, 1.7 125.3 9, 12a, 12b, 14, 15a, 15b 
14 5.35 1H dtt 13, 15a, 15b 10.3, 7.1, 1.4 129.9 12a, 12b, 13, 15a, 15b 
15 2.79 – 2.76 2H m 14, 15b, 16 - 26.0 13, 14, 16, 17 
16 5.37 1H dtt 15a, 15b, 17 10.6, 7.6, 1.7 131.0 14, 15a, 15b, 17, 18a, 18b 
17 5.46 1H dtt 15a, 15b, 16, 18a, 18b 10.6, 7.1, 1.5 125.8 15a, 15b, 16, 18a, 18b, 19 
18a 2.58 – 2.53 1H m 17, 19 - 
32.6 16, 17, 19, 20 
18b 2.50 – 2.45 1H m 17, 19 - 
19 3.70 1H ddd 18a, 18b, 20 10.8, 5.0, 4.0 53.6 17, 18a, 18b, 20, 21 
20 4.14 1H td 19, 21 6.7, 4.0 83.0 18a, 18b, 19, 21, 22 
21a 1.61 – 1.54 1H m 20, 22 - 
24.6 19, 20, 22 
21b 1.49 – 1.43 1H m 20, 22 - 
22 0.63 3H t 21 7.8 8.5 20, 21 
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anti-11.  NBS (1.3 mg, 7.3 mol) was added in one portion to a solution of cycloalkyne anti-
373 (3.4 mg, 8.1 mol) in THF at 0 °C. The solution was allowed to 
warm to ambient temperature and the reaction was closely 
monitored by TLC (pentane/EtOAc, 1/1). After complete consumption 
of the starting material, the reaction mixture was diluted with 
pentane (1 mL) and filtered through a pad of Celite which was 
carefully rinsed with pentane/EtOAc (2 mL, 1:1). The combined filtrates were concentrated 
and the residue was purified by flash chromatography (SiO2, pentane/EtOAc, 1/1  EtOAc 
100%) to give anti-11 as a crystalline colorless solid (1.6 mg, 40%).  [𝛼]D
20 = +18.0 (c = 0.10, 
CHCl3). 
1H NMR (600 MHz, CDCl3):  = 6.13 (s, 1H), 5.68 (dtt, 1H, J = 10.7, 7.4, 1.6 Hz), 5.54 – 
5.48 (m, 2H), 5.45 (dddt, 1H, J = 10.7, 8.0, 6.2, 1.7 Hz), 4.86 (td, 1H, J = 7.1, 3.6 Hz), 4.15 (ddd, 
1H, J = 9.1, 7.1, 4.8 Hz), 2.95 (ddt, 1H, J = 17.1, 6.5, 2.3 Hz), 2.91 – 2.87 (m, 2H), 2.83 (ddt, 1H, 
J = 17.1, 5.9, 2.5 Hz), 2.77 (ddddt, 1H, J = 15.2, 6.1, 4.9, 1.8, 0.9 Hz), 2.66 (dddd, 1H, J = 15.2, 
9.1, 8.0, 1.4 Hz), 2.59 (ddd, 1H, J = 14.6, 9.3, 6.1 Hz), 2.51 (ddd, 1H, J = 14.7, 9.3, 6.3 Hz), 2.27 
– 2.24 (m, 2H), 2.06 (dq, 1H, J = 14.9, 7.4 Hz), 2.05 (ddq, 1H, J = 14.8, 3.7, 7.4 Hz), 1.86 – 1.75 
(m, 2H), 1.58 – 1.55 (m, 2H), 1.07 ppm (t, 3H, J = 7.4 Hz); 13C NMR (150 MHz, CDCl3): 
 = 175.6, 163.3, 161.7, 131.1, 129.9, 125.6, 125.0, 111.7, 92.3, 84.6, 79.2, 79.1, 53.8, 33.4, 
33.0, 28.0, 26.6, 26.1, 25.6, 18.6, 17.1, 9.3 ppm; IR (film): ?̃? =  2921, 2851, 1659, 1633, 1575, 
1468, 1376, 1261, 1090, 800 cm-1; MS (pos. ESI) m/z (%): 521 (M+Na+, 100); HRMS (ESI): m/z: 
calcd. for C22H26O3Br2Na [M+Na
+]: 519.0140, found 519.0141.  
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Table 13: 
1
H and 
13
C NMR data of synthetic 4-pyrone anti-11; 
numbering scheme as shown in the insert. 
 
 
  
 
1
H NMR (600 MHz, CDCl3) 
13
C NMR (150 MHz, CDCl3) 
No.   (ppm) Integral Splitting COSY J (Hz) 
 
(ppm) 
HMBC 
1 - - - - - 161.7 20 
2 - - - - - 92.3 4 
3 - - - - - 175.6 4 
4 6.13 1H s - - 111.7 6a, 6b 
5 - - - - - 163.3 4, 6a, 6b, 7 
6a 2.59 1H ddd 6b, 7 14.6, 9.3, 6.1 
33.0 4, 7, 8 
6b 2.51 1H ddd 6a, 7 14.7, 9.3, 6.3 
7 1.86 – 1.75 2H m 6a, 6b, 8 - 26.6 6a, 6b, 8, 9 
8 1.58 – 1.55 2H m 7, 9 - 28.0 6a, 6b, 7, 9 
9 2.27 – 2.24 2H m 8, 12 - 18.6 7, 8 
10 - - - - - 79.2 8, 9, 12 
11 - - - - - 79.1 9, 12 
12a 2.95 1H ddt 9, 12b, 13 17.1, 6.5, 2.3 
17.1 13, 14 
12b 2.83 1H ddt 9, 12a, 13 17.1, 5.9, 2.5 
13 5.54 – 5.48 1H m 12a, 12b - 125.0 12a, 12b, 15 
14 5.54 – 5.48 1H m 15 - 129.9 13, 15 
15 2.91 – 2.87 2H m 14, 16 - 26.1 13, 14, 17 
16 5.68 1H dtt 15, 17 10.7, 7.4, 1.6 131.1 13, 15, 18a, 18b 
17 5.45 1H dddt 16, 18a, 18b 10.7, 8.0, 6.2, 1.7 125.6 15, 18a, 18b, 19 
18a 2.77 1H ddddt 17, 18b, 19 
15.2, 6.1, 4.9, 1.8, 
0.9 33.4 16, 17, 20 
18b 2.66 1H dddd 17, 18a, 19 15.2, 9.1, 8.0, 1.4 
19 4.15 1H ddd 18a, 18b, 20 9.1, 7.1, 4.8 55.8 18a, 18b, 21a, 21b 
20 4.86 1H td 19, 21a, 21b 7.1, 3.6 84.6 18a, 18b, 19, 21a, 21b, 22 
21a 2.06 1H dq 20, 22 14.9, 7.4 
25.6 19, 20, 22 
21b 2.05 1H ddq 20, 22 14.8, 3.7, 7.4 
22 1.05 3H t 21a, 21b 7.4 9.3 20, 21a, 21b 
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8. Appendix 
8.1. List of Abbreviations 
Ac Acetyl 
acac Acetyl acetonate 
Ar Aromatic group 
BBN Borabicyclo[3.3.1.]nonane 
Bn Benzyl 
br Broad 
Bu Butyl 
Bz Benzoyl 
calc. Calculated 
cat. Catalytic 
CBS Corey-Bakshi-Shibata 
CI Chemical ionization 
CoA Coenzyme A 
COSY Correlation spectroscopy 
Cp Cyclopentadienyl 
CP Core particle 
m-CPBA meta-Chloroperoxybenzoic acid 
CSA Camphersulfonic acid 
Cy Cyclohexyl 
 Reflux temperature 
d Doublet 
dba Dibenzylideneacetone 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC N,N´-Dicyclohexylcarbodiimide 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEPT Distorsionless enhancement by polarization transfer 
DIBAl-H Diisobutylaluminum hydride 
DIPT Diisopropyl tartrate 
DMAP 4-(Dimethylamino)-pyridine 
DMF N,N-Dimethylformamide 
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DMP Dess-Martin periodinane 
DMPU 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMSO Dimethyl sulfoxide 
dppf 1,1´-Bis(diphenylphosphino)ferrocene 
dr Diastereomeric ratio 
EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ee Enantiomeric excess 
EE Ethoxyethyl ether 
EI Electron ionization  
ent Enantiomer 
ESI Electronspray ionization 
Et Ethyl 
equiv Equivalents 
GC Gas chromatography 
HFIP 1,1,1,3,3,3-Hexafluoro-2-propanol 
HMBC Heteronuclear multiple quantum coherence 
HMDS Bis(trimethylsilyl)amine 
HMTA Hexamethylenetetramine 
HPLC High pressure liquid chromatography 
HRMS High resolution mass spectroscopy 
HSQC Heteronuclear single quantum coherence 
HWE Horner-Wadsworth-Emmons 
i Iso 
IBX 2-Iodoxybenzoic acid 
IC50 Half maximal inhibitory concentration 
Imid. Imidazole 
Ipc Isopinocampheyl 
IR Infrared spectroscopy 
LDA Lithium diisopropylamide 
m Multiplet 
Mc Chloromethyl sulfonyl 
Me Methyl 
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MOM Methoxymethyl 
Mp. Melting point 
Ms Methylsulfonyl 
MS Mass spetrometry 
MS Molecular sieves 
MTBE Methyl tert-butyl ether 
MTPA α-Methoxy-α-trifluoromethylphenylacetic acid 
n Normal 
NACM Nitrile alkyne cross-metathesis 
NBS N-Bromosuccinimide 
NIS N-Iodosuccinimide 
NMI 1-Methylimidazole 
NMO N-Methylmorpholine-N-oxide 
NMR Nuclear magnetic resonance 
NOE Nuclear Overhauser effect 
p Para 
PCC Pyridinium chlorochromate 
Ph Phenyl 
Piv Pivaloyl 
PKS Polyketide Synthase 
PLA2 Phospholipase A2 
ppm Parts per million 
PPTS Pyridinium-para-toluenesulfonate 
Pr Propyl 
q Quartet 
quant. Quantitative 
R Organic substituent 
rac Racemic 
RCAM Ring-closing alkyne metathesis 
RCM Ring-closing olefin metathesis 
rt Ambient temperature 
s Singlet 
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SAM S-Adenosyl methionine 
SEM [2-(Trimethylsilyl)ethoxy]methyl acetal 
sext Sextet 
Sp. Species 
SN1 First order nucleophilic substitution 
SN2 Second order nucleophilic substitution 
t Tertiary 
t Triplet 
TBAF Tetra-n-butylammoniumfluoride 
TBAI Tetra-n-butylammoniumiodide 
TBHP tert-Butylhydroperoxide 
TBS tert-Butyldimethylsilyl 
TEMPO (2,2,6,6)-Tetramethylpiperidinyloxyl 
TES Triethylsilyl 
tert Tertiary 
Tf Triflate 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TMEDA Tetramethylethylenediamine 
TMS Trimethylsilyl 
Ts Tosyl 
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8.2. Crystallographic Data of 4-Pyrone syn-11 
 
Identification code  9017sadabs 
Empirical formula  C24 H29 Br2 N O3 
Color  colourless 
Formula weight  539.30  g·mol-1  
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  ORTHORHOMBIC 
Space group  p 21 21 21,  (no. 19)  
Unit cell dimensions a = 4.7865(4) Å = 90° 
 b = 20.3783(16) Å = 90° 
 c = 24.3411(19) Å  = 90° 
Volume 2374.2(3) Å3 
Z 4 
Density (calculated) 1.509  Mg·m-3 
Absorption coefficient 4.525 mm-1 
F(000) 1096 e 
Crystal size 0.25 x 0.07 x 0.05 mm3 
 range for data collection 2.828 to 67.738° 
Index ranges -5  h  5, -24 k  24, -28 l  29 
C23
C24
C9
N1
C10
C8
C11
C12
Br1 C7
C5
C14
C13
C4
C6
O3
C2
C18
C17
Br2
C19
C16
C15
C3
C20
O2
O1
C1
C22
C21
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Reflections collected 63947 
Independent reflections 4285 [Rint = 0.0665] 
Reflections with I>2(I) 4199 
Completeness to  = 67.679° 99.8 %  
Absorption correction Gaussian 
Max. and min. transmission 0.84498 and 0.24515 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4285 / 0 / 273 
Goodness-of-fit on F2 1.064 
Final R indices [I>2(I)] R1 = 0.0331 wR
2 = 0.0877 
R indices (all data) R1 = 0.0339 wR
2 = 0.0885 
Absolute structure parameter -0.009(7) 
Extinction coefficient 0 
Largest diff. peak and hole 1.044 and -0.872 e·Å-3 
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8.3. Comparison of NMR Data of the Natural 4-Pyrone and Synthetic syn- and anti-11 
Table 14: Comparison of 
1
H and 
13
C NMR data of natural 11 and synthetic 4-pyrone syn-11; numbering scheme as shown in 
the insert above. 
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Table 15: Comparison of 
1
H and 
13
C NMR data of natural 11 and synthetic 4-pyrone anti-11; numbering scheme as shown 
in the insert above.  
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8.4. NMR Spectra of 267, 61, 62, 63, syn-11 and anti-11 
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